{"6b2e8452b634820689f92ae1bc2d83ac286038e4": [["BackgroundCritically ill patients are likely to develop respiratory and limb muscle weakness [1] .", [["respiratory", "ANATOMY", 56, 67], ["limb muscle", "ANATOMY", 72, 83], ["BackgroundCritically ill", "DISEASE", 0, 24], ["respiratory and limb muscle weakness", "DISEASE", 56, 92], ["patients", "ORGANISM", 25, 33], ["limb muscle", "ORGANISM_SUBDIVISION", 72, 83], ["patients", "SPECIES", 25, 33], ["respiratory and limb muscle weakness", "PROBLEM", 56, 92], ["limb muscle", "ANATOMY", 72, 83], ["weakness", "OBSERVATION", 84, 92]]], ["It has been clearly established that intensive care unit (ICU)-acquired limb muscle weakness is a frequent condition, associated with poor prognosis [2] [3] [4] [5] [6] .", [["limb muscle", "ANATOMY", 72, 83], ["muscle weakness", "DISEASE", 77, 92], ["limb", "ORGANISM_SUBDIVISION", 72, 76], ["muscle", "ORGAN", 77, 83], ["[2] [3] [4] [5] [6]", "SIMPLE_CHEMICAL", 149, 168], ["acquired limb muscle weakness", "PROBLEM", 63, 92], ["a frequent condition", "PROBLEM", 96, 116], ["poor prognosis", "PROBLEM", 134, 148], ["limb muscle", "ANATOMY", 72, 83], ["weakness", "OBSERVATION", 84, 92]]], ["Although the consequences of respiratory muscle weakness have been less extensively investigated, some evidences suggest that it may be a risk factor for prolonged duration of mechanical ventilation [7] , associated with a higher risk of readmission [8] and higher mortality [9] .", [["respiratory muscle", "ANATOMY", 29, 47], ["respiratory muscle weakness", "DISEASE", 29, 56], ["muscle", "ORGAN", 41, 47], ["respiratory muscle weakness", "PROBLEM", 29, 56], ["mechanical ventilation", "TREATMENT", 176, 198], ["respiratory muscle", "ANATOMY", 29, 47], ["weakness", "OBSERVATION", 48, 56]]], ["Diaphragm dysfunction is frequent in the intensive care unit (more than 60% of mechanically ventilated patients [10] ) and is associated with difficult and prolonged weaning and poor Open Access *Correspondence: martin.dres@aphp.fr 1 Service de Pneumologie, M\u00e9decine intensive -R\u00e9animation (D\u00e9partement \"R3S\"), AP-HP, Sorbonne Universit\u00e9, Groupe Hospitalier Universitaire Piti\u00e9-Salp\u00eatri\u00e8re Charles Foix, 75013 Paris, France Full list of author information is available at the end of the article prognosis [11] [12] [13] [14] .", [["Diaphragm", "ANATOMY", 0, 9], ["Diaphragm dysfunction", "DISEASE", 0, 21], ["Diaphragm", "MULTI-TISSUE_STRUCTURE", 0, 9], ["patients", "ORGANISM", 103, 111], ["[11] [12] [13] [14]", "SIMPLE_CHEMICAL", 505, 524], ["patients", "SPECIES", 103, 111], ["Diaphragm dysfunction", "PROBLEM", 0, 21], ["dysfunction", "OBSERVATION", 10, 21], ["frequent", "OBSERVATION_MODIFIER", 25, 33]]], ["Causes of diaphragm dysfunction are multifactorial and no specific treatment is currently available [10] .", [["diaphragm", "ANATOMY", 10, 19], ["diaphragm dysfunction", "DISEASE", 10, 31], ["diaphragm", "ORGAN", 10, 19], ["diaphragm dysfunction", "PROBLEM", 10, 31], ["specific treatment", "TREATMENT", 58, 76], ["diaphragm", "ANATOMY", 10, 19], ["dysfunction", "OBSERVATION", 20, 31]]], ["Diaphragm dysfunction is responsible for prolonged mechanical ventilation and may contribute to the development of \"chronic critical illness\", a devastating condition for patients and their families [15] .", [["Diaphragm", "ANATOMY", 0, 9], ["Diaphragm dysfunction", "DISEASE", 0, 21], ["chronic critical illness", "DISEASE", 116, 140], ["Diaphragm", "MULTI-TISSUE_STRUCTURE", 0, 9], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["Diaphragm dysfunction", "PROBLEM", 0, 21], ["prolonged mechanical ventilation", "TREATMENT", 41, 73], ["\"chronic critical illness\"", "PROBLEM", 115, 141], ["dysfunction", "OBSERVATION", 10, 21], ["responsible for", "UNCERTAINTY", 25, 40], ["prolonged", "OBSERVATION_MODIFIER", 41, 50], ["mechanical ventilation", "OBSERVATION", 51, 73], ["chronic", "OBSERVATION_MODIFIER", 116, 123]]], ["While the diaphragm undoubtedly plays a crucial role to ensure prompt and safe weaning from mechanical ventilation, recent data suggest that a substantial proportion of patients (up to 44%) can be successfully weaned from the ventilator despite the presence of diaphragm dysfunction [13, 14, 16] .", [["diaphragm", "ANATOMY", 10, 19], ["diaphragm", "ANATOMY", 261, 270], ["diaphragm dysfunction", "DISEASE", 261, 282], ["diaphragm", "ORGAN", 10, 19], ["patients", "ORGANISM", 169, 177], ["diaphragm", "ORGAN", 261, 270], ["patients", "SPECIES", 169, 177], ["mechanical ventilation", "TREATMENT", 92, 114], ["the ventilator", "TREATMENT", 222, 236], ["diaphragm dysfunction", "PROBLEM", 261, 282], ["diaphragm", "ANATOMY", 10, 19], ["substantial", "OBSERVATION_MODIFIER", 143, 154], ["diaphragm", "ANATOMY", 261, 270], ["dysfunction", "OBSERVATION", 271, 282]]], ["Nevertheless, in contrast with the reported negative impact of ICU-acquired weakness on long-term survival and disabilities [3, 4, 17] , it remains unclear whether diaphragm dysfunction per se is responsible for poor medium-term and long-term prognosis.", [["diaphragm", "ANATOMY", 164, 173], ["diaphragm dysfunction", "DISEASE", 164, 185], ["diaphragm", "ORGAN", 164, 173], ["acquired weakness", "PROBLEM", 67, 84], ["long-term survival", "TREATMENT", 88, 106], ["diaphragm dysfunction", "PROBLEM", 164, 185], ["poor medium-term and long-term prognosis", "PROBLEM", 212, 252], ["diaphragm", "ANATOMY", 164, 173], ["dysfunction", "OBSERVATION", 174, 185], ["long-term prognosis", "OBSERVATION_MODIFIER", 233, 252]]], ["The present study therefore used a previous cohort study conducted in our institution [13] to follow up mechanically ventilated patients in whom diaphragm and limb muscle functions were investigated at the time of liberation from mechanical ventilation.", [["diaphragm", "ANATOMY", 145, 154], ["limb muscle", "ANATOMY", 159, 170], ["patients", "ORGANISM", 128, 136], ["diaphragm", "MULTI-TISSUE_STRUCTURE", 145, 154], ["limb muscle", "ORGANISM_SUBDIVISION", 159, 170], ["patients", "SPECIES", 128, 136], ["The present study", "TEST", 0, 17], ["a previous cohort study", "TEST", 33, 56], ["mechanical ventilation", "TREATMENT", 230, 252], ["diaphragm", "ANATOMY", 145, 154], ["limb muscle", "ANATOMY", 159, 170], ["mechanical ventilation", "OBSERVATION", 230, 252]]], ["We tested the hypothesis that diaphragm dysfunction is associated with negative longterm outcomes and that the coexistence of diaphragm dysfunction and ICU-AW has a particular association on long-term prognosis, in line with the known negative synergistic effects of the two conditions on short-term prognosis.MethodsThis study was conducted in a 10-bed medical ICU in a university hospital.", [["diaphragm", "ANATOMY", 30, 39], ["diaphragm", "ANATOMY", 126, 135], ["diaphragm dysfunction", "DISEASE", 30, 51], ["diaphragm dysfunction", "DISEASE", 126, 147], ["diaphragm", "ORGAN", 30, 39], ["diaphragm", "ORGAN", 126, 135], ["diaphragm dysfunction", "PROBLEM", 30, 51], ["diaphragm dysfunction", "PROBLEM", 126, 147], ["This study", "TEST", 317, 327], ["diaphragm", "ANATOMY", 30, 39], ["dysfunction", "OBSERVATION", 40, 51], ["diaphragm", "ANATOMY", 126, 135], ["dysfunction", "OBSERVATION", 136, 147], ["long-term prognosis", "OBSERVATION_MODIFIER", 191, 210], ["negative synergistic", "OBSERVATION_MODIFIER", 235, 255], ["short-term prognosis", "OBSERVATION_MODIFIER", 289, 309]]], ["ICU patients were enrolled over an 8-month period and phone interviews were conducted over a 4-month period.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["The study was approved by the Comit\u00e9 de Protection des Personnes Ile-de-France VI (ID RCB: 2014-A00715-42) and was conducted in accordance with the ethical standards laid down in the 2008 Declaration of Helsinki.", [["The study", "TEST", 0, 9]]], ["Informed consent was obtained from all patients or their relatives.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47]]], ["Some data from this cohort have already been published elsewhere [13, 18, 19] .Initial study populationAs described elsewhere [13] , patients were eligible for the study if they had been intubated and ventilated for at least 24 h and met the readiness-to-wean criteria as routinely assessed by the clinicians in charge on a daily basis according to current guidelines [20] .", [["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["Some data", "PROBLEM", 0, 9], ["Initial study populationAs", "TEST", 79, 105], ["the study", "TEST", 160, 169], ["intubated", "TREATMENT", 187, 196], ["ventilated", "TREATMENT", 201, 211]]], ["Patients presenting factors possibly interfering with tracheal pressure measurements in response to phrenic nerve stimulation (chest tubes, neuromuscular disease), tracheostomy, a contraindication to the phrenic nerve stimulation technique (pacemaker) and patients with withholding or withdrawal of life support decisions at the time of inclusion were not enrolled.Initial study populationDiaphragm function and limb muscle strength were assessed on the same day once after enrolment and before starting the first spontaneous breathing trial.", [["tracheal", "ANATOMY", 54, 62], ["phrenic nerve", "ANATOMY", 100, 113], ["chest tubes", "ANATOMY", 127, 138], ["neuromuscular", "ANATOMY", 140, 153], ["phrenic nerve", "ANATOMY", 204, 217], ["Diaphragm", "ANATOMY", 389, 398], ["limb muscle", "ANATOMY", 412, 423], ["neuromuscular disease", "DISEASE", 140, 161], ["Patients", "ORGANISM", 0, 8], ["tracheal", "MULTI-TISSUE_STRUCTURE", 54, 62], ["phrenic nerve", "MULTI-TISSUE_STRUCTURE", 100, 113], ["chest tubes", "MULTI-TISSUE_STRUCTURE", 127, 138], ["phrenic nerve", "MULTI-TISSUE_STRUCTURE", 204, 217], ["patients", "ORGANISM", 256, 264], ["limb muscle", "ORGANISM_SUBDIVISION", 412, 423], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 256, 264], ["tracheal pressure measurements", "TREATMENT", 54, 84], ["phrenic nerve stimulation", "TREATMENT", 100, 125], ["chest tubes", "TREATMENT", 127, 138], ["neuromuscular disease", "PROBLEM", 140, 161], ["tracheostomy", "TREATMENT", 164, 176], ["the phrenic nerve stimulation technique", "TREATMENT", 200, 239], ["pacemaker", "TREATMENT", 241, 250], ["withdrawal of life support", "TREATMENT", 285, 311], ["Initial study", "TEST", 365, 378], ["the first spontaneous breathing trial", "TREATMENT", 504, 541], ["phrenic nerve", "ANATOMY", 100, 113], ["chest", "ANATOMY", 127, 132], ["neuromuscular", "ANATOMY", 140, 153], ["disease", "OBSERVATION", 154, 161], ["tracheostomy", "OBSERVATION", 164, 176], ["phrenic nerve", "ANATOMY", 204, 217], ["Diaphragm", "ANATOMY", 389, 398], ["limb muscle", "ANATOMY", 412, 423]]], ["Diaphragm function was assessed by the change in tracheal pressure in response to magnetic stimulation (Ptr,stim), as described previously [13] and limb muscle strength was assessed by the Medical Research Council (MRC) score in patients screened for level of consciousness and understanding [2, 21] .", [["Diaphragm", "ANATOMY", 0, 9], ["tracheal", "ANATOMY", 49, 57], ["limb muscle", "ANATOMY", 148, 159], ["Diaphragm", "MULTI-TISSUE_STRUCTURE", 0, 9], ["tracheal", "MULTI-TISSUE_STRUCTURE", 49, 57], ["limb muscle", "TISSUE", 148, 159], ["patients", "ORGANISM", 229, 237], ["patients", "SPECIES", 229, 237], ["tracheal pressure", "TEST", 49, 66], ["magnetic stimulation", "TEST", 82, 102], ["stim", "TEST", 108, 112], ["tracheal", "ANATOMY", 49, 57], ["pressure", "OBSERVATION_MODIFIER", 58, 66], ["limb muscle", "ANATOMY", 148, 159]]], ["Patients with a Ptr,stim less than 11 cm H 2 O were considered to have diaphragm dysfunction and patients with a Ptr,stim less than 7 cmH 2 O were considered to have severe diaphragm dysfunction [18] .", [["diaphragm", "ANATOMY", 71, 80], ["diaphragm", "ANATOMY", 173, 182], ["diaphragm dysfunction", "DISEASE", 71, 92], ["diaphragm dysfunction", "DISEASE", 173, 194], ["Patients", "ORGANISM", 0, 8], ["diaphragm", "ORGAN", 71, 80], ["patients", "ORGANISM", 97, 105], ["diaphragm", "ORGAN", 173, 182], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 97, 105], ["a Ptr", "TEST", 14, 19], ["stim", "TEST", 20, 24], ["diaphragm dysfunction", "PROBLEM", 71, 92], ["a Ptr", "TEST", 111, 116], ["severe diaphragm dysfunction", "PROBLEM", 166, 194], ["diaphragm", "ANATOMY", 71, 80], ["dysfunction", "OBSERVATION", 81, 92], ["severe", "OBSERVATION_MODIFIER", 166, 172], ["diaphragm", "ANATOMY", 173, 182], ["dysfunction", "OBSERVATION", 183, 194]]], ["Patients with an MRC score less than 48 were considered to have ICU-AW [2] .Data collection for long-term prognosis studyVariables pertaining to patient characteristics and ICU stay were collected prospectively during hospitalization: age, sex, comorbidities, the Simplified Acute Physiology Score (SAPS II) and SOFA score computed at ICU admission [22, 23] .", [["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 145, 152], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 145, 152], ["an MRC score", "TEST", 14, 26], ["Data collection", "TEST", 76, 91], ["long-term prognosis study", "PROBLEM", 96, 121], ["the Simplified Acute Physiology Score", "PROBLEM", 260, 297], ["SOFA score", "TEST", 312, 322], ["Acute", "OBSERVATION_MODIFIER", 275, 280]]], ["The dates of ICU admission, intubation, first spontaneous breathing trial, extubation, ICU discharge, hospital discharge and ICU and hospital death were obtained from the hospital medical charts.", [["death", "DISEASE", 142, 147], ["intubation", "TREATMENT", 28, 38], ["first spontaneous breathing trial", "TREATMENT", 40, 73], ["extubation", "TREATMENT", 75, 85]]], ["Survival and health-related quality of life assessment was performed as described below.", [["life assessment", "TEST", 39, 54]]], ["Hospital medical charts were analysed to identify the patient's status (dead or alive) and dates over a 2-year period following inclusion in the study.", [["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["the study", "TEST", 141, 150]]], ["Patients alive 2 years after inclusion were contacted by phone by the first author.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["The patient was asked to complete the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) questionnaire to assess health-related quality of life [24, 25] .", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["Outcomes Study", "TEST", 46, 60]]], ["The SF-36 questionnaire is a general quality of life questionnaire that evaluates physical and emotional quality of life.", [["The SF", "TEST", 0, 6]]], ["The SF-36 questionnaire includes eight multiple-item scales that assess physical functioning, social functioning, physical role, emotional role, mental health, pain, vitality, and general health [26] .", [["pain", "DISEASE", 160, 164], ["The SF", "TEST", 0, 6], ["pain", "PROBLEM", 160, 164]]], ["Interviews were conducted by a single investigator blinded to the patient's status in relation to the presence of diaphragm dysfunction and ICUacquired weakness in the ICU.Study outcomesThe primary outcome was 2-year overall survival following inclusion, and secondary outcomes were healthrelated quality of life and functional disability as assessed by the SF-36 score.Statistical analysisDue to the retrospective nature of this post hoc analysis, no sample size calculation could be made.", [["diaphragm", "ANATOMY", 114, 123], ["diaphragm dysfunction", "DISEASE", 114, 135], ["ICUacquired weakness", "DISEASE", 140, 160], ["functional disability", "DISEASE", 317, 338], ["patient", "ORGANISM", 66, 73], ["diaphragm", "ORGAN", 114, 123], ["patient", "SPECIES", 66, 73], ["diaphragm dysfunction", "PROBLEM", 114, 135], ["ICUacquired weakness", "PROBLEM", 140, 160], ["Study outcomes", "TEST", 172, 186], ["this post hoc analysis", "TEST", 425, 447], ["sample size calculation", "TEST", 452, 475], ["diaphragm", "ANATOMY", 114, 123], ["dysfunction", "OBSERVATION", 124, 135], ["weakness", "OBSERVATION", 152, 160]]], ["All patients from the primary cohort [13] with available data were included in the present analysis.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["available data", "TEST", 47, 61]]], ["A normal distribution was checked by a Kolmogorov-Smirnov test.", [["a Kolmogorov-Smirnov test", "TEST", 37, 62], ["normal", "OBSERVATION", 2, 8], ["distribution", "OBSERVATION_MODIFIER", 9, 21]]], ["Continuous variables were compared by Mann-Whitney test and categorical variables were compared by Fisher's exact test.", [["Fisher's exact test", "TEST", 99, 118]]], ["Kaplan-Meier survival curves were generated to describe cumulative survival following inclusion.", [["Meier survival curves", "TREATMENT", 7, 28]]], ["Survival curves were compared by log-rank (Mantel-Cox) test.Statistical analysisPatient outcomes were compared by means of two classifications.", [["Survival curves", "TEST", 0, 15]]], ["First, patients were classified as follows:Statistical analysis(1) with/without diaphragm dysfunction and (2) with/ without ICU-acquired weakness.", [["diaphragm", "ANATOMY", 80, 89], ["diaphragm dysfunction", "DISEASE", 80, 101], ["patients", "ORGANISM", 7, 15], ["diaphragm", "ORGAN", 80, 89], ["patients", "SPECIES", 7, 15], ["Statistical analysis", "TEST", 43, 63], ["diaphragm dysfunction", "PROBLEM", 80, 101], ["acquired weakness", "PROBLEM", 128, 145], ["without", "UNCERTAINTY", 72, 79], ["diaphragm", "ANATOMY", 80, 89], ["dysfunction", "OBSERVATION", 90, 101], ["weakness", "OBSERVATION", 137, 145]]], ["In a secondary analysis, patients were also classified according to the co-existence of diaphragm dysfunction and ICU-acquired weakness: (a) diaphragm dysfunction only, (b) ICU-acquired weakness only, (c) co-existence of diaphragm dysfunction and ICU-acquired weakness and (d) neither of these two conditions.Statistical analysisThree exploratory analyses were then conducted.", [["diaphragm", "ANATOMY", 88, 97], ["diaphragm", "ANATOMY", 141, 150], ["diaphragm", "ANATOMY", 221, 230], ["diaphragm dysfunction", "DISEASE", 88, 109], ["diaphragm dysfunction", "DISEASE", 141, 162], ["weakness", "DISEASE", 186, 194], ["diaphragm dysfunction", "DISEASE", 221, 242], ["weakness", "DISEASE", 260, 268], ["patients", "ORGANISM", 25, 33], ["diaphragm", "ORGAN", 88, 97], ["diaphragm", "ORGAN", 141, 150], ["diaphragm", "ORGAN", 221, 230], ["patients", "SPECIES", 25, 33], ["a secondary analysis", "TEST", 3, 23], ["diaphragm dysfunction", "PROBLEM", 88, 109], ["acquired weakness", "PROBLEM", 118, 135], ["a) diaphragm dysfunction", "PROBLEM", 138, 162], ["acquired weakness", "PROBLEM", 177, 194], ["diaphragm dysfunction", "PROBLEM", 221, 242], ["acquired weakness", "PROBLEM", 251, 268], ["Statistical analysis", "TEST", 309, 329], ["Three exploratory analyses", "TEST", 329, 355], ["diaphragm", "ANATOMY", 88, 97], ["dysfunction", "OBSERVATION", 98, 109], ["diaphragm", "ANATOMY", 141, 150], ["dysfunction", "OBSERVATION", 151, 162], ["weakness", "OBSERVATION", 186, 194], ["diaphragm", "ANATOMY", 221, 230], ["dysfunction", "OBSERVATION", 231, 242], ["weakness", "OBSERVATION", 260, 268]]], ["A first exploratory analysis assessed the 2-year survival in hospital survivors and a second exploratory analysis assessed the 2-year survival in patients with or without severe diaphragm dysfunction (Ptr,stim < 7 cmH 2 O).", [["diaphragm", "ANATOMY", 178, 187], ["diaphragm dysfunction", "DISEASE", 178, 199], ["patients", "ORGANISM", 146, 154], ["diaphragm", "ORGAN", 178, 187], ["patients", "SPECIES", 146, 154], ["A first exploratory analysis", "TEST", 0, 28], ["a second exploratory analysis", "TEST", 84, 113], ["severe diaphragm dysfunction", "PROBLEM", 171, 199], ["Ptr", "TEST", 201, 204], ["stim", "TEST", 205, 209], ["diaphragm", "ANATOMY", 178, 187], ["dysfunction", "OBSERVATION", 188, 199]]], ["Last, a third exploratory analysis compared SF-36 questionnaire in patients with co-existence of diaphragm dysfunction and ICU-acquired weakness and those who were free from diseases.", [["diaphragm", "ANATOMY", 97, 106], ["diaphragm dysfunction", "DISEASE", 97, 118], ["ICU-acquired weakness", "DISEASE", 123, 144], ["patients", "ORGANISM", 67, 75], ["diaphragm", "ORGAN", 97, 106], ["patients", "SPECIES", 67, 75], ["a third exploratory analysis", "TEST", 6, 34], ["SF", "TEST", 44, 46], ["diaphragm dysfunction", "PROBLEM", 97, 118], ["acquired weakness", "PROBLEM", 127, 144], ["diseases", "PROBLEM", 174, 182], ["diaphragm", "ANATOMY", 97, 106], ["dysfunction", "OBSERVATION", 107, 118], ["diseases", "OBSERVATION", 174, 182]]], ["For all final comparisons, a p-value less than or equal to 0.05 was considered statistically significant.", [["a p-value", "TEST", 27, 36]]], ["Statistical analyses were performed with Prism v.6, GraphPad Software.Patient characteristics and follow-upSeventy-six patients were consecutively enrolled in the primary study (Fig. 1) .", [["patients", "ORGANISM", 119, 127], ["Patient", "SPECIES", 70, 77], ["patients", "SPECIES", 119, 127], ["Statistical analyses", "TEST", 0, 20], ["Prism", "TEST", 41, 46], ["the primary study", "TEST", 159, 176]]], ["Forty-eight (63%) patients were diagnosed with diaphragm dysfunction at the time of weaning, 26 (34%) had ICU-acquired weakness, 16 (21%) had both diaphragm dysfunction and ICU-acquired weakness and 18 (24%) were free of diseases.", [["diaphragm", "ANATOMY", 47, 56], ["diaphragm", "ANATOMY", 147, 156], ["diaphragm dysfunction", "DISEASE", 47, 68], ["ICU-acquired weakness", "DISEASE", 106, 127], ["diaphragm dysfunction", "DISEASE", 147, 168], ["ICU-acquired weakness", "DISEASE", 173, 194], ["patients", "ORGANISM", 18, 26], ["diaphragm", "ORGAN", 47, 56], ["diaphragm", "ORGAN", 147, 156], ["patients", "SPECIES", 18, 26], ["diaphragm dysfunction", "PROBLEM", 47, 68], ["acquired weakness", "PROBLEM", 110, 127], ["both diaphragm dysfunction", "PROBLEM", 142, 168], ["acquired weakness", "PROBLEM", 177, 194], ["diseases", "PROBLEM", 221, 229], ["diaphragm", "ANATOMY", 47, 56], ["dysfunction", "OBSERVATION", 57, 68], ["diaphragm", "ANATOMY", 147, 156], ["dysfunction", "OBSERVATION", 157, 168], ["diseases", "OBSERVATION", 221, 229]]], ["Patient characteristics are presented in Table 1 .", [["Patient", "SPECIES", 0, 7]]], ["Patients had been ventilated for an average of 4 (2-6) days prior to inclusion.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["ventilated", "TREATMENT", 18, 28], ["ventilated", "OBSERVATION", 18, 28]]], ["Patients who were free from diaphragm dysfunction and ICU-AW were more likely placed under mechanical ventilation for coma and were ventilated significantly shorter than others (Table 1) .", [["diaphragm", "ANATOMY", 28, 37], ["diaphragm dysfunction", "DISEASE", 28, 49], ["coma", "DISEASE", 118, 122], ["Patients", "ORGANISM", 0, 8], ["diaphragm", "ORGAN", 28, 37], ["Patients", "SPECIES", 0, 8], ["diaphragm dysfunction", "PROBLEM", 28, 49], ["mechanical ventilation", "TREATMENT", 91, 113], ["coma", "PROBLEM", 118, 122], ["diaphragm", "ANATOMY", 28, 37], ["dysfunction", "OBSERVATION", 38, 49], ["mechanical ventilation", "OBSERVATION", 91, 113]]], ["Overall, 43 (57%) patients were successfully weaned from the ventilator after the first attempt.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["the ventilator", "TREATMENT", 57, 71]]], ["The mean length of ICU stay was 9 (4-18) days and the mean length of hospital stay Fig. 1 Study flowchart.", [["Study flowchart", "TEST", 90, 105], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["length", "OBSERVATION_MODIFIER", 9, 15]]], ["ICU-AW intensive care unit-acquired weakness was 21 (10-30) days.", [["weakness", "DISEASE", 36, 44], ["acquired weakness", "PROBLEM", 27, 44], ["weakness", "OBSERVATION", 36, 44]]], ["All ICU survivors had been liberated from mechanical ventilation at the time of ICU discharge.", [["All ICU survivors", "TREATMENT", 0, 17], ["mechanical ventilation", "TREATMENT", 42, 64], ["mechanical ventilation", "OBSERVATION", 42, 64]]], ["As 7 patients were lost to follow-up, 2-year survival was assessed in only 69 patients and secondary outcomes (health-related quality of life) were assessed in 40 patients (Fig. 1) .Two-year survivalThe overall 2-year survival was 67% (46/69): 64% (29/45) in patients with diaphragm dysfunction, 71% (17/24) in patients without diaphragm dysfunction, 46% (11/24) in patients with ICU-acquired weakness and 76% (34/45) in patients without ICU-acquired weakness.", [["diaphragm", "ANATOMY", 273, 282], ["diaphragm", "ANATOMY", 328, 337], ["diaphragm dysfunction", "DISEASE", 273, 294], ["diaphragm dysfunction", "DISEASE", 328, 349], ["ICU-acquired weakness", "DISEASE", 380, 401], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 163, 171], ["patients", "ORGANISM", 259, 267], ["diaphragm", "ORGAN", 273, 282], ["patients", "ORGANISM", 311, 319], ["diaphragm", "ORGAN", 328, 337], ["patients", "ORGANISM", 366, 374], ["patients", "ORGANISM", 421, 429], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 163, 171], ["patients", "SPECIES", 259, 267], ["patients", "SPECIES", 311, 319], ["patients", "SPECIES", 366, 374], ["patients", "SPECIES", 421, 429], ["diaphragm dysfunction", "PROBLEM", 273, 294], ["diaphragm dysfunction", "PROBLEM", 328, 349], ["acquired weakness", "PROBLEM", 384, 401], ["acquired weakness", "PROBLEM", 442, 459], ["diaphragm", "ANATOMY", 273, 282], ["dysfunction", "OBSERVATION", 283, 294], ["without", "UNCERTAINTY", 320, 327], ["diaphragm", "ANATOMY", 328, 337], ["dysfunction", "OBSERVATION", 338, 349], ["weakness", "OBSERVATION", 393, 401], ["weakness", "OBSERVATION", 451, 459]]], ["Patients with co-existence of diaphragm dysfunction and ICU-acquired weakness had poorer survival than patients without diaphragm function and ICU-acquired weakness (p = 0.01 for overall comparison, see Additional file 1: Figure S1 ).", [["diaphragm", "ANATOMY", 30, 39], ["diaphragm", "ANATOMY", 120, 129], ["diaphragm dysfunction", "DISEASE", 30, 51], ["weakness", "DISEASE", 156, 164], ["Patients", "ORGANISM", 0, 8], ["diaphragm", "ORGAN", 30, 39], ["patients", "ORGANISM", 103, 111], ["diaphragm", "ORGAN", 120, 129], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 103, 111], ["diaphragm dysfunction", "PROBLEM", 30, 51], ["acquired weakness", "PROBLEM", 60, 77], ["diaphragm function", "TEST", 120, 138], ["acquired weakness", "PROBLEM", 147, 164], ["diaphragm", "ANATOMY", 30, 39], ["dysfunction", "OBSERVATION", 40, 51], ["diaphragm", "ANATOMY", 120, 129]]], ["Survival was not significantly different between patients with diaphragm dysfunction and patients without diaphragm dysfunction (see Fig. 2a ), but was significantly poorer in patients with ICU-acquired weakness compared to patients without ICU-acquired weakness (see Fig. 2b ).Exploratory analysis restricted to hospital survivorsAmong the 76 patients enrolled in the study, 61 were alive at the time of hospital discharge.", [["diaphragm", "ANATOMY", 63, 72], ["diaphragm", "ANATOMY", 106, 115], ["diaphragm dysfunction", "DISEASE", 63, 84], ["diaphragm dysfunction", "DISEASE", 106, 127], ["weakness", "DISEASE", 203, 211], ["patients", "ORGANISM", 49, 57], ["diaphragm", "ORGAN", 63, 72], ["patients", "ORGANISM", 89, 97], ["diaphragm", "ORGAN", 106, 115], ["patients", "ORGANISM", 176, 184], ["patients", "ORGANISM", 224, 232], ["patients", "ORGANISM", 344, 352], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 176, 184], ["patients", "SPECIES", 224, 232], ["patients", "SPECIES", 344, 352], ["diaphragm dysfunction", "PROBLEM", 63, 84], ["diaphragm dysfunction", "PROBLEM", 106, 127], ["acquired weakness", "PROBLEM", 194, 211], ["acquired weakness", "PROBLEM", 245, 262], ["Exploratory analysis", "TEST", 278, 298], ["the study", "TEST", 365, 374], ["significantly different", "OBSERVATION_MODIFIER", 17, 40], ["diaphragm", "ANATOMY", 63, 72], ["dysfunction", "OBSERVATION", 73, 84], ["without", "UNCERTAINTY", 98, 105], ["diaphragm", "ANATOMY", 106, 115], ["dysfunction", "OBSERVATION", 116, 127], ["weakness", "OBSERVATION", 254, 262]]], ["From them, 7 were lost of follow-up leading to a sample of 54 patients in the Fig. 3 and Additional file 1: Figure S2 ).", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70]]], ["Although the comparison between groups was not significant, the findings were in line with the primary analysis.Exploratory analysis conducted on patients with severe diaphragm dysfunctionA severe diaphragm dysfunction (Ptr,stim < 7 cmH 2 O) was diagnosed in 31% (24/76) of the patients.", [["diaphragm", "ANATOMY", 167, 176], ["diaphragm", "ANATOMY", 197, 206], ["diaphragm dysfunctionA", "DISEASE", 167, 189], ["diaphragm dysfunction", "DISEASE", 197, 218], ["patients", "ORGANISM", 146, 154], ["diaphragm", "ORGAN", 167, 176], ["diaphragm", "ORGAN", 197, 206], ["patients", "ORGANISM", 278, 286], ["patients", "SPECIES", 146, 154], ["patients", "SPECIES", 278, 286], ["the primary analysis", "TEST", 91, 111], ["Exploratory analysis", "TEST", 112, 132], ["severe diaphragm dysfunctionA severe diaphragm dysfunction", "PROBLEM", 160, 218], ["Ptr", "TEST", 220, 223], ["stim", "TEST", 224, 228], ["severe", "OBSERVATION_MODIFIER", 160, 166], ["diaphragm", "ANATOMY", 167, 176], ["dysfunctionA", "OBSERVATION", 177, 189], ["severe", "OBSERVATION_MODIFIER", 190, 196], ["diaphragm", "ANATOMY", 197, 206], ["dysfunction", "OBSERVATION", 207, 218]]], ["The survival between patients with and without severe diaphragm dysfunction was not significantly different (p = 0.07) (see Additional file 1: Figure S3 ).Health-related quality of lifeThe SF-36 questionnaire was completed at the end of the study in 40 patients.", [["diaphragm", "ANATOMY", 54, 63], ["diaphragm dysfunction", "DISEASE", 54, 75], ["patients", "ORGANISM", 21, 29], ["diaphragm", "ORGAN", 54, 63], ["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 253, 261], ["severe diaphragm dysfunction", "PROBLEM", 47, 75], ["The SF", "TEST", 185, 191], ["the study", "TEST", 237, 246], ["diaphragm", "ANATOMY", 54, 63], ["dysfunction", "OBSERVATION", 64, 75]]], ["Figure 4 displays the values of the SF-36 components (mental and physical) in patients with and without diaphragm dysfunction and in patients with and without ICU-acquired weakness.", [["diaphragm", "ANATOMY", 104, 113], ["diaphragm dysfunction", "DISEASE", 104, 125], ["patients", "ORGANISM", 78, 86], ["diaphragm", "ORGAN", 104, 113], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 133, 141], ["the SF", "TEST", 32, 38], ["diaphragm dysfunction", "PROBLEM", 104, 125], ["acquired weakness", "PROBLEM", 163, 180], ["without", "UNCERTAINTY", 96, 103], ["diaphragm", "ANATOMY", 104, 113], ["dysfunction", "OBSERVATION", 114, 125], ["weakness", "OBSERVATION", 172, 180]]], ["No significant difference in terms of SF-36 categories was observed between groups.", [["SF", "PROTEIN", 38, 40], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION_MODIFIER", 15, 25]]], ["The exploratory analysis comparing patients with co-existence of diaphragm dysfunction and ICU-acquired weakness and those who were free from diseases found no difference in term of SF-36 mental and physical components (see Additional file 1: Figure S4 ).DiscussionThis study reports the long-term-up to 2 years-survival and health-related quality of life of critically ill patients with diaphragm dysfunction, ICU-acquired weakness or a combination of the two at the time of liberation from mechanical ventilation.", [["diaphragm", "ANATOMY", 65, 74], ["diaphragm", "ANATOMY", 388, 397], ["diaphragm dysfunction", "DISEASE", 65, 86], ["ICU-acquired weakness", "DISEASE", 91, 112], ["critically ill", "DISEASE", 359, 373], ["diaphragm dysfunction", "DISEASE", 388, 409], ["weakness", "DISEASE", 424, 432], ["patients", "ORGANISM", 35, 43], ["diaphragm", "ORGAN", 65, 74], ["patients", "ORGANISM", 374, 382], ["diaphragm", "ORGAN", 388, 397], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 374, 382], ["The exploratory analysis", "TEST", 0, 24], ["diaphragm dysfunction", "PROBLEM", 65, 86], ["acquired weakness", "PROBLEM", 95, 112], ["diseases", "PROBLEM", 142, 150], ["SF", "TEST", 182, 184], ["mental and physical components", "PROBLEM", 188, 218], ["diaphragm dysfunction", "PROBLEM", 388, 409], ["acquired weakness", "PROBLEM", 415, 432], ["mechanical ventilation", "TREATMENT", 492, 514], ["diaphragm", "ANATOMY", 65, 74], ["dysfunction", "OBSERVATION", 75, 86], ["no", "UNCERTAINTY", 157, 159], ["diaphragm", "ANATOMY", 388, 397], ["dysfunction", "OBSERVATION", 398, 409], ["mechanical ventilation", "OBSERVATION", 492, 514]]], ["The main findings can be summarized as follows: (1) 2-year survival was much better in patients without diaphragm dysfunction and ICU-acquired weakness at the time of liberation from mechanical ventilation than in patients presenting both of these conditions (79% versus 36%, respectively); (2) survival was not significantly different between patients with diaphragm dysfunction without ICU-acquired weakness and patients not presenting either of the two conditions (77% versus 79%, respectively); (3) survival appeared to be much more markedly influenced by the presence of ICU-acquired weakness than by the presence of diaphragm dysfunction and (4) the study failed [3] .", [["diaphragm", "ANATOMY", 104, 113], ["diaphragm", "ANATOMY", 358, 367], ["diaphragm", "ANATOMY", 622, 631], ["diaphragm dysfunction", "DISEASE", 104, 125], ["weakness", "DISEASE", 143, 151], ["diaphragm dysfunction", "DISEASE", 358, 379], ["ICU-acquired weakness", "DISEASE", 388, 409], ["weakness", "DISEASE", 589, 597], ["diaphragm dysfunction", "DISEASE", 622, 643], ["patients", "ORGANISM", 87, 95], ["diaphragm", "ORGAN", 104, 113], ["patients", "ORGANISM", 214, 222], ["patients", "ORGANISM", 344, 352], ["diaphragm", "ORGAN", 358, 367], ["patients", "ORGANISM", 414, 422], ["diaphragm", "ORGAN", 622, 631], ["patients", "SPECIES", 87, 95], ["patients", "SPECIES", 214, 222], ["patients", "SPECIES", 344, 352], ["patients", "SPECIES", 414, 422], ["diaphragm dysfunction", "PROBLEM", 104, 125], ["acquired weakness", "PROBLEM", 134, 151], ["mechanical ventilation", "TREATMENT", 183, 205], ["diaphragm dysfunction", "PROBLEM", 358, 379], ["acquired weakness", "PROBLEM", 392, 409], ["acquired weakness", "PROBLEM", 580, 597], ["diaphragm dysfunction", "PROBLEM", 622, 643], ["the study", "TEST", 652, 661], ["main", "OBSERVATION_MODIFIER", 4, 8], ["without", "UNCERTAINTY", 96, 103], ["diaphragm", "ANATOMY", 104, 113], ["dysfunction", "OBSERVATION", 114, 125], ["weakness", "OBSERVATION", 143, 151], ["mechanical ventilation", "OBSERVATION", 183, 205], ["diaphragm", "ANATOMY", 358, 367], ["dysfunction", "OBSERVATION", 368, 379], ["weakness", "OBSERVATION", 401, 409], ["weakness", "OBSERVATION", 589, 597], ["diaphragm", "ANATOMY", 622, 631], ["dysfunction", "OBSERVATION", 632, 643]]], ["In a study with prolonged follow-up (up to 1 year), Hermans et al. reported a 68% survival rate in patients with ICUacquired weakness [4] .", [["weakness", "DISEASE", 125, 133], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["a study", "TEST", 3, 10], ["ICUacquired weakness", "PROBLEM", 113, 133], ["weakness", "OBSERVATION", 125, 133]]], ["In our study, patients with ICUacquired weakness had a 2-year survival of 46%.", [["ICUacquired weakness", "DISEASE", 28, 48], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["our study", "TEST", 3, 12], ["ICUacquired weakness", "PROBLEM", 28, 48]]], ["This lower survival rate in our cohort could be explained by the timing of the assessment of ICU-acquired weakness (earlier in our study than in other studies) and the prolonged duration of follow-up.", [["weakness", "DISEASE", 106, 114], ["This lower survival rate", "PROBLEM", 0, 24], ["the assessment", "TEST", 75, 89], ["acquired weakness", "PROBLEM", 97, 114], ["our study", "TEST", 127, 136], ["other studies", "TEST", 145, 158], ["weakness", "OBSERVATION", 106, 114]]], ["It remains unclear whether diaphragm dysfunction is one of several features of ICUacquired weakness or whether the two conditions are distinct [7, 13, 27] .", [["diaphragm", "ANATOMY", 27, 36], ["diaphragm dysfunction", "DISEASE", 27, 48], ["ICUacquired weakness", "DISEASE", 79, 99], ["diaphragm", "ORGAN", 27, 36], ["diaphragm dysfunction", "PROBLEM", 27, 48], ["ICUacquired weakness", "PROBLEM", 79, 99], ["diaphragm", "ANATOMY", 27, 36], ["dysfunction", "OBSERVATION", 37, 48], ["ICUacquired", "OBSERVATION_MODIFIER", 79, 90], ["weakness", "OBSERVATION", 91, 99], ["distinct", "OBSERVATION_MODIFIER", 134, 142]]], ["Two studies conducted at the time of weaning demonstrated a weak but significant correlation between diaphragm function and limb muscle strength [13, 14] .", [["diaphragm", "ANATOMY", 101, 110], ["limb muscle", "ANATOMY", 124, 135], ["diaphragm", "ORGAN", 101, 110], ["limb muscle", "TISSUE", 124, 135], ["Two studies", "TEST", 0, 11], ["a weak", "PROBLEM", 58, 64], ["diaphragm", "ANATOMY", 101, 110], ["limb muscle", "ANATOMY", 124, 135]]], ["One of these studies also suggested a difference in prognosis between the two conditions, as ICU-acquired weakness was more strongly associated with prolonged hospital stay and duration of mechanical ventilation, while diaphragm dysfunction was mostly associated with difficult/prolonged weaning and ICU and hospital mortality [13] .", [["diaphragm", "ANATOMY", 219, 228], ["weakness", "DISEASE", 106, 114], ["diaphragm dysfunction", "DISEASE", 219, 240], ["diaphragm", "ORGAN", 219, 228], ["these studies", "TEST", 7, 20], ["acquired weakness", "PROBLEM", 97, 114], ["mechanical ventilation", "TREATMENT", 189, 211], ["diaphragm dysfunction", "PROBLEM", 219, 240], ["mechanical ventilation", "OBSERVATION", 189, 211], ["diaphragm", "ANATOMY", 219, 228], ["dysfunction", "OBSERVATION", 229, 240]]], ["The present study reports novel findings in this context, suggesting that ICU-acquired weakness may be associated with a more severe impact on long-term outcome than diaphragm dysfunction.", [["diaphragm", "ANATOMY", 166, 175], ["weakness", "DISEASE", 87, 95], ["diaphragm dysfunction", "DISEASE", 166, 187], ["diaphragm", "ORGAN", 166, 175], ["The present study", "TEST", 0, 17], ["acquired weakness", "PROBLEM", 78, 95], ["a more severe impact on long-term outcome", "PROBLEM", 119, 160], ["diaphragm dysfunction", "PROBLEM", 166, 187], ["weakness", "OBSERVATION", 87, 95], ["severe", "OBSERVATION_MODIFIER", 126, 132], ["long-term", "OBSERVATION_MODIFIER", 143, 152], ["diaphragm", "ANATOMY", 166, 175], ["dysfunction", "OBSERVATION", 176, 187]]], ["The association of diaphragm dysfunction with longterm prognosis has never been previously investigated.", [["diaphragm", "ANATOMY", 19, 28], ["diaphragm dysfunction", "DISEASE", 19, 40], ["diaphragm", "ORGAN", 19, 28], ["diaphragm dysfunction", "PROBLEM", 19, 40], ["diaphragm", "ANATOMY", 19, 28], ["dysfunction", "OBSERVATION", 29, 40], ["longterm", "OBSERVATION_MODIFIER", 46, 54]]], ["One study investigated the impact of global respiratory weakness (as assessed by the maximal inspiratory pressure) and reported a higher 1-year mortality (31%) in the group of patients with low maximal inspiratory pressure compared to patients with high maximal inspiratory pressure, in whom the 1-year mortality was 7% [9] .", [["respiratory", "ANATOMY", 44, 55], ["respiratory weakness", "DISEASE", 44, 64], ["patients", "ORGANISM", 176, 184], ["patients", "ORGANISM", 235, 243], ["patients", "SPECIES", 176, 184], ["patients", "SPECIES", 235, 243], ["One study", "TEST", 0, 9], ["global respiratory weakness", "PROBLEM", 37, 64], ["the maximal inspiratory pressure", "TEST", 81, 113], ["low maximal inspiratory pressure", "PROBLEM", 190, 222], ["high maximal inspiratory pressure", "PROBLEM", 249, 282], ["global", "OBSERVATION_MODIFIER", 37, 43], ["respiratory weakness", "OBSERVATION", 44, 64], ["inspiratory pressure", "OBSERVATION", 202, 222], ["inspiratory pressure", "OBSERVATION", 262, 282]]], ["However, limb muscle strength was not analysed in this study.", [["limb muscle", "ANATOMY", 9, 20], ["limb muscle", "TISSUE", 9, 20], ["this study", "TEST", 50, 60], ["limb muscle", "ANATOMY", 9, 20]]], ["Our findings suggest that the long-term prognosis of these patients is mainly driven by the presence of ICUacquired weakness rather than diaphragm dysfunction.", [["diaphragm", "ANATOMY", 137, 146], ["weakness", "DISEASE", 116, 124], ["diaphragm dysfunction", "DISEASE", 137, 158], ["patients", "ORGANISM", 59, 67], ["diaphragm", "ORGAN", 137, 146], ["patients", "SPECIES", 59, 67], ["ICUacquired weakness", "PROBLEM", 104, 124], ["diaphragm dysfunction", "PROBLEM", 137, 158], ["long-term", "OBSERVATION_MODIFIER", 30, 39], ["weakness", "OBSERVATION", 116, 124], ["diaphragm", "ANATOMY", 137, 146], ["dysfunction", "OBSERVATION", 147, 158]]], ["Nevertheless, as expected, the co-existence of these two conditions was associated with a poor survival.", [["a poor survival", "PROBLEM", 88, 103]]], ["The presence of diaphragm dysfunction in critically ill patients has been associated with poor short-term prognosis in some studies [11, 13, 14, 28] , but not in others [29, 30] .DiscussionRemarkably, a recent study demonstrated that diaphragm dysfunction was not associated with an increased risk of extubation failure in patients who successfully passed the weaning trial [29] , which is in line with our findings, suggesting that diaphragm function is a critical determinant in the outcome of the weaning trial, but once patients have been weaned from the ventilator, the long-term prognosis is mainly determined by other risk factors, notably ICU-acquired weakness.DiscussionOur study also investigated the respective association of ICU-acquired weakness and diaphragm dysfunction with health-related quality of life and indicated that health-related quality of life was not significantly different 2 years after the ICU stay regardless of the presence or absence of diaphragm dysfunction or ICU-acquired weakness.", [["diaphragm", "ANATOMY", 16, 25], ["diaphragm", "ANATOMY", 234, 243], ["diaphragm", "ANATOMY", 433, 442], ["diaphragm", "ANATOMY", 763, 772], ["diaphragm", "ANATOMY", 971, 980], ["diaphragm dysfunction", "DISEASE", 16, 37], ["critically ill", "DISEASE", 41, 55], ["diaphragm dysfunction", "DISEASE", 234, 255], ["extubation failure", "DISEASE", 301, 319], ["weakness", "DISEASE", 750, 758], ["diaphragm dysfunction", "DISEASE", 763, 784], ["diaphragm dysfunction", "DISEASE", 971, 992], ["diaphragm", "ORGAN", 16, 25], ["patients", "ORGANISM", 56, 64], ["diaphragm", "ORGAN", 234, 243], ["patients", "ORGANISM", 323, 331], ["diaphragm", "ORGAN", 433, 442], ["patients", "ORGANISM", 524, 532], ["diaphragm", "ORGAN", 763, 772], ["diaphragm", "ORGAN", 971, 980], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 323, 331], ["patients", "SPECIES", 524, 532], ["diaphragm dysfunction", "PROBLEM", 16, 37], ["poor short-term prognosis", "PROBLEM", 90, 115], ["some studies", "TEST", 119, 131], ["a recent study", "TEST", 201, 215], ["diaphragm dysfunction", "PROBLEM", 234, 255], ["extubation failure", "PROBLEM", 301, 319], ["the weaning trial", "TREATMENT", 356, 373], ["the weaning trial", "TREATMENT", 496, 513], ["the ventilator", "TREATMENT", 555, 569], ["acquired weakness", "PROBLEM", 651, 668], ["DiscussionOur study", "TEST", 669, 688], ["acquired weakness", "PROBLEM", 741, 758], ["diaphragm dysfunction", "PROBLEM", 763, 784], ["diaphragm dysfunction", "PROBLEM", 971, 992], ["acquired weakness", "PROBLEM", 1000, 1017], ["diaphragm", "ANATOMY", 16, 25], ["dysfunction", "OBSERVATION", 26, 37], ["short-term prognosis", "OBSERVATION_MODIFIER", 95, 115], ["diaphragm", "ANATOMY", 234, 243], ["dysfunction", "OBSERVATION", 244, 255], ["not associated with", "UNCERTAINTY", 260, 279], ["increased", "OBSERVATION_MODIFIER", 283, 292], ["extubation failure", "OBSERVATION", 301, 319], ["diaphragm", "ANATOMY", 433, 442], ["weakness", "OBSERVATION", 660, 668], ["weakness", "OBSERVATION", 750, 758], ["diaphragm", "ANATOMY", 763, 772], ["dysfunction", "OBSERVATION", 773, 784], ["diaphragm", "ANATOMY", 971, 980], ["dysfunction", "OBSERVATION", 981, 992]]], ["These findings are in contrast with previous data reporting substantial impairments in physical function and health-related quality of life in acute lung injury survivors [31] .", [["lung", "ANATOMY", 149, 153], ["acute lung injury", "DISEASE", 143, 160], ["lung", "ORGAN", 149, 153], ["previous data", "TEST", 36, 49], ["substantial impairments in physical function", "PROBLEM", 60, 104], ["acute lung injury survivors", "PROBLEM", 143, 170], ["substantial", "OBSERVATION_MODIFIER", 60, 71], ["impairments", "OBSERVATION", 72, 83], ["acute", "OBSERVATION_MODIFIER", 143, 148], ["lung", "ANATOMY", 149, 153], ["injury", "OBSERVATION", 154, 160]]], ["This discrepancy may be explained by the timing of ICU-acquired weakness evaluation (after a few days of mechanical ventilation in our study as compared to 3 months after the acute lung injury in the study by Fan et al.) and the different period of time for both investigations (2014-2015 in our study versus 2004-2007 in the study by Fan et al.) [31] .", [["lung", "ANATOMY", 181, 185], ["lung injury", "DISEASE", 181, 192], ["lung", "ORGAN", 181, 185], ["acquired weakness evaluation", "PROBLEM", 55, 83], ["mechanical ventilation", "TREATMENT", 105, 127], ["our study", "TEST", 131, 140], ["the acute lung injury", "PROBLEM", 171, 192], ["the study", "TEST", 196, 205], ["may be explained", "UNCERTAINTY", 17, 33], ["acute", "OBSERVATION_MODIFIER", 175, 180], ["lung", "ANATOMY", 181, 185], ["injury", "OBSERVATION", 186, 192]]], ["Although not statistically significant, the SF-36 questionnaire score indicated better health-related quality of life in patients not presenting either of these two conditions.", [["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["the SF", "TEST", 40, 46], ["not", "UNCERTAINTY", 9, 12], ["statistically", "OBSERVATION_MODIFIER", 13, 26], ["significant", "OBSERVATION_MODIFIER", 27, 38]]], ["Importantly, this difference may be underestimated by the competitive risk of death.", [["death", "DISEASE", 78, 83], ["death", "PROBLEM", 78, 83]]], ["The findings of this study could possibly be explained by a lack of power, but they could also be the consequence of self-adaptive quality of life perception [32] .", [["this study", "TEST", 16, 26]]], ["Eventually, the findings on SF-36 questionnaire should be considered as an exploratory analysis according to the sample size and warrant further studies.Strengths and limitationsThe main strength of our study is the phrenic nerve stimulation that was used to evaluate diaphragm function, and this method is considered to be the reference method in the ICU.", [["phrenic nerve", "ANATOMY", 216, 229], ["diaphragm", "ANATOMY", 268, 277], ["phrenic nerve", "MULTI-TISSUE_STRUCTURE", 216, 229], ["diaphragm", "ORGAN", 268, 277], ["SF", "TEST", 28, 30], ["an exploratory analysis", "TEST", 72, 95], ["the sample size", "TEST", 109, 124], ["further studies", "TEST", 137, 152], ["our study", "TEST", 199, 208], ["the phrenic nerve stimulation", "TREATMENT", 212, 241], ["main", "OBSERVATION_MODIFIER", 182, 186], ["strength", "OBSERVATION_MODIFIER", 187, 195], ["phrenic nerve", "ANATOMY", 216, 229], ["diaphragm", "ANATOMY", 268, 277]]], ["In addition, our study provides insight into the association of diaphragm dysfunction and ICUacquired weakness with survival and quality of life over a long period of time after the ICU stay.", [["diaphragm", "ANATOMY", 64, 73], ["diaphragm dysfunction", "DISEASE", 64, 85], ["ICUacquired weakness", "DISEASE", 90, 110], ["diaphragm", "ORGAN", 64, 73], ["our study", "TEST", 13, 22], ["diaphragm dysfunction", "PROBLEM", 64, 85], ["ICUacquired weakness", "PROBLEM", 90, 110], ["survival", "TREATMENT", 116, 124], ["diaphragm", "ANATOMY", 64, 73], ["dysfunction", "OBSERVATION", 74, 85]]], ["The first and main limitation concerns the small sample size finally analysed.", [["the small sample size", "PROBLEM", 39, 60], ["main", "OBSERVATION_MODIFIER", 14, 18], ["small", "OBSERVATION_MODIFIER", 43, 48], ["sample", "OBSERVATION_MODIFIER", 49, 55], ["size", "OBSERVATION_MODIFIER", 56, 60]]], ["Indeed, this is a cohort study with a significant risk of confounding and relatively small event rates.", [["a cohort study", "TEST", 16, 30], ["relatively small event rates", "PROBLEM", 74, 102], ["small", "OBSERVATION_MODIFIER", 85, 90]]], ["As such the statistical analyses do not adjust for potential confounding and explore simple associations.", [["the statistical analyses", "TEST", 8, 32]]], ["Our findings must therefore be interpreted cautiously and larger studies are warranted.", [["larger studies", "TEST", 58, 72]]], ["Secondly, diaphragm function and limb muscle strength were not repeatedly assessed in our study.", [["diaphragm", "ANATOMY", 10, 19], ["limb muscle", "ANATOMY", 33, 44], ["diaphragm", "ORGAN", 10, 19], ["limb muscle", "MULTI-TISSUE_STRUCTURE", 33, 44], ["our study", "TEST", 86, 95], ["diaphragm", "ANATOMY", 10, 19], ["limb muscle", "ANATOMY", 33, 44]]], ["Consequently, the findings in terms of survival and quality of life could not be correlated with possible recovery of either diaphragm function or limb muscle strength.", [["diaphragm", "ANATOMY", 125, 134], ["limb muscle", "ANATOMY", 147, 158], ["diaphragm", "ORGAN", 125, 134], ["limb muscle", "ORGANISM_SUBDIVISION", 147, 158], ["diaphragm", "ANATOMY", 125, 134], ["limb muscle", "ANATOMY", 147, 158]]], ["Thirdly, ICU-acquired weakness was assessed with MRC score that relies on the cooperation of the patients.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["acquired weakness", "PROBLEM", 13, 30], ["MRC score", "TEST", 49, 58], ["weakness", "OBSERVATION", 22, 30]]], ["Therefore, even if patients were confirmed awake, it is a volitional measurement that may be associated with a ceiling effect and poor responsiveness.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["a volitional measurement", "TEST", 56, 80], ["a ceiling effect", "PROBLEM", 109, 125], ["poor responsiveness", "PROBLEM", 130, 149]]], ["Fourthly, due to small size of the cohort, competing risk of death could not be take into account which may have created a bias in the assessment of health care quality of life.ConclusionAt the time of starting the process of weaning from mechanical ventilation, diaphragm dysfunction and ICU-acquired weakness were associated with distinct outcomes.", [["diaphragm", "ANATOMY", 263, 272], ["death", "DISEASE", 61, 66], ["diaphragm dysfunction", "DISEASE", 263, 284], ["weakness", "DISEASE", 302, 310], ["diaphragm", "MULTI-TISSUE_STRUCTURE", 263, 272], ["death", "PROBLEM", 61, 66], ["the assessment", "TEST", 131, 145], ["mechanical ventilation", "TREATMENT", 239, 261], ["diaphragm dysfunction", "PROBLEM", 263, 284], ["acquired weakness", "PROBLEM", 293, 310], ["small", "OBSERVATION_MODIFIER", 17, 22], ["size", "OBSERVATION_MODIFIER", 23, 27], ["mechanical ventilation", "OBSERVATION", 239, 261], ["diaphragm", "ANATOMY", 263, 272], ["dysfunction", "OBSERVATION", 273, 284]]], ["ICU-acquired weakness was associated with a poorer 2-year survival of critically ill patients than diaphragm dysfunction, whereas the presence of diaphragm dysfunction appears to be more likely a determinant of early prognosis.", [["diaphragm", "ANATOMY", 99, 108], ["diaphragm", "ANATOMY", 146, 155], ["weakness", "DISEASE", 13, 21], ["critically ill", "DISEASE", 70, 84], ["diaphragm dysfunction", "DISEASE", 99, 120], ["diaphragm dysfunction", "DISEASE", 146, 167], ["patients", "ORGANISM", 85, 93], ["diaphragm", "ORGAN", 99, 108], ["diaphragm", "ORGAN", 146, 155], ["patients", "SPECIES", 85, 93], ["acquired weakness", "PROBLEM", 4, 21], ["diaphragm dysfunction", "PROBLEM", 99, 120], ["diaphragm dysfunction", "PROBLEM", 146, 167], ["weakness", "OBSERVATION", 13, 21], ["critically ill", "OBSERVATION_MODIFIER", 70, 84], ["diaphragm", "ANATOMY", 99, 108], ["dysfunction", "OBSERVATION", 109, 120], ["diaphragm", "ANATOMY", 146, 155], ["dysfunction", "OBSERVATION", 156, 167], ["appears to be more likely", "UNCERTAINTY", 168, 193]]], ["Eventually, the co-existence of both diseases was associated with the worse outcome.Supplementary informationSupplementary information accompanies this paper at https ://doi. org/10.1186/s1361 3-019-0618-4.Supplementary informationAdditional file 1: Figure S1 .", [["both diseases", "PROBLEM", 32, 45], ["both", "OBSERVATION_MODIFIER", 32, 36], ["diseases", "OBSERVATION", 37, 45]]], ["Kaplan-Meier two-year survival curves in patients with diaphragm dysfunction, intensive care unit-acquired weakness (ICU-AW), no disease or both diseases.", [["diaphragm", "ANATOMY", 55, 64], ["diaphragm dysfunction", "DISEASE", 55, 76], ["patients", "ORGANISM", 41, 49], ["diaphragm", "ORGAN", 55, 64], ["patients", "SPECIES", 41, 49], ["survival curves", "TEST", 22, 37], ["diaphragm dysfunction", "PROBLEM", 55, 76], ["acquired weakness", "PROBLEM", 98, 115], ["disease", "PROBLEM", 129, 136], ["both diseases", "PROBLEM", 140, 153], ["diaphragm", "ANATOMY", 55, 64], ["dysfunction", "OBSERVATION", 65, 76], ["weakness", "OBSERVATION", 107, 115], ["no", "UNCERTAINTY", 126, 128], ["disease", "OBSERVATION", 129, 136], ["both", "OBSERVATION_MODIFIER", 140, 144], ["diseases", "OBSERVATION", 145, 153]]], ["Kaplan-Meier twoyear survival curves in patients with diaphragm dysfunction, intensive care unit-acquired weakness (ICU-AW), no disease or both (sensitivity analysis restricted to hospital survivors).", [["diaphragm", "ANATOMY", 54, 63], ["diaphragm dysfunction", "DISEASE", 54, 75], ["patients", "ORGANISM", 40, 48], ["diaphragm", "ORGAN", 54, 63], ["patients", "SPECIES", 40, 48], ["diaphragm dysfunction", "PROBLEM", 54, 75], ["acquired weakness", "PROBLEM", 97, 114], ["disease", "PROBLEM", 128, 135], ["sensitivity analysis", "TEST", 145, 165], ["diaphragm", "ANATOMY", 54, 63], ["dysfunction", "OBSERVATION", 64, 75], ["no", "UNCERTAINTY", 125, 127], ["disease", "OBSERVATION", 128, 135]]], ["Kaplan-Meier two-year survival curves in patients with and without severe diaphragm dysfunction as defined by a change in tracheal pressure in response to magnetic stimulation < 7 cmH2O.", [["diaphragm", "ANATOMY", 74, 83], ["tracheal", "ANATOMY", 122, 130], ["diaphragm dysfunction", "DISEASE", 74, 95], ["patients", "ORGANISM", 41, 49], ["diaphragm", "ORGAN", 74, 83], ["tracheal", "ORGAN", 122, 130], ["patients", "SPECIES", 41, 49], ["survival curves", "TEST", 22, 37], ["severe diaphragm dysfunction", "PROBLEM", 67, 95], ["a change in tracheal pressure", "PROBLEM", 110, 139], ["magnetic stimulation", "TEST", 155, 175], ["diaphragm", "ANATOMY", 74, 83], ["dysfunction", "OBSERVATION", 84, 95], ["tracheal", "ANATOMY", 122, 130], ["pressure", "OBSERVATION_MODIFIER", 131, 139]]], ["SF-36 physical component scores at two years among patients with diaphragm dysfunction only, with intensive care unit acquired weakness only, with none of the diseases and with both diseases (panel A) and SF-36 mental component scores among patients with diaphragm dysfunction only, with intensive care unit acquired weakness only, with none of the diseases and with both diseases (panel B) (n = 40 patients).AbbreviationsPtr,stim: tracheal pressure in response to bilateral magnetic stimulation of the phrenic nerves; ICU: intensive care unit; HRQOL: health-related quality of life; SF-36: Short Form (36) Health Survey.", [["diaphragm", "ANATOMY", 65, 74], ["diaphragm", "ANATOMY", 255, 264], ["tracheal", "ANATOMY", 432, 440], ["phrenic nerves", "ANATOMY", 503, 517], ["diaphragm dysfunction", "DISEASE", 65, 86], ["weakness", "DISEASE", 127, 135], ["diaphragm dysfunction", "DISEASE", 255, 276], ["weakness", "DISEASE", 317, 325], ["patients", "ORGANISM", 51, 59], ["diaphragm", "ORGAN", 65, 74], ["patients", "ORGANISM", 241, 249], ["diaphragm", "ORGAN", 255, 264], ["patients", "ORGANISM", 399, 407], ["tracheal", "MULTI-TISSUE_STRUCTURE", 432, 440], ["phrenic nerves", "MULTI-TISSUE_STRUCTURE", 503, 517], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 241, 249], ["patients", "SPECIES", 399, 407], ["diaphragm dysfunction", "PROBLEM", 65, 86], ["acquired weakness", "PROBLEM", 118, 135], ["the diseases", "PROBLEM", 155, 167], ["both diseases (panel A) and SF-36 mental component scores", "PROBLEM", 177, 234], ["diaphragm dysfunction", "PROBLEM", 255, 276], ["acquired weakness", "PROBLEM", 308, 325], ["the diseases", "PROBLEM", 345, 357], ["both diseases", "PROBLEM", 367, 380], ["tracheal pressure", "TEST", 432, 449], ["bilateral magnetic stimulation", "TREATMENT", 465, 495], ["diaphragm", "ANATOMY", 65, 74], ["dysfunction", "OBSERVATION", 75, 86], ["weakness", "OBSERVATION", 127, 135], ["diseases", "OBSERVATION", 159, 167], ["diaphragm", "ANATOMY", 255, 264], ["dysfunction", "OBSERVATION", 265, 276], ["weakness", "OBSERVATION", 317, 325], ["diseases", "OBSERVATION", 349, 357], ["tracheal", "ANATOMY", 432, 440], ["phrenic nerves", "ANATOMY", 503, 517]]]], "65a29504e9fb777dea5b6642112095999a8892ec": [["Initial phases were improved by mutation of the sequence to poly-Ala followed by \"atoms update and refinement\" mode of ARP/wARP (Perrakis et al., 2001) .", [["poly-Ala", "CHEMICAL", 60, 68], ["poly-Ala", "CHEMICAL", 60, 68], ["poly-Ala", "SIMPLE_CHEMICAL", 60, 68], ["ARP", "PROTEIN", 119, 122], ["wARP", "PROTEIN", 123, 127]]], ["Symmetry operators were applied to the first monomer to create the two trimers.", [["Symmetry operators", "TREATMENT", 0, 18]]], ["The structure was refined with iterative cycles of manual model-building using COOT (Emsley and Cowtan, 2004) , restrained refinement with REFMAC5 (Murshudov et al., 1997) and density improvement with ARP/wARP as the correct sequence was gradually built into the improving electron density maps.", [["ARP", "PROTEIN", 201, 204], ["wARP", "PROTEIN", 205, 209], ["iterative cycles", "TREATMENT", 31, 47], ["ARP/wARP", "TREATMENT", 201, 209]]], ["Data collection and final refinement statistics are summarised in Table 1 .Small angle X-ray scattering experiments and data analysisSmall angle X-ray scattering (SAXS) data of UspA1 and the N-CEACAM1/UspA1 (527-665) complex were collected on beamline X33 at the European Molecular Biology Laboratory (EMBL) of the Deutsches Elektronen Synchrotron (DESY, Hamburg, Germany) at a wavelength of \u03bb = 0.15 nm.", [["UspA1", "GENE_OR_GENE_PRODUCT", 177, 182], ["N-CEACAM1", "GENE_OR_GENE_PRODUCT", 191, 200], ["UspA1", "PROTEIN", 177, 182], ["N-CEACAM1", "PROTEIN", 191, 200], ["UspA1", "PROTEIN", 201, 206], ["527-665) complex", "PROTEIN", 208, 224], ["Data collection", "TEST", 0, 15], ["Small angle X-ray scattering experiments", "TEST", 75, 115], ["data analysis", "TEST", 120, 133], ["Small angle X-ray scattering", "TEST", 133, 161], ["UspA1", "TEST", 177, 182], ["the N-CEACAM1/UspA1", "TEST", 187, 206], ["angle", "OBSERVATION_MODIFIER", 81, 86], ["Small", "OBSERVATION_MODIFIER", 133, 138], ["angle", "OBSERVATION_MODIFIER", 139, 144]]], ["The sample to detector distance was 2.4 m, covering a scattering range of 0.16 nm -1 < q < 4.85 nm -1 (q = 4\u03c0 sin\u03b8/\u03bb, where 2\u03b8 is the scattering vector).", [["nm", "TEST", 96, 98], ["sin\u03b8/\u03bb", "TEST", 110, 116]]], ["Samples of the complex at concentrations of 2, 5 and 10 mg/ml were exposed for 60s.", [["Samples", "ANATOMY", 0, 7]]], ["Images were integrated and corrected for background buffer scattering using in-house software at station X33 and then merged using PRIMUS (Konarev, 2003) .", [["Images", "TEST", 0, 6]]], ["The particle distance distribution function, p(r), and the radius of gyration, Rg, were calculated using GNOM (Semenyuk and Svergun, 1991) The shape of the protein was evaluated using DAMMIN (Svergun, 1999) .", [["particle", "OBSERVATION_MODIFIER", 4, 12], ["radius", "ANATOMY_MODIFIER", 59, 65], ["shape", "OBSERVATION_MODIFIER", 143, 148]]], ["Twenty four reconstructions of the N-CEACAM1/UspA1 (527-665) complex were generated and the resulting structures were filtered and averaged in DAMAVER .Molecular modellingN-CEACAM1 was manually docked into its putative binding site (the hydrophobic patch identified from the crystal structure) on UspA1 (527-665) using guidance from the mutational data of both components and visual inspection of shape complementarity.", [["N-CEACAM1", "GENE_OR_GENE_PRODUCT", 35, 44], ["N-CEACAM1", "PROTEIN", 35, 44], ["UspA1", "PROTEIN", 45, 50], ["527-665) complex", "PROTEIN", 52, 68], ["DAMAVER", "PROTEIN", 143, 150], ["modellingN-CEACAM1", "PROTEIN", 162, 180], ["putative binding site", "DNA", 210, 231], ["the N-CEACAM1/UspA1", "TEST", 31, 50], ["Molecular modellingN-CEACAM1", "PROBLEM", 152, 180], ["the hydrophobic patch", "TREATMENT", 233, 254], ["the mutational data", "TEST", 333, 352], ["visual inspection", "TEST", 376, 393], ["putative binding site", "OBSERVATION", 210, 231], ["hydrophobic", "OBSERVATION_MODIFIER", 237, 248], ["crystal", "OBSERVATION_MODIFIER", 275, 282], ["shape complementarity", "OBSERVATION", 397, 418]]], ["This model complex was then soaked with a 5 \u00c5 layer of water and relaxed with 2000 steps of conjugate gradient energy minimisation and the CVFF forcefield.", [["water", "SIMPLE_CHEMICAL", 55, 60], ["a 5 \u00c5 layer of water", "TREATMENT", 40, 60], ["conjugate gradient energy minimisation", "TREATMENT", 92, 130], ["the CVFF forcefield", "TREATMENT", 135, 154], ["complex", "OBSERVATION_MODIFIER", 11, 18]]], ["Multiple 0.1 ns molecular dynamics simulations of UspA1 -with none, one and two N-CEACAM1s bound -were performed at 300 K under 12 different initial random velocities to investigate possible bending of the coiled-coil.", [["UspA1", "SIMPLE_CHEMICAL", 50, 55], ["UspA1", "PROTEIN", 50, 55], ["N-CEACAM1s", "PROTEIN", 80, 90], ["coiled-coil", "PROTEIN", 206, 217], ["UspA1", "TEST", 50, 55], ["the coiled-coil", "TREATMENT", 202, 217], ["coiled", "OBSERVATION", 206, 212]]], ["InsightII 2005/ Discover 2.98 (Accelrys) were used to view, manipulate molecules and for the molecular mechanics calculations.Electron microscopyBacterial cells were disrupted with 0.5mm glass beads at 48000 oscillations per minute for 30 sec in a mini-bead beater\u2122 (Biospec Products Inc. OK, USA).", [["microscopyBacterial cells", "ANATOMY", 135, 160], ["microscopyBacterial cells", "CELL", 135, 160], ["microscopyBacterial cells", "CELL_TYPE", 135, 160], ["the molecular mechanics calculations", "TEST", 89, 125], ["Electron microscopyBacterial cells", "PROBLEM", 126, 160], ["0.5mm glass beads", "TREATMENT", 181, 198], ["microscopyBacterial cells", "OBSERVATION", 135, 160]]], ["Unruptured bacteria were removed by centrifugation (2500g, 5 min), bacterial membranes were collected by ultracentrifugation (30,000g, 30 min at 4 o C) and suspended in PBS.", [["membranes", "ANATOMY", 77, 86], ["Unruptured bacteria", "PROBLEM", 0, 19], ["bacterial membranes", "PROBLEM", 67, 86], ["bacteria", "OBSERVATION", 11, 19], ["bacterial membranes", "ANATOMY", 67, 86]]], ["Samples (5 \u00b5l) of envelopes, either native or pre-incubated with N-CEACAM1 (2.5 ng/ml) were applied to glow-discharged collodion coated copper grids.", [["Samples", "ANATOMY", 0, 7], ["copper", "CHEMICAL", 136, 142], ["copper", "CHEMICAL", 136, 142], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 67, 74], ["copper grids", "SIMPLE_CHEMICAL", 136, 148], ["N-CEACAM1", "PROTEIN", 65, 74], ["Samples", "TEST", 0, 7], ["envelopes", "PROBLEM", 18, 27], ["N-CEACAM1", "TREATMENT", 65, 74], ["collodion coated copper grids", "TREATMENT", 119, 148]]], ["The grids were then washed by placing face down on two consecutive drops of sterile filtered water and negatively stained using 1% methylamine tungstate.", [["methylamine tungstate", "CHEMICAL", 131, 152], ["methylamine tungstate", "CHEMICAL", 131, 152], ["methylamine tungstate", "SIMPLE_CHEMICAL", 131, 152], ["sterile filtered water", "TREATMENT", 76, 98], ["1% methylamine tungstate", "TREATMENT", 128, 152]]], ["Images were recorded at 39,000 x magnification on Kodak 4489 film with the first zero of the contrast transfer function in the range 20 -25\u00c5.", [["Images", "TEST", 0, 6], ["Kodak", "TEST", 50, 55]]]], "2a0e063bded9ae87e9862bdcad4ca234fe14b22f": [["IntroductionThe COVID-19 pandemic has strongly affected many persons, either for medical reasons or for the economic aftermath of the various prophylactic measures decided by governments, in particular lockdowns.", [["persons", "ORGANISM", 61, 68], ["persons", "SPECIES", 61, 68], ["the various prophylactic measures", "TREATMENT", 130, 163]]], ["The evolution of financial markets during the pandemic provides an illustration of the economic impact of these measures.", [["financial markets", "TREATMENT", 17, 34], ["these measures", "TREATMENT", 106, 120]]], ["According to several empirical studies, financial markets have indeed been strongly disturbed during this period [3, 5, 34, 62] .", [["several empirical studies", "TEST", 13, 38]]], ["The question of the reaction of financial markets to a crisis is not specific to the COVID-19 pandemic.", [["the reaction", "PROBLEM", 16, 28], ["a crisis", "PROBLEM", 53, 61], ["the COVID", "TEST", 81, 90], ["pandemic", "PROBLEM", 94, 102]]], ["For example, we can cite a study of the impact of crisis in the 80s and the 90s on a model of dynamic for a stock market [18] .", [["a study", "TEST", 25, 32], ["crisis", "PROBLEM", 50, 56]]], ["In general, these studies focus on variations of several statistics, such as jump intensity, implied volatility, parameters of factor models, divergence of price return densities, etc. To the best of our knowledge, no paper focuses on measuring the impact of the COVID-19 pandemic on market efficiency.IntroductionMarket efficiency is the ability of market prices to reflect all the available information, so that no arbitrage is possible.", [["these studies", "TEST", 12, 25], ["factor models", "PROBLEM", 127, 140], ["the COVID", "TEST", 259, 268], ["volatility", "OBSERVATION_MODIFIER", 101, 111], ["densities", "OBSERVATION", 169, 178]]], ["Even if this dogma is sometimes questionable in calm periods, we wonder if it can resist to a crisis.", [["a crisis", "PROBLEM", 92, 100]]], ["We also wonder if we can observe regional disparities, hypothetically related to the magnitude of the outbreak in these regions, and how fast financial markets recover.IntroductionThe Hurst exponent is a widespread indicator of market efficiency.", [["market efficiency", "PROBLEM", 228, 245], ["Hurst exponent", "OBSERVATION_MODIFIER", 184, 198], ["widespread", "OBSERVATION_MODIFIER", 204, 214], ["market efficiency", "OBSERVATION", 228, 245]]], ["The long-range feature associated to a Hurst exponent above 1/2 is indeed traditionally interpreted as indicating predictability of a time series.", [["a Hurst exponent", "PROBLEM", 37, 53], ["long-range", "OBSERVATION_MODIFIER", 4, 14]]], ["It is often related to a model of dynamic with a specific fractal property, namely the fractional Brownian motion (fBm), introduced by Mandelbrot and van Ness [54] .", [["Brownian motion", "OBSERVATION", 98, 113]]], ["The fractal property states that the variance of increments of duration \u03c4 is \u03c4 2H \u03c3 2 , where H is the Hurst exponent and \u03c3 2 the variance of increments of duration 1.", [["fractal property", "OBSERVATION", 4, 20]]], ["The fBm assumes that increments follow a Gaussian distribution.", [["fBm", "PROTEIN", 4, 7], ["Gaussian distribution", "OBSERVATION", 41, 62]]], ["The fractal property of the fBm is then obtained by introducing a positive (respectively negative) correlation among increments if the Hurst exponent is above (resp. below) 1/2.", [["fBm", "GENE_OR_GENE_PRODUCT", 28, 31], ["fBm", "DNA", 28, 31], ["fractal", "OBSERVATION", 4, 11], ["fBm", "ANATOMY", 28, 31]]], ["In the case where the Hurst exponent is 1/2, the fBm is simply a standard Brownian motion (Bm), that is with independent increments.", [["fBm", "DNA", 49, 52], ["Brownian motion", "OBSERVATION", 74, 89]]], ["In the fBm framework, this value of the Hurst exponent is thus the only one consistent with the efficient market hypothesis (EMH).IntroductionHowever, the approach using the fBm assumes Gaussian price returns.", [["fBm", "DNA", 174, 177]]], ["It is not very realistic, since the presence of fat tails in the distribution of price returns is well documented [48, 60, 29] .", [["fat", "ANATOMY", 48, 51], ["fat", "TISSUE", 48, 51], ["not", "UNCERTAINTY", 6, 9], ["very", "OBSERVATION_MODIFIER", 10, 14], ["realistic", "OBSERVATION", 15, 24], ["fat tails", "OBSERVATION", 48, 57], ["distribution", "OBSERVATION_MODIFIER", 65, 77]]], ["As an alternative to the Gaussian distribution, the alpha-stable distribution is appealing because it includes the Gaussian distribution as a particular case and entails fat tails, whose amplitude is directly related to \u03b1, a parameter of this distribution.", [["fat tails", "ANATOMY", 170, 179], ["fat", "TISSUE", 170, 173], ["\u03b1", "GENE_OR_GENE_PRODUCT", 220, 221], ["\u03b1", "PROTEIN", 220, 221], ["the alpha-stable distribution", "PROBLEM", 48, 77], ["Gaussian distribution", "OBSERVATION", 115, 136]]], ["When combining alpha-stable distributions and dependence between the successive price returns, we can get the fractional L\u00e9vy-stable motion (fLsm), which is thus a non-Gaussian extension of the fBm [70, 73, 71] .", [["combining alpha-stable distributions", "PROBLEM", 5, 41], ["the fractional L\u00e9vy", "TEST", 106, 125], ["dependence", "OBSERVATION_MODIFIER", 46, 56], ["stable", "OBSERVATION_MODIFIER", 126, 132]]], ["We thus use this memory parameter as an alternative efficiency indicator.IntroductionThe estimation of the fLsm partly relies on the estimation of alpha-stable distributions.", [["fLsm", "GENE_OR_GENE_PRODUCT", 107, 111], ["fLsm", "DNA", 107, 111], ["this memory parameter", "TREATMENT", 12, 33]]], ["In particular, we will focus on McCulloch's method, which is based on empirical quantiles [55] .", [["McCulloch's method", "TREATMENT", 32, 50]]], ["In this paper, we are in addition interested in the dynamic estimation of this distribution, because we want to depict the chronology of the crisis, day after day.", [["crisis", "OBSERVATION", 141, 147]]], ["The case of parametric densities is simpler as it consists in estimating timevarying parameters.", [["parametric densities", "PROBLEM", 12, 32], ["parametric densities", "OBSERVATION", 12, 32]]], ["The balance between the previous estimation and the new observation is tuned by a discount factor.", [["discount factor", "PROTEIN", 82, 97], ["the previous estimation", "TEST", 20, 43], ["balance", "OBSERVATION", 4, 11]]], ["We focus on the minimization of a criterion related to arguments coming from the field of validation of density forecast [34, 22] .IntroductionIn the empirical part of the paper, we study the evolution of the two indicators of market efficiency, H and m for several stock indices, with a significance analysis.", [["a significance analysis", "TEST", 286, 309]]], ["We have discovered that the Hurst exponent H detects less often a market inefficiency than does the memory parameter m of an fLsm.", [["fLsm", "GENE_OR_GENE_PRODUCT", 125, 129], ["an fLsm", "PROBLEM", 122, 129]]], ["We foster the use of this parameter as efficiency indicator instead of the Hurst exponent.", [["this parameter", "TREATMENT", 21, 35]]], ["It indeed improves the standard Hurst approach insofar as it filters the kurtosis of price returns, which biases the Hurst indicator.IntroductionBesides the analysis of the impact of the COVID-19 on market efficiency, the innovative aspects of this paper include a selection rule for the discount factor of a dynamic parametric distribution, an estimation method of dynamic Hurst exponents, and the introduction of the memory parameter of an fLsm as efficiency indicator.IntroductionThe rest of the paper is organized as follows.", [["fLsm", "GENE_OR_GENE_PRODUCT", 442, 446], ["COVID-19", "DNA", 187, 195], ["discount factor", "PROTEIN", 288, 303], ["fLsm", "PROTEIN", 442, 446], ["the analysis", "TEST", 153, 165], ["the COVID", "TREATMENT", 183, 192], ["dynamic Hurst exponents", "PROBLEM", 366, 389]]], ["Section 2 introduces the estimation of dynamic alpha-stable distributions, along with the selection rule of the discount factor.", [["discount factor", "PROTEIN", 112, 127]]], ["Section 4 empirically studies the impact of COVID-19 on market efficiency.", [["COVID", "TEST", 44, 49]]], ["Section 5 concludes.Alpha-stable distributionsThe alpha-stable distribution is a generalization of the Gaussian distribution, appreciated for entailing fat tails.", [["fat tails", "ANATOMY", 152, 161], ["fat", "TISSUE", 152, 155], ["Alpha", "TEST", 20, 25], ["stable", "OBSERVATION_MODIFIER", 26, 32], ["distributions", "OBSERVATION_MODIFIER", 33, 46], ["alpha-stable", "OBSERVATION_MODIFIER", 50, 62], ["distribution", "OBSERVATION_MODIFIER", 63, 75], ["generalization", "OBSERVATION_MODIFIER", 81, 95], ["Gaussian distribution", "OBSERVATION", 103, 124]]], ["For this reason, it has been widely invoked in signal processing [69, 32, 33] , with applications for example in medicine [68, 71] or in finance [48, 60, 29] .Alpha-stable distributionsWe present below the estimation of a time-varying alpha-stable distribution, which we will apply later in this paper to financial time series.", [["Alpha", "TEST", 159, 164], ["stable", "OBSERVATION_MODIFIER", 165, 171], ["distributions", "OBSERVATION_MODIFIER", 172, 185]]], ["For this purpose, we present first the static estimation as well as the various representations of alpha-stable distributions.", [["the static estimation", "TEST", 35, 56], ["alpha-stable distributions", "PROBLEM", 99, 125], ["alpha-stable distributions", "OBSERVATION", 99, 125]]], ["Regarding the dynamic distribution, a free parameter is to be selected.", [["dynamic distribution", "OBSERVATION", 14, 34]]], ["It is the discount factor.", [["discount factor", "PROTEIN", 10, 25]]], ["We propose a rule of selection in the last subsection.RepresentationFour parameters are used to depict a random variable following a stable distribution: X \u223c S \u03b1 (\u03b3, \u03b2, \u00b5).", [["X \u223c S \u03b1", "CELL_LINE", 154, 161], ["\u03b3, \u03b2, \u00b5", "CELL_LINE", 163, 170], ["stable", "OBSERVATION_MODIFIER", 133, 139]]], ["It determines the thickness of the tails.", [["thickness", "OBSERVATION_MODIFIER", 18, 27], ["tails", "ANATOMY_MODIFIER", 35, 40]]], ["If \u03b1 = 2 and \u03b2 = 0, we retrieve the Gaussian distribution.", [["\u03b1", "TEST", 3, 4], ["Gaussian distribution", "OBSERVATION", 36, 57]]], ["The last two parameters stand for the location (\u00b5 \u2208 R) and the scale (\u03b3 > 0) of the distribution.", [["the scale", "TEST", 59, 68]]], ["We do not have any analytic expression for the probability density of X, but we can characterize the stable distribution by the mean of its characteristic function:RepresentationWe could use the Fourier transform to get the pdf from the characteristic function [68] , but the above parameterization is not totally satisfactory insofar as the pdf is not continuous in the parameters, in particular when \u03b1 = 1 [59, 2] .", [["the Fourier transform", "TREATMENT", 191, 212], ["stable", "OBSERVATION_MODIFIER", 101, 107]]], ["Indeed, when \u03b2 > 0, the density is shifted right when \u03b1 < 1 and left when \u03b1 > 1, with a shift toward +\u221e (respectively \u2212\u221e) when \u03b1 tends toward 1 by below (resp. above) [59] .", [["\u03b1", "PROTEIN", 127, 128], ["density", "OBSERVATION", 24, 31], ["shifted", "OBSERVATION_MODIFIER", 35, 42], ["right", "ANATOMY_MODIFIER", 43, 48], ["left", "ANATOMY_MODIFIER", 64, 68]]], ["For this reason, Nolan has proposed to use Zolotarev's (M) parameterization [76] , which is also often called the S 0 parameterization.", [["Zolotarev's", "TREATMENT", 43, 54]]], ["The characteristic function corresponding to X \u223c S 0 \u03b1 (\u03b3, \u03b2, \u00b5 0 ) is [59, 2] :Representation(1) This alternative parameterization is not far from the S \u03b1 one.", [["The characteristic function", "TEST", 0, 27], ["S", "TEST", 49, 50], ["\u03b1", "TEST", 53, 54], ["\u03b3", "TEST", 56, 57], ["\u03b2", "TEST", 59, 60]]], ["The only difference is about the location parameter, which, in this new setting, corrects the shift exposed above for values of \u03b1 close to 1:RepresentationA Fourier transform makes it possible to get the pdf of a standard variable S 0 \u03b1 (1, \u03b2, 0) [59] :RepresentationWe also obtain the pdf of a variable X \u223c S 0 \u03b1 (\u03b3, \u03b2, \u00b5 0 ) with \u03b3 = 1 and \u00b5 0 = 0, by the mean of a translation, a scaling, and the substitution s = \u03b3t, starting from the characteristic function provided in equation (1):RepresentationThe formula of p contains an integral on an unbounded interval.", [["\u03b2", "PROTEIN", 318, 319], ["a standard variable S", "TEST", 211, 232], ["the pdf", "TEST", 282, 289], ["a variable X \u223c S", "TEST", 293, 309], ["\u03b3", "TEST", 315, 316], ["\u03b2", "TEST", 318, 319], ["\u03b3", "TEST", 332, 333], ["a scaling", "PROBLEM", 381, 390], ["the substitution s", "TEST", 396, 414], ["\u03b3t", "TEST", 417, 419], ["difference", "OBSERVATION_MODIFIER", 9, 19]]], ["However, in the application to financial series, we find values of \u03b1 far from 0, so that the truncated integral converges rapidly.", [["\u03b1", "PROTEIN", 67, 68], ["financial series", "TEST", 31, 47]]], ["We also get the corresponding cdf by numerically integrating f (x; \u03b1, \u03b3, \u03b2, \u00b5 0 ).EstimationMany estimation methods of stable distributions exist [2, 12] .", [["cdf", "DNA", 30, 33], ["stable", "OBSERVATION_MODIFIER", 119, 125]]], ["Some of them focus on the sole \u03b1 parameter, using for instance a regression of extreme quantiles along with the extreme value theory [37] .", [["extreme quantiles", "PROBLEM", 79, 96]]], ["In this class of methods, we can cite the estimation using L-moments, provided that \u03b1 > 1 [2, 39] , empirical quantiles [55] , the empirical characteristic function [66, 61, 45, 44, 71] , and the maximum likelihood method [23] .", [["the empirical characteristic function", "TEST", 127, 164]]], ["This last method relies on the knowledge of the pdf, which may be approximated as exposed in the previous subsection, using Nolan's work [59] .EstimationWe focus on the method using empirical quantiles, which has been introduced first by Fama and Roll, with the following assumptions: \u03b1 > 1, \u03b2 = 0, and \u00b5 = 0 [26] .", [["pdf", "GENE_OR_GENE_PRODUCT", 48, 51], ["pdf", "DNA", 48, 51], ["empirical quantiles", "TREATMENT", 182, 201], ["\u00b5", "TEST", 303, 304], ["may be", "UNCERTAINTY", 59, 65]]], ["This version is also less restrictive with respect to the parameters, insofar as it only requires to have \u03b1 \u2265 0.6.EstimationThe McCulloch's method consists in linking the four parameters to five empirical quantiles of probability levels 5%, 25%, 50%, 75%, and 95%.", [["Estimation", "TEST", 114, 124], ["The McCulloch's method", "TEST", 124, 146], ["probability levels", "TEST", 218, 236], ["less restrictive", "OBSERVATION_MODIFIER", 21, 37]]], ["To this end, we first have to define two intermediate quantities: where Q(p) is the theoretical quantile of probability p for a S \u03b1 (\u03b3, \u03b2, \u00b5) variable [55, 2, 12] .", [["S \u03b1", "PROTEIN", 128, 131], ["a S \u03b1", "TEST", 126, 131]]], ["Neither v \u03b1 nor v \u03b2 depend on \u03b3 and \u00b5, so that \u03b1 and \u03b2 are functions of v \u03b1 and v \u03b2 : \u03b1 = \u03c6 1 (v \u03b1 , v \u03b2 ) and \u03b2 = \u03c6 2 (v \u03b1 , v \u03b2 ).", [["v \u03b1", "GENE_OR_GENE_PRODUCT", 8, 11], ["v \u03b2", "GENE_OR_GENE_PRODUCT", 16, 19], ["\u03b3", "GENE_OR_GENE_PRODUCT", 30, 31], ["\u03b1", "GENE_OR_GENE_PRODUCT", 47, 48], ["\u03b2", "GENE_OR_GENE_PRODUCT", 53, 54], ["v \u03b1", "GENE_OR_GENE_PRODUCT", 72, 75], ["v \u03b2", "GENE_OR_GENE_PRODUCT", 80, 83], ["v \u03b1 , v \u03b2", "GENE_OR_GENE_PRODUCT", 95, 104], ["\u03b2 = \u03c6 2", "GENE_OR_GENE_PRODUCT", 111, 118], ["v \u03b1", "GENE_OR_GENE_PRODUCT", 120, 123], ["v \u03b2", "GENE_OR_GENE_PRODUCT", 126, 129], ["v \u03b1", "PROTEIN", 8, 11], ["v \u03b2", "PROTEIN", 16, 19], ["\u03b3 and \u00b5", "PROTEIN", 30, 37], ["\u03b1", "PROTEIN", 47, 48], ["\u03b2", "PROTEIN", 53, 54], ["\u03b1", "PROTEIN", 74, 75], ["\u03b2", "PROTEIN", 82, 83], ["\u03b1", "PROTEIN", 86, 87], ["\u03c6 1", "PROTEIN", 90, 93], ["\u03b1", "PROTEIN", 97, 98], ["\u03b2", "PROTEIN", 103, 104], ["\u03b2", "PROTEIN", 111, 112], ["\u03c6 2", "PROTEIN", 115, 118], ["\u03b1", "PROTEIN", 122, 123], ["\u03b2", "PROTEIN", 128, 129]]], ["Replacing the theoretical quantiles Q(p) by empirical quantiles Q(p), we get estimators v \u03b1 for v \u03b1 and v \u03b2 for v \u03b2 , as well as the following estimators for \u03b1 and \u03b2:EstimationThe estimation of \u03b3 and \u00b5 relies on two other intermediate quantities which only depend on the already estimated \u03b1 and \u03b2.", [["v \u03b1", "GENE_OR_GENE_PRODUCT", 96, 99], ["v \u03b2", "GENE_OR_GENE_PRODUCT", 104, 107], ["v \u03b2", "GENE_OR_GENE_PRODUCT", 112, 115], ["\u03b1", "PROTEIN", 98, 99], ["\u03b2", "PROTEIN", 106, 107], ["\u03b2", "PROTEIN", 114, 115], ["\u03b1", "PROTEIN", 158, 159], ["\u03b3", "CELL_LINE", 194, 195], ["\u03b1", "PROTEIN", 289, 290]]], ["For simplicity, we introduce the variable \u03b6 defined by:EstimationThe intermediate quantities are:EstimationThey are such that v \u03b3 = \u03c6 3 (\u03b1, \u03b2) and v \u03b6 = \u03c6 4 (\u03b1, \u03b2).", [["v \u03b6 = \u03c6 4", "GENE_OR_GENE_PRODUCT", 147, 156], ["\u03b1, \u03b2", "GENE_OR_GENE_PRODUCT", 158, 162], ["\u03b2", "PROTEIN", 140, 141], ["\u03c6 4", "PROTEIN", 153, 156], ["\u03b1", "PROTEIN", 158, 159], ["\u03b2", "PROTEIN", 161, 162], ["v", "TEST", 126, 127], ["\u03b2", "TEST", 140, 141], ["v", "TEST", 147, 148]]], ["Their estimators v \u03b3 and v \u03b6 are obtained by replacing the quantiles by empirical ones.", [["v \u03b3", "GENE_OR_GENE_PRODUCT", 17, 20], ["v \u03b6", "GENE_OR_GENE_PRODUCT", 25, 28], ["Their estimators v", "TEST", 0, 18]]], ["Time-varying quantiles make it also possible to define the last two McCulloch statistics and finally to fully estimate a dynamic alpha-stable probability distribution.Dynamic estimationThe subject of estimating dynamic quantiles is largely handled by the econometric literature.", [["Dynamic estimation", "TEST", 167, 185]]], ["A drawback of quantile regression is that different quantiles may cross: the monotonicity of quantiles is not necessarily preserved.", [["quantile regression", "PROBLEM", 14, 33], ["not necessarily", "UNCERTAINTY", 106, 121], ["preserved", "OBSERVATION", 122, 131]]], ["The dynamic additive quantile, while keeping the autoregressive approach, deals with this limitation [36] .Dynamic estimationHowever, all the quantile autoregressions are based on a model of dynamic and we prefer to introduce a method in which we do not specify the evolution of quantiles with respect to previously estimated ones.", [["Dynamic estimation", "TEST", 107, 125], ["a method", "TREATMENT", 226, 234]]], ["The inspiration of such a model-free approach comes from the non-parametric statistics literature, in which we can estimate for example time-varying moments or even timevarying probability densities [38] .", [["a model-free approach", "TREATMENT", 24, 45]]], ["In the EWMA approach, the average A t , estimated at time t, incorporates the average estimated at time t \u2212 1 and the new observation at time t, X t , in the following manner:Dynamic estimationwhere \u03c9 \u2208 (0, 1] is the discount factor.", [["new", "OBSERVATION_MODIFIER", 118, 121]]], ["The higher \u03c9, the more stable the series A t .", [["higher", "OBSERVATION_MODIFIER", 4, 10], ["stable", "OBSERVATION_MODIFIER", 23, 29]]], ["Indeed, A t\u22121 is a weighted average of observations till time t \u2212 1, and it is a mathematical expectation under a specific probability if the sum of the weights is equal to 1.", [["A t\u22121", "GENE_OR_GENE_PRODUCT", 8, 13], ["the weights", "TEST", 149, 160]]], ["If we suppose it is the case for the statistic A t\u22121 , then the probability associated in A t to each past observation is multiplied by \u03c9, and is thus globally equal to \u03c9, whereas the new observation has the probability complementary to 1, that is 1 \u2212 \u03c9.", [["t\u22121", "DNA", 49, 52]]], ["We thus have an underlying probability distribution at each time t, which associates the probability p \u03c9 t,i to the i-th observation, for 1 \u2264 i \u2264 t:Dynamic estimationFor \u03c9 = 1 and big values of t, \u03c9 t is close to zero and we have the approximation p \u03c9 t,i \u2248 (1 \u2212 \u03c9)\u03c9 t\u2212i .", [["big values", "TEST", 180, 190], ["t\u2212i", "TEST", 267, 270], ["probability", "OBSERVATION_MODIFIER", 27, 38], ["distribution", "OBSERVATION_MODIFIER", 39, 51]]], ["From these updating probabilities, it is possible to estimate time-varying kernel densities [38] but also time-varying quantiles.", [["varying kernel densities", "PROBLEM", 67, 91]]], ["These dynamic quantiles may rely on the dynamic kernel densities but we prefer to work here with simple empirical quantiles, in order to avoid the complexity of estimating dynamic kernel densities [74, 38] .", [["kernel densities", "OBSERVATION", 180, 196]]], ["For extreme quantiles, the algorithmic complexity of our method is less than linear with respect to the number of observations considered at each date.Dynamic estimationWe begin with a first estimation at date t 0 of the quantile of probability p, Q \u03c9 t0 (p).", [["extreme quantiles", "PROBLEM", 4, 21]]], ["To estimate the quantile, we build the matrix M \u03c9 t0 containing the past observed price returns till t 0 , {X i } i\u2264t0 , sorted in descending order, along with their corresponding historical EWMA-like probability:Dynamic estimation. . . . . .Dynamic estimation. . . . . .Dynamic estimationwhere X \u03c0t 0 (i) is the i-th order statistic among the t 0 first observations and is obtained with the help of a permutation \u03c0 t0 : minDynamic estimationFollowing the definition of the generalized quantile, we get the following estimator for the quantile of probability p:Dynamic estimationwhich is simply the lowest price return such that the cumulated probability associated to lower returns reaches p.Dynamic estimationIteratively, we can update this quantile in the following manner.", [["Dynamic estimation", "TEST", 242, 260], ["descending", "ANATOMY_MODIFIER", 131, 141]]], ["We first apply a probability decay to M \u03c9 t\u22121 by a simple matrix product, so that we get a new matrix M \u03c9 t\u22121 containing sorted past observations till time t \u2212 1 along with their new probability at time t:Dynamic estimationThen, we insert the new observation of time t in the matrix M \u03c9 t\u22121 thanks to a binary search in its first column.", [["a new matrix M \u03c9 t\u22121", "TREATMENT", 89, 109], ["new", "OBSERVATION_MODIFIER", 243, 246]]], ["In the inserted line, we write the corresponding probability 1 \u2212 \u03c9 in the second column.", [["inserted line", "OBSERVATION", 7, 20]]], ["If we write I t the position of the new observation, we get the new probability distribution matrix M \u03c9 t by:Dynamic estimation. . . . . .Dynamic estimation. . . . . .Dynamic estimationWe can then calculate the empirical quantile in a manner similar to equation (5):Dynamic estimationIn order to diminish the algorithmic complexity of this method, if we are looking for a quantile above the probability 0.5, we prefer the following definition of the quantile, which is mathematically consistent with the one provided above:Dynamic estimationFinally, using McCulloch's method, these time-varying estimations of quantiles make it possible to estimate the dynamic parameters of the stable distribution, that we note \u03b1 \u03c9 t , \u03b2 \u03c9 t , \u03b3 \u03c9 t , and \u00b5 \u03c9 t .Selection of the discount factorThe above dynamic estimation of quantiles and of the parameters of stable distributions relies on a free parameter, the discount factor \u03c9, which depicts how fast the dynamic distribution evolves.Selection of the discount factorIf \u03c9 is close to 1, the distribution is almost constant.", [["discount factor", "PROTEIN", 765, 780], ["discount factor \u03c9", "PROTEIN", 900, 917], ["discount factor", "PROTEIN", 992, 1007], ["McCulloch's method", "TREATMENT", 556, 574], ["stable", "OBSERVATION_MODIFIER", 679, 685], ["stable", "OBSERVATION_MODIFIER", 847, 853], ["distributions", "OBSERVATION_MODIFIER", 854, 867], ["dynamic distribution", "OBSERVATION", 946, 966], ["almost", "OBSERVATION_MODIFIER", 1047, 1053], ["constant", "OBSERVATION_MODIFIER", 1054, 1062]]], ["If \u03c9 is lower, the evolution of the distribution is faster and the description of the last observations will be more accurate.", [["lower", "OBSERVATION_MODIFIER", 8, 13], ["faster", "OBSERVATION_MODIFIER", 52, 58]]], ["Nevertheless, this accuracy may be excessive and the evolution of the distribution may be non-significant.", [["excessive", "OBSERVATION_MODIFIER", 35, 44], ["may be", "UNCERTAINTY", 83, 89], ["non-significant", "OBSERVATION_MODIFIER", 90, 105]]], ["Indeed, in the extreme situation where \u03c9 is close to zero, the distribution will be very narrow and centered on the last observation, with a big divergence between two successive distributions.", [["a big divergence", "PROBLEM", 139, 155], ["very", "OBSERVATION_MODIFIER", 84, 88], ["narrow", "OBSERVATION", 89, 95], ["successive", "OBSERVATION_MODIFIER", 168, 178], ["distributions", "OBSERVATION_MODIFIER", 179, 192]]], ["In order to find a good balance between accuracy and robustness, we decide to select the \u03c9 maximizing the ability of the density f \u03c9 t estimated at date t to forecast the density of X t+1 , the price return at time t + 1.Selection of the discount factorSeveral definitions of what a good density forecast is are possible.", [["density", "OBSERVATION", 121, 128], ["density", "OBSERVATION", 171, 178], ["good", "OBSERVATION_MODIFIER", 283, 287], ["density", "OBSERVATION", 288, 295]]], ["Indeed, the true density at time t + 1 is never observed, so that we can only rely on one observation drawn in this density.", [["true", "OBSERVATION_MODIFIER", 12, 16], ["density", "OBSERVATION", 17, 24]]], ["In the non-parametric literature about time-varying densities, we find for instance a selection rule for the free parameter of the densities based on the maximization of a likelihood criterion [38] .", [["a selection rule", "TEST", 84, 100], ["the densities", "PROBLEM", 127, 140], ["varying", "OBSERVATION_MODIFIER", 44, 51], ["densities", "OBSERVATION", 52, 61], ["densities", "OBSERVATION", 131, 140]]], ["We think that this criterion does not take properly into account the possibility of the occurrence of extreme events.", [["extreme events", "PROBLEM", 102, 116]]], ["The alternative solution we follow is based on an adaptation of a method coming from the literature of density forecast evaluation [34] .", [["a method", "TREATMENT", 64, 72], ["forecast evaluation", "TEST", 111, 130]]], ["This transformation is the probability integral transform (PIT), usually introduced in the perspective of density forecast evaluation [22] :Selection of the discount factorwhere F \u03c9 t\u22121 is the cdf corresponding to f \u03c9 t\u22121 .", [["cdf", "PROTEIN", 193, 196], ["forecast evaluation", "TEST", 114, 133]]], ["In this literature, two conditions are required for the PITs: the Z \u03c9 t must follow a uniform distribution in [0, 1] and they must be independent from each other.Selection of the discount factorThe translation of these rules to the selection of free parameters in density estimation leads to two properties regarding \u03c9 [34] : uniformity of the PITs Z \u03c9 t0 , ..., Z \u03c9 T : \u03c9 is to be selected so as to minimize the divergence between their empirical distribution and a uniform distribution, independence of the PITs: \u03c9 is to be selected so as to minimize the discrepancy, that is, for each subinterval of [t 0 , T ] of size greater than a threshold \u03bd, the divergence between the empirical distribution of the corresponding PITs and a uniform distribution is to be minimized.Selection of the discount factorIn the perspective of the selection of a free parameter of a time-varying distribution, we can define the above divergence as a Kolmogorov-Smirnov statistic with an adaptation to compare directly divergences of distributions estimated on samples of different sizes [34] .", [["discount factor", "PROTEIN", 179, 194], ["Z", "PROTEIN", 363, 364], ["\u03c9", "PROTEIN", 371, 372], ["PITs", "PROTEIN", 509, 513], ["\u03c9", "PROTEIN", 515, 516], ["discount factor", "PROTEIN", 789, 804], ["the PITs Z", "TEST", 340, 350], ["the corresponding PITs", "PROBLEM", 703, 725], ["uniform", "OBSERVATION_MODIFIER", 467, 474], ["distribution", "OBSERVATION_MODIFIER", 475, 487], ["PITs", "OBSERVATION_MODIFIER", 721, 725], ["uniform", "OBSERVATION_MODIFIER", 732, 739], ["sizes", "OBSERVATION_MODIFIER", 1063, 1068]]], ["Moreover, the minimal size \u03bd of the subintervals considered is intended to be a threshold above which the asymptotic framework required by the Kolmogorov-Smirnov statistic is satisfied.", [["minimal", "OBSERVATION_MODIFIER", 14, 21], ["size", "OBSERVATION_MODIFIER", 22, 26]]], ["We consider \u03bd = 22 days, so that we expect the PITs to be uniform for scales larger than one month.", [["the PITs", "PROBLEM", 43, 51]]], ["As a consequence, the criterion to be minimized is:Selection of the discount factorin which k is the standard Kolmogorov-Smirnov statistic with respect to the uniform distribution:Selection of the discount factorwhere v \u2208 a, b \u2192 \u03c1(v; a, b) is a permutation of a, b defining the new order Z \u03c9 \u03c1(a;a,b) \u2264 Z \u03c9 \u03c1(a+1;a,b) \u2264 ... \u2264 Z \u03c9 \u03c1(b\u22121;a,b) \u2264 Z \u03c9 \u03c1(b;a,b) [34] .", [["Z", "PROTEIN", 326, 327], ["Z", "PROTEIN", 343, 344], ["Z", "TEST", 303, 304], ["\u03c9", "TEST", 305, 306], ["\u03c1", "TEST", 307, 308], ["a", "TEST", 309, 310], ["a", "TEST", 313, 314], ["b", "TEST", 315, 316], ["\u2264", "TEST", 318, 319], ["Z", "TEST", 326, 327], ["\u03c9", "TEST", 328, 329], ["\u03c1", "TEST", 330, 331], ["b", "TEST", 332, 333], ["\u2212", "TEST", 333, 334], ["a", "TEST", 336, 337], ["b", "TEST", 338, 339], ["Z", "TEST", 343, 344], ["b", "TEST", 349, 350], ["a,b)", "TEST", 351, 355]]], ["In equation (7), (u \u2212 s)/(t \u2212 s) is the empirical cdf of the PITs, whereas the sorted PIT Z \u03c9 \u03c1(u;s,t) is the theoretical uniform cdf.", [["PITs", "PROTEIN", 61, 65], ["cdf", "PROTEIN", 130, 133], ["the PITs", "TEST", 57, 65], ["the sorted PIT", "TEST", 75, 89], ["the theoretical uniform cdf", "PROBLEM", 106, 133], ["uniform", "OBSERVATION_MODIFIER", 122, 129], ["cdf", "OBSERVATION", 130, 133]]], ["Finally, the optimal discount factor is defined as the solution of the following equation:Selection of the discount factorWe can easily apply the above method to the case of an alpha-stable distribution.", [["discount factor", "PROTEIN", 21, 36], ["alpha", "OBSERVATION", 177, 182], ["stable", "OBSERVATION_MODIFIER", 183, 189], ["distribution", "OBSERVATION_MODIFIER", 190, 202]]], ["Indeed, it relies on the cdf, which does not follow a simple expression for alpha-stable distributions.", [["cdf", "GENE_OR_GENE_PRODUCT", 25, 28], ["cdf", "PROTEIN", 25, 28], ["alpha", "PROTEIN", 76, 81], ["alpha-stable distributions", "PROBLEM", 76, 102]]], ["Nevertheless, as exposed in Subsection 2.1, numerical methods make it possible to calculate both the pdf and the cdf of an alpha-stable distribution.", [["numerical methods", "TREATMENT", 44, 61], ["alpha", "OBSERVATION", 123, 128], ["stable", "OBSERVATION_MODIFIER", 129, 135], ["distribution", "OBSERVATION_MODIFIER", 136, 148]]], ["Therefore, the estimated cdf x \u2192 F \u03c9 t\u22121 (x) in equation (6) is the numerically evaluated cdf of an alpha-stable distribution with estimated parameters:Market efficiencyThe market efficiency is a usual assumption in finance, which is in particular invoked when pricing derivatives.", [["the estimated cdf", "TEST", 11, 28], ["Market efficiency", "PROBLEM", 152, 169], ["alpha", "OBSERVATION", 100, 105], ["stable", "OBSERVATION", 106, 112], ["efficiency", "OBSERVATION", 159, 169], ["market efficiency", "OBSERVATION", 173, 190]]], ["The EMH states that asset price series follow a random walk [25] .", [["EMH", "OBSERVATION", 4, 7]]], ["The EMH is convenient, because working with independent price returns makes the financial mathematics easier.", [["EMH", "OBSERVATION", 4, 7]]], ["But practitioners know that the EMH is not very realistic.", [["EMH", "OBSERVATION", 32, 35]]], ["The asset management industry in general aims at performing statistical arbitrages, whatever the transaction time scale, whether it is less than a second or more than a month.", [["The asset management", "TREATMENT", 0, 20]]], ["Standard models relying on the EMH, such as the widespread geometric Brownian motion, are not consistent with the existence of statistical arbitrages.Market efficiencyWe can also stress other unrealistic components of the EMH, such as the availability of the same information for every investor and market maker, as well as the rationality of all the agents, or the fact that we can substitute two assets provided that they are equally risky.", [["statistical arbitrages", "PROBLEM", 127, 149], ["Brownian motion", "OBSERVATION", 69, 84], ["not consistent with", "UNCERTAINTY", 90, 109], ["EMH", "OBSERVATION", 222, 225]]], ["The AMH is a good compromise between the standard EMH and the reality of statistical arbitrage.", [["AMH", "GENE_OR_GENE_PRODUCT", 4, 7], ["good", "OBSERVATION_MODIFIER", 13, 17], ["compromise", "OBSERVATION", 18, 28]]], ["The AMH thus leads to a long-term efficiency of the market and allows statistical arbitrages for small time scales only.Market efficiencyBesides, it is worth noting that the price series of some assets are not far from the EMH.", [["AMH", "GENE_OR_GENE_PRODUCT", 4, 7], ["AMH", "PROTEIN", 4, 7], ["The AMH", "PROBLEM", 0, 7], ["Market efficiency", "PROBLEM", 120, 137], ["long-term efficiency", "OBSERVATION_MODIFIER", 24, 44], ["efficiency", "OBSERVATION", 127, 137], ["EMH", "OBSERVATION", 223, 226]]], ["But empirical studies show that these indices have fluctuating efficiency and may encounter a loss of efficiency during financial crisis [1, 52] .", [["empirical studies", "TEST", 4, 21], ["fluctuating efficiency", "PROBLEM", 51, 73], ["a loss of efficiency", "PROBLEM", 92, 112], ["fluctuating efficiency", "OBSERVATION", 51, 73]]], ["Some of them look for a predictability of price returns [17] , using for example the amplitude of the parameters of a timevarying AR model [41, 58] .", [["AR", "PROTEIN", 130, 132], ["a timevarying AR model", "TEST", 116, 138]]], ["Other indicators measure a deviation from a random walk, using for example variance ratios [15] or a combination of several statistics such as fractal dimension and entropy [47, 46] .", [["a deviation", "PROBLEM", 25, 36], ["a random walk", "TREATMENT", 42, 55], ["example variance ratios", "TEST", 67, 90]]], ["But the most widespread indicator of market efficiency seems to be the Hurst exponent [51, 13, 56, 28] .Market efficiencyThe Hurst exponent is an indicator of long-range memory.", [["market efficiency", "OBSERVATION", 37, 54], ["Hurst exponent", "OBSERVATION_MODIFIER", 125, 139]]], ["Mandelbrot and van Ness introduced the fBm as a model consistent with a given Hurst exponent and extending the standard Bm by making the increments dependent on each other [54] .", [["Bm", "DNA", 120, 122], ["Hurst exponent", "PROBLEM", 78, 92]]], ["In the fBm, the Hurst exponent H is also linked to the fractal property of the series, insofar as the variance of the increments of duration \u03c4 is \u03c4 2H times the variance of increments of duration 1.", [["fBm", "DNA", 7, 10], ["fBm", "ANATOMY", 7, 10]]], ["Some estimators of the Hurst exponent use this fractal property instead of the long-range memory.", [["Hurst exponent", "OBSERVATION_MODIFIER", 23, 37]]], ["However, given the fractal property estimated on the dataset, the fBm is not the only possible model.", [["fBm", "GENE_OR_GENE_PRODUCT", 66, 69], ["fBm", "DNA", 66, 69], ["not the only possible", "UNCERTAINTY", 73, 94]]], ["This fact has been documented for instance for foreign exchange rates, for which the stationarity of the time series biases the estimation of the Hurst exponent in the perspective of an fBm [30, 31] .", [["foreign exchange rates", "PROBLEM", 47, 69]]], ["Indicators of market efficiency should not bypass the diversity of models featuring a fractal property and consistent with the estimated Hurst exponent.", [["market efficiency", "PROBLEM", 14, 31], ["the estimated Hurst exponent", "PROBLEM", 123, 151], ["market efficiency", "OBSERVATION", 14, 31], ["fractal", "OBSERVATION_MODIFIER", 86, 93], ["consistent with", "UNCERTAINTY", 107, 122], ["Hurst", "OBSERVATION_MODIFIER", 137, 142], ["exponent", "OBSERVATION_MODIFIER", 143, 151]]], ["Extensions of the fBm include some specificities for the Hurst exponent: it may vary deterministically through time, as in the multifractional Brownian motion [63, 8, 16, 28] , it may be a random process, as in the multifractional process with random exponent [4, 11, 27, 29] , or it may even be asymmetric [14, 72] .Market efficiencyIn what follows, after a presentation of the Hurst exponent in the perspective of the fBm, we will focus on a model in which increments are not necessarily Gaussian.", [["fBm", "GENE_OR_GENE_PRODUCT", 18, 21], ["fBm", "DNA", 18, 21], ["fBm", "DNA", 420, 423], ["the fBm", "PROBLEM", 14, 21], ["a random process", "PROBLEM", 187, 203], ["Market efficiency", "PROBLEM", 317, 334], ["fBm", "ANATOMY", 18, 21], ["may be", "UNCERTAINTY", 180, 186], ["efficiency", "OBSERVATION", 324, 334], ["fBm", "ANATOMY", 420, 423]]], ["In this framework, the fLsm is a natural extension of the fBm, in which increments follow an alpha-stable distribution [73, 75, 71, 29] .", [["fLsm", "GENE_OR_GENE_PRODUCT", 23, 27], ["fBm", "GENE_OR_GENE_PRODUCT", 58, 61], ["fLsm", "DNA", 23, 27], ["fBm", "DNA", 58, 61], ["fBm", "ANATOMY", 58, 61], ["stable", "OBSERVATION_MODIFIER", 99, 105]]], ["The fractal property of this process takes into account both the dependence between increments and the tail parameter of the alpha-stable distribution.", [["fractal", "OBSERVATION_MODIFIER", 4, 11], ["property", "OBSERVATION_MODIFIER", 12, 20], ["both", "OBSERVATION_MODIFIER", 56, 60], ["dependence", "OBSERVATION_MODIFIER", 65, 75], ["tail", "OBSERVATION_MODIFIER", 103, 107], ["alpha-stable", "OBSERVATION_MODIFIER", 125, 137], ["distribution", "OBSERVATION_MODIFIER", 138, 150]]], ["This model thus makes it possible to disentangle the kurtosis of price returns and the efficiency of the market.", [["makes it possible", "UNCERTAINTY", 16, 33], ["efficiency", "OBSERVATION_MODIFIER", 87, 97]]], ["This refinement is not superfluous.", [["not", "UNCERTAINTY", 19, 22], ["superfluous", "OBSERVATION_MODIFIER", 23, 34]]], ["We will indeed see in the empirical section that the conclusions regarding the efficiency of stock indices are not the same if we consider the Hurst exponent or the fLsm-based indicator of market efficiency.Hurst exponentsThe Hurst exponent was originally introduced by Harold Edwin Hurst as an indicator of longrange memory that could be obtained thanks to the rescaled range (R/S) analysis [40] .", [["fLsm", "PROTEIN", 165, 169], ["stock indices", "TEST", 93, 106], ["the Hurst exponent", "PROBLEM", 139, 157], ["Hurst exponents", "PROBLEM", 207, 222], ["market efficiency", "OBSERVATION", 189, 206]]], ["Later, alternative estimation methods appeared, such as the detrended fluctuation analysis [64] , or the absolute-moment method [8, 7, 9, 28] , which is related to the notion of generalized Hurst exponent (GHE) [6, 21] .", [["alternative estimation methods", "TEST", 7, 37], ["the detrended fluctuation analysis", "TEST", 56, 90], ["generalized Hurst exponent", "PROBLEM", 178, 204], ["generalized", "OBSERVATION_MODIFIER", 178, 189], ["Hurst exponent", "OBSERVATION_MODIFIER", 190, 204]]], ["The absolute-moment method is a method mainly used by the community of statisticians of stochastic processes, because, contrary to the R/S analysis, it is strongly related to a stochastic process, namely the fBm.Hurst exponentsThe fBm is a generalization of the standard Bm.", [["fBm", "GENE_OR_GENE_PRODUCT", 208, 211], ["fBm", "GENE_OR_GENE_PRODUCT", 231, 234], ["fBm", "PROTEIN", 208, 211], ["The absolute-moment method", "TREATMENT", 0, 26], ["the R/S analysis", "TEST", 131, 147], ["Hurst exponents", "PROBLEM", 212, 227], ["absolute", "OBSERVATION_MODIFIER", 4, 12], ["-moment", "OBSERVATION_MODIFIER", 12, 19]]], ["Increments of the fBm are Gaussian, since the fBm is a fractional integral or a fractional derivative of a Bm, W t [54] :Hurst exponentsThe two parameters of the fBm are the Hurst exponent H, and the volatility parameter \u03c3.", [["fBm", "GENE_OR_GENE_PRODUCT", 18, 21], ["fBm", "DNA", 18, 21], ["fBm", "DNA", 46, 49], ["Hurst exponents", "PROBLEM", 121, 136], ["the volatility parameter", "TEST", 196, 220], ["Hurst exponents", "OBSERVATION_MODIFIER", 121, 136], ["fBm", "ANATOMY", 162, 165]]], ["If H = 1/2, the fBm is a Bm.", [["fBm", "GENE_OR_GENE_PRODUCT", 16, 19], ["fBm", "DNA", 16, 19]]], ["If H > 1/2 (respectively H < 1/2), the fBm is the fractional integral (resp. fractional derivative) of order H \u22121/2 (resp.", [["fBm", "GENE_OR_GENE_PRODUCT", 39, 42], ["fractional derivative)", "TREATMENT", 77, 99], ["resp", "ANATOMY", 117, 121]]], ["1/2\u2212H) of a Bm; increments are thus positively (resp. negatively) correlated.Hurst exponentsThe absolute-moment method uses another definition of the fBm, which is consistent with the integral form provided above.", [["fBm", "GENE_OR_GENE_PRODUCT", 150, 153], ["fBm", "DNA", 150, 153], ["Hurst exponents", "PROBLEM", 77, 92], ["The absolute-moment method", "TREATMENT", 92, 118], ["Bm", "OBSERVATION", 12, 14], ["absolute", "OBSERVATION_MODIFIER", 96, 104], ["-moment", "OBSERVATION_MODIFIER", 104, 111], ["consistent with", "UNCERTAINTY", 164, 179]]], ["Indeed, an fBm is also the only zero-mean Gaussian process, with zero at the origin, such that, for s, t \u2265 0:Hurst exponentsFrom this covariance, we get the self-similarity property:Hurst exponentsfor k > 0.", [["fBm", "GENE_OR_GENE_PRODUCT", 11, 14], ["fBm", "DNA", 11, 14], ["origin", "ANATOMY_MODIFIER", 77, 83]]], ["This property states that the k-order absolute moment of the increments of duration |t \u2212 s| is proportional to |t \u2212 s| kH .", [["|t", "PROTEIN", 111, 113]]], ["Comparing two scales thus makes it possible to estimate H. If we focus on an order k = 2 and on the two smallest scales, we indeed get the following estimator, for a time series of log-prices X 1 , X 2 , ..., X t [28] :Hurst exponentswhich converges almost surely toward H [8, 7] .Hurst exponentsWe could use this estimator of H as an indicator of market efficiency.", [["log-prices", "TREATMENT", 181, 191], ["Hurst exponents", "PROBLEM", 281, 296], ["market efficiency", "OBSERVATION", 348, 365]]], ["But, we are mostly interested here in evaluating the evolution of market efficiency through time.", [["market efficiency", "OBSERVATION", 66, 83]]], ["We need therefore a time-varying version of this estimator.", [["this estimator", "TREATMENT", 44, 58]]], ["This question is not new and the solution put forward in the literature is often based on the estimation in sliding windows [16, 10] , possibly with a smoothing of the raw series of Hurst exponents as a post-processing [28] .", [["the estimation in sliding windows", "TEST", 90, 123], ["Hurst exponents", "PROBLEM", 182, 197], ["not", "UNCERTAINTY", 17, 20], ["new", "OBSERVATION_MODIFIER", 21, 24]]], ["But we prefer a method more consistent with the smoothing applied above for estimating the parameters of a distribution, that is in the manner of an EWMA, insofar as it overweights more recent observations and is thus a more relevant picture of the current state of the market.", [["the smoothing", "TREATMENT", 44, 57]]], ["The main difference with the method we propose is that the GHE is always based on a linear regression of log-absolute moments of increments on several log time scales.", [["GHE", "DNA", 59, 62], ["log-absolute moments of increments", "TREATMENT", 105, 139], ["main", "OBSERVATION_MODIFIER", 4, 8], ["difference", "OBSERVATION_MODIFIER", 9, 19]]], ["Contrary to the GHE, we focus on only two scales, so that we get a simpler closed-form estimator:Hurst exponentsBeyond this simple formula, a more efficient implementation method is possible.", [["Hurst exponents", "PROBLEM", 97, 112], ["this simple formula", "TREATMENT", 119, 138]]], ["Given the one-stepHurst exponentsit consists in the following recurrence:Hurst exponentsThe question of the optimal choice of the discount factor \u03c9 in the estimator H \u03c9 t is also to be addressed.", [["discount factor", "PROTEIN", 130, 145], ["Hurst exponents", "PROBLEM", 73, 88], ["Hurst exponents", "OBSERVATION_MODIFIER", 73, 88]]], ["We could imagine to adapt the method exposed in section 2.4 to the case of an fBm.", [["fBm", "OBSERVATION", 78, 81]]], ["We will thus simply use the discount factor chosen for estimating the time-varying stable distribution.Fractional L\u00e9vy-stable motionThe fLsm is a generalization of the fBm in which increments follow an alpha-stable distribution, which admits the Gaussian distribution as a particular case.", [["fLsm", "GENE_OR_GENE_PRODUCT", 136, 140], ["discount factor", "PROTEIN", 28, 43], ["fLsm", "PROTEIN", 136, 140], ["fBm", "DNA", 168, 171], ["the discount factor", "TREATMENT", 24, 43], ["Fractional L\u00e9vy", "TEST", 103, 118], ["the fBm", "PROBLEM", 164, 171], ["varying", "OBSERVATION_MODIFIER", 75, 82], ["stable", "OBSERVATION", 83, 89], ["stable motion", "OBSERVATION", 119, 132], ["stable", "OBSERVATION_MODIFIER", 208, 214]]], ["The fLsm is defined as the fractional integral or fractional derivative of a symmetric L\u00e9vy-stable motion [70, 73, 71] :Fractional L\u00e9vy-stable motionwhere L \u03b1 (t) is a symmetric \u03b1-stable process andFractional L\u00e9vy-stable motionIn other words, increments follow a symmetric stable law and, if and only if H \u2212 1/\u03b1 > 0, nonoverlapping increments are positively dependent, that is with a positive codifference or a positive covariation [49] .", [["fLsm", "GENE_OR_GENE_PRODUCT", 4, 8], ["H \u2212 1", "GENE_OR_GENE_PRODUCT", 304, 309], ["fLsm", "PROTEIN", 4, 8], ["H", "PROTEIN", 304, 305], ["Fractional L\u00e9vy", "TEST", 120, 135], ["Fractional L\u00e9vy", "TEST", 198, 213], ["a positive codifference", "PROBLEM", 382, 405], ["symmetric", "OBSERVATION_MODIFIER", 77, 86], ["stable", "OBSERVATION_MODIFIER", 92, 98], ["stable", "OBSERVATION_MODIFIER", 136, 142], ["stable", "OBSERVATION", 180, 186], ["stable", "OBSERVATION_MODIFIER", 214, 220], ["symmetric", "OBSERVATION_MODIFIER", 263, 272], ["stable", "OBSERVATION", 273, 279]]], ["The parameter H controls the scaling behaviour of the process, in the same manner as in the fBm, and the parameter \u03b1 controls the thickness of the tails.", [["fBm", "PROTEIN", 92, 95], ["\u03b1", "PROTEIN", 115, 116], ["tails", "ANATOMY_MODIFIER", 147, 152]]], ["The lower \u03b1, the fatter the tails.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 10, 11], ["\u03b1", "PROTEIN", 10, 11], ["lower", "ANATOMY_MODIFIER", 4, 9], ["fatter", "OBSERVATION", 17, 23], ["tails", "ANATOMY_MODIFIER", 28, 33]]], ["If \u03b1 = 2, increments are Gaussian and the fLsm is an fBm.", [["\u03b1 = 2", "GENE_OR_GENE_PRODUCT", 3, 8], ["fLsm", "GENE_OR_GENE_PRODUCT", 42, 46], ["fBm", "GENE_OR_GENE_PRODUCT", 53, 56], ["fLsm", "DNA", 42, 46], ["fBm", "DNA", 53, 56]]], ["When comparing an fBm and an fLsm, the fractal feature of the latter is not obtained only by adjusting the dependence of the increments but, in addition, by tuning the kurtosis of the underlying law.", [["fBm", "PROTEIN", 18, 21], ["fLsm", "PROTEIN", 29, 33], ["an fBm", "TEST", 15, 21]]], ["Therefore, we can write the Hurst exponent as the combination of a tail component, 1/\u03b1, and a memory parameter, m:Fractional L\u00e9vy-stable motionIn this framework, the Hurst exponent is not the most relevant indicator of market efficiency and one should instead use m.", [["tail component", "PROTEIN", 67, 81], ["\u03b1", "PROTEIN", 85, 86], ["a tail component", "TREATMENT", 65, 81], ["stable", "OBSERVATION_MODIFIER", 130, 136]]], ["As we have proposed time-varying estimators both for \u03b1 and for H, we write the following time-varying estimator for m:Fractional L\u00e9vy-stable motionwhere \u03b1 \u03c9 t is the estimator of the parameter of the stable law defined in section 2.3.", [["\u03b1", "PROTEIN", 53, 54], ["Fractional L\u00e9vy", "TEST", 118, 133], ["stable", "OBSERVATION", 134, 140], ["stable", "OBSERVATION", 200, 206]]], ["Efficient markets then correspond to m \u03c9 t close to zero.Empirical studyWe apply the above method to ten stock indices of various regions: USA (S&P 500, S&P 100), Europe (EURO STOXX 50, Euronext 100, DAX, CAC 40), Asia (Nikkei, KOSPI, SSE 180), and Australia (S&P/ASX 200).", [["Empirical studyWe", "TREATMENT", 57, 74], ["the above method", "TREATMENT", 81, 97], ["S&P", "TEST", 144, 147], ["Europe (EURO STOXX", "TREATMENT", 163, 181], ["Euronext", "TREATMENT", 186, 194], ["CAC", "TEST", 205, 208]]], ["The first date at which we estimate stable densities and the parameters of an fBm and an fLsm, that is t 0 , is the 1st November 2019.", [["an fBm", "PROBLEM", 75, 81], ["stable", "OBSERVATION_MODIFIER", 36, 42], ["densities", "OBSERVATION", 43, 52]]], ["The period of study includes the financial crisis sparked by the COVID-19 pandemic.Empirical studyWe first determine for each stock index the optimal discount factor \u03c9 as in equation (8).", [["discount factor", "PROTEIN", 150, 165], ["the financial crisis", "PROBLEM", 29, 49], ["the COVID", "TEST", 61, 70], ["pandemic", "PROBLEM", 74, 82]]], ["We observe that the optimal discount factors are close to 0.95, whatever the index considered.", [["the index", "TEST", 73, 82]]], ["For the rest of the empirical study, we consider a common discount factor \u03c9 m , so that we can make fair comparisons between stock indices.", [["the empirical study", "TEST", 16, 35]]], ["We choose \u03c9 m = 0.956, which is the highest optimal discount factor measured for the various stock indices.", [["discount factor", "PROTEIN", 52, 67]]], ["This conservative choice limits the risk of providing a new observation with a too high weight in the dynamic estimators.Empirical studyA lower value could lead to spurious conclusions regarding the market efficiency for some stock indices.", [["This conservative choice", "TREATMENT", 0, 24], ["Empirical study", "TEST", 121, 136], ["spurious conclusions", "PROBLEM", 164, 184], ["some stock indices", "PROBLEM", 221, 239]]], ["We display in Figure 1 these densities for four stock indices corresponding to regions with a different timing in the growth of the outbreak: S&P 500, the French CAC 40, the Chinese SSE 180, and the S&P/ASX 200 indices.", [["four stock indices", "TEST", 43, 61], ["the S&P/ASX", "TEST", 195, 206], ["different", "OBSERVATION_MODIFIER", 94, 103], ["growth", "OBSERVATION_MODIFIER", 118, 124]]], ["For each of these indices, we plot the pdf before the crisis, in November 2019, at the peak of the crisis, and a the end of our sample, late June 2020.", [["these indices", "TEST", 12, 25], ["crisis", "OBSERVATION", 99, 105]]], ["The peak of the crisis is not the same for all the indices.", [["peak", "OBSERVATION_MODIFIER", 4, 8], ["crisis", "OBSERVATION", 16, 22]]], ["For the four indices, the pdf at the peak shows fat tails and asymmetry.", [["fat", "ANATOMY", 48, 51], ["pdf", "GENE_OR_GENE_PRODUCT", 26, 29], ["fat", "TISSUE", 48, 51], ["pdf", "DNA", 26, 29], ["the four indices", "TEST", 4, 20], ["the pdf", "TEST", 22, 29], ["asymmetry", "PROBLEM", 62, 71], ["fat tails", "OBSERVATION", 48, 57], ["asymmetry", "OBSERVATION", 62, 71]]], ["Late June, the pdf still has these features, except for SSE 180 index, for which the pdf is very similar to the one before the crisis, indicating a very fast recovery in China.", [["pdf", "DNA", 15, 18], ["SSE 180 index", "TEST", 56, 69], ["very", "OBSERVATION_MODIFIER", 148, 152]]], ["The case of CAC 40 at the peak is also of interest, because the advent of fat tails and asymmetry is so abrupt that it does not crush the body of the pdf, contrary to other indices.", [["fat tails", "ANATOMY", 74, 83], ["body", "ANATOMY", 138, 142], ["fat", "TISSUE", 74, 77], ["body", "ORGANISM_SUBDIVISION", 138, 142], ["pdf", "GENE_OR_GENE_PRODUCT", 150, 153], ["CAC", "TEST", 12, 15]]], ["In this paper, we are mostly interested in determining whether the financial markets are efficient during a financial crisis.", [["a financial crisis", "PROBLEM", 106, 124]]], ["The first one is the widespread Hurst exponent, estimated here in a dynamic fashion as exposed in Section 3.1.", [["widespread", "OBSERVATION_MODIFIER", 21, 31], ["Hurst", "OBSERVATION_MODIFIER", 32, 37], ["exponent", "OBSERVATION_MODIFIER", 38, 46]]], ["In a more general framework, if we consider the possibility of fat tails by the mean of an alpha-stable distribution, we define another efficiency indicator by the memory parameter m of an fLsm, as exposed in Section 3.2.", [["fat tails", "ANATOMY", 63, 72], ["fat tails", "MULTI-TISSUE_STRUCTURE", 63, 72], ["fLsm", "GENE_OR_GENE_PRODUCT", 189, 193], ["fat tails", "PROBLEM", 63, 72], ["stable", "OBSERVATION_MODIFIER", 97, 103]]], ["We consider that the right price model corresponding to H 0 is a geometric Bm.", [["H 0", "CHEMICAL", 56, 59], ["right", "ANATOMY_MODIFIER", 21, 26]]], ["We thus simulate a time series following this model.", [["this model", "TREATMENT", 41, 51]]], ["The length of the simulated series used for estimating the first parameters in t 0 is the same as in our financial dataset.", [["the simulated series", "TEST", 14, 34], ["length", "OBSERVATION_MODIFIER", 4, 10]]], ["For each of these dates, we estimate H, m, and \u03b1 dynamically, using the discount factor \u03c9 m .", [["discount factor", "PROTEIN", 72, 87]]], ["We consider that the bounds of the confidence interval with confidence level p, for the estimated H, m, and \u03b1, are the empirical quantiles of the corresponding parameters, estimated on the simulations, for probabilities (1 \u2212 p)/2 and (1 + p)/2.Stock indexWe display the time-varying Hurst exponent in Figure 2 for the four focal stock indices of our study.", [["\u03b1", "PROTEIN", 108, 109], ["the simulations", "TEST", 185, 200], ["probabilities", "TEST", 206, 219], ["our study", "TEST", 346, 355]]], ["Before the crisis, which begins in February or March with respect to the region, the Hurst exponent is not significantly different from 1/2, so that we cannot reject H 0 during this period.", [["H 0", "CHEMICAL", 166, 169], ["the crisis", "PROBLEM", 7, 17], ["crisis", "OBSERVATION", 11, 17], ["not", "UNCERTAINTY", 103, 106], ["significantly different", "OBSERVATION_MODIFIER", 107, 130]]], ["During the crisis, we observe very low Hurst exponents for the S&P 500 index which make it possible to reject H 0 with a confidence of more than 99%.", [["H 0", "CHEMICAL", 110, 113], ["very low Hurst exponents", "PROBLEM", 30, 54], ["very", "OBSERVATION_MODIFIER", 30, 34], ["low Hurst", "OBSERVATION_MODIFIER", 35, 44]]], ["But for the three other indices, the drawdown of the Hurst exponent is much less significant, in particular for the SSE 180 index.", [["much less", "OBSERVATION_MODIFIER", 71, 80], ["significant", "OBSERVATION_MODIFIER", 81, 92]]], ["According to this approach, the market becomes clearly inefficient if we consider the S&P 500 index, whereas we cannot ascertain the inefficiency of the three other indices.", [["the S&P 500 index", "TEST", 82, 99]]], ["It is also worth noting that after a peak downward, the Hurst exponent reaches abnormally high values for the French and the Australian indices.", [["abnormally high values", "PROBLEM", 79, 101], ["abnormally", "OBSERVATION_MODIFIER", 79, 89], ["high values", "OBSERVATION_MODIFIER", 90, 101]]], ["It suggests a persistence of the crisis: a short mean-reverting phenomenon followed by positively correlated price returns.", [["the crisis", "PROBLEM", 29, 39], ["a short mean-reverting phenomenon", "PROBLEM", 41, 74], ["persistence", "OBSERVATION_MODIFIER", 14, 25], ["crisis", "OBSERVATION", 33, 39]]], ["If we consider another indicator of market efficiency, namely the memory parameter m of an fLsm, the conclusions regarding the impact of COVID-19 on the market efficiency are not the same.", [["COVID-19", "CHEMICAL", 137, 145], ["fLsm", "GENE_OR_GENE_PRODUCT", 91, 95], ["COVID", "TEST", 137, 142]]], ["In Figure 3 , we observe first that m is in general negative, even before the crisis.", [["the crisis", "PROBLEM", 74, 84]]], ["It indicates a dominating mean-reversion phenomenon in the stock markets.", [["a dominating mean-reversion phenomenon", "PROBLEM", 13, 51], ["dominating", "OBSERVATION_MODIFIER", 15, 25], ["mean", "OBSERVATION_MODIFIER", 26, 30], ["-reversion phenomenon", "OBSERVATION", 30, 51], ["stock markets", "OBSERVATION", 59, 72]]], ["When the crisis occurs, m goes downward and H 0 is rejected with a confidence higher than 99%, whatever the stock index.", [["the crisis", "PROBLEM", 5, 15], ["crisis", "OBSERVATION", 9, 15]]], ["The duration of the significant inefficiency varies among the indices.", [["the significant inefficiency", "PROBLEM", 16, 44], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["inefficiency", "OBSERVATION", 32, 44]]], ["The S&P/ASX 200 has a very short period of inefficiency.", [["S&P", "CHEMICAL", 4, 7], ["ASX", "CHEMICAL", 8, 11], ["The S&P/ASX", "TREATMENT", 0, 11]]], ["It is also interesting to track another important parameter of the fLsm, namely \u03b1, which depicts the size of the tails of the distribution of price returns.", [["fLsm", "GENE_OR_GENE_PRODUCT", 67, 71], ["\u03b1", "GENE_OR_GENE_PRODUCT", 80, 81], ["fLsm", "PROTEIN", 67, 71], ["\u03b1", "PROTEIN", 80, 81], ["size", "OBSERVATION_MODIFIER", 101, 105], ["tails", "OBSERVATION_MODIFIER", 113, 118]]], ["The lower \u03b1, the fatter the tails.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 10, 11], ["\u03b1", "PROTEIN", 10, 11], ["lower", "ANATOMY_MODIFIER", 4, 9], ["fatter", "OBSERVATION", 17, 23], ["tails", "ANATOMY_MODIFIER", 28, 33]]], ["For the American, French, and Australian indices, we observe in Figure 4 a negative impact of the crisis on \u03b1.", [["\u03b1.", "SPECIES", 108, 110], ["Australian indices", "TEST", 30, 48], ["the crisis", "PROBLEM", 94, 104]]], ["It means that extreme events tend to occur more frequently and with a larger magnitude.", [["extreme events", "PROBLEM", 14, 28]]], ["The evolution of \u03b1 in the Chinese market is not similar to the three other indices and the values reached are less significantly different from 2.", [["less significantly different", "OBSERVATION_MODIFIER", 110, 138]]], ["A progressive recovery toward high values of \u03b1 is visible for the CAC 40 and the S&P/ASX 200 indices.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 45, 46], ["\u03b1", "PROTEIN", 45, 46], ["ASX", "PROTEIN", 85, 88], ["A progressive recovery", "PROBLEM", 0, 22], ["the CAC", "TEST", 62, 69], ["the S&P/ASX", "TEST", 77, 88], ["progressive", "OBSERVATION_MODIFIER", 2, 13], ["recovery", "OBSERVATION_MODIFIER", 14, 22]]], ["For the S&P 500 index, we also observe an abrupt increase of \u03b1 after the peak of the crisis, but it is of limited amplitude and \u03b1 remains at a fairly low value.Stock indexWe display in Tables 2 and 3 indicators, H and m, for the ten stock indices considered.", [["\u03b1", "PROTEIN", 61, 62], ["\u03b1", "PROTEIN", 128, 129], ["the S&P 500 index", "TEST", 4, 21], ["an abrupt increase of \u03b1", "PROBLEM", 39, 62], ["the crisis", "PROBLEM", 81, 91], ["abrupt", "OBSERVATION_MODIFIER", 42, 48], ["increase", "OBSERVATION_MODIFIER", 49, 57], ["crisis", "OBSERVATION", 85, 91], ["index", "OBSERVATION_MODIFIER", 166, 171]]], ["These tables confirm that the greatest impact of COVID-19 on market efficiency occurred for US indices, whatever the efficiency indicator.", [["COVID-19", "CHEMICAL", 49, 57], ["COVID", "TEST", 49, 54], ["US indices", "TEST", 92, 102], ["greatest", "OBSERVATION_MODIFIER", 30, 38]]], ["Indeed, the observed upper bounds in the period are never significantly different from 0.", [["upper", "ANATOMY_MODIFIER", 21, 26]]], ["On the contrary, for the Hurst exponent, we find downward peaks below 1/2 as well as upward peaks above 1/2, so that it is unclear whether inefficiency leads to high or low values for H. In fact, the presence of fatter tails during the crisis biases this efficiency indicator.", [["downward peaks", "PROBLEM", 49, 63], ["fatter tails", "PROBLEM", 212, 224], ["the crisis biases", "PROBLEM", 232, 249]]], ["Other regions seem less affected: the maximal |m| is indeed lower in Asia and Australia.", [["less", "OBSERVATION_MODIFIER", 19, 23], ["affected", "OBSERVATION", 24, 32], ["lower", "OBSERVATION_MODIFIER", 60, 65]]], ["However, the biased H indicator suggests a similar loss of efficiency in Europe and in Asia.", [["a similar loss of efficiency", "PROBLEM", 41, 69], ["similar", "OBSERVATION_MODIFIER", 43, 50], ["loss", "OBSERVATION", 51, 55], ["efficiency", "OBSERVATION_MODIFIER", 59, 69]]], ["This underpins again the relevance of the refinement of the efficiency indicator to take into account the kurtosis.", [["the kurtosis", "PROBLEM", 102, 114]]], ["An efficient market corresponds to m close to 0.ConclusionWe have shown to which extent the stock markets become inefficient during the COVID-19 crisis.", [["the COVID", "TEST", 132, 141], ["efficient", "OBSERVATION_MODIFIER", 3, 12], ["market", "OBSERVATION", 13, 19]]], ["The efficiency is clearly rejected in the case of the S&P index.", [["S&P", "GENE_OR_GENE_PRODUCT", 54, 57], ["S&P", "PROTEIN", 54, 57], ["efficiency", "OBSERVATION_MODIFIER", 4, 14], ["rejected", "OBSERVATION", 26, 34]]], ["On the contrary, the Hurst exponent does not make it possible to conclude about a loss of efficiency for the CAC 40, SSE 180, and S&P/ASX 200 indices.", [["a loss of efficiency", "PROBLEM", 80, 100], ["the CAC", "TEST", 105, 112]]], ["Therefore, if we use the more appropriate memory parameter of an fLsm, we observe the occurrence of an inefficiency period almost at the beginning of the crisis, even though it is less noticeable for the Chinese and the Australian indices.ConclusionWe have also introduced in this paper the tools used for this analysis, namely the estimation of a dynamic stable distribution along with the estimation of the dynamic Hurst exponent and memory parameter of an fLsm.", [["fLsm", "GENE_OR_GENE_PRODUCT", 65, 69], ["fLsm", "GENE_OR_GENE_PRODUCT", 459, 463], ["fLsm", "PROTEIN", 459, 463], ["an inefficiency period", "PROBLEM", 100, 122], ["this analysis", "TEST", 306, 319], ["inefficiency", "OBSERVATION", 103, 115], ["stable", "OBSERVATION", 356, 362]]], ["An important free parameter in this approach is the discount factor which is related to the speed at which the weight of past information decreases.", [["discount factor", "PROTEIN", 52, 67], ["free parameter", "OBSERVATION", 13, 27]]], ["We have used a selection rule based on the minimization of a criterion depicting the uniformity and the independence of the PITs, consistently with the literature on the validation of density forecasts.", [["a selection rule", "TEST", 13, 29], ["PITs", "OBSERVATION_MODIFIER", 124, 128], ["density", "OBSERVATION", 184, 191]]]], "PMC7150015": [], "PMC4884538": [["IntroductionThe selective packaging of genomic RNA (gRNA) into assembling virions is a fundamental problem faced by many RNA viruses.", [["virions", "ANATOMY", 74, 81], ["genomic RNA", "RNA", 39, 50], ["gRNA", "RNA", 52, 56], ["The selective packaging of genomic RNA (gRNA)", "TREATMENT", 12, 57], ["a fundamental problem", "PROBLEM", 85, 106], ["many RNA viruses", "PROBLEM", 116, 132], ["selective", "OBSERVATION_MODIFIER", 16, 25], ["genomic RNA", "OBSERVATION", 39, 50], ["RNA viruses", "OBSERVATION", 121, 132]]], ["Coronaviruses occupy a unique niche among positive-strand RNA viruses in two respects.", [["Coronaviruses", "PROBLEM", 0, 13], ["strand RNA viruses", "PROBLEM", 51, 69], ["strand RNA viruses", "OBSERVATION", 51, 69]]], ["First, they have helically symmetric nucleocapsids and, consequently, are not subject to the architectural constraints that govern packaging for viruses with icosahedral capsids (Prevelige, 2016).", [["nucleocapsids", "ANATOMY", 37, 50], ["nucleocapsids", "CELLULAR_COMPONENT", 37, 50], ["helically symmetric nucleocapsids", "PROBLEM", 17, 50], ["symmetric", "OBSERVATION_MODIFIER", 27, 36], ["nucleocapsids", "OBSERVATION", 37, 50]]], ["Second, although they synthesize a large molar excess of multiple subgenomic RNA (sgRNA) species during infection, coronaviruses very selectively incorporate gRNA into virions (Makino et al., 1990, Escors et al., 2003).IntroductionCoronavirus gRNA packaging has been most intensively studied in two betacoronaviruses, mouse hepatitis virus (MHV) and bovine coronavirus (BCoV), and in the alphacoronavirus transmissible gastroenteritis virus (TGEV).", [["infection", "DISEASE", 104, 113], ["mouse hepatitis virus (MHV) and bovine coronavirus", "DISEASE", 318, 368], ["transmissible gastroenteritis", "DISEASE", 405, 434], ["coronaviruses", "ORGANISM", 115, 128], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 231, 242], ["mouse hepatitis virus (MHV)", "ORGANISM", 318, 345], ["bovine coronavirus", "ORGANISM", 350, 368], ["BCoV", "CANCER", 370, 374], ["alphacoronavirus transmissible gastroenteritis virus", "ORGANISM", 388, 440], ["TGEV", "ORGANISM", 442, 446], ["subgenomic RNA", "RNA", 66, 80], ["mouse", "SPECIES", 318, 323], ["hepatitis virus", "SPECIES", 324, 339], ["bovine", "SPECIES", 350, 356], ["coronavirus", "SPECIES", 357, 368], ["transmissible gastroenteritis virus", "SPECIES", 405, 440], ["TGEV", "SPECIES", 442, 446], ["mouse hepatitis virus", "SPECIES", 318, 339], ["MHV", "SPECIES", 341, 344], ["bovine coronavirus", "SPECIES", 350, 368], ["BCoV", "SPECIES", 370, 374], ["alphacoronavirus transmissible gastroenteritis virus", "SPECIES", 388, 440], ["TGEV", "SPECIES", 442, 446], ["a large molar excess", "PROBLEM", 33, 53], ["multiple subgenomic RNA (sgRNA) species during infection", "PROBLEM", 57, 113], ["coronaviruses", "PROBLEM", 115, 128], ["IntroductionCoronavirus gRNA packaging", "TREATMENT", 219, 257], ["mouse hepatitis virus", "PROBLEM", 318, 339], ["bovine coronavirus", "PROBLEM", 350, 368], ["the alphacoronavirus transmissible gastroenteritis virus", "PROBLEM", 384, 440], ["large", "OBSERVATION_MODIFIER", 35, 40], ["molar", "OBSERVATION", 41, 46], ["multiple", "OBSERVATION_MODIFIER", 57, 65], ["subgenomic RNA", "OBSERVATION", 66, 80], ["Coronavirus gRNA", "OBSERVATION", 231, 247], ["most intensively", "OBSERVATION_MODIFIER", 267, 283]]], ["For MHV, a genomic packaging signal (PS) was originally identified through analyses of packaged defective-interfering (DI) RNAs, which are extensively deleted genomic remnants that replicate by appropriating the RNA synthesis machinery of a helper virus (Makino et al., 1990, van der Most et al., 1991).", [["packaged defective-interfering (DI) RNAs", "RNA", 87, 127], ["MHV", "SPECIES", 4, 7], ["MHV", "PROBLEM", 4, 7], ["packaged defective", "PROBLEM", 87, 105], ["interfering (DI) RNAs", "PROBLEM", 106, 127], ["defective", "OBSERVATION", 96, 105]]], ["The MHV PS is situated roughly 20.3 kb from the 5\u2032 end of the genome, embedded in the segment of gene 1 that encodes the nonstructural protein 15 (nsp15) subunit of the replicase-transcriptase (Fosmire et al., 1992, Cologna and Hogue, 2000, Narayanan and Makino, 2001).", [["MHV PS", "ORGANISM", 4, 10], ["nonstructural protein 15", "GENE_OR_GENE_PRODUCT", 121, 145], ["nsp15", "GENE_OR_GENE_PRODUCT", 147, 152], ["5\u2032 end", "DNA", 48, 54], ["gene 1", "DNA", 97, 103], ["nonstructural protein 15 (nsp15) subunit", "PROTEIN", 121, 161], ["replicase-transcriptase", "PROTEIN", 169, 192], ["MHV", "SPECIES", 4, 7], ["The MHV PS", "TEST", 0, 10], ["the nonstructural protein", "TEST", 117, 142], ["the replicase", "TREATMENT", 165, 178], ["MHV", "OBSERVATION", 4, 7], ["genome", "OBSERVATION", 62, 68], ["segment", "ANATOMY_MODIFIER", 86, 93]]], ["This localization places the PS solely in gRNA and not in any of the six species forming the 3\u2032-nested set of sgRNAs of MHV.IntroductionA structure recently proposed for the MHV PS (Chen et al., 2007b) models it as a 95-nt bulged stem-loop containing four repeat units, each with an AA (or GA) bulge; an internal loop separates the PS into quasi-symmetric upper and lower halves (Fig. 1A).", [["sgRNAs", "GENE_OR_GENE_PRODUCT", 110, 116], ["MHV", "ORGANISM", 120, 123], ["upper", "ORGANISM_SUBDIVISION", 356, 361], ["gRNA", "RNA", 42, 46], ["3\u2032", "DNA", 93, 95], ["sgRNAs", "PROTEIN", 110, 116], ["MHV", "SPECIES", 120, 123], ["MHV", "SPECIES", 174, 177], ["sgRNAs of MHV", "TREATMENT", 110, 123], ["the MHV PS", "TREATMENT", 170, 180], ["four repeat units", "TREATMENT", 251, 268], ["an AA (or GA) bulge", "PROBLEM", 280, 299], ["an internal loop", "TREATMENT", 301, 317], ["gRNA", "OBSERVATION", 42, 46], ["MHV", "ANATOMY", 120, 123], ["bulge", "OBSERVATION", 294, 299], ["internal loop", "OBSERVATION", 304, 317], ["upper", "ANATOMY_MODIFIER", 356, 361], ["lower halves", "ANATOMY", 366, 378]]], ["This structure is consistent with chemical and enzymatic probing profiles and is highly conserved among lineage A betacoronaviruses (such as MHV and BCoV).", [["lineage A betacoronaviruses", "CELL", 104, 131], ["MHV", "ORGANISM", 141, 144], ["BCoV", "CANCER", 149, 153], ["BCoV", "PROTEIN", 149, 153], ["A betacoronaviruses", "SPECIES", 112, 131], ["MHV", "SPECIES", 141, 144], ["BCoV", "SPECIES", 149, 153], ["chemical and enzymatic probing profiles", "PROBLEM", 34, 73], ["MHV and BCoV)", "TREATMENT", 141, 154], ["consistent with", "UNCERTAINTY", 18, 33], ["chemical", "OBSERVATION_MODIFIER", 34, 42], ["enzymatic probing", "OBSERVATION", 47, 64]]], ["We previously manipulated the MHV PS in the intact virus, rather than in DI RNAs, with the goal of obtaining insights into the mechanism of packaging (Kuo and Masters, 2013).", [["MHV", "ORGANISM", 30, 33], ["DI RNAs", "RNA", 73, 80], ["MHV", "SPECIES", 30, 33], ["the MHV PS", "TREATMENT", 26, 36], ["the intact virus", "PROBLEM", 40, 56], ["MHV PS", "OBSERVATION", 30, 36], ["intact virus", "OBSERVATION", 44, 56]]], ["Extensive disruption of the PS structure with 20 coding-silent mutations (in a mutant designated silPS) or outright deletion of the PS resulted in the packaging of abundant amounts of sgRNA in addition to gRNA in highly purified virions.", [["virions", "ANATOMY", 229, 236], ["sgRNA", "GENE_OR_GENE_PRODUCT", 184, 189], ["20 coding-silent mutations", "DNA", 46, 72], ["silPS", "DNA", 97, 102], ["PS", "DNA", 132, 134], ["sgRNA", "PROTEIN", 184, 189], ["gRNA", "RNA", 205, 209], ["Extensive disruption of the PS structure", "PROBLEM", 0, 40], ["20 coding-silent mutations", "PROBLEM", 46, 72], ["outright deletion of the PS", "PROBLEM", 107, 134], ["the packaging", "TREATMENT", 147, 160], ["sgRNA", "PROBLEM", 184, 189], ["gRNA in highly purified virions", "PROBLEM", 205, 236], ["disruption", "OBSERVATION", 10, 20], ["PS structure", "OBSERVATION", 28, 40], ["abundant", "OBSERVATION_MODIFIER", 164, 172], ["amounts", "OBSERVATION_MODIFIER", 173, 180], ["sgRNA", "OBSERVATION", 184, 189], ["gRNA", "OBSERVATION", 205, 209], ["highly", "OBSERVATION_MODIFIER", 213, 219], ["purified virions", "OBSERVATION", 220, 236]]], ["We found that the PS was not essential for MHV viability, but it conferred a distinct selective advantage to genomes that harbored it.", [["PS", "GENE_OR_GENE_PRODUCT", 18, 20], ["MHV", "ORGANISM", 43, 46], ["MHV", "SPECIES", 43, 46], ["the PS", "TEST", 14, 20], ["MHV viability", "PROBLEM", 43, 56]]], ["Additionally, the PS remained functional when transposed to an ectopic genomic site, a noncoding region created downstream of the replicase-transcriptase gene.", [["replicase-transcriptase", "GENE_OR_GENE_PRODUCT", 130, 153], ["ectopic genomic site", "DNA", 63, 83], ["noncoding region", "DNA", 87, 103], ["replicase-transcriptase gene", "DNA", 130, 158], ["an ectopic genomic site", "PROBLEM", 60, 83], ["the replicase", "TREATMENT", 126, 139], ["ectopic", "OBSERVATION", 63, 70]]], ["This work showed that the PS indeed governs the selective incorporation of gRNA into virions.IntroductionTo begin to identify interacting partners of the PS, we modified the nucleocapsid (N) protein, the molecule that coats the gRNA and winds it into a helically symmetric filament within the virion (Masters, 2006).", [["virions", "ANATOMY", 85, 92], ["gRNA", "CELLULAR_COMPONENT", 228, 232], ["filament", "CELLULAR_COMPONENT", 273, 281], ["virion", "CELLULAR_COMPONENT", 293, 299], ["gRNA", "RNA", 75, 79], ["nucleocapsid (N) protein", "PROTEIN", 174, 198], ["gRNA", "PROTEIN", 228, 232], ["helically symmetric filament", "PROTEIN", 253, 281], ["the PS", "TREATMENT", 22, 28], ["gRNA into virions", "PROBLEM", 75, 92], ["the nucleocapsid (N) protein", "TREATMENT", 170, 198], ["selective", "OBSERVATION_MODIFIER", 48, 57], ["gRNA", "OBSERVATION", 75, 79], ["gRNA", "OBSERVATION", 228, 232], ["helically symmetric", "OBSERVATION_MODIFIER", 253, 272], ["filament", "OBSERVATION_MODIFIER", 273, 281], ["virion", "ANATOMY", 293, 299]]], ["N is a mostly basic phosphoprotein containing two structurally separate RNA-binding domains, the amino-terminal domain (NTD) and the carboxy-terminal domain (CTD) (Fig. 1B).", [["carboxy", "CHEMICAL", 133, 140], ["basic phosphoprotein", "PROTEIN", 14, 34], ["RNA-binding domains", "PROTEIN", 72, 91], ["amino-terminal domain", "PROTEIN", 97, 118], ["NTD", "PROTEIN", 120, 123], ["carboxy-terminal domain", "PROTEIN", 133, 156], ["CTD", "PROTEIN", 158, 161], ["Fig. 1B", "PROTEIN", 164, 171], ["a mostly basic phosphoprotein", "PROBLEM", 5, 34], ["the amino-terminal domain (NTD", "PROBLEM", 93, 123], ["the carboxy-terminal domain (CTD)", "TREATMENT", 129, 162]]], ["(For a comprehensive review of coronavirus N protein structure, see Chang et al., 2014.)", [["coronavirus", "ORGANISM", 31, 42], ["coronavirus N protein structure", "PROTEIN", 31, 62], ["coronavirus N protein structure", "PROBLEM", 31, 62]]], ["The CTD additionally mediates N-N dimerization and higher-order interactions in the nucleocapsid (Chang et al., 2013).", [["N-N", "CHEMICAL", 30, 33], ["N-N", "CHEMICAL", 30, 33], ["CTD", "GENE_OR_GENE_PRODUCT", 4, 7], ["CTD", "PROTEIN", 4, 7], ["N-N dimerization", "TREATMENT", 30, 46]]], ["This nomenclature can obscure the point that the actual carboxy terminus of N protein consists of a linker (spacer B) joining the CTD to N3, an acidic domain that binds to the endodomain of the membrane (M) protein during virion assembly (Kuo and Masters, 2002; Hurst et al., 2005; Verma et al., 2006, Verma et al., 2007; Kuo et al., 2016).", [["membrane", "ANATOMY", 194, 202], ["carboxy", "CHEMICAL", 56, 63], ["N3", "CHEMICAL", 137, 139], ["membrane", "CELLULAR_COMPONENT", 194, 202], ["virion", "CELLULAR_COMPONENT", 222, 228], ["carboxy terminus", "PROTEIN", 56, 72], ["N protein", "PROTEIN", 76, 85], ["spacer B", "PROTEIN", 108, 116], ["CTD", "PROTEIN", 130, 133], ["N3", "PROTEIN", 137, 139], ["acidic domain", "PROTEIN", 144, 157], ["endodomain", "PROTEIN", 176, 186], ["membrane (M) protein", "PROTEIN", 194, 214], ["the actual carboxy terminus of N protein", "PROBLEM", 45, 85], ["a linker (spacer B) joining the CTD to N3", "TREATMENT", 98, 139], ["an acidic domain", "PROBLEM", 141, 157]]], ["Another linker, between the NTD and CTD, encompasses a serine- and arginine-rich region that associates with replicase subunit nsp3 in a crucial early event of infection (Hurst et al., 2010).IntroductionAlthough the MHV PS is conserved among lineage A betacoronaviruses, it is clear that severe acute respiratory syndrome coronavirus (SARS-CoV), a lineage B betacoronavirus, does not contain a homolog of the MHV PS (Joseph et al., 2007, Chen and Olsthoorn, 2010).", [["arginine", "CHEMICAL", 67, 75], ["infection", "DISEASE", 160, 169], ["acute respiratory syndrome coronavirus", "DISEASE", 295, 333], ["SARS-CoV)", "DISEASE", 335, 344], ["serine", "CHEMICAL", 55, 61], ["arginine", "CHEMICAL", 67, 75], ["CTD", "GENE_OR_GENE_PRODUCT", 36, 39], ["serine", "AMINO_ACID", 55, 61], ["arginine", "AMINO_ACID", 67, 75], ["nsp3", "GENE_OR_GENE_PRODUCT", 127, 131], ["MHV PS", "ORGANISM", 216, 222], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 288, 333], ["SARS-CoV", "ORGANISM", 335, 343], ["MHV PS", "ORGANISM", 409, 415], ["NTD", "PROTEIN", 28, 31], ["CTD", "PROTEIN", 36, 39], ["serine- and arginine-rich region", "PROTEIN", 55, 87], ["replicase subunit nsp3", "PROTEIN", 109, 131], ["MHV PS", "PROTEIN", 216, 222], ["MHV", "SPECIES", 216, 219], ["severe acute respiratory syndrome coronavirus", "SPECIES", 288, 333], ["SARS-CoV", "SPECIES", 335, 343], ["B betacoronavirus", "SPECIES", 356, 373], ["MHV", "SPECIES", 409, 412], ["Another linker", "PROBLEM", 0, 14], ["the NTD", "PROBLEM", 24, 31], ["CTD", "PROBLEM", 36, 39], ["a serine", "TEST", 53, 61], ["infection", "PROBLEM", 160, 169], ["the MHV PS", "TREATMENT", 212, 222], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 288, 333], ["a lineage B betacoronavirus", "TREATMENT", 346, 373], ["linker", "OBSERVATION_MODIFIER", 8, 14], ["CTD", "OBSERVATION", 36, 39], ["replicase", "OBSERVATION_MODIFIER", 109, 118], ["subunit nsp3", "OBSERVATION", 119, 131], ["crucial", "OBSERVATION_MODIFIER", 137, 144], ["early", "OBSERVATION_MODIFIER", 145, 150], ["infection", "OBSERVATION", 160, 169], ["severe", "OBSERVATION_MODIFIER", 288, 294], ["acute", "OBSERVATION_MODIFIER", 295, 300], ["respiratory syndrome coronavirus", "OBSERVATION", 301, 333]]], ["We therefore turned to SARS-CoV chimeras for evidence of interacting partners of this RNA element, constructing MHV N protein mutants in which either of the two RNA-binding domains of N was substituted by its SARS-CoV counterpart (Kuo et al., 2014).", [["CoV", "ORGANISM", 28, 31], ["RNA element", "DNA", 86, 97], ["MHV N protein mutants", "PROTEIN", 112, 133], ["RNA-binding domains", "PROTEIN", 161, 180], ["SARS-CoV", "SPECIES", 23, 31], ["MHV", "SPECIES", 112, 115], ["SARS-CoV chimeras", "TREATMENT", 23, 40], ["this RNA element", "PROBLEM", 81, 97], ["MHV N protein mutants", "TREATMENT", 112, 133]]], ["Strikingly, we found that the SARS-CoV CTD chimera recapitulated the defective packaging phenotype of the silPS mutant and the PS deletion mutant.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 30, 38], ["silPS", "GENE_OR_GENE_PRODUCT", 106, 111], ["PS", "GENE_OR_GENE_PRODUCT", 127, 129], ["SARS-CoV CTD chimera", "PROTEIN", 30, 50], ["silPS mutant", "PROTEIN", 106, 118], ["PS deletion mutant", "PROTEIN", 127, 145], ["SARS-CoV", "SPECIES", 30, 38], ["the SARS-CoV CTD chimera", "PROBLEM", 26, 50], ["the PS deletion mutant", "PROBLEM", 123, 145], ["defective packaging phenotype", "OBSERVATION", 69, 98]]], ["Furthermore, the region affecting PS recognition was localized in a partial CTD chimera to a central segment of 30 amino acids, which corresponds to helices \u03b14-\u03b16 of the SARS-CoV CTD (Chen et al., 2007a).", [["amino acids", "CHEMICAL", 115, 126], ["amino acids", "CHEMICAL", 115, 126], ["PS", "CELLULAR_COMPONENT", 34, 36], ["amino acids", "AMINO_ACID", 115, 126], ["\u03b14-\u03b16", "GENE_OR_GENE_PRODUCT", 157, 162], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 170, 178], ["CTD chimera", "PROTEIN", 76, 87], ["\u03b14", "PROTEIN", 157, 159], ["\u03b16", "PROTEIN", 160, 162], ["SARS-CoV CTD", "PROTEIN", 170, 182], ["SARS-CoV", "SPECIES", 170, 178], ["amino acids", "TEST", 115, 126], ["helices", "TEST", 149, 156], ["the SARS", "PROBLEM", 166, 174], ["partial", "OBSERVATION_MODIFIER", 68, 75], ["CTD", "OBSERVATION", 76, 79], ["central", "ANATOMY_MODIFIER", 93, 100], ["segment", "ANATOMY_MODIFIER", 101, 108]]], ["Conversely, gRNA packaging selectivity in the SARS-CoV NTD chimera was identical to that of wild-type MHV.", [["SARS", "DISEASE", 46, 50], ["SARS-CoV", "ORGANISM", 46, 54], ["wild-type MHV", "ORGANISM", 92, 105], ["SARS-CoV NTD chimera", "PROTEIN", 46, 66], ["wild-type MHV", "PROTEIN", 92, 105], ["SARS-CoV", "SPECIES", 46, 54], ["MHV", "SPECIES", 102, 105], ["the SARS", "PROBLEM", 42, 50], ["CoV NTD chimera", "PROBLEM", 51, 66], ["gRNA", "OBSERVATION", 12, 16], ["packaging selectivity", "OBSERVATION", 17, 38]]], ["This demonstrated that the second RNA-binding domain of N, the CTD, is the major protein determinant of MHV PS recognition.", [["CTD", "GENE_OR_GENE_PRODUCT", 63, 66], ["MHV", "ORGANISM", 104, 107], ["RNA-binding domain", "PROTEIN", 34, 52], ["N", "PROTEIN", 56, 57], ["CTD", "PROTEIN", 63, 66], ["MHV", "SPECIES", 104, 107], ["the CTD", "PROBLEM", 59, 66], ["MHV PS recognition", "TREATMENT", 104, 122], ["MHV PS", "OBSERVATION", 104, 110]]], ["In the work reported here, we show that PS recognition additionally depends upon a segment of the carboxy-terminal tail of the N protein, domain N3.", [["carboxy", "CHEMICAL", 98, 105], ["carboxy-terminal tail", "PROTEIN", 98, 119], ["N protein", "PROTEIN", 127, 136], ["domain N3", "PROTEIN", 138, 147], ["PS recognition", "PROBLEM", 40, 54]]], ["This finding suggests a mechanism by which selective genome packaging is carried out.Substitution of the TGEV CTD in MHV N abolishes recognition of the MHV PS ::: ResultsWe found previously that selective packaging of MHV genomic RNA was abrogated by the substitution of the SARS-CoV CTD, but not the NTD, into the MHV N protein.", [["SARS", "DISEASE", 275, 279], ["TGEV", "ORGANISM", 105, 109], ["MHV N", "ORGANISM", 117, 122], ["MHV", "ORGANISM", 218, 221], ["SARS-CoV CTD", "GENE_OR_GENE_PRODUCT", 275, 287], ["MHV N protein", "GENE_OR_GENE_PRODUCT", 315, 328], ["TGEV CTD", "PROTEIN", 105, 113], ["MHV N", "PROTEIN", 117, 122], ["MHV genomic RNA", "RNA", 218, 233], ["SARS-CoV CTD", "PROTEIN", 275, 287], ["NTD", "PROTEIN", 301, 304], ["MHV N protein", "PROTEIN", 315, 328], ["TGEV", "SPECIES", 105, 109], ["MHV", "SPECIES", 117, 120], ["MHV", "SPECIES", 152, 155], ["MHV", "SPECIES", 218, 221], ["SARS-CoV", "SPECIES", 275, 283], ["MHV", "SPECIES", 315, 318], ["selective genome packaging", "TREATMENT", 43, 69], ["the TGEV CTD", "TREATMENT", 101, 113], ["MHV genomic RNA", "TREATMENT", 218, 233], ["the SARS", "PROBLEM", 271, 279], ["CoV CTD", "PROBLEM", 280, 287], ["selective", "OBSERVATION_MODIFIER", 195, 204], ["MHV", "OBSERVATION_MODIFIER", 218, 221], ["genomic RNA", "OBSERVATION", 222, 233]]], ["To extend this result to a still more phylogenetically distant N protein, we chose TGEV, an alphacoronavirus for which selective genomic packaging has been clearly demonstrated (Escors et al., 2003, Morales et al., 2013).", [["TGEV", "ORGANISM", 83, 87], ["alphacoronavirus", "CANCER", 92, 108], ["N protein", "PROTEIN", 63, 72], ["TGEV", "SPECIES", 83, 87], ["TGEV", "PROBLEM", 83, 87], ["an alphacoronavirus", "PROBLEM", 89, 108], ["selective genomic packaging", "TREATMENT", 119, 146]]], ["As is the case with SARS-CoV, the TGEV genome does not contain a counterpart of the MHV PS in the nsp15 coding region (Chen and Olsthoorn, 2010).", [["SARS", "DISEASE", 20, 24], ["SARS-CoV", "ORGANISM", 20, 28], ["TGEV", "ORGANISM", 34, 38], ["MHV PS", "ORGANISM", 84, 90], ["TGEV genome", "DNA", 34, 45], ["nsp15 coding region", "DNA", 98, 117], ["SARS-CoV", "SPECIES", 20, 28], ["TGEV", "SPECIES", 34, 38], ["MHV", "SPECIES", 84, 87], ["the TGEV genome", "PROBLEM", 30, 45], ["the MHV PS", "TREATMENT", 80, 90], ["MHV", "OBSERVATION", 84, 87]]], ["We would consequently expect that the TGEV N protein did not evolve the capacity to recognize the MHV PS.Substitution of the TGEV CTD in MHV N abolishes recognition of the MHV PS ::: ResultsTo construct TGEV N protein substitution mutants, we used the reverse-genetic technique of targeted RNA recombination (Kuo et al., 2000, Goebel et al., 2004).", [["TGEV", "ORGANISM", 38, 42], ["TGEV", "ORGANISM", 125, 129], ["MHV N", "ORGANISM", 137, 142], ["TGEV", "ORGANISM", 203, 207], ["TGEV N protein", "PROTEIN", 38, 52], ["MHV PS", "PROTEIN", 98, 104], ["TGEV CTD", "PROTEIN", 125, 133], ["MHV N", "PROTEIN", 137, 142], ["TGEV N protein", "PROTEIN", 203, 217], ["TGEV", "SPECIES", 38, 42], ["MHV", "SPECIES", 98, 101], ["TGEV", "SPECIES", 125, 129], ["MHV", "SPECIES", 137, 140], ["MHV", "SPECIES", 172, 175], ["TGEV", "SPECIES", 203, 207], ["the TGEV N protein", "TEST", 34, 52], ["the capacity", "PROBLEM", 68, 80], ["the MHV PS", "TREATMENT", 94, 104], ["the TGEV CTD", "TREATMENT", 121, 133], ["ResultsTo construct TGEV N protein substitution mutants", "TREATMENT", 183, 238], ["the reverse-genetic technique", "TREATMENT", 248, 277], ["MHV PS", "OBSERVATION", 98, 104]]], ["Because no structures are available for the NTD or CTD of any alphacoronavirus N protein, it was not straightforward to clearly define the boundaries of these domains in TGEV N. In the case of the TGEV NTD, multiple attempts made with each of five different sets of boundaries were all unsuccessful in producing a viable chimeric virus.", [["alphacoronavirus N", "GENE_OR_GENE_PRODUCT", 62, 80], ["TGEV N.", "ORGANISM", 170, 177], ["TGEV", "ORGANISM", 197, 201], ["chimeric virus", "ORGANISM", 321, 335], ["NTD", "PROTEIN", 44, 47], ["CTD", "PROTEIN", 51, 54], ["alphacoronavirus N protein", "PROTEIN", 62, 88], ["TGEV N.", "SPECIES", 170, 177], ["TGEV", "SPECIES", 197, 201], ["structures", "PROBLEM", 11, 21], ["the NTD", "PROBLEM", 40, 47], ["the TGEV NTD", "TREATMENT", 193, 205], ["a viable chimeric virus", "PROBLEM", 312, 335], ["virus", "OBSERVATION", 330, 335]]], ["This possibly indicates that the NTD mediates some sequence-specific RNA-binding function (other than packaging) which cannot be exchanged between alpha- and betacoronaviruses.", [["alpha", "GENE_OR_GENE_PRODUCT", 147, 152], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 158, 175], ["NTD", "PROTEIN", 33, 36], ["alpha- and betacoronaviruses", "PROTEIN", 147, 175], ["the NTD mediates", "PROBLEM", 29, 45], ["packaging", "TREATMENT", 102, 111], ["alpha", "TEST", 147, 152]]], ["For the CTD, we generated an alignment of the corresponding domains of MHV and TGEV (Fig. 1C), guided by the MHV and SARS-CoV CTD alignment that was already known to produce a functional substitution (Kuo et al., 2014).", [["MHV", "ORGANISM", 71, 74], ["TGEV", "ORGANISM", 79, 83], ["MHV", "ORGANISM", 109, 112], ["CTD", "PROTEIN", 8, 11], ["MHV", "SPECIES", 71, 74], ["TGEV", "SPECIES", 79, 83], ["MHV", "SPECIES", 109, 112], ["SARS-CoV", "SPECIES", 117, 125], ["MHV and TGEV", "TREATMENT", 71, 83], ["SARS-CoV CTD alignment", "TEST", 117, 139], ["MHV", "ANATOMY", 71, 74], ["MHV", "ANATOMY", 109, 112]]], ["The MHV CTD retains only 25% amino-acid identity with the TGEV CTD, an even greater divergence than the 35% identity between the MHV and SARS-CoV CTDs.Substitution of the TGEV CTD in MHV N abolishes recognition of the MHV PS ::: ResultsThree independent isolates of the TGEV-CTD mutant were obtained.", [["amino-acid", "CHEMICAL", 29, 39], ["SARS-CoV CTDs", "DISEASE", 137, 150], ["amino-acid", "CHEMICAL", 29, 39], ["MHV", "ORGANISM", 4, 7], ["amino-acid", "SIMPLE_CHEMICAL", 29, 39], ["TGEV", "ORGANISM", 58, 62], ["MHV", "ORGANISM", 129, 132], ["SARS-CoV CTDs", "ORGANISM", 137, 150], ["TGEV", "ORGANISM", 171, 175], ["MHV N", "ORGANISM", 183, 188], ["TGEV", "ORGANISM", 270, 274], ["CTD", "GENE_OR_GENE_PRODUCT", 275, 278], ["MHV CTD", "PROTEIN", 4, 11], ["TGEV CTD", "PROTEIN", 58, 66], ["TGEV CTD", "PROTEIN", 171, 179], ["MHV N", "PROTEIN", 183, 188], ["TGEV-CTD mutant", "PROTEIN", 270, 285], ["TGEV", "SPECIES", 270, 274], ["MHV", "SPECIES", 4, 7], ["TGEV", "SPECIES", 58, 62], ["MHV", "SPECIES", 129, 132], ["SARS-CoV", "SPECIES", 137, 145], ["TGEV", "SPECIES", 171, 175], ["MHV", "SPECIES", 183, 186], ["MHV", "SPECIES", 218, 221], ["TGEV", "SPECIES", 270, 274], ["The MHV CTD", "TEST", 0, 11], ["the TGEV CTD", "TEST", 54, 66], ["SARS", "PROBLEM", 137, 141], ["CoV CTDs", "PROBLEM", 142, 150], ["the TGEV CTD", "TREATMENT", 167, 179], ["the TGEV-CTD mutant", "TEST", 266, 285], ["MHV", "ANATOMY", 129, 132]]], ["All three produced small plaques and grew slowly compared to the wild type.", [["plaques", "ANATOMY", 25, 32], ["small plaques", "PROBLEM", 19, 32], ["three", "OBSERVATION_MODIFIER", 4, 9], ["produced", "OBSERVATION_MODIFIER", 10, 18], ["small", "OBSERVATION_MODIFIER", 19, 24], ["plaques", "OBSERVATION", 25, 32], ["grew", "OBSERVATION_MODIFIER", 37, 41], ["slowly", "OBSERVATION_MODIFIER", 42, 48]]], ["However, after two to three passages, cultures of the original mutants rapidly became overrun by revertants that produced nearly wild-type-sized plaques at 37 \u00b0C. From these we isolated three independent revertants and found that the two most robust growers each contained the mutation G78R in the (MHV) NTD of N protein.", [["plaques", "ANATOMY", 145, 152], ["plaques", "PATHOLOGICAL_FORMATION", 145, 152], ["N protein", "PROTEIN", 311, 320], ["MHV", "SPECIES", 299, 302], ["cultures", "TEST", 38, 46], ["type-sized plaques", "PROBLEM", 134, 152], ["the mutation G78R", "TEST", 273, 290], ["sized", "OBSERVATION_MODIFIER", 139, 144], ["plaques", "OBSERVATION", 145, 152]]], ["Thus, to facilitate better growth for virion purification, we reconstructed the G78R mutation into the TGEV chimeric mutant, now designated T-CTD-R (Fig. 1D).", [["G78R", "GENE_OR_GENE_PRODUCT", 80, 84], ["TGEV", "ORGANISM", 103, 107], ["T-CTD-R", "GENE_OR_GENE_PRODUCT", 140, 147], ["G78R", "PROTEIN", 80, 84], ["TGEV chimeric mutant", "PROTEIN", 103, 123], ["CTD", "PROTEIN", 142, 145], ["TGEV", "SPECIES", 103, 107], ["virion purification", "TREATMENT", 38, 57]]], ["We subsequently learned that the G78R mutation had no impact on the packaging phenotype (data not shown).", [["G78R", "GENE_OR_GENE_PRODUCT", 33, 37], ["G78R", "DNA", 33, 37], ["the G78R mutation", "PROBLEM", 29, 46]]], ["In this respect, the G78R mutation was similar to a second-site mutation of the previously studied SARS-CoV CTD chimera that enhanced growth of that mutant but had no effect on packaging (Kuo et al., 2014).Substitution of the TGEV CTD in MHV N abolishes recognition of the MHV PS ::: ResultsRNA was isolated from equal amounts of purified wild-type and T-CTD-R virions that had been normalized by Western blotting of the two most abundant structural proteins, N and M (Fig. 1E).", [["G78R", "GENE_OR_GENE_PRODUCT", 21, 25], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 99, 107], ["TGEV", "ORGANISM", 226, 230], ["MHV N", "ORGANISM", 238, 243], ["ResultsRNA", "GENE_OR_GENE_PRODUCT", 284, 294], ["T-CTD-R", "GENE_OR_GENE_PRODUCT", 353, 360], ["G78R", "DNA", 21, 25], ["SARS-CoV CTD chimera", "PROTEIN", 99, 119], ["TGEV CTD", "PROTEIN", 226, 234], ["MHV N", "PROTEIN", 238, 243], ["ResultsRNA", "PROTEIN", 284, 294], ["CTD", "PROTEIN", 355, 358], ["structural proteins", "PROTEIN", 439, 458], ["N", "PROTEIN", 460, 461], ["Fig. 1E", "PROTEIN", 469, 476], ["SARS-CoV", "SPECIES", 99, 107], ["TGEV", "SPECIES", 226, 230], ["MHV", "SPECIES", 238, 241], ["MHV", "SPECIES", 273, 276], ["the G78R mutation", "PROBLEM", 17, 34], ["a second-site mutation", "PROBLEM", 50, 72], ["the previously studied SARS", "PROBLEM", 76, 103], ["CoV CTD chimera", "PROBLEM", 104, 119], ["the TGEV CTD", "TREATMENT", 222, 234], ["ResultsRNA", "TEST", 284, 294]]], ["Northern blot analysis of virion RNA with a probe specific for the upstream half of the N gene revealed that, as seen previously, wild-type virions exhibited almost complete stringency in packaging gRNA and excluding sgRNA (Fig. 1F).", [["virion RNA", "RNA", 26, 36], ["upstream half", "DNA", 67, 80], ["N gene", "DNA", 88, 94], ["packaging gRNA", "RNA", 188, 202], ["sgRNA", "PROTEIN", 217, 222], ["Northern blot analysis", "TEST", 0, 22], ["virion RNA", "PROBLEM", 26, 36], ["wild-type virions", "PROBLEM", 130, 147], ["packaging gRNA", "TREATMENT", 188, 202], ["sgRNA", "PROBLEM", 217, 222], ["virion RNA", "OBSERVATION", 26, 36], ["packaging gRNA", "OBSERVATION", 188, 202]]], ["By contrast, the T-CTD-R mutant packaged plentiful amounts of sgRNAs, proportional to the relative levels of these species found in infected cells.", [["cells", "ANATOMY", 141, 146], ["T-CTD-R", "GENE_OR_GENE_PRODUCT", 17, 24], ["sgRNAs", "GENE_OR_GENE_PRODUCT", 62, 68], ["cells", "CELL", 141, 146], ["CTD", "PROTEIN", 19, 22], ["R mutant", "PROTEIN", 23, 31], ["sgRNAs", "PROTEIN", 62, 68], ["infected cells", "CELL_TYPE", 132, 146], ["sgRNAs", "PROBLEM", 62, 68], ["these species", "PROBLEM", 109, 122], ["infected cells", "PROBLEM", 132, 146], ["plentiful", "OBSERVATION_MODIFIER", 41, 50], ["amounts", "OBSERVATION_MODIFIER", 51, 58], ["sgRNAs", "OBSERVATION", 62, 68], ["infected cells", "OBSERVATION", 132, 146]]], ["This was the same phenotype we had observed previously for other packaging-defective MHV mutants (Kuo and Masters, 2013, Kuo et al., 2014).", [["MHV", "ORGANISM", 85, 88], ["MHV mutants", "PROTEIN", 85, 96], ["defective MHV", "OBSERVATION", 75, 88]]], ["It should be noted that in the T-CTD-R mutant only the N gene and not the MHV PS had been altered.", [["T-CTD-R", "GENE_OR_GENE_PRODUCT", 31, 38], ["MHV PS", "ORGANISM", 74, 80], ["CTD", "PROTEIN", 33, 36], ["N gene", "DNA", 55, 61], ["MHV PS", "PROTEIN", 74, 80], ["MHV", "SPECIES", 74, 77], ["the MHV PS", "TREATMENT", 70, 80]]], ["Therefore, this result confirmed our previous finding that the CTD is a major determinant of PS recognition.Substitution of the TGEV CTD in MHV N abolishes recognition of the MHV PS ::: ResultsTo determine whether the T-CTD-R mutant could be used to capture the TGEV PS, we constructed two additional mutants in which TGEV sequence was inserted at a site immediately downstream of MHV gene 1 (Fig. 1D).", [["CTD", "GENE_OR_GENE_PRODUCT", 63, 66], ["TGEV", "ORGANISM", 128, 132], ["MHV N", "ORGANISM", 140, 145], ["T-CTD-R", "GENE_OR_GENE_PRODUCT", 218, 225], ["TGEV", "ORGANISM", 262, 266], ["TGEV", "ORGANISM", 318, 322], ["CTD", "PROTEIN", 63, 66], ["TGEV CTD", "PROTEIN", 128, 136], ["MHV N", "PROTEIN", 140, 145], ["CTD", "PROTEIN", 220, 223], ["R mutant", "PROTEIN", 224, 232], ["TGEV sequence", "DNA", 318, 331], ["MHV gene 1", "DNA", 381, 391], ["TGEV", "SPECIES", 128, 132], ["MHV", "SPECIES", 140, 143], ["MHV", "SPECIES", 175, 178], ["TGEV", "SPECIES", 262, 266], ["TGEV", "SPECIES", 318, 322], ["MHV", "SPECIES", 381, 384], ["the TGEV CTD", "TREATMENT", 124, 136], ["the TGEV PS", "TREATMENT", 258, 269], ["TGEV sequence", "TREATMENT", 318, 331]]], ["We had previously shown that the MHV PS remains fully functional when it is inserted at this ectopic position and deleted from its native site (Kuo and Masters, 2013).", [["MHV PS", "ORGANISM", 33, 39], ["MHV", "SPECIES", 33, 36], ["the MHV PS", "TREATMENT", 29, 39], ["MHV", "OBSERVATION", 33, 36]]], ["The first mutant, T-CTD-R-PS1, incorporated nt 1-650 of the TGEV genome, which has been shown to harbor the TGEV PS, through analyses of packaged DI RNAs (Escors et al., 2003, Morales et al., 2013).", [["T-CTD-R-PS1", "GENE_OR_GENE_PRODUCT", 18, 29], ["TGEV", "ORGANISM", 60, 64], ["TGEV", "ORGANISM", 108, 112], ["CTD", "PROTEIN", 20, 23], ["R", "PROTEIN", 24, 25], ["PS1", "PROTEIN", 26, 29], ["nt 1-650", "DNA", 44, 52], ["TGEV genome", "DNA", 60, 71], ["TGEV", "SPECIES", 60, 64], ["TGEV", "SPECIES", 108, 112], ["CTD", "TEST", 20, 23], ["the TGEV genome", "PROBLEM", 56, 71], ["TGEV genome", "OBSERVATION", 60, 71], ["TGEV PS", "OBSERVATION", 108, 115], ["DI RNAs", "OBSERVATION", 146, 153]]], ["The second mutant, T-CTD-R-PS2, incorporated a subregion, nt 156-327, which contains a triply-repeated hairpin-loop motif that has been proposed to constitute the alphacoronavirus PS (Chen and Olsthoorn, 2010).", [["nt 156-327", "CHEMICAL", 58, 68], ["T-CTD-R-PS2", "GENE_OR_GENE_PRODUCT", 19, 30], ["CTD", "PROTEIN", 21, 24], ["R", "PROTEIN", 25, 26], ["PS2", "PROTEIN", 27, 30], ["nt 156-327", "DNA", 58, 68], ["triply-repeated hairpin-loop motif", "PROTEIN", 87, 121], ["nt", "TEST", 58, 60], ["a triply-repeated hairpin-loop motif", "TREATMENT", 85, 121]]], ["However, both mutants displayed the same packaging-negative phenotype as the T-CTD-R mutant (Fig. 1E and F); that is, incorporation of the putative TGEV PS did not restore gRNA packaging selectivity to T-CTD-R.", [["T-CTD-R", "GENE_OR_GENE_PRODUCT", 77, 84], ["TGEV", "ORGANISM", 148, 152], ["CTD", "PROTEIN", 79, 82], ["R mutant", "PROTEIN", 83, 91], ["Fig. 1E and F", "PROTEIN", 93, 106], ["T-CTD", "PROTEIN", 202, 207], ["TGEV", "SPECIES", 148, 152], ["R.", "ANATOMY", 208, 210]]], ["Although we could not eliminate other potential explanations for this negative result, this outcome suggested that there exists some viral factor, in addition to the N protein CTD, that is required for PS recognition.MHV chimeras containing the SARS-CoV M protein are packaging-defective ::: ResultsOne candidate for an additional viral factor involved in genome packaging is the membrane (M) protein (Narayanan and Makino, 2001, Narayanan et al., 2003).", [["membrane", "ANATOMY", 380, 388], ["CTD", "GENE_OR_GENE_PRODUCT", 176, 179], ["MHV chimeras", "ORGANISM", 217, 229], ["SARS-CoV M", "GENE_OR_GENE_PRODUCT", 245, 255], ["genome", "CELLULAR_COMPONENT", 356, 362], ["membrane", "CELLULAR_COMPONENT", 380, 388], ["viral factor", "PROTEIN", 133, 145], ["N protein CTD", "PROTEIN", 166, 179], ["MHV chimeras", "PROTEIN", 217, 229], ["SARS-CoV M protein", "PROTEIN", 245, 263], ["viral factor", "PROTEIN", 331, 343], ["membrane (M) protein", "PROTEIN", 380, 400], ["MHV", "SPECIES", 217, 220], ["SARS-CoV", "SPECIES", 245, 253], ["some viral factor", "PROBLEM", 128, 145], ["the N protein CTD", "TREATMENT", 162, 179], ["PS recognition", "TEST", 202, 216], ["MHV chimeras", "TREATMENT", 217, 229], ["the SARS", "PROBLEM", 241, 249], ["an additional viral factor", "PROBLEM", 317, 343]]], ["We recently constructed MHV chimeras containing whole or partial substitutions of the SARS-CoV M protein for the purpose of learning more about intermolecular interactions of M in virion assembly (Kuo et al., 2016).", [["MHV", "ORGANISM", 24, 27], ["SARS-CoV M", "GENE_OR_GENE_PRODUCT", 86, 96], ["MHV chimeras", "PROTEIN", 24, 36], ["SARS-CoV M protein", "PROTEIN", 86, 104], ["MHV", "SPECIES", 24, 27], ["SARS-CoV", "SPECIES", 86, 94], ["MHV chimeras", "TREATMENT", 24, 36], ["the SARS", "PROBLEM", 82, 90], ["CoV M protein", "TREATMENT", 91, 104], ["MHV chimeras", "OBSERVATION", 24, 36], ["partial", "OBSERVATION_MODIFIER", 57, 64], ["substitutions", "OBSERVATION_MODIFIER", 65, 78]]], ["MHV and SARS-CoV, which fall into different lineages of the betacoronavirus genus, have M proteins that share only 38% amino-acid sequence identity.", [["amino-acid", "CHEMICAL", 119, 129], ["amino-acid", "CHEMICAL", 119, 129], ["MHV", "ORGANISM", 0, 3], ["SARS-CoV", "ORGANISM", 8, 16], ["betacoronavirus genus", "ORGANISM", 60, 81], ["amino-acid", "AMINO_ACID", 119, 129], ["M proteins", "PROTEIN", 88, 98], ["MHV", "SPECIES", 0, 3], ["SARS-CoV", "SPECIES", 8, 16], ["MHV", "PROBLEM", 0, 3], ["SARS", "PROBLEM", 8, 12], ["CoV", "PROBLEM", 13, 16], ["M proteins", "TEST", 88, 98], ["SARS", "OBSERVATION", 8, 12]]], ["We reasoned that, as with previously studied N gene chimeras (Hurst et al., 2010, Kuo et al., 2014), this degree of divergence might impair particular viral functions.", [["N gene chimeras", "DNA", 45, 60], ["viral functions", "OBSERVATION", 151, 166]]], ["One conclusion of this work was that the carboxy-terminal tail of N protein, N3, is both necessary and sufficient for virion assembly interactions between the coronavirus N and M proteins, a result that is supported by numerous prior studies (Kuo and Masters, 2002, Hurst et al., 2005, Verma et al., 2006, 2007; Luo et al., 2006).", [["carboxy", "CHEMICAL", 41, 48], ["M proteins", "GENE_OR_GENE_PRODUCT", 177, 187], ["carboxy-terminal tail", "PROTEIN", 41, 62], ["N protein", "PROTEIN", 66, 75], ["N3", "PROTEIN", 77, 79], ["coronavirus N and M proteins", "PROTEIN", 159, 187], ["the carboxy", "TEST", 37, 48], ["virion assembly interactions", "PROBLEM", 118, 146]]], ["Thus, the constructed SARS-CoV M chimeric mutants necessarily also incorporated SARS-CoV domain N3, which is extremely divergent from that of MHV, retaining little to no amino-acid sequence homology.MHV chimeras containing the SARS-CoV M protein are packaging-defective ::: ResultsTo examine the potential effect of M protein on the selective packaging of MHV gRNA, we examined two chimeric mutants that were sufficiently robust to allow extensive purification of virions.", [["virions", "ANATOMY", 464, 471], ["SARS", "DISEASE", 80, 84], ["amino-acid", "CHEMICAL", 170, 180], ["amino-acid", "CHEMICAL", 170, 180], ["SARS-CoV", "ORGANISM", 22, 30], ["MHV", "ORGANISM", 142, 145], ["MHV chimeras", "ORGANISM", 199, 211], ["SARS-CoV M", "GENE_OR_GENE_PRODUCT", 227, 237], ["M protein", "GENE_OR_GENE_PRODUCT", 316, 325], ["MHV", "ORGANISM", 356, 359], ["SARS-CoV domain N3", "PROTEIN", 80, 98], ["MHV chimeras", "PROTEIN", 199, 211], ["SARS-CoV M protein", "PROTEIN", 227, 245], ["M protein", "PROTEIN", 316, 325], ["MHV gRNA", "RNA", 356, 364], ["SARS-CoV", "SPECIES", 22, 30], ["SARS-CoV", "SPECIES", 80, 88], ["MHV", "SPECIES", 142, 145], ["MHV", "SPECIES", 199, 202], ["SARS-CoV", "SPECIES", 227, 235], ["MHV", "SPECIES", 356, 359], ["the constructed SARS-CoV M chimeric mutants", "PROBLEM", 6, 49], ["CoV domain N3", "PROBLEM", 85, 98], ["MHV chimeras", "TREATMENT", 199, 211], ["the SARS", "PROBLEM", 223, 231], ["M protein", "TREATMENT", 316, 325], ["the selective packaging of MHV gRNA", "TREATMENT", 329, 364], ["two chimeric mutants", "PROBLEM", 378, 398], ["extensive purification of virions", "TREATMENT", 438, 471], ["MHV gRNA", "OBSERVATION", 356, 364]]], ["One of these, MN8, contained the three transmembrane domains plus the endodomain of SARS-CoV M protein (Fig. 2A).", [["MN8", "GENE_OR_GENE_PRODUCT", 14, 17], ["SARS-CoV M", "GENE_OR_GENE_PRODUCT", 84, 94], ["Fig. 2A", "GENE_OR_GENE_PRODUCT", 104, 111], ["MN8", "DNA", 14, 17], ["transmembrane domains", "PROTEIN", 39, 60], ["endodomain", "PROTEIN", 70, 80], ["SARS-CoV M protein", "PROTEIN", 84, 102], ["Fig. 2A", "PROTEIN", 104, 111], ["SARS-CoV", "SPECIES", 84, 92], ["SARS", "PROBLEM", 84, 88], ["CoV M protein", "TEST", 89, 102]]], ["The other mutant, MN10, contained the endodomain of SARS-CoV M. Both mutants were engineered to also contain an envelope (E) protein point mutation, F20S, which had been found to enhance the growth of the M chimeras (Kuo et al., 2016).", [["SARS-CoV M.", "GENE_OR_GENE_PRODUCT", 52, 63], ["MN10", "PROTEIN", 18, 22], ["envelope (E) protein", "PROTEIN", 112, 132], ["F20S", "PROTEIN", 149, 153], ["SARS-CoV", "SPECIES", 52, 60], ["SARS", "PROBLEM", 52, 56], ["an envelope (E) protein point mutation", "PROBLEM", 109, 147]]], ["Viruses of the MN8 and MN10 mutants were grown and purified side-by-side with the wild type and the silPS mutant (Kuo and Masters, 2013), the latter two as positive and negative packaging controls, respectively.", [["MN8", "GENE_OR_GENE_PRODUCT", 15, 18], ["MN10", "GENE_OR_GENE_PRODUCT", 23, 27], ["silPS", "GENE_OR_GENE_PRODUCT", 100, 105], ["MN8 and MN10 mutants", "PROTEIN", 15, 35], ["silPS mutant", "PROTEIN", 100, 112]]], ["Purified virions were normalized by Western blots probed with antibodies specific for the N and M proteins (Fig. 2B).", [["virions", "ANATOMY", 9, 16], ["antibodies", "PROTEIN", 62, 72], ["N and M proteins", "PROTEIN", 90, 106], ["Fig. 2B", "PROTEIN", 108, 115], ["Purified virions", "PROBLEM", 0, 16], ["Western blots", "TEST", 36, 49], ["antibodies", "TEST", 62, 72], ["the N and M proteins", "TEST", 86, 106], ["virions", "OBSERVATION", 9, 16]]], ["It should be noted that the mobilities of the MN8 and MN10 N and M proteins differ from those of the wild type because of the altered molecular masses and amino-acid compositions of the chimeric proteins (Kuo et al., 2016).", [["amino-acid", "CHEMICAL", 155, 165], ["amino-acid", "CHEMICAL", 155, 165], ["MN8", "GENE_OR_GENE_PRODUCT", 46, 49], ["MN10 N", "GENE_OR_GENE_PRODUCT", 54, 60], ["M proteins", "GENE_OR_GENE_PRODUCT", 65, 75], ["amino-acid", "AMINO_ACID", 155, 165], ["MN8 and MN10 N and M proteins", "PROTEIN", 46, 75], ["chimeric proteins", "PROTEIN", 186, 203], ["the MN8", "TEST", 42, 49], ["the altered molecular masses", "PROBLEM", 122, 150], ["amino-acid compositions", "TREATMENT", 155, 178], ["altered", "OBSERVATION_MODIFIER", 126, 133], ["molecular", "OBSERVATION_MODIFIER", 134, 143], ["masses", "OBSERVATION", 144, 150]]], ["Analysis of isolated virion RNA by Northern blotting showed that both the MN8 and the MN10 mutant were markedly impaired in their ability to selectively package gRNA (Fig. 2C).", [["MN8", "GENE_OR_GENE_PRODUCT", 74, 77], ["MN10", "GENE_OR_GENE_PRODUCT", 86, 90], ["virion RNA", "RNA", 21, 31], ["MN8", "DNA", 74, 77], ["MN10 mutant", "PROTEIN", 86, 97], ["gRNA", "RNA", 161, 165], ["Analysis", "TEST", 0, 8], ["isolated virion RNA", "PROBLEM", 12, 31], ["Northern blotting", "TEST", 35, 52], ["markedly impaired", "PROBLEM", 103, 120], ["virion RNA", "OBSERVATION", 21, 31], ["markedly", "OBSERVATION_MODIFIER", 103, 111], ["impaired", "OBSERVATION", 112, 120]]], ["Although the M chimeras did not appear to be as thoroughly defective as the silPS mutant, they nonetheless incorporated substantial amounts of sgRNA into virions, compared to the wild type.", [["virions", "ANATOMY", 154, 161], ["silPS", "GENE_OR_GENE_PRODUCT", 76, 81], ["sgRNA", "GENE_OR_GENE_PRODUCT", 143, 148], ["silPS mutant", "PROTEIN", 76, 88], ["sgRNA", "PROTEIN", 143, 148], ["the M chimeras", "PROBLEM", 9, 23], ["sgRNA into virions", "PROBLEM", 143, 161], ["substantial", "OBSERVATION_MODIFIER", 120, 131], ["amounts", "OBSERVATION_MODIFIER", 132, 139], ["sgRNA", "OBSERVATION", 143, 148]]], ["There also appeared to be considerably less gRNA than we had observed in previous Northern blots of silPS virion RNA (Kuo and Masters, 2013, Kuo et al., 2014) and in dot blots of MN8 virion gRNA (Kuo et al., 2016).", [["silPS", "GENE_OR_GENE_PRODUCT", 100, 105], ["MN8", "GENE_OR_GENE_PRODUCT", 179, 182], ["gRNA", "RNA", 44, 48], ["silPS virion RNA", "RNA", 100, 116], ["considerably less gRNA", "PROBLEM", 26, 48], ["MN8 virion gRNA", "TREATMENT", 179, 194], ["appeared to be", "UNCERTAINTY", 11, 25], ["considerably", "OBSERVATION_MODIFIER", 26, 38], ["less", "OBSERVATION_MODIFIER", 39, 43], ["gRNA", "OBSERVATION", 44, 48]]], ["We believe that this was due to sample-to-sample variation in the recovery and blotting transfer efficiency of this unusually large (31-kb) RNA molecule.MHV chimeras containing the SARS-CoV M protein are packaging-defective ::: ResultsUnlike, the silPS mutant, MN8 and MN10 each carry the wild-type MHV PS (Fig. 2A).", [["MHV chimeras", "ORGANISM", 153, 165], ["SARS-CoV M", "GENE_OR_GENE_PRODUCT", 181, 191], ["silPS", "GENE_OR_GENE_PRODUCT", 247, 252], ["MN8", "CELL", 261, 264], ["MN10", "GENE_OR_GENE_PRODUCT", 269, 273], ["MHV PS", "ORGANISM", 299, 305], ["MHV chimeras", "PROTEIN", 153, 165], ["SARS-CoV M protein", "PROTEIN", 181, 199], ["silPS mutant", "PROTEIN", 247, 259], ["MN8", "PROTEIN", 261, 264], ["MN10", "PROTEIN", 269, 273], ["MHV", "SPECIES", 153, 156], ["SARS-CoV", "SPECIES", 181, 189], ["this unusually large (31-kb) RNA molecule", "PROBLEM", 111, 152], ["MHV chimeras", "TREATMENT", 153, 165], ["the SARS", "PROBLEM", 177, 185], ["type MHV PS", "TREATMENT", 294, 305], ["large", "OBSERVATION_MODIFIER", 126, 131]]], ["Thus, their packaging defect had to be a consequence of one or more of their structural protein mutations.", [["their packaging defect", "PROBLEM", 6, 28], ["their structural protein mutations", "PROBLEM", 71, 105], ["defect", "OBSERVATION", 22, 28], ["protein mutations", "OBSERVATION", 88, 105]]], ["One of these alterations, the E protein F20S mutation, assists viral growth through aiding incorporation of the spike (S) protein into virions (Kuo et al., 2016).", [["E protein F20S", "PROTEIN", 30, 44], ["spike (S) protein", "PROTEIN", 112, 129], ["these alterations", "PROBLEM", 7, 24], ["the E protein F20S mutation", "TREATMENT", 26, 53], ["assists viral growth", "PROBLEM", 55, 75], ["alterations", "OBSERVATION", 13, 24]]], ["However, this mutation is not relevant to the packaging phenotype, since we observed the same packaging defect in two other M chimeras that contain the wild-type E protein, MN3 and MN9 (data not shown).", [["E", "GENE_OR_GENE_PRODUCT", 162, 163], ["MN3", "GENE_OR_GENE_PRODUCT", 173, 176], ["M chimeras", "CELL_LINE", 124, 134], ["wild-type E protein", "PROTEIN", 152, 171], ["MN3", "PROTEIN", 173, 176], ["MN9", "PROTEIN", 181, 184], ["this mutation", "PROBLEM", 9, 22], ["the same packaging defect", "PROBLEM", 85, 110], ["defect", "OBSERVATION", 104, 110]]], ["MN3 has the entire SARS-CoV M protein, while MN9 is identical to MN10, except that it lacks the F20S mutation.", [["MN3", "CHEMICAL", 0, 3], ["MN3", "GENE_OR_GENE_PRODUCT", 0, 3], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 19, 27], ["MN9", "GENE_OR_GENE_PRODUCT", 45, 48], ["MN10", "GENE_OR_GENE_PRODUCT", 65, 69], ["F20S", "GENE_OR_GENE_PRODUCT", 96, 100], ["MN3", "PROTEIN", 0, 3], ["SARS-CoV M protein", "PROTEIN", 19, 37], ["MN9", "PROTEIN", 45, 48], ["MN10", "PROTEIN", 65, 69], ["F20S", "PROTEIN", 96, 100], ["SARS-CoV", "SPECIES", 19, 27], ["CoV M protein", "TEST", 24, 37], ["the F20S mutation", "PROBLEM", 92, 109]]], ["Therefore, our data indicate that in addition to the N protein CTD, selective packaging of MHV gRNA must entail a role for the endodomain of M protein or else domain N3 and spacer B of the N protein.Domain N3 of the N protein plays a role in PS recognition ::: ResultsOwing to the essential virion assembly interaction between the M protein endodomain and N protein domain N3, it was not possible to separate their potential roles in packaging through further dissection of the SARS-CoV M chimeras.", [["MHV", "ORGANISM", 91, 94], ["M protein", "GENE_OR_GENE_PRODUCT", 141, 150], ["spacer B", "GENE_OR_GENE_PRODUCT", 173, 181], ["virion", "CELLULAR_COMPONENT", 291, 297], ["N protein CTD", "PROTEIN", 53, 66], ["MHV gRNA", "RNA", 91, 99], ["M protein", "PROTEIN", 141, 150], ["else domain N3", "PROTEIN", 154, 168], ["spacer B", "PROTEIN", 173, 181], ["N protein", "PROTEIN", 189, 198], ["N protein", "PROTEIN", 216, 225], ["M protein endodomain", "PROTEIN", 331, 351], ["N protein domain N3", "PROTEIN", 356, 375], ["SARS-CoV M chimeras", "PROTEIN", 478, 497], ["MHV", "SPECIES", 91, 94], ["the N protein CTD", "TREATMENT", 49, 66], ["selective packaging of MHV gRNA", "TREATMENT", 68, 99], ["the endodomain of M protein", "TREATMENT", 123, 150], ["spacer B of the N protein", "TREATMENT", 173, 198], ["the M protein endodomain", "TREATMENT", 327, 351], ["N protein domain N3", "TREATMENT", 356, 375], ["further dissection", "TREATMENT", 452, 470], ["the SARS", "PROBLEM", 474, 482], ["MHV gRNA", "OBSERVATION", 91, 99], ["dissection", "OBSERVATION", 460, 470]]], ["We had previously found that a chimeric construct that paired the MHV M protein with SARS-CoV domain N3 was lethal; conversely, a chimeric construct that paired the SARS-CoV M protein with MHV domain N3 was lethal (Hurst et al., 2010, Kuo et al., 2016).", [["SARS", "DISEASE", 165, 169], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 85, 93], ["SARS-CoV M", "GENE_OR_GENE_PRODUCT", 165, 175], ["MHV M protein", "PROTEIN", 66, 79], ["SARS-CoV domain N3", "PROTEIN", 85, 103], ["SARS-CoV M protein", "PROTEIN", 165, 183], ["MHV domain N3", "PROTEIN", 189, 202], ["MHV", "SPECIES", 66, 69], ["SARS-CoV", "SPECIES", 85, 93], ["SARS-CoV", "SPECIES", 165, 173], ["a chimeric construct", "TEST", 29, 49], ["SARS", "PROBLEM", 85, 89], ["CoV domain N3", "TREATMENT", 90, 103], ["lethal", "PROBLEM", 108, 114], ["a chimeric construct", "TEST", 128, 148], ["the SARS", "PROBLEM", 161, 169]]], ["However, an alternative route to exploring the functions of domain N3 was afforded by a collection of domain N3 mutants that had been constructed for other purposes or had arisen in reversion analyses.", [["domain N3", "PROTEIN", 60, 69], ["domain N3 mutants", "PROTEIN", 102, 119], ["the functions of domain N3", "PROBLEM", 43, 69], ["a collection of domain N3 mutants", "TREATMENT", 86, 119]]], ["We initially examined one of these, a mutant here designated MMA.", [["MMA", "CHEMICAL", 61, 64], ["MMA", "CHEMICAL", 61, 64], ["MMA", "SIMPLE_CHEMICAL", 61, 64]]], ["The mutation in MMA originally arose as an intergenic suppressor of a highly deleterious two-amino-acid deletion of the carboxy terminus of the M protein endodomain (Kuo and Masters, 2002).", [["MMA", "CHEMICAL", 16, 19], ["amino-acid", "CHEMICAL", 93, 103], ["carboxy", "CHEMICAL", 120, 127], ["MMA", "GENE_OR_GENE_PRODUCT", 16, 19], ["MMA", "DNA", 16, 19], ["carboxy terminus", "PROTEIN", 120, 136], ["M protein endodomain", "PROTEIN", 144, 164], ["The mutation in MMA", "PROBLEM", 0, 19], ["a highly deleterious two-amino-acid deletion", "PROBLEM", 68, 112]]], ["This suppressor (Q437MMA) consisted of a 10-nt deletion in domain N3 that resulted in a frameshift replacing the carboxy-terminal 18 amino acids of N protein with only three residues, MMA.", [["amino acids", "CHEMICAL", 133, 144], ["MMA", "CHEMICAL", 184, 187], ["carboxy", "CHEMICAL", 113, 120], ["amino acids", "CHEMICAL", 133, 144], ["MMA", "CHEMICAL", 184, 187], ["amino acids", "AMINO_ACID", 133, 144], ["MMA", "SIMPLE_CHEMICAL", 184, 187], ["Q437MMA", "DNA", 17, 24], ["10-nt deletion", "DNA", 41, 55], ["domain N3", "DNA", 59, 68], ["carboxy-terminal 18 amino acids", "PROTEIN", 113, 144], ["N protein", "PROTEIN", 148, 157], ["This suppressor (Q437MMA)", "TREATMENT", 0, 25], ["a 10-nt deletion in domain N3", "TREATMENT", 39, 68], ["the carboxy-terminal 18 amino acids of N protein", "TREATMENT", 109, 157]]], ["In the MMA mutant, this N3 mutation had been reconstructed in the background of a wild-type M protein, producing a virus with a phenotype indistinguishable from that of the wild type.", [["MMA", "CHEMICAL", 7, 10], ["MMA", "GENE_OR_GENE_PRODUCT", 7, 10], ["wild-type M protein", "PROTEIN", 82, 101], ["this N3 mutation", "PROBLEM", 19, 35], ["a wild-type M protein", "PROBLEM", 80, 101], ["a virus", "PROBLEM", 113, 120]]], ["Infections with two independent isolates of the MMA mutant produced quantities of virions identical to wild type and containing the same relative amounts of N and M protein (Fig. 3A).", [["Infections", "DISEASE", 0, 10], ["MMA", "CHEMICAL", 48, 51], ["MMA", "GENE_OR_GENE_PRODUCT", 48, 51], ["MMA mutant", "PROTEIN", 48, 58], ["N and M protein", "PROTEIN", 157, 172], ["Fig. 3A", "PROTEIN", 174, 181], ["Infections", "PROBLEM", 0, 10], ["the MMA mutant produced quantities of virions", "PROBLEM", 44, 89]]], ["Remarkably, the MMA mutant possessed the same packaging-defective trait as the silPS mutant (Fig. 3B).Domain N3 of the N protein plays a role in PS recognition ::: ResultsThis finding led us to screen additional N3 mutants.", [["MMA", "CHEMICAL", 16, 19], ["MMA", "GENE_OR_GENE_PRODUCT", 16, 19], ["silPS", "GENE_OR_GENE_PRODUCT", 79, 84], ["MMA mutant", "PROTEIN", 16, 26], ["silPS mutant", "PROTEIN", 79, 91], ["Fig. 3B", "PROTEIN", 93, 100], ["N protein", "PROTEIN", 119, 128], ["N3 mutants", "PROTEIN", 212, 222], ["the MMA mutant", "PROBLEM", 12, 26], ["defective trait", "PROBLEM", 56, 71], ["defective trait", "OBSERVATION", 56, 71]]], ["Three of these were constructed clustered charged-to-alanine mutants: CCA2 (R421A, R425A, R426E), CCA3 (E430A, D431A, R432A), and CCA5 (D446A, E449A, D450A, D451A) (Hurst et al., 2005).", [["alanine", "CHEMICAL", 53, 60], ["alanine", "CHEMICAL", 53, 60], ["alanine", "AMINO_ACID", 53, 60], ["CCA2", "PROTEIN", 70, 74], ["CCA3", "PROTEIN", 98, 102], ["CCA5", "PROTEIN", 130, 134], ["CCA2", "TEST", 70, 74], ["CCA3", "TEST", 98, 102], ["D431A", "TEST", 111, 116], ["CCA5", "TEST", 130, 134], ["E449A", "TEST", 143, 148]]], ["The fourth, CCA4rev, had been isolated as a suppressor (rev26) of the lethal pair of charged-to-alanine mutations D440A-D441A.", [["alanine", "CHEMICAL", 96, 103], ["alanine", "CHEMICAL", 96, 103], ["CCA4rev", "GENE_OR_GENE_PRODUCT", 12, 19], ["alanine", "AMINO_ACID", 96, 103], ["CCA4rev", "PROTEIN", 12, 19], ["a suppressor", "TREATMENT", 42, 54], ["fourth", "OBSERVATION_MODIFIER", 4, 10]]], ["CCA4rev contained the additional mutations I438S and D451NAATLSFIGWSSS, the latter of which was due to a 40-nt insertion in domain N3 that resulted in a frameshift replacing the carboxy-terminal four amino acids of the N molecule by 13 heterologous residues (Hurst et al., 2005).", [["amino acids", "CHEMICAL", 200, 211], ["carboxy", "CHEMICAL", 178, 185], ["amino acids", "CHEMICAL", 200, 211], ["N", "CHEMICAL", 219, 220], ["CCA4rev", "GENE_OR_GENE_PRODUCT", 0, 7], ["amino acids", "AMINO_ACID", 200, 211], ["CCA4rev", "PROTEIN", 0, 7], ["40-nt insertion", "DNA", 105, 120], ["domain N3", "DNA", 124, 133], ["carboxy-terminal four amino acids", "PROTEIN", 178, 211], ["N molecule", "PROTEIN", 219, 229], ["D451NAATLSFIGWSSS", "TREATMENT", 53, 70], ["a 40-nt insertion in domain N3", "TREATMENT", 103, 133], ["a frameshift", "PROBLEM", 151, 163], ["the carboxy-terminal four amino acids", "TREATMENT", 174, 211]]], ["As with the MMA mutant, all of these mutants were fully competent in virion assembly, having phenotypes similar or identical to the wild type and forming virions with a normal complement of N and M proteins (Fig. 3C).", [["virions", "ANATOMY", 154, 161], ["MMA", "CHEMICAL", 12, 15], ["MMA", "CHEMICAL", 12, 15], ["MMA", "GENE_OR_GENE_PRODUCT", 12, 15], ["MMA mutant", "PROTEIN", 12, 22], ["N and M proteins", "PROTEIN", 190, 206], ["Fig. 3C", "PROTEIN", 208, 215], ["the MMA mutant", "PROBLEM", 8, 22], ["phenotypes", "PROBLEM", 93, 103]]], ["Although the MMA and CCA4rev mutants lack the D440 and D441 residues that play a major role in interaction with the M endodomain, we have previously postulated that they were selected through their ability to form compensating hydrophobic interactions with other regions of the M endodomain.Domain N3 of the N protein plays a role in PS recognition ::: ResultsIn infected cells, all of the domain N3 mutants synthesized the same sgRNAs, and in similar relative amounts, as those produced by wild-type MHV (Fig. 3D).", [["cells", "ANATOMY", 372, 377], ["MMA", "CHEMICAL", 13, 16], ["MMA", "CHEMICAL", 13, 16], ["MMA", "GENE_OR_GENE_PRODUCT", 13, 16], ["CCA4rev", "GENE_OR_GENE_PRODUCT", 21, 28], ["D440", "GENE_OR_GENE_PRODUCT", 46, 50], ["cells", "CELL", 372, 377], ["wild-type MHV", "ORGANISM", 491, 504], ["MMA and CCA4rev mutants", "PROTEIN", 13, 36], ["D440 and D441 residues", "PROTEIN", 46, 68], ["M endodomain", "PROTEIN", 116, 128], ["M endodomain", "PROTEIN", 278, 290], ["N protein", "PROTEIN", 308, 317], ["infected cells", "CELL_TYPE", 363, 377], ["domain N3 mutants", "PROTEIN", 390, 407], ["sgRNAs", "PROTEIN", 429, 435], ["MHV", "SPECIES", 501, 504], ["the MMA", "TEST", 9, 16], ["the D440 and D441 residues", "TREATMENT", 42, 68], ["infected cells", "PROBLEM", 363, 377], ["infected cells", "OBSERVATION", 363, 377]]], ["Mutants CCA2, CCA3, and CCA5 transcribed proportionately less sgRNA4 because they had been constructed by an earlier version of targeted RNA recombination, using a vector lacking a mutation that upregulates transcription of this particular sgRNA (Kuo et al., 2000).", [["CCA2", "GENE_OR_GENE_PRODUCT", 8, 12], ["CCA3", "GENE_OR_GENE_PRODUCT", 14, 18], ["CCA5", "GENE_OR_GENE_PRODUCT", 24, 28], ["sgRNA4", "GENE_OR_GENE_PRODUCT", 62, 68], ["CCA2", "PROTEIN", 8, 12], ["CCA3", "PROTEIN", 14, 18], ["CCA5", "PROTEIN", 24, 28], ["sgRNA4", "PROTEIN", 62, 68], ["sgRNA", "DNA", 240, 245], ["Mutants CCA2", "TEST", 0, 12], ["CCA3", "TEST", 14, 18], ["targeted RNA recombination", "TREATMENT", 128, 154], ["a vector", "TREATMENT", 162, 170], ["a mutation", "TREATMENT", 179, 189]]], ["Among the additional N3 mutants, only CCA5 was observed to be defective in selective packaging of gRNA (Fig. 3E).", [["CCA5", "GENE_OR_GENE_PRODUCT", 38, 42], ["N3 mutants", "PROTEIN", 21, 31], ["CCA5", "PROTEIN", 38, 42], ["gRNA", "RNA", 98, 102], ["selective packaging of gRNA", "TREATMENT", 75, 102], ["N3 mutants", "OBSERVATION", 21, 31], ["gRNA", "OBSERVATION", 98, 102]]], ["Mutants CCA2, CCA3 and CCA4rev all exhibited the same stringent packaging of gRNA displayed by the wild type.", [["CCA2", "GENE_OR_GENE_PRODUCT", 8, 12], ["CCA3", "GENE_OR_GENE_PRODUCT", 14, 18], ["CCA4rev", "GENE_OR_GENE_PRODUCT", 23, 30], ["CCA2", "PROTEIN", 8, 12], ["CCA3", "PROTEIN", 14, 18], ["CCA4rev", "PROTEIN", 23, 30], ["gRNA", "RNA", 77, 81], ["Mutants CCA2", "TEST", 0, 12], ["CCA3", "TEST", 14, 18], ["gRNA", "PROBLEM", 77, 81], ["stringent packaging", "OBSERVATION", 54, 73], ["of gRNA", "OBSERVATION", 74, 81], ["wild type", "OBSERVATION", 99, 108]]], ["To reinforce this outcome, we verified that all mutants, including MMA, contained the wild-type sequences for the N protein CTD and for the PS in nsp15, using the same purified RNA that had been analyzed by Northern blotting.", [["MMA", "CHEMICAL", 67, 70], ["MMA", "SIMPLE_CHEMICAL", 67, 70], ["nsp15", "GENE_OR_GENE_PRODUCT", 146, 151], ["MMA", "PROTEIN", 67, 70], ["wild-type sequences", "DNA", 86, 105], ["N protein CTD", "PROTEIN", 114, 127], ["PS", "PROTEIN", 140, 142], ["nsp15", "PROTEIN", 146, 151], ["purified RNA", "RNA", 168, 180], ["the N protein CTD", "TREATMENT", 110, 127], ["the PS in nsp15", "TREATMENT", 136, 151], ["the same purified RNA", "TREATMENT", 159, 180]]], ["These results thus showed that domain N3 plays a role equally important to that of the CTD in the selective packaging of MHV gRNA.", [["CTD", "GENE_OR_GENE_PRODUCT", 87, 90], ["MHV", "ORGANISM", 121, 124], ["domain N3", "PROTEIN", 31, 40], ["CTD", "PROTEIN", 87, 90], ["MHV gRNA", "RNA", 121, 129], ["MHV", "SPECIES", 121, 124], ["the CTD", "PROBLEM", 83, 90], ["the selective packaging of MHV gRNA", "TREATMENT", 94, 129], ["MHV gRNA", "OBSERVATION", 121, 129]]], ["Moreover, comparison of packaging-competent and packaging-defective mutants of domain N3 allowed us to map the packaging role of N3 to a short segment near the carboxy terminus of N, amino acids 442-450 (Fig. 3F).", [["amino acids 442-450", "CHEMICAL", 183, 202], ["N3", "CHEMICAL", 129, 131], ["carboxy", "CHEMICAL", 160, 167], ["N", "CHEMICAL", 180, 181], ["amino acids", "CHEMICAL", 183, 194], ["amino acids", "AMINO_ACID", 183, 194], ["442-450", "AMINO_ACID", 195, 202], ["packaging-defective mutants", "PROTEIN", 48, 75], ["domain N3", "PROTEIN", 79, 88], ["N3", "PROTEIN", 129, 131], ["carboxy terminus", "PROTEIN", 160, 176], ["N", "PROTEIN", 180, 181], ["amino acids 442-450", "PROTEIN", 183, 202], ["packaging", "TREATMENT", 24, 33], ["defective mutants of domain N3", "PROBLEM", 58, 88], ["amino acids", "TEST", 183, 194], ["carboxy", "ANATOMY_MODIFIER", 160, 167]]], ["Mutants MMA and CCA5 either lack or are mutated in this segment; mutants CCA2, CCA3, and CCA4rev retain wild-type sequence in this segment, despite harboring other nearby mutations.", [["MMA", "CHEMICAL", 8, 11], ["MMA", "GENE_OR_GENE_PRODUCT", 8, 11], ["CCA5", "GENE_OR_GENE_PRODUCT", 16, 20], ["CCA2", "GENE_OR_GENE_PRODUCT", 73, 77], ["CCA3", "GENE_OR_GENE_PRODUCT", 79, 83], ["CCA4rev", "GENE_OR_GENE_PRODUCT", 89, 96], ["CCA5", "PROTEIN", 16, 20], ["CCA2", "PROTEIN", 73, 77], ["CCA3", "PROTEIN", 79, 83], ["CCA4rev", "PROTEIN", 89, 96], ["wild-type sequence", "DNA", 104, 122], ["Mutants MMA", "PROBLEM", 0, 11], ["mutants CCA2", "TEST", 65, 77], ["CCA3", "TEST", 79, 83], ["harboring other nearby mutations", "PROBLEM", 148, 180]]], ["Notably, this segment is adjacent to, but distinct from the D440-D441 residues critical for the virion assembly interaction of N3 (Hurst et al., 2005, Verma et al., 2006).", [["D440", "PROTEIN", 60, 64], ["the D440-D441 residues", "TREATMENT", 56, 78], ["segment", "ANATOMY_MODIFIER", 14, 21]]], ["One additional mutant, N-BPR, which replaced spacer B with a completely heterologous peptide linker (Hurst et al., 2009), was also packaging-defective.", [["N-BPR", "SIMPLE_CHEMICAL", 23, 28], ["N-BPR", "PROTEIN", 23, 28], ["spacer B", "PROTEIN", 45, 53], ["N-BPR", "PROBLEM", 23, 28], ["spacer B", "TREATMENT", 45, 53], ["defective", "OBSERVATION", 141, 150]]], ["This may indicate a requirement for spacer B to participate in packaging, but as discussed below, we believe this role is ancillary.DiscussionThe coronavirus N protein NTD and CTD each possess nonspecific RNA-binding capabilities (Chang et al., 2009), in accord with the function of N in the helical encapsidation of the entire 30-kb viral genome.", [["spacer B", "GENE_OR_GENE_PRODUCT", 36, 44], ["coronavirus", "ORGANISM", 146, 157], ["CTD", "GENE_OR_GENE_PRODUCT", 176, 179], ["coronavirus N protein", "PROTEIN", 146, 167], ["NTD", "PROTEIN", 168, 171], ["CTD", "PROTEIN", 176, 179], ["30-kb viral genome", "DNA", 328, 346], ["spacer B", "TREATMENT", 36, 44], ["packaging", "TREATMENT", 63, 72], ["The coronavirus N protein NTD", "TREATMENT", 142, 171], ["CTD each possess", "TEST", 176, 192], ["nonspecific RNA-binding capabilities", "PROBLEM", 193, 229], ["viral genome", "OBSERVATION", 334, 346]]], ["Our previous work (Kuo et al., 2014) as well as data shown here (Fig. 1) suggest that, in addition, the MHV CTD has evolved to specifically recognize a unique gRNA element, the MHV PS.", [["MHV CTD", "ORGANISM", 104, 111], ["MHV CTD", "PROTEIN", 104, 111], ["gRNA element", "DNA", 159, 171], ["MHV", "SPECIES", 104, 107], ["MHV", "SPECIES", 177, 180], ["the MHV CTD", "PROBLEM", 100, 111], ["a unique gRNA element", "PROBLEM", 150, 171], ["the MHV PS", "TREATMENT", 173, 183], ["gRNA element", "OBSERVATION", 159, 171], ["MHV PS", "OBSERVATION", 177, 183]]], ["The key finding of the present study is that domain N3, the region of N protein that binds to the M protein endodomain, is also involved in the gRNA packaging process (Fig. 3).DiscussionTaken together, these two results lead to a model for the obligatory coupling of gRNA encapsidation to virion assembly (Fig. 4).", [["virion", "CELLULAR_COMPONENT", 289, 295], ["domain N3", "PROTEIN", 45, 54], ["N protein", "PROTEIN", 70, 79], ["M protein endodomain", "PROTEIN", 98, 118], ["the present study", "TEST", 19, 36], ["domain N3", "PROBLEM", 45, 54], ["the M protein endodomain", "TEST", 94, 118], ["gRNA encapsidation", "TREATMENT", 267, 285], ["gRNA packaging process", "OBSERVATION", 144, 166], ["gRNA encapsidation", "OBSERVATION", 267, 285]]], ["We hypothesize that the largely acidic domain N3 is initially bound to the CTD, occluding at least part of the basic RNA-binding surface of the CTD (Chen et al., 2007a).", [["CTD", "GENE_OR_GENE_PRODUCT", 75, 78], ["acidic domain N3", "PROTEIN", 32, 48], ["CTD", "PROTEIN", 75, 78], ["CTD", "PROTEIN", 144, 147], ["the largely acidic domain N3", "PROBLEM", 20, 48], ["the CTD", "PROBLEM", 71, 78], ["CTD", "OBSERVATION", 75, 78], ["basic RNA", "OBSERVATION", 111, 120], ["surface", "OBSERVATION_MODIFIER", 129, 136], ["CTD", "ANATOMY", 144, 147]]], ["This interaction contributes to the specificity of RNA binding by the CTD, since, among the multiplicity of available RNA species, only the PS has sufficiently high affinity to efficiently dislodge domain N3.", [["CTD", "GENE_OR_GENE_PRODUCT", 70, 73], ["CTD", "PROTEIN", 70, 73], ["domain N3", "PROTEIN", 198, 207], ["RNA binding", "PROBLEM", 51, 62], ["the CTD", "PROBLEM", 66, 73], ["available RNA species", "PROBLEM", 108, 129], ["sufficiently high affinity", "PROBLEM", 147, 173], ["efficiently dislodge domain N3", "PROBLEM", 177, 207]]], ["Binding of the PS to the CTD releases domain N3, making it accessible for binding to the M endodomain.", [["CTD", "PROTEIN", 25, 28], ["domain N3", "PROTEIN", 38, 47], ["M endodomain", "PROTEIN", 89, 101]]], ["This nucleation step in gRNA recognition would then be propagated by conformational interactions that allow subsequent N molecules to nonspecifically bind to adjacent sites along the gRNA strand, thereby encapsidating the genome.", [["genome", "CELLULAR_COMPONENT", 222, 228], ["N molecules", "PROTEIN", 119, 130], ["gRNA strand", "RNA", 183, 194], ["This nucleation step in gRNA recognition", "PROBLEM", 0, 40], ["subsequent N molecules", "TREATMENT", 108, 130], ["gRNA strand", "OBSERVATION", 183, 194]]], ["The binding of additional N molecules, in turn, would free progressively more N3 domains to contact M endodomains, driving virion budding.", [["N", "CHEMICAL", 26, 27], ["virion", "CELLULAR_COMPONENT", 123, 129], ["N molecules", "PROTEIN", 26, 37], ["N3 domains", "PROTEIN", 78, 88], ["M endodomains", "PROTEIN", 100, 113], ["additional N molecules", "TREATMENT", 15, 37]]], ["In this model, sequestering of domain N3 by the CTD thus serves two purposes: first, it imparts to the CTD a higher selectivity for the PS; second, it ensures that N3 is not allowed to bind to the M endodomain until the CTD has bound to gRNA.DiscussionOur data could be taken to support an alternative hypothesis \u2013 that domain N3 combines with the CTD to form an extended RNA-binding site for the PS.", [["N3", "CHEMICAL", 164, 166], ["N3", "SIMPLE_CHEMICAL", 164, 166], ["CTD", "GENE_OR_GENE_PRODUCT", 220, 223], ["gRNA", "CELLULAR_COMPONENT", 237, 241], ["CTD", "GENE_OR_GENE_PRODUCT", 348, 351], ["domain N3", "PROTEIN", 31, 40], ["CTD", "PROTEIN", 48, 51], ["CTD", "PROTEIN", 103, 106], ["M endodomain", "PROTEIN", 197, 209], ["CTD", "PROTEIN", 220, 223], ["gRNA", "RNA", 237, 241], ["domain N3", "PROTEIN", 320, 329], ["CTD", "PROTEIN", 348, 351], ["domain N3", "TREATMENT", 31, 40], ["the CTD", "PROBLEM", 216, 223], ["gRNA", "PROBLEM", 237, 241], ["domain N3", "TREATMENT", 320, 329], ["the CTD", "TREATMENT", 344, 351], ["an extended RNA", "TREATMENT", 360, 375], ["the PS", "TREATMENT", 393, 399], ["N3", "OBSERVATION", 164, 166], ["CTD", "OBSERVATION", 220, 223], ["gRNA", "OBSERVATION", 237, 241]]], ["However, this scenario seems unlikely, since such binding would block, rather than enhance, the association of N3 with the M endodomain.", [["M endodomain", "PROTEIN", 123, 135], ["seems unlikely", "UNCERTAINTY", 23, 37]]], ["Additionally, the region in N3 to which the packaging role localizes is set among a high density of negatively-charged residues (Fig. 3F).", [["high density", "OBSERVATION_MODIFIER", 84, 96]]], ["We also note that the binding of N3 to the CTD was anticipated by two prior studies that observed N3 to participate in N-N interactions (Hurst et al., 2009, Lo et al., 2013), although neither postulated that the CTD was the interacting partner of N3.DiscussionIt is well established for MHV and BCoV that both gRNA and all sgRNAs are co-immunoprecipitated from infected cell extracts by anti-N antibodies (Cologna et al., 2000, Narayanan et al., 2000).", [["cell extracts", "ANATOMY", 370, 383], ["N3", "CHEMICAL", 33, 35], ["N3", "CHEMICAL", 98, 100], ["N-N", "CHEMICAL", 119, 122], ["N3", "CHEMICAL", 247, 249], ["CTD", "GENE_OR_GENE_PRODUCT", 43, 46], ["N3", "SIMPLE_CHEMICAL", 98, 100], ["CTD", "GENE_OR_GENE_PRODUCT", 212, 215], ["MHV", "ORGANISM", 287, 290], ["BCoV", "CANCER", 295, 299], ["sgRNAs", "GENE_OR_GENE_PRODUCT", 323, 329], ["cell extracts", "ORGANISM_SUBSTANCE", 370, 383], ["anti-N antibodies", "GENE_OR_GENE_PRODUCT", 387, 404], ["CTD", "PROTEIN", 43, 46], ["CTD", "PROTEIN", 212, 215], ["N3", "PROTEIN", 247, 249], ["gRNA", "RNA", 310, 314], ["sgRNAs", "PROTEIN", 323, 329], ["N antibodies", "PROTEIN", 392, 404], ["MHV", "SPECIES", 287, 290], ["two prior studies", "TEST", 66, 83], ["MHV", "TREATMENT", 287, 290], ["BCoV", "TREATMENT", 295, 299], ["both gRNA", "PROBLEM", 305, 314], ["all sgRNAs", "PROBLEM", 319, 329], ["infected cell extracts", "PROBLEM", 361, 383], ["infected cell", "OBSERVATION", 361, 374]]], ["If our model is correct, then this would suggest that it is the NTD that is responsible for binding to sgRNAs, by either nonspecific or sequence-specific binding.", [["sgRNAs", "GENE_OR_GENE_PRODUCT", 103, 109], ["NTD", "PROTEIN", 64, 67], ["sgRNAs", "PROTEIN", 103, 109], ["the NTD", "PROBLEM", 60, 67], ["binding to sgRNAs", "PROBLEM", 92, 109]]], ["Evidence has been presented for high-affinity binding of the MHV NTD to the transcription-regulating sequence found at the leader-body junction of all sgRNAs (Grossoehme et al., 2009).", [["body junction", "ANATOMY", 130, 143], ["MHV", "ORGANISM", 61, 64], ["MHV NTD", "PROTEIN", 61, 68], ["MHV", "SPECIES", 61, 64], ["high-affinity binding", "PROBLEM", 32, 53], ["the transcription", "TEST", 72, 89], ["MHV", "ANATOMY", 61, 64], ["body junction", "ANATOMY", 130, 143], ["all sgRNAs", "ANATOMY", 147, 157]]], ["However, such sequence-specific binding does not appear to be a general property of coronavirus NTDs (Keane et al., 2012).", [["coronavirus NTDs", "DISEASE", 84, 100], ["coronavirus", "ORGANISM", 84, 95], ["coronavirus NTDs", "PROBLEM", 84, 100]]], ["Consistent with our model, it has been demonstrated that anti-M protein antibody co-immunoprecipitates only the fraction of N protein that is bound to gRNA or to an engineered heterologous RNA containing the MHV PS (Narayanan et al., 2000, Narayanan and Makino, 2001).", [["anti-M", "GENE_OR_GENE_PRODUCT", 57, 63], ["anti-M protein antibody", "PROTEIN", 57, 80], ["N protein", "PROTEIN", 124, 133], ["gRNA", "RNA", 151, 155], ["heterologous RNA", "RNA", 176, 192], ["anti-M protein antibody", "TEST", 57, 80], ["N protein", "PROBLEM", 124, 133], ["gRNA", "PROBLEM", 151, 155], ["an engineered heterologous RNA", "TREATMENT", 162, 192], ["the MHV PS", "TREATMENT", 204, 214], ["heterologous RNA", "OBSERVATION", 176, 192]]], ["Although we cannot rule out a direct role for M protein in packaging (Narayanan et al., 2003), our data suggests that the participation of M is secondary, through selecting N protein that has bound to the PS.DiscussionThe model in Fig. 4 necessarily simplifies a number of details that remain to be clarified.", [["M protein", "GENE_OR_GENE_PRODUCT", 46, 55], ["M protein", "PROTEIN", 46, 55], ["N protein", "PROTEIN", 173, 182], ["selecting N protein", "TREATMENT", 163, 182], ["Fig", "OBSERVATION_MODIFIER", 231, 234]]], ["One of these is the stoichiometry of N protein to RNA.", [["N protein", "PROTEIN", 37, 46], ["RNA", "RNA", 50, 53], ["N protein to RNA", "TREATMENT", 37, 53]]], ["In the helical nucleocapsids of nonsegmented negative-strand RNA viruses, one N protein molecule binds from six to nine nucleotides of single-stranded RNA (Green et al., 2006, Alayyoubi et al., 2015, Gutsche et al., 2015).", [["nucleotides", "CHEMICAL", 120, 131], ["N protein molecule", "PROTEIN", 78, 96], ["strand RNA viruses", "PROBLEM", 54, 72], ["one N protein molecule binds", "PROBLEM", 74, 102], ["strand RNA viruses", "OBSERVATION", 54, 72], ["stranded RNA", "OBSERVATION_MODIFIER", 142, 154]]], ["A model for the SARS-CoV nucleocapsid has estimated a ratio of one N molecule per 7 nucleotides of RNA (Chang et al., 2014).", [["SARS", "DISEASE", 16, 20], ["N", "CHEMICAL", 67, 68], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 16, 24], ["SARS-CoV nucleocapsid", "PROTEIN", 16, 37], ["N molecule", "PROTEIN", 67, 77], ["SARS-CoV", "SPECIES", 16, 24], ["the SARS-CoV nucleocapsid", "PROBLEM", 12, 37]]], ["It thus seems likely that the 95-nt MHV PS accommodates multiple CTDs, the accumulation of which nucleates cooperative encapsidation of the entire viral genome.", [["CTDs", "DISEASE", 65, 69], ["viral genome", "DNA", 147, 159], ["MHV", "SPECIES", 36, 39], ["nt MHV PS", "TREATMENT", 33, 42], ["multiple CTDs", "PROBLEM", 56, 69], ["seems likely", "UNCERTAINTY", 8, 20], ["multiple", "OBSERVATION_MODIFIER", 56, 64], ["CTDs", "OBSERVATION", 65, 69], ["entire", "OBSERVATION_MODIFIER", 140, 146], ["viral genome", "OBSERVATION", 147, 159]]], ["A single AA-bulge repeat unit (Fig. 1A) is a good candidate for the minimal relevant substructure within the PS that is recognized by one CTD.", [["AA", "CHEMICAL", 9, 11], ["AA-bulge repeat unit", "DNA", 9, 29], ["CTD", "PROTEIN", 138, 141]]], ["A second issue to be resolved is the role of CTD dimerization in PS binding and the propagation of the nucleation event to trigger nonspecific binding of N to the remainder of the genome.", [["N", "CHEMICAL", 154, 155], ["CTD", "GENE_OR_GENE_PRODUCT", 45, 48], ["PS", "SIMPLE_CHEMICAL", 65, 67], ["genome", "CELLULAR_COMPONENT", 180, 186], ["CTD", "PROTEIN", 45, 48], ["CTD dimerization in PS binding", "PROBLEM", 45, 75], ["the nucleation event", "PROBLEM", 99, 119]]], ["CTD dimerization also raises the possibility that N3-CTD association could occur in trans in the dimer, rather than in cis.", [["N3-CTD", "GENE_OR_GENE_PRODUCT", 50, 56], ["CTD", "PROTEIN", 0, 3], ["CTD", "PROTEIN", 53, 56], ["dimer", "PROTEIN", 97, 102], ["CTD dimerization", "PROBLEM", 0, 16], ["N3-CTD association", "PROBLEM", 50, 68], ["raises the possibility", "UNCERTAINTY", 22, 44]]], ["A third uncertainty is the role of spacer B. The N-BPR mutant lost the ability to selectively package gRNA (Fig. 3E).", [["N-BPR", "GENE_OR_GENE_PRODUCT", 49, 54], ["N-BPR mutant", "PROTEIN", 49, 61], ["gRNA", "RNA", 102, 106]]], ["However, the nearly total absence of charge in spacer B of the N-BPR mutant may prevent the association of its domain N3 with the CTD, causing N3 to be constitutively displayed for binding to the M endodomain.", [["spacer B", "CHEMICAL", 47, 55], ["N-BPR", "CHEMICAL", 63, 68], ["N3", "CHEMICAL", 118, 120], ["N3", "CHEMICAL", 143, 145], ["N-BPR", "GENE_OR_GENE_PRODUCT", 63, 68], ["N-BPR mutant", "PROTEIN", 63, 75], ["domain N3", "PROTEIN", 111, 120], ["CTD", "PROTEIN", 130, 133], ["N3", "PROTEIN", 143, 145], ["M endodomain", "PROTEIN", 196, 208], ["charge in spacer", "TREATMENT", 37, 53], ["the N-BPR mutant", "TREATMENT", 59, 75], ["the CTD", "PROBLEM", 126, 133], ["N3", "PROBLEM", 143, 145]]], ["A more directed mutational analysis of spacer B will be required to learn if it has some function beyond serving as a flexible linker.", [["spacer B", "GENE_OR_GENE_PRODUCT", 39, 47], ["spacer B", "DNA", 39, 47], ["A more directed mutational analysis of spacer", "TREATMENT", 0, 45], ["a flexible linker", "TREATMENT", 116, 133]]], ["Finally, it should be pointed out that MHV domain N3 contains two residues that are phosphorylation targets, S424 and T428 (White et al., 2007).", [["MHV domain N3", "PROTEIN", 39, 52], ["MHV domain N3", "PROBLEM", 39, 52], ["phosphorylation targets", "TEST", 84, 107], ["two", "OBSERVATION_MODIFIER", 62, 65], ["residues", "OBSERVATION_MODIFIER", 66, 74]]], ["This could conceivable provide a level of regulation to coordinate the roles of gRNA as a translation and transcription template and as a constituent of progeny virions.Cells and viruses ::: Materials and methodsWild-type MHV-A59 and mutants were propagated in mouse 17 clone 1 (17Cl1) cells; plaque titrations and plaque purifications were performed with mouse L2 cells.", [["virions", "ANATOMY", 161, 168], ["Cells", "ANATOMY", 169, 174], ["17Cl1) cells", "ANATOMY", 279, 291], ["plaque", "ANATOMY", 293, 299], ["plaque", "ANATOMY", 315, 321], ["L2 cells", "ANATOMY", 362, 370], ["Cells", "CELL", 169, 174], ["MHV", "ORGANISM", 222, 225], ["A59", "GENE_OR_GENE_PRODUCT", 226, 229], ["mouse", "ORGANISM", 261, 266], ["17Cl1) cells", "CELL", 279, 291], ["mouse", "ORGANISM", 356, 361], ["L2 cells", "CELL", 362, 370], ["gRNA", "DNA", 80, 84], ["A59", "PROTEIN", 226, 229], ["mouse 17 clone 1 (17Cl1) cells", "CELL_LINE", 261, 291], ["mouse L2 cells", "CELL_LINE", 356, 370], ["mouse", "SPECIES", 261, 266], ["mouse", "SPECIES", 356, 361], ["mouse", "SPECIES", 261, 266], ["mouse", "SPECIES", 356, 361], ["gRNA", "TREATMENT", 80, 84], ["a translation and transcription template", "TREATMENT", 88, 128], ["Materials", "TEST", 191, 200], ["methodsWild", "TEST", 205, 216], ["mutants", "TREATMENT", 234, 241], ["plaque titrations", "TREATMENT", 293, 310], ["plaque purifications", "TEST", 315, 335], ["progeny virions", "OBSERVATION", 153, 168], ["viruses", "OBSERVATION", 179, 186], ["L2 cells", "OBSERVATION", 362, 370]]], ["Murine cell lines were grown in Dulbecco\u2019s modified minimal essential medium (DMEM) supplemented with 10% fetal bovine serum.", [["cell lines", "ANATOMY", 7, 17], ["fetal bovine serum", "ANATOMY", 106, 124], ["Murine", "ORGANISM", 0, 6], ["cell lines", "CELL", 7, 17], ["bovine", "ORGANISM", 112, 118], ["serum", "ORGANISM_SUBSTANCE", 119, 124], ["Murine cell lines", "CELL_LINE", 0, 17], ["Murine", "SPECIES", 0, 6], ["bovine", "SPECIES", 112, 118], ["bovine", "SPECIES", 112, 118], ["Murine cell lines", "TREATMENT", 0, 17], ["minimal essential medium (DMEM", "TREATMENT", 52, 82], ["10% fetal bovine serum", "TREATMENT", 102, 124], ["cell lines", "OBSERVATION", 7, 17], ["minimal", "OBSERVATION_MODIFIER", 52, 59], ["essential", "OBSERVATION_MODIFIER", 60, 69], ["medium", "OBSERVATION_MODIFIER", 70, 76]]], ["The host-range chimeric coronavirus fMHV.v2 (Goebel et al., 2004), which was used for reverse genetics, was grown in feline FCWF cells maintained in low-glucose DMEM containing 10% fetal bovine serum.MHV mutant construction ::: Materials and methodsAll mutants in this study were created by targeted RNA recombination (Kuo et al., 2000, Goebel et al., 2004).", [["FCWF cells", "ANATOMY", 124, 134], ["fetal bovine serum", "ANATOMY", 181, 199], ["glucose", "CHEMICAL", 153, 160], ["glucose", "CHEMICAL", 153, 160], ["coronavirus", "ORGANISM", 24, 35], ["fMHV", "ORGANISM", 36, 40], ["feline", "ORGANISM", 117, 123], ["FCWF cells", "CELL", 124, 134], ["bovine", "ORGANISM", 187, 193], ["serum", "ORGANISM_SUBSTANCE", 194, 199], ["MHV mutant", "ORGANISM", 200, 210], ["feline FCWF cells", "CELL_LINE", 117, 134], ["coronavirus", "SPECIES", 24, 35], ["feline", "SPECIES", 117, 123], ["bovine", "SPECIES", 187, 193], ["coronavirus fMHV", "SPECIES", 24, 40], ["bovine", "SPECIES", 187, 193], ["MHV", "SPECIES", 200, 203], ["chimeric coronavirus fMHV", "TREATMENT", 15, 40], ["fetal bovine serum", "TEST", 181, 199], ["this study", "TEST", 264, 274]]], ["Mutants MN8 and MN10 (Kuo et al., 2016), silPS (Kuo and Masters, 2013), MMA (Kuo and Masters, 2002), CCA2, CCA3, and CCA5 (Hurst et al., 2005), and N-BPR (Hurst et al., 2009) have been described previously.", [["MMA", "CHEMICAL", 72, 75], ["CCA2", "TEST", 101, 105], ["CCA3", "TEST", 107, 111]]], ["Donor RNAs for generation of the T-CTD-R, T-CTD-R-PS1, and T-CTD-R-PS2 mutants were transcribed from plasmids derived from the vector pPM9, which contains the 3\u2019 end of the MHV-A59 genome, starting from the middle of nsp14, and including a 2.1-kbp deletion that removes TRS2, gene 2a, and most of the HE gene (Kuo and Masters, 2013).", [["plasmids", "ANATOMY", 101, 109], ["T-CTD-R", "GENE_OR_GENE_PRODUCT", 33, 40], ["T-CTD", "GENE_OR_GENE_PRODUCT", 42, 47], ["R-PS1", "GENE_OR_GENE_PRODUCT", 48, 53], ["T-CTD", "GENE_OR_GENE_PRODUCT", 59, 64], ["R-PS2", "GENE_OR_GENE_PRODUCT", 65, 70], ["pPM9", "GENE_OR_GENE_PRODUCT", 134, 138], ["3\u2019 end", "CELLULAR_COMPONENT", 159, 165], ["MHV-A59", "ORGANISM", 173, 180], ["nsp14", "GENE_OR_GENE_PRODUCT", 217, 222], ["TRS2", "GENE_OR_GENE_PRODUCT", 270, 274], ["gene 2a", "GENE_OR_GENE_PRODUCT", 276, 283], ["HE", "GENE_OR_GENE_PRODUCT", 301, 303], ["Donor RNAs", "RNA", 0, 10], ["CTD", "PROTEIN", 35, 38], ["R", "PROTEIN", 39, 40], ["T", "PROTEIN", 42, 43], ["CTD", "PROTEIN", 44, 47], ["R", "PROTEIN", 48, 49], ["PS1", "PROTEIN", 50, 53], ["T", "PROTEIN", 59, 60], ["CTD", "PROTEIN", 61, 64], ["R", "PROTEIN", 65, 66], ["PS2", "PROTEIN", 67, 70], ["plasmids", "DNA", 101, 109], ["pPM9", "DNA", 134, 138], ["3\u2019 end", "DNA", 159, 165], ["MHV-A59 genome", "DNA", 173, 187], ["nsp14", "DNA", 217, 222], ["2.1-kbp deletion", "DNA", 240, 256], ["TRS2, gene 2a", "DNA", 270, 283], ["HE gene", "DNA", 301, 308], ["MHV-A59", "SPECIES", 173, 180], ["the T", "TEST", 29, 34], ["CTD", "TEST", 35, 38], ["CTD", "TEST", 44, 47], ["PS1", "TEST", 50, 53], ["T", "TEST", 59, 60], ["CTD", "TEST", 61, 64], ["PS2 mutants", "PROBLEM", 67, 78], ["a 2.1-kbp deletion", "PROBLEM", 238, 256], ["TRS2", "TREATMENT", 270, 274], ["MHV", "OBSERVATION", 173, 176], ["A59 genome", "OBSERVATION", 177, 187], ["middle", "ANATOMY_MODIFIER", 207, 213]]], ["The TGEV CTD substitution was initially constructed by PCR from overlapping oligonucleotides and inserted between the unique NgoMIV and BstXI sites of MHV N gene plasmid pCK70XB (Kuo et al., 2014).", [["TGEV", "ORGANISM", 4, 8], ["NgoMIV", "GENE_OR_GENE_PRODUCT", 125, 131], ["BstXI", "GENE_OR_GENE_PRODUCT", 136, 141], ["MHV N", "GENE_OR_GENE_PRODUCT", 151, 156], ["NgoMIV and BstXI sites", "DNA", 125, 147], ["MHV N gene plasmid pCK70XB", "DNA", 151, 177], ["TGEV", "SPECIES", 4, 8], ["MHV", "SPECIES", 151, 154], ["The TGEV CTD substitution", "TREATMENT", 0, 25], ["PCR", "TEST", 55, 58], ["overlapping oligonucleotides", "TREATMENT", 64, 92], ["the unique NgoMIV", "TREATMENT", 114, 131], ["BstXI sites", "TREATMENT", 136, 147], ["MHV N gene plasmid pCK70XB", "TREATMENT", 151, 177]]], ["The chimeric N gene was then shuttled into pPM9 to produce pPM9-T2b, which was used for construction of the original TGEV-CTD mutant.", [["pPM9", "GENE_OR_GENE_PRODUCT", 43, 47], ["pPM9-T2b", "GENE_OR_GENE_PRODUCT", 59, 67], ["TGEV", "ORGANISM", 117, 121], ["CTD", "GENE_OR_GENE_PRODUCT", 122, 125], ["chimeric N gene", "DNA", 4, 19], ["pPM9", "PROTEIN", 43, 47], ["pPM9", "PROTEIN", 59, 63], ["T2b", "PROTEIN", 64, 67], ["TGEV-CTD mutant", "PROTEIN", 117, 132], ["The chimeric N gene", "TREATMENT", 0, 19]]], ["The vector for the T-CTD-R mutant (pT2bR) was subsequently made by transfer of a cDNA fragment encoding the reverting mutation G78R between the unique EagI (M gene) and NheI (N gene) sites in pPM9-T2b.", [["T-CTD-R", "GENE_OR_GENE_PRODUCT", 19, 26], ["EagI (M gene", "GENE_OR_GENE_PRODUCT", 151, 163], ["NheI (N gene", "GENE_OR_GENE_PRODUCT", 169, 181], ["pPM9-T2b", "GENE_OR_GENE_PRODUCT", 192, 200], ["CTD", "PROTEIN", 21, 24], ["R mutant", "PROTEIN", 25, 33], ["pT2bR", "PROTEIN", 35, 40], ["cDNA fragment", "DNA", 81, 94], ["EagI (M gene", "DNA", 151, 163], ["NheI (N gene) sites", "DNA", 169, 188], ["pPM9", "DNA", 192, 196], ["T2b", "DNA", 197, 200], ["The vector", "TREATMENT", 0, 10], ["the T-CTD-R mutant (pT2bR)", "TREATMENT", 15, 41], ["a cDNA fragment", "PROBLEM", 79, 94], ["the unique EagI (M gene)", "TREATMENT", 140, 164], ["NheI (N gene)", "TREATMENT", 169, 182]]], ["Plasmids pT2bR-PS1 and pT2bR-PS2, transcription vectors for the T-CTD-R-PS1 and T-CTD-R-PS2 mutants, were constructed by insertion of cDNA for nt 1-650 or nt 156-327 of the TGEV genome between the unique SalI and AscI sites downstream of the nsp16 stop codon in pT2bR.MHV mutant construction ::: Materials and methodsFollowing targeted RNA recombination and plaque purification, verification of constructed mutants was carried out by reverse transcription of isolated RNA with a random hexanucleotide primer and avian myeloblastosis virus reverse transcriptase (Life Sciences).", [["plaque", "ANATOMY", 358, 364], ["pT2bR-PS1", "GENE_OR_GENE_PRODUCT", 9, 18], ["pT2bR-PS2", "GENE_OR_GENE_PRODUCT", 23, 32], ["T-CTD", "GENE_OR_GENE_PRODUCT", 64, 69], ["R-PS1", "GENE_OR_GENE_PRODUCT", 70, 75], ["T-CTD-R-PS2", "GENE_OR_GENE_PRODUCT", 80, 91], ["TGEV", "ORGANISM", 173, 177], ["SalI", "GENE_OR_GENE_PRODUCT", 204, 208], ["AscI", "GENE_OR_GENE_PRODUCT", 213, 217], ["nsp16", "GENE_OR_GENE_PRODUCT", 242, 247], ["MHV mutant", "ORGANISM", 268, 278], ["avian myeloblastosis virus", "ORGANISM", 512, 538], ["pT2bR", "PROTEIN", 9, 14], ["PS1", "PROTEIN", 15, 18], ["pT2bR", "PROTEIN", 23, 28], ["PS2", "DNA", 29, 32], ["transcription vectors", "DNA", 34, 55], ["CTD", "PROTEIN", 66, 69], ["R", "PROTEIN", 70, 71], ["PS1", "PROTEIN", 72, 75], ["T", "PROTEIN", 80, 81], ["CTD", "PROTEIN", 82, 85], ["R", "PROTEIN", 86, 87], ["PS2", "PROTEIN", 88, 91], ["cDNA", "DNA", 134, 138], ["nt 1-650 or nt 156-327", "DNA", 143, 165], ["TGEV genome", "DNA", 173, 184], ["unique SalI and AscI sites", "DNA", 197, 223], ["nsp16 stop codon", "DNA", 242, 258], ["pT2bR", "DNA", 262, 267], ["hexanucleotide primer", "DNA", 486, 507], ["avian myeloblastosis virus reverse transcriptase", "PROTEIN", 512, 560], ["avian myeloblastosis virus", "SPECIES", 512, 538], ["TGEV", "SPECIES", 173, 177], ["MHV", "SPECIES", 268, 271], ["avian myeloblastosis virus", "SPECIES", 512, 538], ["Plasmids", "TEST", 0, 8], ["PS1", "TEST", 15, 18], ["pT2bR", "TEST", 23, 28], ["transcription vectors", "TREATMENT", 34, 55], ["the T", "TEST", 60, 65], ["CTD", "TEST", 66, 69], ["PS1", "TEST", 72, 75], ["T", "TEST", 80, 81], ["CTD", "TEST", 82, 85], ["insertion of cDNA", "TREATMENT", 121, 138], ["nt", "TEST", 143, 145], ["nt", "TEST", 155, 157], ["the TGEV genome", "PROBLEM", 169, 184], ["the unique SalI", "TREATMENT", 193, 208], ["AscI sites", "PROBLEM", 213, 223], ["methods", "TREATMENT", 310, 317], ["targeted RNA recombination", "TREATMENT", 327, 353], ["plaque purification", "TREATMENT", 358, 377], ["constructed mutants", "PROBLEM", 395, 414], ["isolated RNA", "PROBLEM", 459, 471], ["a random hexanucleotide primer", "TREATMENT", 477, 507], ["avian myeloblastosis virus", "TREATMENT", 512, 538], ["isolated RNA", "OBSERVATION", 459, 471]]], ["PCR amplification of cDNA was performed with the Expand High Fidelity PCR System (Roche), and PCR products were purified with QIAquick spin columns (Qiagen) prior to Sanger DNA sequencing.", [["DNA", "CELLULAR_COMPONENT", 173, 176], ["cDNA", "DNA", 21, 25], ["PCR products", "DNA", 94, 106], ["PCR amplification of cDNA", "TEST", 0, 25], ["PCR products", "TREATMENT", 94, 106], ["QIAquick spin columns", "TREATMENT", 126, 147], ["Sanger DNA sequencing", "TREATMENT", 166, 187]]], ["The isogenic wild-type strain used for comparison with TGEV CTD mutants was Alb649 (Kuo and Masters, 2013); the isogenic wild-type strain for all other mutants was Alb741 (Kuo et al., 2014).Virus purification ::: Materials and methodsMonolayers of 17Cl1 cells grown in Eagle\u2019s medium containing 10% fetal bovine serum were inoculated at a multiplicity of 1 PFU/cell.", [["Monolayers", "ANATOMY", 234, 244], ["17Cl1 cells", "ANATOMY", 248, 259], ["fetal bovine serum", "ANATOMY", 299, 317], ["cell", "ANATOMY", 361, 365], ["TGEV", "ORGANISM", 55, 59], ["CTD", "GENE_OR_GENE_PRODUCT", 60, 63], ["Alb649", "ORGANISM", 76, 82], ["wild-type strain", "ORGANISM", 121, 137], ["Virus", "ORGANISM", 190, 195], ["Monolayers", "CELL", 234, 244], ["17Cl1 cells", "CELL", 248, 259], ["bovine", "ORGANISM", 305, 311], ["serum", "ORGANISM_SUBSTANCE", 312, 317], ["cell", "CELL", 361, 365], ["TGEV CTD mutants", "PROTEIN", 55, 71], ["17Cl1 cells", "CELL_LINE", 248, 259], ["bovine", "SPECIES", 305, 311], ["TGEV", "SPECIES", 55, 59], ["bovine", "SPECIES", 305, 311], ["The isogenic wild-type strain", "PROBLEM", 0, 29], ["TGEV CTD mutants", "TEST", 55, 71], ["Alb", "TEST", 76, 79], ["the isogenic wild-type strain", "PROBLEM", 108, 137], ["Alb", "TEST", 164, 167], ["methodsMonolayers", "TEST", 227, 244], ["17Cl1 cells", "PROBLEM", 248, 259], ["fetal bovine serum", "TEST", 299, 317], ["Eagle", "OBSERVATION_MODIFIER", 269, 274]]], ["Infections were allowed to proceed for 12\u201316 h, to a point where syncytia formation was maximal but little or no cell lysis or detachment had occurred.", [["syncytia", "ANATOMY", 65, 73], ["cell", "ANATOMY", 113, 117], ["syncytia", "CELL", 65, 73], ["cell", "CELL", 113, 117], ["Infections", "PROBLEM", 0, 10], ["syncytia formation", "PROBLEM", 65, 83], ["cell lysis", "PROBLEM", 113, 123], ["detachment", "PROBLEM", 127, 137], ["syncytia", "OBSERVATION", 65, 73], ["no", "UNCERTAINTY", 110, 112], ["cell lysis", "OBSERVATION", 113, 123], ["detachment", "OBSERVATION", 127, 137]]], ["Released virus in harvested extracellular medium was precipitated with polyethylene glycol and resuspended in magnesium- and calcium-free phosphate-buffered saline, pH 7.4 (PBS).", [["extracellular", "ANATOMY", 28, 41], ["polyethylene glycol", "CHEMICAL", 71, 90], ["magnesium", "CHEMICAL", 110, 119], ["calcium", "CHEMICAL", 125, 132], ["phosphate", "CHEMICAL", 138, 147], ["polyethylene glycol", "CHEMICAL", 71, 90], ["magnesium", "CHEMICAL", 110, 119], ["calcium", "CHEMICAL", 125, 132], ["phosphate", "CHEMICAL", 138, 147], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 28, 41], ["polyethylene glycol", "SIMPLE_CHEMICAL", 71, 90], ["magnesium", "SIMPLE_CHEMICAL", 110, 119], ["calcium", "SIMPLE_CHEMICAL", 125, 132], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 138, 163], ["Released virus in harvested extracellular medium", "TREATMENT", 0, 48], ["polyethylene glycol", "TREATMENT", 71, 90], ["magnesium", "TREATMENT", 110, 119], ["calcium-free phosphate", "TREATMENT", 125, 147], ["buffered saline", "TREATMENT", 148, 163], ["pH", "TEST", 165, 167], ["virus", "OBSERVATION", 9, 14]]], ["Virions were sedimented onto cushions of 60% sucrose in PBS by centrifugation at 151,000\u00d7g for 2.5 h in a Beckman SW41 rotor at 4 \u00b0C. Samples were removed from cushions, diluted with PBS to contain 10% sucrose and layered onto 10\u201320\u201340\u201360% sucrose step gradients.", [["Samples", "ANATOMY", 134, 141], ["sucrose", "CHEMICAL", 45, 52], ["sucrose", "CHEMICAL", 202, 209], ["sucrose", "CHEMICAL", 240, 247], ["sucrose", "CHEMICAL", 45, 52], ["sucrose", "CHEMICAL", 202, 209], ["sucrose", "CHEMICAL", 240, 247], ["sucrose", "SIMPLE_CHEMICAL", 45, 52], ["sucrose", "SIMPLE_CHEMICAL", 202, 209], ["sucrose", "SIMPLE_CHEMICAL", 240, 247], ["a Beckman SW41 rotor", "TREATMENT", 104, 124], ["Samples", "TEST", 134, 141], ["PBS", "TREATMENT", 183, 186], ["10% sucrose", "TREATMENT", 198, 209], ["sedimented", "OBSERVATION", 13, 23]]], ["Virion bands were collected from the 20\u201340% sucrose interface after centrifugation at 151,000\u00d7g for 2.5 h in a Beckman SW41 rotor at 4 \u00b0C. For the SARS-CoV M chimera set (Fig. 2) and the domain N3 mutant set (Fig. 3), virions were further purified by pulldown with anti-M monoclonal antibody J.1.3 and nProtein A Sepharose beads (GE Healthcare) exactly as described previously (Kuo and Masters, 2013).Analysis of viral RNA and protein ::: Materials and methodsRNA was extracted from purified virions or from infected cells with Ultraspec reagent (Biotecx) according to the manufacturer\u05f3s instructions and then isolated with Direct-zol RNA MiniPrep spin columns (Zymo Research).", [["virions", "ANATOMY", 218, 225], ["virions", "ANATOMY", 492, 499], ["cells", "ANATOMY", 517, 522], ["sucrose", "CHEMICAL", 44, 51], ["sucrose", "CHEMICAL", 44, 51], ["sucrose", "SIMPLE_CHEMICAL", 44, 51], ["virions", "ORGANISM_SUBSTANCE", 218, 225], ["cells", "CELL", 517, 522], ["N3", "PROTEIN", 194, 196], ["M monoclonal antibody J.1.3", "PROTEIN", 270, 297], ["nProtein A", "PROTEIN", 302, 312], ["viral RNA", "RNA", 413, 422], ["infected cells", "CELL_TYPE", 508, 522], ["SARS-CoV", "SPECIES", 147, 155], ["Virion bands", "PROBLEM", 0, 12], ["a Beckman SW41 rotor", "TREATMENT", 109, 129], ["the SARS", "TEST", 143, 151], ["CoV M chimera set (Fig. 2", "TREATMENT", 152, 177], ["the domain N3 mutant set (Fig.", "TREATMENT", 183, 213], ["virions", "TREATMENT", 218, 225], ["pulldown", "TEST", 251, 259], ["anti-M monoclonal antibody", "TREATMENT", 265, 291], ["nProtein A Sepharose beads", "TREATMENT", 302, 328], ["viral RNA", "TEST", 413, 422], ["methodsRNA", "PROBLEM", 453, 463], ["purified virions", "PROBLEM", 483, 499], ["infected cells", "PROBLEM", 508, 522], ["Ultraspec reagent", "TREATMENT", 528, 545], ["Direct-zol RNA", "TREATMENT", 624, 638], ["viral RNA", "OBSERVATION", 413, 422], ["infected cells", "OBSERVATION", 508, 522]]], ["Northern blotting analysis of purified virion RNA was conducted as described in detail previously (Kuo and Masters, 2010).", [["purified virion RNA", "RNA", 30, 49], ["Northern blotting analysis", "TEST", 0, 26], ["purified virion RNA", "PROBLEM", 30, 49], ["virion RNA", "OBSERVATION", 39, 49]]], ["RNA was probed with a PCR product corresponding to nt \u221217 through +747 of the MHV N gene; the probe was labeled with an AlkPhos Direct kit and was visualized using CDP-Star detection reagent (GE Healthcare).Analysis of viral RNA and protein ::: Materials and methodsProteins from purified virions were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), with prestained protein standards included in adjacent lanes, and analyzed by Western blotting exactly as described previously (Hurst et al., 2009).", [["virions", "ANATOMY", 289, 296], ["CDP", "CHEMICAL", 164, 167], ["sodium dodecyl sulfate", "CHEMICAL", 315, 337], ["sodium dodecyl sulfate", "CHEMICAL", 315, 337], ["polyacrylamide", "CHEMICAL", 338, 352], ["MHV N", "GENE_OR_GENE_PRODUCT", 78, 83], ["CDP", "SIMPLE_CHEMICAL", 164, 167], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 315, 337], ["RNA", "RNA", 0, 3], ["nt \u221217", "DNA", 51, 57], ["MHV N gene", "DNA", 78, 88], ["viral RNA", "RNA", 219, 228], ["MHV", "SPECIES", 78, 81], ["a PCR product", "TREATMENT", 20, 33], ["nt", "TEST", 51, 53], ["the MHV N gene", "TREATMENT", 74, 88], ["an AlkPhos Direct kit", "TEST", 117, 138], ["CDP", "TEST", 164, 167], ["viral RNA", "TEST", 219, 228], ["purified virions", "TREATMENT", 280, 296], ["sodium dodecyl sulfate", "TREATMENT", 315, 337], ["polyacrylamide gel electrophoresis", "TREATMENT", 338, 372], ["prestained protein standards", "TREATMENT", 390, 418], ["viral RNA", "OBSERVATION", 219, 228]]], ["Proteins were detected with anti-MHV M protein monoclonal antibody J.1.3 (Fig. 1, Fig. 2, Fig. 3) and either anti-MHV N protein monoclonal antibody J.3.3 (Fig. 1) or else anti-MHV N protein rabbit polyclonal antibody (Fig. 2, Fig. 3).", [["rabbit", "ORGANISM", 190, 196], ["anti-MHV M protein monoclonal antibody J.1.3", "PROTEIN", 28, 72], ["Fig. 1", "PROTEIN", 74, 80], ["Fig. 3", "PROTEIN", 90, 96], ["anti-MHV N protein monoclonal antibody J.3.3 (Fig. 1", "PROTEIN", 109, 161], ["anti-MHV N protein rabbit polyclonal antibody", "PROTEIN", 171, 216], ["rabbit", "SPECIES", 190, 196], ["rabbit", "SPECIES", 190, 196], ["Proteins", "TEST", 0, 8], ["anti-MHV M protein monoclonal antibody", "TEST", 28, 66], ["Fig.", "TEST", 74, 78], ["Fig.", "TEST", 82, 86], ["Fig.", "TEST", 90, 94], ["anti-MHV N protein monoclonal antibody", "TEST", 109, 147], ["Fig", "TEST", 155, 158], ["else anti-MHV N protein rabbit", "TEST", 166, 196], ["polyclonal antibody", "TEST", 197, 216]]], ["Bound antibodies were visualized by enhanced chemiluminescence detection (Pierce).", [["Bound antibodies", "PROTEIN", 0, 16], ["Bound antibodies", "TEST", 0, 16], ["enhanced chemiluminescence detection", "TEST", 36, 72]]], ["For normalization of purified virions prior to RNA extraction, chemiluminescence was quantitated with a BioRad ChemiDoc XRS+ instrument.", [["purified virions", "PROBLEM", 21, 37], ["RNA extraction", "TREATMENT", 47, 61], ["chemiluminescence", "TEST", 63, 80], ["a BioRad ChemiDoc XRS", "TEST", 102, 123], ["virions", "OBSERVATION", 30, 37]]], ["Both monoclonal antibodies were generously provided by John Fleming (University of Wisconsin, Madison).", [["monoclonal antibodies", "PROTEIN", 5, 26], ["monoclonal antibodies", "OBSERVATION", 5, 26]]], ["Antibody J.1.3 recognizes an epitope in the M protein ectodomain (de Haan et al., 1998); antibody J.3.3 recognizes an epitope in N protein domain N3 (Hurst et al., 2005).", [["J.1.3", "PROTEIN", 9, 14], ["M protein ectodomain", "PROTEIN", 44, 64], ["antibody J.3.3", "PROTEIN", 89, 103], ["N protein domain N3", "PROTEIN", 129, 148], ["Antibody", "TEST", 0, 8], ["an epitope", "PROBLEM", 26, 36], ["antibody", "TEST", 89, 97]]]], "PMC7164493": [["BackgroundCurrent medical treatments for conditions involving an impaired respiratory system provide inefficient methods of delivering oxygen to the patient.", [["respiratory system", "ANATOMY", 74, 92], ["oxygen", "CHEMICAL", 135, 141], ["oxygen", "CHEMICAL", 135, 141], ["oxygen", "SIMPLE_CHEMICAL", 135, 141], ["patient", "ORGANISM", 149, 156], ["patient", "SPECIES", 149, 156], ["BackgroundCurrent medical treatments", "TREATMENT", 0, 36], ["an impaired respiratory system", "PROBLEM", 62, 92], ["delivering oxygen", "TREATMENT", 124, 141], ["respiratory system", "OBSERVATION", 74, 92]]], ["Patients with these respiratory dysfunctions are often unable to get the required amount of oxygen to the brain and body.", [["respiratory", "ANATOMY", 20, 31], ["brain", "ANATOMY", 106, 111], ["body", "ANATOMY", 116, 120], ["respiratory dysfunctions", "DISEASE", 20, 44], ["oxygen", "CHEMICAL", 92, 98], ["oxygen", "CHEMICAL", 92, 98], ["Patients", "ORGANISM", 0, 8], ["oxygen", "SIMPLE_CHEMICAL", 92, 98], ["brain", "ORGAN", 106, 111], ["body", "ORGANISM_SUBDIVISION", 116, 120], ["Patients", "SPECIES", 0, 8], ["these respiratory dysfunctions", "PROBLEM", 14, 44], ["oxygen", "TREATMENT", 92, 98], ["respiratory dysfunctions", "OBSERVATION", 20, 44], ["brain", "ANATOMY", 106, 111], ["body", "ANATOMY", 116, 120]]], ["This can lead to delayed recovery from acute illness, multisystem organ failure, and ultimately death.", [["organ", "ANATOMY", 66, 71], ["multisystem organ failure", "DISEASE", 54, 79], ["death", "DISEASE", 96, 101], ["organ", "ORGAN", 66, 71], ["acute illness", "PROBLEM", 39, 52], ["multisystem organ failure", "PROBLEM", 54, 79], ["ultimately death", "PROBLEM", 85, 101], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["illness", "OBSERVATION", 45, 52], ["multisystem", "OBSERVATION_MODIFIER", 54, 65], ["organ", "ANATOMY", 66, 71], ["failure", "OBSERVATION", 72, 79]]], ["The mortality rate for cases of respiratory dysfunctions has been recently reported in the range of 31\u201375% [1].", [["respiratory", "ANATOMY", 32, 43], ["respiratory dysfunctions", "DISEASE", 32, 56], ["The mortality rate", "TEST", 0, 18], ["respiratory dysfunctions", "PROBLEM", 32, 56], ["respiratory dysfunctions", "OBSERVATION", 32, 56]]], ["This is especially troubling considering there are many causes of respiratory failure leading to acute respiratory distress syndrome (ARDS), including pneumonia, sepsis, trauma, chemical inhalation, and bacterial or viral infection.BackgroundMethods of oxygenation and ventilation that bypass the lungs have been explored in an effort to promote lung recovery.", [["respiratory", "ANATOMY", 66, 77], ["respiratory", "ANATOMY", 103, 114], ["lungs", "ANATOMY", 297, 302], ["lung", "ANATOMY", 346, 350], ["respiratory failure", "DISEASE", 66, 85], ["acute respiratory distress syndrome", "DISEASE", 97, 132], ["ARDS", "DISEASE", 134, 138], ["pneumonia", "DISEASE", 151, 160], ["sepsis", "DISEASE", 162, 168], ["trauma", "DISEASE", 170, 176], ["bacterial or viral infection", "DISEASE", 203, 231], ["lungs", "ORGAN", 297, 302], ["lung", "ORGAN", 346, 350], ["respiratory failure", "PROBLEM", 66, 85], ["acute respiratory distress syndrome", "PROBLEM", 97, 132], ["ARDS)", "PROBLEM", 134, 139], ["pneumonia", "PROBLEM", 151, 160], ["sepsis", "PROBLEM", 162, 168], ["trauma", "PROBLEM", 170, 176], ["chemical inhalation", "TREATMENT", 178, 197], ["bacterial or viral infection", "PROBLEM", 203, 231], ["ventilation", "TREATMENT", 269, 280], ["bypass", "TREATMENT", 286, 292], ["respiratory failure", "OBSERVATION", 66, 85], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["respiratory distress syndrome", "OBSERVATION", 103, 132], ["ARDS", "OBSERVATION", 134, 138], ["pneumonia", "OBSERVATION", 151, 160], ["sepsis", "OBSERVATION", 162, 168], ["bacterial", "OBSERVATION_MODIFIER", 203, 212], ["viral", "OBSERVATION_MODIFIER", 216, 221], ["infection", "OBSERVATION", 222, 231], ["oxygenation", "OBSERVATION_MODIFIER", 253, 264], ["bypass", "OBSERVATION", 286, 292], ["lungs", "ANATOMY", 297, 302], ["lung", "ANATOMY", 346, 350], ["recovery", "OBSERVATION", 351, 359]]], ["So far, only extracorporeal membrane oxygenation (ECMO) has been approved for medical use.", [["extracorporeal membrane", "ANATOMY", 13, 36], ["extracorporeal membrane oxygenation", "TREATMENT", 13, 48], ["ECMO", "TREATMENT", 50, 54], ["extracorporeal", "OBSERVATION_MODIFIER", 13, 27], ["membrane", "OBSERVATION_MODIFIER", 28, 36], ["oxygenation", "OBSERVATION", 37, 48]]], ["However, ECMO is an unsatisfactory treatment as it possesses many of its own risks, including hemorrhage, thrombosis, and cannula malfunction.", [["hemorrhage", "DISEASE", 94, 104], ["thrombosis", "DISEASE", 106, 116], ["ECMO", "TREATMENT", 9, 13], ["an unsatisfactory treatment", "TREATMENT", 17, 44], ["hemorrhage", "PROBLEM", 94, 104], ["thrombosis", "PROBLEM", 106, 116], ["cannula malfunction", "TREATMENT", 122, 141], ["hemorrhage", "OBSERVATION", 94, 104], ["thrombosis", "OBSERVATION", 106, 116], ["cannula malfunction", "OBSERVATION", 122, 141]]], ["These risks eliminate ECMO as a viable treatment alternative for many patients.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["ECMO", "TREATMENT", 22, 26], ["a viable treatment alternative", "TREATMENT", 30, 60]]], ["Therefore, we have researched an alternative technology for delivering oxygen to the body through the peritoneal cavity.BackgroundWe have developed a peritoneal dosing system (PDS) which delivers an infusate solution to the peritoneal cavity.", [["body", "ANATOMY", 85, 89], ["peritoneal cavity", "ANATOMY", 102, 119], ["peritoneal", "ANATOMY", 150, 160], ["peritoneal cavity", "ANATOMY", 224, 241], ["oxygen", "CHEMICAL", 71, 77], ["oxygen", "CHEMICAL", 71, 77], ["oxygen", "SIMPLE_CHEMICAL", 71, 77], ["body", "ORGANISM_SUBDIVISION", 85, 89], ["peritoneal cavity", "MULTI-TISSUE_STRUCTURE", 102, 119], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 150, 160], ["peritoneal cavity", "MULTI-TISSUE_STRUCTURE", 224, 241], ["delivering oxygen", "TREATMENT", 60, 77], ["a peritoneal dosing system", "TREATMENT", 148, 174], ["an infusate solution to the peritoneal cavity", "TREATMENT", 196, 241], ["peritoneal cavity", "ANATOMY", 102, 119], ["peritoneal", "ANATOMY", 150, 160], ["peritoneal cavity", "ANATOMY", 224, 241]]], ["In order to provide a patient with supplemental oxygenation, phospholipid shelled oxygen microbubbles (OMBs) would be administered to the patient.", [["oxygen", "CHEMICAL", 82, 88], ["oxygen", "CHEMICAL", 82, 88], ["patient", "ORGANISM", 22, 29], ["phospholipid shelled oxygen microbubbles", "SIMPLE_CHEMICAL", 61, 101], ["OMBs", "SIMPLE_CHEMICAL", 103, 107], ["patient", "ORGANISM", 138, 145], ["patient", "SPECIES", 22, 29], ["patient", "SPECIES", 138, 145], ["supplemental oxygenation", "TREATMENT", 35, 59], ["phospholipid shelled oxygen microbubbles", "TREATMENT", 61, 101]]], ["Previously, we have shown that peritoneal membrane oxygenation (PMO) with OMBs is a possible treatment method in acute lung injury models [2].", [["peritoneal membrane", "ANATOMY", 31, 50], ["lung", "ANATOMY", 119, 123], ["acute lung injury", "DISEASE", 113, 130], ["peritoneal membrane", "MULTI-TISSUE_STRUCTURE", 31, 50], ["OMBs", "SIMPLE_CHEMICAL", 74, 78], ["lung", "ORGAN", 119, 123], ["peritoneal membrane oxygenation (PMO", "TREATMENT", 31, 67], ["treatment method", "TREATMENT", 93, 109], ["acute lung injury models", "PROBLEM", 113, 137], ["peritoneal", "ANATOMY", 31, 41], ["membrane oxygenation", "OBSERVATION", 42, 62], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["lung", "ANATOMY", 119, 123], ["injury", "OBSERVATION", 124, 130]]], ["We are now extending the validity of PMO treatment by testing in long term disease models, which more accurately reflect clinical scenarios.", [["PMO treatment", "TREATMENT", 37, 50], ["long term disease models", "PROBLEM", 65, 89], ["long term", "OBSERVATION_MODIFIER", 65, 74]]], ["ARDS is a medical condition that has been well established in animal models.", [["ARDS", "DISEASE", 0, 4], ["ARDS", "PROBLEM", 0, 4], ["a medical condition", "PROBLEM", 8, 27]]], ["Rat models of ARDS have been well established by tracheal delivery of the endotoxin, lipopolysaccharide (LPS) [3].", [["tracheal", "ANATOMY", 49, 57], ["ARDS", "DISEASE", 14, 18], ["lipopolysaccharide", "CHEMICAL", 85, 103], ["LPS", "CHEMICAL", 105, 108], ["tracheal", "MULTI-TISSUE_STRUCTURE", 49, 57], ["endotoxin", "SIMPLE_CHEMICAL", 74, 83], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 85, 103], ["LPS", "SIMPLE_CHEMICAL", 105, 108], ["ARDS", "PROBLEM", 14, 18], ["the endotoxin", "TREATMENT", 70, 83], ["lipopolysaccharide (LPS)", "TREATMENT", 85, 109], ["ARDS", "OBSERVATION", 14, 18], ["tracheal", "ANATOMY", 49, 57]]], ["Our study involves two phases: (1) development and characterization of the ARDS disease model in rats; (2) design and validation of ambulatory infusion device.MethodsIn all phases, male Wistar rats are housed and cared for according to the University of Nebraska IACUC guidelines.", [["ARDS", "DISEASE", 75, 79], ["rats", "ORGANISM", 97, 101], ["Wistar rats", "ORGANISM", 186, 197], ["rats", "SPECIES", 97, 101], ["rats", "SPECIES", 193, 197], ["Our study", "TEST", 0, 9], ["the ARDS disease model in rats", "PROBLEM", 71, 101], ["ambulatory infusion device", "TREATMENT", 132, 158], ["ARDS", "OBSERVATION", 75, 79]]], ["Animals are allowed to acclimate for 4 days prior to the experiments.", [["Animals", "ORGANISM", 0, 7]]], ["In phase 1, the model for ARDS is evaluated and characterized.", [["ARDS", "DISEASE", 26, 30], ["ARDS", "PROBLEM", 26, 30], ["ARDS", "OBSERVATION", 26, 30]]], ["Rats are sedated with ketamine\u2013xylazine (18\u20132 mg/kg).", [["ketamine\u2013xylazine", "CHEMICAL", 22, 39], ["ketamine\u2013xylazine", "CHEMICAL", 22, 39], ["Rats", "ORGANISM", 0, 4], ["ketamine\u2013xylazine", "SIMPLE_CHEMICAL", 22, 39], ["Rats", "SPECIES", 0, 4], ["ketamine\u2013xylazine", "TREATMENT", 22, 39]]], ["Healthy baseline measurements of weight, chest radiographs (PRX 90, Bowie), pulse oximetry (PhysioSuite, Kent Scientific Corp.), and venous blood analysis are then done.", [["chest", "ANATOMY", 41, 46], ["venous blood", "ANATOMY", 133, 145], ["blood", "ORGANISM_SUBSTANCE", 140, 145], ["weight", "TEST", 33, 39], ["chest radiographs", "TEST", 41, 58], ["PRX", "TEST", 60, 63], ["pulse oximetry", "TEST", 76, 90], ["venous blood analysis", "TEST", 133, 154], ["chest", "ANATOMY", 41, 46], ["venous", "ANATOMY", 133, 139]]], ["Analysis of venous blood from the tail vein was performed with a handheld blood analyzer (VetScan iSTAT 1, Abaxis) to determine the animal's blood gases, pH, chemistry, and hematocrit.", [["venous blood", "ANATOMY", 12, 24], ["tail vein", "ANATOMY", 34, 43], ["blood", "ANATOMY", 74, 79], ["blood", "ANATOMY", 141, 146], ["venous blood", "ORGANISM_SUBSTANCE", 12, 24], ["tail vein", "MULTI-TISSUE_STRUCTURE", 34, 43], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["blood", "ORGANISM_SUBSTANCE", 141, 146], ["venous blood from the tail vein", "PROBLEM", 12, 43], ["a handheld blood analyzer", "TEST", 63, 88], ["VetScan iSTAT", "TEST", 90, 103], ["the animal's blood gases", "TEST", 128, 152], ["pH", "TEST", 154, 156], ["chemistry", "TEST", 158, 167], ["hematocrit", "TEST", 173, 183], ["venous blood", "ANATOMY", 12, 24], ["tail vein", "ANATOMY", 34, 43]]], ["Intratracheal administration of 0.5 ml saline with LPS (7 mg/kg, Sigma-Aldrich) was performed with the MicroSprayer\u00aeAerosolizer (Model IA-1B-R, PennCentury).", [["Intratracheal", "ANATOMY", 0, 13], ["LPS", "CHEMICAL", 51, 54], ["Intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["saline", "SIMPLE_CHEMICAL", 39, 45], ["LPS", "SIMPLE_CHEMICAL", 51, 54], ["Intratracheal administration", "TREATMENT", 0, 28], ["0.5 ml saline", "TREATMENT", 32, 45], ["LPS", "TREATMENT", 51, 54], ["Aerosolizer", "TEST", 116, 127]]], ["An additional negative control (NC) group was not administered with any intratracheal solution.", [["An additional negative control (NC) group", "TREATMENT", 0, 41], ["any intratracheal solution", "TREATMENT", 68, 94], ["negative", "OBSERVATION", 14, 22]]], ["Observation and collection of daily blood samples and chest radiographs of each animal were performed until death or at 7 days post LPS administration.", [["blood samples", "ANATOMY", 36, 49], ["chest", "ANATOMY", 54, 59], ["death", "DISEASE", 108, 113], ["LPS", "CHEMICAL", 132, 135], ["blood samples", "ORGANISM_SUBSTANCE", 36, 49], ["LPS", "SIMPLE_CHEMICAL", 132, 135], ["collection of daily blood samples", "TEST", 16, 49], ["chest radiographs", "TEST", 54, 71], ["LPS administration", "TREATMENT", 132, 150], ["chest", "ANATOMY", 54, 59]]], ["Upon completion of the observation period, living animals are then euthanized with sodium pentobarbital.", [["sodium pentobarbital", "CHEMICAL", 83, 103], ["sodium pentobarbital", "CHEMICAL", 83, 103], ["animals", "ORGANISM", 50, 57], ["sodium", "SIMPLE_CHEMICAL", 83, 89], ["pentobarbital", "SIMPLE_CHEMICAL", 90, 103], ["sodium pentobarbital", "TREATMENT", 83, 103]]], ["Lung tissue was hematoxylin and eosin stained and sent to an independent pathologist for lung injury scoring [4].MethodsPhase 2 is the development of an ambulatory delivery system that will infuse fluid to the rat's peritoneal cavity for treatment.", [["Lung tissue", "ANATOMY", 0, 11], ["lung", "ANATOMY", 89, 93], ["fluid", "ANATOMY", 197, 202], ["peritoneal cavity", "ANATOMY", 216, 233], ["lung injury", "DISEASE", 89, 100], ["hematoxylin", "CHEMICAL", 16, 27], ["eosin", "CHEMICAL", 32, 37], ["Lung tissue", "TISSUE", 0, 11], ["hematoxylin", "SIMPLE_CHEMICAL", 16, 27], ["eosin", "SIMPLE_CHEMICAL", 32, 37], ["lung", "ORGAN", 89, 93], ["fluid", "ORGANISM_SUBSTANCE", 197, 202], ["rat", "ORGANISM", 210, 213], ["peritoneal cavity", "MULTI-TISSUE_STRUCTURE", 216, 233], ["rat", "SPECIES", 210, 213], ["lung injury scoring", "PROBLEM", 89, 108], ["an ambulatory delivery system", "TREATMENT", 150, 179], ["fluid", "TREATMENT", 197, 202], ["treatment", "TREATMENT", 238, 247], ["tissue", "ANATOMY", 5, 11], ["lung", "ANATOMY", 89, 93], ["injury", "OBSERVATION", 94, 100], ["peritoneal cavity", "ANATOMY", 216, 233]]], ["The PDS must fulfill several design criteria: (1) continuously treat four rats simultaneously with the same or different infusates; (2) infusate needs to be stored at a temperature range of 2\u20138 \u00b0C; (3) warm the infusate to 37 \u00b0C immediately before delivery to the animal; (4) gently agitate solution to prevent dissociation of microbubbles; (5) prevent tubing from restraining the rat or being harmed by the rat; (6) be compatible with current facility housing and cages.", [["rats", "ORGANISM", 74, 78], ["rat", "ORGANISM", 381, 384], ["rat", "ORGANISM", 408, 411], ["rats", "SPECIES", 74, 78], ["rat", "SPECIES", 381, 384], ["rat", "SPECIES", 408, 411], ["warm the infusate", "TREATMENT", 202, 219], ["delivery", "TREATMENT", 248, 256], ["gently agitate solution", "TREATMENT", 276, 299], ["dissociation of microbubbles", "PROBLEM", 311, 339], ["tubing", "TREATMENT", 353, 359]]], ["The PDS will be validated by constant observation in trials with healthy animals to ensure the system fulfills the animal's safety and tubing requirements.ResultsFor phase 1, trials have been completed for 7 day LPS and NC groups.", [["LPS", "SIMPLE_CHEMICAL", 212, 215], ["healthy animals", "TREATMENT", 65, 80], ["tubing requirements", "TREATMENT", 135, 154], ["NC groups", "TREATMENT", 220, 229]]], ["Eight rats (m = 541 \u00b1 60 g) were successfully administered aerosolized LPS and all developed ARDS while two rats (m = 556 \u00b1 96 g) were selected for the NC group.", [["LPS", "CHEMICAL", 71, 74], ["ARDS", "DISEASE", 93, 97], ["rats", "ORGANISM", 6, 10], ["LPS", "SIMPLE_CHEMICAL", 71, 74], ["rats", "ORGANISM", 108, 112], ["rats", "SPECIES", 6, 10], ["rats", "SPECIES", 108, 112], ["aerosolized LPS", "TREATMENT", 59, 74], ["ARDS", "PROBLEM", 93, 97], ["the NC group", "TREATMENT", 148, 160], ["ARDS", "OBSERVATION", 93, 97]]], ["The overall mortality rate was 37.5% for LPS trials and 0% for NC trials.", [["LPS", "CHEMICAL", 41, 44], ["The overall mortality rate", "TEST", 0, 26], ["LPS trials", "TREATMENT", 41, 51], ["NC trials", "TREATMENT", 63, 72]]], ["All deaths occurred within 24 hr after administration of LPS.", [["deaths", "DISEASE", 4, 10], ["LPS", "CHEMICAL", 57, 60], ["LPS", "SIMPLE_CHEMICAL", 57, 60], ["LPS", "TREATMENT", 57, 60]]], ["The remaining LPS rats began recovering over the course of the 7 day observation period.", [["rats", "ORGANISM", 18, 22], ["rats", "SPECIES", 18, 22], ["remaining", "OBSERVATION_MODIFIER", 4, 13], ["LPS", "OBSERVATION_MODIFIER", 14, 17], ["rats", "OBSERVATION_MODIFIER", 18, 22]]], ["Chest radiographs taken of LPS rats show clear indications of bilateral infiltrates and interstitial edema in the lungs (Fig. 1).", [["interstitial edema", "ANATOMY", 88, 106], ["lungs", "ANATOMY", 114, 119], ["interstitial edema", "DISEASE", 88, 106], ["rats", "ORGANISM", 31, 35], ["interstitial edema", "PATHOLOGICAL_FORMATION", 88, 106], ["lungs", "ORGAN", 114, 119], ["rats", "SPECIES", 31, 35], ["Chest radiographs", "TEST", 0, 17], ["LPS rats", "TEST", 27, 35], ["bilateral infiltrates", "PROBLEM", 62, 83], ["interstitial edema in the lungs", "PROBLEM", 88, 119], ["clear", "OBSERVATION", 41, 46], ["bilateral", "ANATOMY_MODIFIER", 62, 71], ["infiltrates", "OBSERVATION", 72, 83], ["interstitial", "ANATOMY_MODIFIER", 88, 100], ["edema", "OBSERVATION", 101, 106], ["lungs", "ANATOMY", 114, 119]]], ["The LPS group showed a dramatic loss in lung function from the observed SpO2 levels when compared to NCs (Fig. 2).", [["lung", "ANATOMY", 40, 44], ["LPS", "CHEMICAL", 4, 7], ["LPS", "SIMPLE_CHEMICAL", 4, 7], ["lung", "ORGAN", 40, 44], ["The LPS group", "TEST", 0, 13], ["a dramatic loss in lung function", "PROBLEM", 21, 53], ["SpO2 levels", "TEST", 72, 83], ["NCs", "TEST", 101, 104], ["dramatic", "OBSERVATION_MODIFIER", 23, 31], ["loss", "OBSERVATION", 32, 36], ["lung", "ANATOMY", 40, 44]]], ["Table 1 shows lung injury scores from LPS deaths at day 1, and NC and LPS trials euthanized on day 7.ResultsIn phase 2, final design of the PDS has been completed (Fig. 3).", [["lung", "ANATOMY", 14, 18], ["lung injury", "DISEASE", 14, 25], ["LPS", "CHEMICAL", 38, 41], ["deaths", "DISEASE", 42, 48], ["LPS", "CHEMICAL", 70, 73], ["lung", "ORGAN", 14, 18], ["lung injury scores", "PROBLEM", 14, 32], ["LPS deaths", "PROBLEM", 38, 48], ["NC", "TREATMENT", 63, 65], ["LPS trials", "TREATMENT", 70, 80], ["the PDS", "TEST", 136, 143], ["lung", "ANATOMY", 14, 18], ["injury", "OBSERVATION", 19, 25]]], ["The PDS is comprised of a peristaltic pump, warm water bath, a spring pullbox for dynamic tubing restraint, and a LabVIEW control system.", [["a peristaltic pump", "TREATMENT", 24, 42], ["warm water bath", "TREATMENT", 44, 59], ["a spring pullbox", "TREATMENT", 61, 77], ["dynamic tubing restraint", "TREATMENT", 82, 106], ["a LabVIEW control system", "TREATMENT", 112, 136], ["peristaltic pump", "OBSERVATION", 26, 42]]], ["The PDS is compatible with current housing arrangements of the rats and will not restrict their mobility.", [["rats", "ORGANISM", 63, 67], ["rats", "SPECIES", 63, 67], ["compatible with", "UNCERTAINTY", 11, 26]]], ["Once the prototype of the PDS has been constructed, tests will be completed with healthy rats to validate the system and provide the rat with full mobility.", [["rats", "ORGANISM", 89, 93], ["rat", "ORGANISM", 133, 136], ["PDS", "DNA", 26, 29], ["rats", "SPECIES", 89, 93], ["rat", "SPECIES", 133, 136], ["tests", "TEST", 52, 57]]], ["We expect to be able to continuously dose saline, inert gas microbubbles (IMBs), and OMBs into the peritoneal cavity of four animals with the current PDS design.ResultsBased upon our previous animal experiments with lung injuries, we anticipate improved pulse oximetry, blood gases, and survivability in rats provided OMBs compared to those administered saline or IMBs.InterpretationWe have developed an alternative extrapulmonary oxygenation method by delivering OMBs to the peritoneal cavity.", [["peritoneal cavity", "ANATOMY", 99, 116], ["lung", "ANATOMY", 216, 220], ["blood", "ANATOMY", 270, 275], ["extrapulmonary", "ANATOMY", 416, 430], ["peritoneal cavity", "ANATOMY", 476, 493], ["lung injuries", "DISEASE", 216, 229], ["saline", "SIMPLE_CHEMICAL", 42, 48], ["OMBs", "SIMPLE_CHEMICAL", 85, 89], ["peritoneal cavity", "MULTI-TISSUE_STRUCTURE", 99, 116], ["lung", "ORGAN", 216, 220], ["blood", "ORGANISM_SUBSTANCE", 270, 275], ["rats", "ORGANISM", 304, 308], ["OMBs", "SIMPLE_CHEMICAL", 318, 322], ["saline", "SIMPLE_CHEMICAL", 354, 360], ["OMBs", "SIMPLE_CHEMICAL", 464, 468], ["peritoneal cavity", "MULTI-TISSUE_STRUCTURE", 476, 493], ["rats", "SPECIES", 304, 308], ["continuously dose saline", "TREATMENT", 24, 48], ["inert gas microbubbles", "TREATMENT", 50, 72], ["lung injuries", "PROBLEM", 216, 229], ["pulse oximetry", "TEST", 254, 268], ["blood gases", "TEST", 270, 281], ["those administered saline", "TREATMENT", 335, 360], ["IMBs", "TREATMENT", 364, 368], ["an alternative extrapulmonary oxygenation method", "TREATMENT", 401, 449], ["peritoneal cavity", "ANATOMY", 99, 116], ["lung", "ANATOMY", 216, 220], ["injuries", "OBSERVATION", 221, 229], ["extrapulmonary", "ANATOMY", 416, 430], ["oxygenation method", "OBSERVATION", 431, 449], ["peritoneal cavity", "ANATOMY", 476, 493]]], ["In verifying the clinical benefits of PMO treatment we have devised the current study.", [["PMO", "SIMPLE_CHEMICAL", 38, 41], ["PMO treatment", "TREATMENT", 38, 51], ["the current study", "TEST", 68, 85]]], ["Trials of phase 1 show that we are able to repeatedly induce ARDS in rats with our current methodology.", [["ARDS", "DISEASE", 61, 65], ["rats", "ORGANISM", 69, 73], ["rats", "SPECIES", 69, 73], ["ARDS in rats", "PROBLEM", 61, 73]]], ["Analysis of BAL specimens is pending, as we recently identified a lab able to conduct the analysis.", [["BAL specimens", "ANATOMY", 12, 25], ["BAL specimens", "CANCER", 12, 25], ["Analysis of BAL specimens", "TEST", 0, 25], ["the analysis", "TEST", 86, 98]]], ["The final design of the PDS has been completed and build of the prototype has begun.", [["PDS", "DNA", 24, 27], ["the PDS", "TEST", 20, 27], ["the prototype", "TREATMENT", 60, 73]]], ["Upon completion of phase 1 and 2, PMO treatment will be evaluated.InterpretationThe future direction of this work after validation will focus on reproducing results in large-animal models of moderate to severe ARDS, and commercializing the technology.", [["ARDS", "DISEASE", 210, 214], ["PMO treatment", "TREATMENT", 34, 47], ["moderate to severe ARDS", "PROBLEM", 191, 214], ["large", "OBSERVATION_MODIFIER", 168, 173], ["moderate", "OBSERVATION_MODIFIER", 191, 199], ["severe", "OBSERVATION_MODIFIER", 203, 209], ["ARDS", "OBSERVATION", 210, 214]]], ["We will begin development of large scale manufacture of OMBs.", [["OMBs", "SIMPLE_CHEMICAL", 56, 60], ["large scale manufacture of OMBs", "TREATMENT", 29, 60], ["large", "OBSERVATION_MODIFIER", 29, 34]]], ["We believe PMO treatment will prove to be a safe and reliable lung bypass therapy for patients with severe ARDS who cannot tolerate the significant risk profile inherent to ECMO.", [["lung", "ANATOMY", 62, 66], ["ARDS", "DISEASE", 107, 111], ["PMO", "SIMPLE_CHEMICAL", 11, 14], ["lung", "ORGAN", 62, 66], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["PMO treatment", "TREATMENT", 11, 24], ["a safe and reliable lung bypass therapy", "TREATMENT", 42, 81], ["severe ARDS", "PROBLEM", 100, 111], ["ECMO", "TREATMENT", 173, 177], ["lung", "ANATOMY", 62, 66], ["bypass", "OBSERVATION", 67, 73], ["ARDS", "OBSERVATION", 107, 111]]], ["As we move toward clinical translation, we foresee the implementation of PMO in intensive care units, military combat settings, and even space exploration vehicles.", [["military combat settings", "TREATMENT", 102, 126]]]], "41ee771b9bd14efb72c392edf03b3cff55c9d570": [["IntroductionNeonatal calf diarrhea (NCD) is the most common cause of calf morbidity and mortality, which can exceed 20% in certain instances (Uetake, 2013) .", [["calf diarrhea", "DISEASE", 21, 34], ["NCD", "DISEASE", 36, 39], ["calf", "ORGANISM_SUBDIVISION", 21, 25], ["calf", "ORGANISM_SUBDIVISION", 69, 73], ["calf", "SPECIES", 21, 25], ["calf", "SPECIES", 69, 73], ["Neonatal calf diarrhea", "PROBLEM", 12, 34], ["calf morbidity", "PROBLEM", 69, 83], ["calf", "ANATOMY", 21, 25], ["diarrhea", "OBSERVATION", 26, 34], ["calf", "ANATOMY", 69, 73], ["morbidity", "OBSERVATION", 74, 83]]], ["The factors that influence the etiology of this syndrome include nutritional and sanitary management, immunological aspects, and infectious agents, such as bacteria, viruses, and protozoa (Coura et al., 2015) .", [["this syndrome", "PROBLEM", 43, 56], ["nutritional and sanitary management", "TREATMENT", 65, 100], ["infectious agents", "TREATMENT", 129, 146], ["bacteria", "PROBLEM", 156, 164], ["viruses", "PROBLEM", 166, 173], ["protozoa", "PROBLEM", 179, 187]]], ["Bovine rotavirus A (RVA) is one of the most prevalent viral agents associated with NCD in dairy and beef cattle herds worldwide (Al Mawly et al., 2015; Coura et al., 2015) .IntroductionThe non-enveloped virion of RVA is composed of a triple-layered capsid that surrounds 11 dsRNA segments that encode 6 structural (VP1-VP4, VP6, and VP7) and 6 nonstructural (NSP1-NSP5/6) proteins (Greenberg and Estes, 2009 ).", [["rotavirus A", "CHEMICAL", 7, 18], ["NCD", "DISEASE", 83, 86], ["Bovine rotavirus A", "ORGANISM", 0, 18], ["VP1-VP4", "GENE_OR_GENE_PRODUCT", 315, 322], ["VP6", "GENE_OR_GENE_PRODUCT", 324, 327], ["VP7", "GENE_OR_GENE_PRODUCT", 333, 336], ["NSP1-NSP5/6", "GENE_OR_GENE_PRODUCT", 359, 370], ["RVA", "PROTEIN", 213, 216], ["triple-layered capsid", "PROTEIN", 234, 255], ["VP1", "PROTEIN", 315, 318], ["VP4", "PROTEIN", 319, 322], ["VP6", "PROTEIN", 324, 327], ["VP7", "PROTEIN", 333, 336], ["nonstructural (NSP1-NSP5/6) proteins", "PROTEIN", 344, 380], ["Bovine", "SPECIES", 0, 6], ["beef", "SPECIES", 100, 104], ["cattle", "SPECIES", 105, 111], ["Bovine rotavirus A", "SPECIES", 0, 18], ["RVA", "SPECIES", 20, 23], ["beef", "SPECIES", 100, 104], ["cattle", "SPECIES", 105, 111], ["Bovine rotavirus A (RVA)", "TREATMENT", 0, 24], ["The non-enveloped virion of RVA", "TREATMENT", 185, 216], ["a triple-layered capsid", "TREATMENT", 232, 255], ["VP1", "TEST", 315, 318], ["VP4", "TEST", 319, 322], ["VP6", "TEST", 324, 327], ["VP7", "TEST", 333, 336], ["nonstructural", "TEST", 344, 357], ["NSP1", "TEST", 359, 363], ["NSP5", "TEST", 364, 368], ["proteins", "TEST", 372, 380], ["dsRNA segments", "OBSERVATION", 274, 288]]], ["Based on their antigenic characteristics and sequence analyses of the VP6 gene, viruses within the Rotavirus genus are primarily classified into 9 distinct groups/species (ICTV, 2017; Matthijnssens et al., 2012; Mihalov-Kovacs et al., 2015) ; a newly-proposed species J has been described in the bat .", [["VP6", "GENE_OR_GENE_PRODUCT", 70, 73], ["Rotavirus genus", "ORGANISM", 99, 114], ["bat", "ORGANISM", 296, 299], ["VP6 gene", "DNA", 70, 78], ["sequence analyses", "TEST", 45, 62], ["viruses", "PROBLEM", 80, 87], ["the Rotavirus genus", "PROBLEM", 95, 114], ["species J", "OBSERVATION", 260, 269]]], ["The VP7 and VP4 genes encode 2 structural proteins responsible for the induction of the immune protective response and are used for the binary classification of RVA strains in terms of their G and P genotypes, respectively.", [["VP7", "GENE_OR_GENE_PRODUCT", 4, 7], ["VP4", "GENE_OR_GENE_PRODUCT", 12, 15], ["VP7 and VP4 genes", "DNA", 4, 21], ["structural proteins", "PROTEIN", 31, 50], ["The VP7", "TEST", 0, 7], ["RVA strains", "PROBLEM", 161, 172]]], ["Currently, 36 G and 51 P genotypes are recognized by the Rotavirus Classification Working Group (RCWG, 2017) .IntroductionCalves aged 1 to 3 weeks have antibody levels from passive immunity decreasing to a level that is still sufficiently high to block responses to vaccines but is not sufficiently high to combat infection.", [["Rotavirus", "DISEASE", 57, 66], ["infection", "DISEASE", 314, 323], ["Calves", "ORGANISM", 122, 128], ["P genotypes", "DNA", 23, 34], ["Calves", "SPECIES", 122, 128], ["antibody levels", "TEST", 152, 167], ["passive immunity", "PROBLEM", 173, 189], ["vaccines", "TREATMENT", 266, 274], ["infection", "PROBLEM", 314, 323], ["infection", "OBSERVATION", 314, 323]]], ["Thus, this period is considered a window of opportunity for the infection of microorganisms and, consequently, the occurrence of disease (Chase et al., 2008) .", [["infection", "DISEASE", 64, 73], ["the infection of microorganisms", "PROBLEM", 60, 91], ["disease", "PROBLEM", 129, 136], ["infection", "OBSERVATION", 64, 73], ["disease", "OBSERVATION", 129, 136]]], ["Therefore, the implementation of a cow vaccination program is an important strategy to protect the calves from RVA infection and consequent neonatal diarrhea.IntroductionThe commercial vaccines that are available in Brazil contain inactivated RVA and other infectious agents that are implicated in NCD.", [["RVA infection", "DISEASE", 111, 124], ["diarrhea", "DISEASE", 149, 157], ["NCD", "DISEASE", 298, 301], ["cow", "ORGANISM", 35, 38], ["calves", "ORGANISM", 99, 105], ["calves", "SPECIES", 99, 105], ["cow", "SPECIES", 35, 38], ["RVA", "SPECIES", 111, 114], ["a cow vaccination program", "TREATMENT", 33, 58], ["RVA infection", "PROBLEM", 111, 124], ["consequent neonatal diarrhea", "PROBLEM", 129, 157], ["The commercial vaccines", "TREATMENT", 170, 193], ["other infectious agents", "TREATMENT", 251, 274], ["calves", "ANATOMY", 99, 105], ["RVA", "OBSERVATION_MODIFIER", 111, 114], ["infection", "OBSERVATION", 115, 124], ["infectious", "OBSERVATION", 257, 267]]], ["There were 2 different RVA Brazilian vaccine formulations: i) the bivalent vaccine G10P[11] and G6P[1]; ii) and monovalent G6P[5] genotype, which is the most prevalent genotype worldwide (Papp et al., 2013) as well as in Brazil (Medeiros, 2016) .IntroductionThe aim of this study was to determine the frequency and intensity of neonatal diarrhea and the incidence of RVA and to identify the RVA G and P genotypes circulating in dairy calves born from cows that are regularly vaccinated with the RVA G6P[5] strain in a high milk yield dairy cattle herd.Herd informationThis study was conducted in a Brazilian dairy farm that is operated as a closed dairy cattle herd with 1800 Holstein cows in lactation.", [["G10P", "CHEMICAL", 83, 87], ["G6P", "CHEMICAL", 96, 99], ["G6P", "CHEMICAL", 123, 126], ["diarrhea", "DISEASE", 337, 345], ["G6P", "CHEMICAL", 499, 502], ["G6P", "CHEMICAL", 123, 126], ["G6P[1]", "SIMPLE_CHEMICAL", 96, 102], ["G6P[5]", "SIMPLE_CHEMICAL", 123, 129], ["calves", "ORGANISM", 434, 440], ["cows", "ORGANISM", 451, 455], ["G6P[5", "ORGANISM", 499, 504], ["milk", "ORGANISM_SUBSTANCE", 523, 527], ["calves", "SPECIES", 434, 440], ["cows", "SPECIES", 451, 455], ["cattle", "SPECIES", 540, 546], ["cattle", "SPECIES", 654, 660], ["cows", "SPECIES", 685, 689], ["cattle", "SPECIES", 540, 546], ["cattle", "SPECIES", 654, 660], ["2 different RVA Brazilian vaccine formulations", "TREATMENT", 11, 57], ["the bivalent vaccine G10P", "TEST", 62, 87], ["G6P", "TEST", 96, 99], ["monovalent G6P", "TEST", 112, 126], ["genotype", "TEST", 130, 138], ["this study", "TEST", 269, 279], ["neonatal diarrhea", "PROBLEM", 328, 345], ["RVA", "PROBLEM", 367, 370], ["the RVA G", "TREATMENT", 387, 396], ["This study", "TEST", 568, 578]]], ["The cows were managed using appropriate nutritional and health practices.", [["cows", "ORGANISM", 4, 8], ["cows", "SPECIES", 4, 8]]], ["This high milk yield dairy cattle herd produces an average of 37 liters/ day/cow.", [["milk", "ANATOMY", 10, 14], ["milk", "ORGANISM_SUBSTANCE", 10, 14], ["cow", "ORGANISM_SUBDIVISION", 77, 80], ["cattle", "SPECIES", 27, 33], ["cattle", "SPECIES", 27, 33], ["cow", "SPECIES", 77, 80]]], ["The calves are reared in individual pens on elevated floors.", [["calves", "ORGANISM", 4, 10], ["calves", "SPECIES", 4, 10], ["elevated floors", "TREATMENT", 44, 59], ["calves", "ANATOMY", 4, 10]]], ["The colostrum intake began shortly after birth and has taken place with adequate frequency and quantity for all newborn calves.Vaccination of cowsSixty or 45 days before calving, the cows were vaccinated against NCD.", [["colostrum", "ANATOMY", 4, 13], ["cowsSixty", "CHEMICAL", 142, 151], ["NCD", "DISEASE", 212, 215], ["colostrum", "ORGANISM", 4, 13], ["calves", "ORGANISM", 120, 126], ["cows", "ORGANISM", 183, 187], ["calves", "SPECIES", 120, 126], ["cows", "SPECIES", 183, 187], ["Vaccination of cowsSixty", "TREATMENT", 127, 151], ["colostrum intake", "OBSERVATION", 4, 20]]], ["The commercial vaccine used in this study contained inactivated rotavirus A (UK-Compton strain -G6P[5]), inactivated bovine coronavirus (Mebus strain), and E. coli (K99) adesine F5.", [["bovine coronavirus", "DISEASE", 117, 135], ["rotavirus A", "ORGANISM", 64, 75], ["UK-Compton strain -G6P[5]", "ORGANISM", 77, 102], ["bovine coronavirus", "ORGANISM", 117, 135], ["Mebus strain", "ORGANISM", 137, 149], ["E. coli", "ORGANISM", 156, 163], ["bovine", "SPECIES", 117, 123], ["coronavirus", "SPECIES", 124, 135], ["E. coli", "SPECIES", 156, 163], ["rotavirus A", "SPECIES", 64, 75], ["bovine coronavirus", "SPECIES", 117, 135], ["E. coli", "SPECIES", 156, 163], ["The commercial vaccine", "TREATMENT", 0, 22], ["this study", "TEST", 31, 41], ["inactivated bovine coronavirus (Mebus strain", "PROBLEM", 105, 149], ["E. coli", "PROBLEM", 156, 163]]], ["The vaccination was performed according to the manufacturer's instructions.Fecal samplesThe fecal samples from 122 heifer calves born from RVA-vaccinated cows were collected at 10 different time points (1, 4, 7, 10, 14, 17, 21, 24, 28 , and 30 days after birth), regardless of the presence or absence of diarrhea.", [["Fecal samples", "ANATOMY", 75, 88], ["fecal samples", "ANATOMY", 92, 105], ["diarrhea", "DISEASE", 304, 312], ["Fecal samples", "ORGANISM_SUBSTANCE", 75, 88], ["fecal samples", "ORGANISM_SUBSTANCE", 92, 105], ["calves", "ORGANISM", 122, 128], ["cows", "ORGANISM", 154, 158], ["calves", "SPECIES", 122, 128], ["cows", "SPECIES", 154, 158], ["The vaccination", "TREATMENT", 0, 15], ["Fecal samples", "TEST", 75, 88], ["The fecal samples", "TEST", 88, 105], ["RVA", "TEST", 139, 142], ["vaccinated cows", "PROBLEM", 143, 158], ["diarrhea", "PROBLEM", 304, 312], ["fecal", "ANATOMY", 92, 97], ["diarrhea", "OBSERVATION", 304, 312]]], ["The samples were collected between March and May 2017, and a total of 1220 fecal samples were stored at -20\u00b0C until analysis.", [["samples", "ANATOMY", 4, 11], ["fecal samples", "ANATOMY", 75, 88], ["fecal samples", "CANCER", 75, 88], ["The samples", "TEST", 0, 11], ["fecal samples", "TEST", 75, 88], ["analysis", "TEST", 116, 124]]], ["At the time of collection, all of the fecal samples were classified according to their consistency using the following scale: 0, normal; 1, pasty; 2, soft; 3, watery.", [["fecal samples", "ANATOMY", 38, 51], ["watery", "DISEASE", 159, 165], ["fecal samples", "CANCER", 38, 51], ["watery", "ORGANISM_SUBDIVISION", 159, 165], ["collection", "PROBLEM", 15, 25], ["the fecal samples", "TEST", 34, 51], ["watery", "PROBLEM", 159, 165], ["collection", "OBSERVATION", 15, 25], ["fecal", "ANATOMY", 38, 43]]], ["A score of 0 or 1 was considered non-diarrheic, and scores of 2 or 3 were considered diarrheic.Determination of the presence of RVAThe 10 fecal samples from the same animal that were collected at different time points were processed at the same time to avoid any bias.", [["fecal samples", "ANATOMY", 138, 151], ["diarrheic", "DISEASE", 85, 94], ["A score", "TEST", 0, 7], ["scores", "TEST", 52, 58], ["diarrheic", "PROBLEM", 85, 94], ["RVAThe", "TREATMENT", 128, 134], ["fecal samples", "TEST", 138, 151]]], ["The nucleic acid extraction was performed using a combination of the phenol/chloroform/isoamyl alcohol (25:24:1) and silica/guanidinium isothiocyanate extraction methods according to Alfieri et al. (2006) .Determination of the presence of RVAThe presence of RVA dsRNA in fecal samples was evaluated using polyacrylamide gel electrophoresis (PAGE) (Pereira et al., 1983) followed by silver staining (Herring et al., 1982) .", [["fecal samples", "ANATOMY", 271, 284], ["nucleic acid", "CHEMICAL", 4, 16], ["phenol/chloroform/isoamyl alcohol", "CHEMICAL", 69, 102], ["25:24:1", "CHEMICAL", 104, 111], ["silica", "CHEMICAL", 117, 123], ["guanidinium isothiocyanate", "CHEMICAL", 124, 150], ["silver", "CHEMICAL", 382, 388], ["phenol", "CHEMICAL", 69, 75], ["chloroform", "CHEMICAL", 76, 86], ["isoamyl alcohol", "CHEMICAL", 87, 102], ["silica", "CHEMICAL", 117, 123], ["guanidinium isothiocyanate", "CHEMICAL", 124, 150], ["polyacrylamide", "CHEMICAL", 305, 319], ["silver", "CHEMICAL", 382, 388], ["nucleic acid", "SIMPLE_CHEMICAL", 4, 16], ["phenol", "SIMPLE_CHEMICAL", 69, 75], ["chloroform", "SIMPLE_CHEMICAL", 76, 86], ["isoamyl alcohol", "SIMPLE_CHEMICAL", 87, 102], ["25:24:1", "SIMPLE_CHEMICAL", 104, 111], ["silica", "SIMPLE_CHEMICAL", 117, 123], ["guanidinium isothiocyanate", "SIMPLE_CHEMICAL", 124, 150], ["fecal samples", "ORGANISM_SUBSTANCE", 271, 284], ["RVA dsRNA", "RNA", 258, 267], ["The nucleic acid extraction", "TREATMENT", 0, 27], ["the phenol/chloroform", "TREATMENT", 65, 86], ["isoamyl alcohol", "TREATMENT", 87, 102], ["silica/guanidinium isothiocyanate extraction methods", "TREATMENT", 117, 169], ["RVA dsRNA", "PROBLEM", 258, 267], ["fecal samples", "TEST", 271, 284], ["polyacrylamide gel electrophoresis", "TREATMENT", 305, 339], ["RVA dsRNA", "OBSERVATION", 258, 267]]], ["Fecal samples with doubtful PAGE results, as bands with low intensity or in anomalous positions, extra bands or undefined electropherotype were confirmed by reverse transcription polymerase chain reaction (RT-PCR) assay.RVA genotypingThe presence of RVA in the fecal samples that were determined to be positive for RVA via PAGE was confirmed by RT-PCR using consensus primers to amplify a 1062 bp fragment from the VP7 gene (Gouvea et al., 1990 ) and a 876 bp fragment from the VP4 (VP8*) gene (Gentsch et al., 1992; Martella et al., 2006) .", [["Fecal samples", "ANATOMY", 0, 13], ["fecal samples", "ANATOMY", 261, 274], ["Fecal samples", "ORGANISM_SUBSTANCE", 0, 13], ["fecal samples", "ORGANISM_SUBSTANCE", 261, 274], ["VP7", "GENE_OR_GENE_PRODUCT", 415, 418], ["VP4", "GENE_OR_GENE_PRODUCT", 478, 481], ["consensus primers", "DNA", 358, 375], ["1062 bp fragment", "DNA", 389, 405], ["VP7 gene", "DNA", 415, 423], ["876 bp fragment", "DNA", 453, 468], ["VP4 (VP8*) gene", "DNA", 478, 493], ["Fecal samples", "TEST", 0, 13], ["bands", "PROBLEM", 45, 50], ["low intensity", "PROBLEM", 56, 69], ["extra bands", "PROBLEM", 97, 108], ["undefined electropherotype", "PROBLEM", 112, 138], ["RT-PCR", "TEST", 206, 212], ["RVA genotyping", "TEST", 220, 234], ["RVA", "PROBLEM", 250, 253], ["the fecal samples", "TEST", 257, 274], ["RVA", "PROBLEM", 315, 318], ["RT-PCR", "TEST", 345, 351], ["consensus primers", "TREATMENT", 358, 375], ["a 1062 bp fragment", "TREATMENT", 387, 405], ["a 876 bp fragment", "TEST", 451, 468], ["the VP4", "TEST", 474, 481], ["low intensity", "OBSERVATION_MODIFIER", 56, 69], ["anomalous", "OBSERVATION", 76, 85], ["RVA", "OBSERVATION", 250, 253], ["fecal", "ANATOMY", 261, 266]]], ["The RT-PCR products were analyzed using electrophoresis with 2% agarose gels stained with ethidium bromide and observed under ultraviolet (UV) light.", [["ethidium bromide", "CHEMICAL", 90, 106], ["ethidium bromide", "CHEMICAL", 90, 106], ["agarose", "SIMPLE_CHEMICAL", 64, 71], ["ethidium bromide", "SIMPLE_CHEMICAL", 90, 106], ["The RT-PCR products", "TREATMENT", 0, 19], ["electrophoresis", "TEST", 40, 55], ["2% agarose gels", "TREATMENT", 61, 76], ["ethidium bromide", "TREATMENT", 90, 106]]], ["Ten RT-PCR products of good quality from the RVA-positive fecal samples from 10 calves of 7 different ages in the range of 10 to 31 days old and 7 collections, including beginning, middle, and end of the experiment, were selected for sequence analysis.RVA genotypingThe RT-PCR products were purified using an Illustra GFX PCR DNA and Gel Band Purification Kit (GE \u00ae , Buckinghamshire, UK), quantified using a Qubit \u00ae Fluorometer (Invitrogen \u00ae Life Technologies, Eugene, OR, USA), and sequenced using an ABI3500 Genetic Analyzer sequencer with a BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems \u00ae , Foster City, CA, USA).RVA genotypingThe Phred and CAP3 software packages were used for the nucleotide (nt) quality analysis and contig assembly of the RVA sequences, respectively (http://asparagin.cenargen.embrapa.br).", [["fecal samples", "ANATOMY", 58, 71], ["nucleotide", "CHEMICAL", 704, 714], ["nucleotide", "CHEMICAL", 704, 714], ["fecal samples", "MULTI-TISSUE_STRUCTURE", 58, 71], ["calves", "ORGANISM", 80, 86], ["DNA", "CELLULAR_COMPONENT", 326, 329], ["RT-PCR products", "DNA", 270, 285], ["Illustra GFX PCR DNA", "DNA", 309, 329], ["Phred and CAP3 software packages", "DNA", 653, 685], ["RVA sequences", "DNA", 764, 777], ["calves", "SPECIES", 80, 86], ["Ten RT-PCR products", "TEST", 0, 19], ["the RVA", "TEST", 41, 48], ["7 collections", "TEST", 145, 158], ["sequence analysis", "TEST", 234, 251], ["RVA genotyping", "TEST", 252, 266], ["The RT-PCR products", "TREATMENT", 266, 285], ["an Illustra GFX PCR", "TEST", 306, 325], ["Gel Band Purification", "TEST", 334, 355], ["a Qubit \u00ae Fluorometer", "TREATMENT", 407, 428], ["a BigDye Terminator", "TREATMENT", 543, 562], ["RVA genotyping", "TREATMENT", 635, 649], ["The Phred and CAP3 software packages", "TREATMENT", 649, 685], ["the nucleotide (nt) quality analysis", "TEST", 700, 736], ["the RVA sequences", "TEST", 760, 777], ["good", "OBSERVATION_MODIFIER", 23, 27], ["quality", "OBSERVATION_MODIFIER", 28, 35], ["RVA", "OBSERVATION", 45, 48], ["positive", "OBSERVATION_MODIFIER", 49, 57], ["fecal samples", "OBSERVATION", 58, 71], ["middle", "ANATOMY_MODIFIER", 181, 187]]], ["Sequence similarity searches were performed using the basic local alignment search tool (BLAST) software (http://blast.ncbi.nlm.nih.gov/), and the genotype identification was performed using the ROTAC 2.0 tool (http://rotac. regatools.be/).RVA genotypingPhylogenetic trees were obtained using the neighbor-joining method with Kimura 2-parameter model in MEGA V7 software.", [["regatools", "PROTEIN", 225, 234], ["Sequence similarity searches", "TEST", 0, 28], ["the basic local alignment search tool", "TEST", 50, 87], ["the genotype identification", "TEST", 143, 170], ["the ROTAC", "TEST", 191, 200], ["RVA genotypingPhylogenetic trees", "PROBLEM", 240, 272]]], ["The bootstrapping probabilities were calculated using 1000 replicates.", [["The bootstrapping probabilities", "TEST", 0, 31]]], ["The BioEdit software, version 7.0.8.0, was used for the construction of the nt sequence identity matrix.", [["matrix", "CELLULAR_COMPONENT", 97, 103], ["the nt sequence identity matrix", "TREATMENT", 72, 103]]], ["The gene sequences described in the present study have been deposited in the GenBank database under accession numbers: MH016179 and MH016180.Results and discussionSeventy-six (62.3%) of the 122 heifer calves were RVA-positive according to at least 1 of the 10 fecal samples evaluated, and of these, 19 (15.6%) calves were determined to have excreted RVA on more than one occasion.", [["fecal samples", "ANATOMY", 260, 273], ["MH016180", "CHEMICAL", 132, 140], ["heifer", "ORGANISM", 194, 200], ["calves", "ORGANISM", 201, 207], ["calves", "ORGANISM", 310, 316], ["calves", "SPECIES", 201, 207], ["calves", "SPECIES", 310, 316], ["The gene sequences", "TEST", 0, 18], ["the present study", "TEST", 32, 49], ["discussionSeventy", "TEST", 153, 170], ["RVA", "TEST", 213, 216], ["fecal samples", "TEST", 260, 273]]], ["Worldwide, the percentage of calves that are RVA-positive varies based on the experimental design used in each study.", [["calves", "ORGANISM", 29, 35], ["calves", "SPECIES", 29, 35], ["RVA", "TEST", 45, 48], ["positive varies", "PROBLEM", 49, 64], ["each study", "TEST", 106, 116], ["calves", "ANATOMY", 29, 35], ["positive", "OBSERVATION", 49, 57]]], ["In Scotland and northern England (Snodgrass et al., 1986) and New Zealand (Al Mawly et al., 2015) , both using commercial enzyme-linked immunosorbent assay (ELISA), rates of RVA infection of 45.9% (161/ 351) and 19.9% (246/1,226), respectively, were reported.Results and discussionIn Brazil, also using the PAGE technique, Coura et al. (2015) reported that 49.2% (33/67) of dairy heifer calves that were 0-30 days old excreted RVA during a longitudinal study, and in a transversal study only 138 of 683 (20.2%) of dairy calves 0-30 days old were found to be RVA-positive (Alfieri et al., 2006) .Results and discussionThe percentage of RVA-positive fecal samples obtained during this study was 8.1% (99/1220).", [["fecal samples", "ANATOMY", 648, 661], ["RVA infection", "DISEASE", 174, 187], ["calves", "ORGANISM", 387, 393], ["calves", "ORGANISM", 520, 526], ["calves", "SPECIES", 387, 393], ["calves", "SPECIES", 520, 526], ["commercial enzyme", "TEST", 111, 128], ["immunosorbent assay", "TEST", 136, 155], ["ELISA", "TEST", 157, 162], ["RVA infection", "PROBLEM", 174, 187], ["a longitudinal study", "TEST", 438, 458], ["a transversal study", "TEST", 467, 486], ["dairy calves", "TEST", 514, 526], ["RVA", "TEST", 558, 561], ["RVA", "TEST", 635, 638], ["this study", "TEST", 678, 688], ["positive", "OBSERVATION", 562, 570]]], ["Other longitudinal studies that have been conducted in Brazil to determine the level of RVA infection in calves born from vaccinated dairy cows had percentages of RVA-positive diarrheic fecal samples that were 5.7% (49/850) (Coura et al., 2015) and 3.9% (11/281) (Rocha et al., 2017) .Results and discussionThe distribution of the total samples and the RVA-positive fecal samples for each fecal consistency score and time point at sample collection are shown in Table 1 .", [["fecal samples", "ANATOMY", 186, 199], ["samples", "ANATOMY", 337, 344], ["fecal samples", "ANATOMY", 366, 379], ["fecal", "ANATOMY", 389, 394], ["RVA infection", "DISEASE", 88, 101], ["calves", "ORGANISM", 105, 111], ["cows", "ORGANISM", 139, 143], ["fecal samples", "MULTI-TISSUE_STRUCTURE", 366, 379], ["calves", "SPECIES", 105, 111], ["cows", "SPECIES", 139, 143], ["calves", "SPECIES", 105, 111], ["Other longitudinal studies", "TEST", 0, 26], ["RVA infection", "PROBLEM", 88, 101], ["RVA", "TEST", 163, 166], ["positive diarrheic fecal samples", "PROBLEM", 167, 199], ["the total samples", "TEST", 327, 344], ["the RVA", "TEST", 349, 356], ["positive fecal samples", "PROBLEM", 357, 379], ["each fecal consistency score", "TEST", 384, 412], ["sample collection", "TEST", 431, 448], ["RVA", "OBSERVATION_MODIFIER", 88, 91], ["infection", "OBSERVATION", 92, 101]]], ["The frequency of diarrhea in calves during the experiment, shown in the table, was not high.", [["diarrhea", "DISEASE", 17, 25], ["calves", "ORGANISM", 29, 35], ["calves", "SPECIES", 29, 35], ["diarrhea in calves", "PROBLEM", 17, 35], ["diarrhea", "OBSERVATION", 17, 25], ["high", "OBSERVATION", 87, 91]]], ["Fecal samples with scores of 0 and 1 (n = 863) represented 70.7% of the total samples, while samples with scores of 2 and 3, indicating the presence of diarrhea, comprised 17.0% (n = 208) and 12.2% (n = 149) of the total samples, respectively.", [["Fecal samples", "ANATOMY", 0, 13], ["samples", "ANATOMY", 78, 85], ["samples", "ANATOMY", 93, 100], ["samples", "ANATOMY", 221, 228], ["diarrhea", "DISEASE", 152, 160], ["Fecal samples", "ORGANISM_SUBSTANCE", 0, 13], ["samples", "CANCER", 78, 85], ["Fecal samples", "TEST", 0, 13], ["scores", "TEST", 19, 25], ["the total samples", "TEST", 68, 85], ["scores", "TEST", 106, 112], ["diarrhea", "PROBLEM", 152, 160], ["the total samples", "TEST", 211, 228], ["diarrhea", "OBSERVATION", 152, 160]]], ["In a similar study conducted in Brazil on RVAunvaccinated dairy cattle herds, the proportion of diarrheic fecal samples (36.7%; 312/850) within the total number of samples was greater than that in this study (Coura et al., 2015) .Results and discussionPrevious studies have indicated that the presence of RVA infection in feces from diarrheic calves is significantly higher than that in nondiarrheic feces (Al Mawly et al., 2015; Bartels et al., 2010; Chitambar et al., 2011) .", [["fecal samples", "ANATOMY", 106, 119], ["samples", "ANATOMY", 164, 171], ["feces", "ANATOMY", 322, 327], ["RVA infection", "DISEASE", 305, 318], ["fecal samples", "MULTI-TISSUE_STRUCTURE", 106, 119], ["feces", "ORGANISM_SUBDIVISION", 322, 327], ["calves", "ORGANISM", 343, 349], ["feces", "ORGANISM_SUBDIVISION", 400, 405], ["cattle", "SPECIES", 64, 70], ["calves", "SPECIES", 343, 349], ["cattle", "SPECIES", 64, 70], ["a similar study", "TEST", 3, 18], ["diarrheic fecal samples", "TEST", 96, 119], ["this study", "TEST", 197, 207], ["Previous studies", "TEST", 252, 268], ["RVA infection in feces", "PROBLEM", 305, 327], ["diarrheic calves", "PROBLEM", 333, 349], ["total", "OBSERVATION_MODIFIER", 148, 153], ["greater", "OBSERVATION_MODIFIER", 176, 183], ["RVA", "OBSERVATION_MODIFIER", 305, 308], ["infection", "OBSERVATION", 309, 318], ["significantly", "OBSERVATION_MODIFIER", 353, 366], ["higher", "OBSERVATION_MODIFIER", 367, 373]]], ["Forty-eight of the 357 (13.4%) diarrheic fecal samples evaluated were RVA-positive.", [["fecal samples", "ANATOMY", 41, 54], ["fecal samples", "CANCER", 41, 54], ["diarrheic fecal samples", "TEST", 31, 54], ["RVA", "TEST", 70, 73]]], ["On average, the frequency of RVA-positive samples obtained from diarrheic feces in calves worldwide ranges between 5.5 and 57.9% (Alfieri et al., 2006; Badaracco et al., 2012; Barreiros et al., 2004; Brito et al., 2000; Buzinaro et al., 2009; Caruzo et al., 2010; Chitambar et al., 2011; Falcone et al., 1999; Malik et al., 2012; Silva et al., 2012) .", [["samples", "ANATOMY", 42, 49], ["feces", "ANATOMY", 74, 79], ["diarrheic feces", "DISEASE", 64, 79], ["feces", "ORGANISM_SUBDIVISION", 74, 79], ["calves", "ORGANISM", 83, 89], ["calves", "SPECIES", 83, 89], ["RVA", "TEST", 29, 32], ["positive samples", "PROBLEM", 33, 49], ["diarrheic feces", "TEST", 64, 79]]], ["In this study, dsRNA to from the RVA was identified in 5.9% (51/863) of the fecal samples with scores of 0 or 1 and in 12.5% (26/208) and 14.8% (22/149) of the fecal samples with scores of 2 and 3, respectively.", [["fecal samples", "ANATOMY", 76, 89], ["fecal samples", "ANATOMY", 160, 173], ["fecal samples", "CANCER", 76, 89], ["this study", "TEST", 3, 13], ["dsRNA", "PROBLEM", 15, 20], ["the RVA", "TEST", 29, 36], ["the fecal samples", "TEST", 72, 89], ["scores", "TEST", 95, 101], ["the fecal samples", "TEST", 156, 173], ["scores", "TEST", 179, 185], ["fecal", "ANATOMY", 76, 81], ["fecal", "ANATOMY", 160, 165]]], ["Although RVA was more frequent in diarrheic calves, the overall frequency of RVA diagnosis was lower than that observed in unvaccinated herds (Rocha et al., 2017) .Results and discussionThe distribution of the fecal samples according to the age of the calves reveals that during the first and fourth weeks, the frequency of diagnosis of RVA was 2.2% (8/366) and 6.8% (25/366), respectively.", [["fecal samples", "ANATOMY", 210, 223], ["RVA", "DISEASE", 337, 340], ["calves", "ORGANISM", 44, 50], ["fecal samples", "MULTI-TISSUE_STRUCTURE", 210, 223], ["calves", "ORGANISM", 252, 258], ["calves", "SPECIES", 44, 50], ["calves", "SPECIES", 252, 258], ["RVA", "PROBLEM", 9, 12], ["diarrheic calves", "PROBLEM", 34, 50], ["the fecal samples", "TEST", 206, 223], ["RVA", "TEST", 337, 340], ["more", "OBSERVATION_MODIFIER", 17, 21], ["frequent", "OBSERVATION_MODIFIER", 22, 30], ["diarrheic calves", "OBSERVATION", 34, 50], ["distribution", "OBSERVATION_MODIFIER", 190, 202], ["fecal", "ANATOMY", 210, 215], ["calves", "ANATOMY", 252, 258]]], ["However, in the second and third weeks, the frequency of RVA-positive fecal samples was higher, with the rate for the second week reaching 13.5%.", [["fecal samples", "ANATOMY", 70, 83], ["RVA", "TEST", 57, 60], ["positive fecal samples", "PROBLEM", 61, 83], ["the rate", "TEST", 101, 109], ["fecal samples", "OBSERVATION", 70, 83]]], ["This finding suggests the occurrence of a decrease in passive immunity, corroborating the findings of previous studies that suggest that passive immunity protects calves during their first week and that their own natural resistance is not initiated until 4 weeks of age (Alfieri et al., 2006) ; suggesting the high susceptibility of these animals to disease during the period between the first and fourth week.", [["calves", "ORGANISM", 163, 169], ["calves", "SPECIES", 163, 169], ["a decrease in passive immunity", "PROBLEM", 40, 70], ["previous studies", "TEST", 102, 118], ["decrease", "OBSERVATION_MODIFIER", 42, 50], ["passive immunity", "OBSERVATION", 54, 70]]], ["Meganck et al. (2014) and Coura et al. (2015) reported that diarrhea caused by RVA is most frequent in 1-to 3-week-old calves, and Alfieri et al. (2006) suggested that animals from dairy cattle herds were most susceptible to RVA infection at 2 to 3 weeks of age.Results and discussionIn order to reduce the occurrence of neonatal diarrhea, the dairy farm utilizes vaccination with a commercial vaccine containing the RVA UK-Compton strain with the genotype G6P[5] .", [["diarrhea", "DISEASE", 60, 68], ["RVA", "DISEASE", 79, 82], ["RVA infection", "DISEASE", 225, 238], ["neonatal diarrhea", "DISEASE", 321, 338], ["calves", "ORGANISM", 119, 125], ["UK", "GENE_OR_GENE_PRODUCT", 421, 423], ["calves", "SPECIES", 119, 125], ["cattle", "SPECIES", 187, 193], ["cattle", "SPECIES", 187, 193], ["RVA", "SPECIES", 225, 228], ["diarrhea", "PROBLEM", 60, 68], ["RVA", "PROBLEM", 79, 82], ["dairy cattle herds", "TREATMENT", 181, 199], ["RVA infection", "PROBLEM", 225, 238], ["neonatal diarrhea", "PROBLEM", 321, 338], ["vaccination", "TREATMENT", 364, 375], ["a commercial vaccine", "TREATMENT", 381, 401], ["diarrhea", "OBSERVATION", 60, 68], ["calves", "ANATOMY", 119, 125], ["infection", "OBSERVATION", 229, 238]]], ["This vaccine is frequently used in dairy and beef cattle herds both from Brazil and other countries around the world mainly in countries of the Northern Hemisphere such as Canada, the USA, and the European Union.", [["beef", "SPECIES", 45, 49], ["cattle", "SPECIES", 50, 56], ["dairy", "SPECIES", 35, 40], ["beef", "SPECIES", 45, 49], ["cattle", "SPECIES", 50, 56], ["This vaccine", "TREATMENT", 0, 12]]], ["To determine the G and P genotypes of RVA strains present in the fecal samples collected during this study, 10 RVA-positive fecal samples were selected from 10 calves of different ages and collections for nt sequence analysis of the VP7 and VP4 amplicons.", [["fecal samples", "ANATOMY", 65, 78], ["fecal samples", "ANATOMY", 124, 137], ["fecal samples", "ORGANISM_SUBSTANCE", 65, 78], ["fecal samples", "CANCER", 124, 137], ["calves", "ORGANISM", 160, 166], ["VP7", "GENE_OR_GENE_PRODUCT", 233, 236], ["VP4", "GENE_OR_GENE_PRODUCT", 241, 244], ["VP7 and VP4 amplicons", "DNA", 233, 254], ["calves", "SPECIES", 160, 166], ["RVA strains", "PROBLEM", 38, 49], ["the fecal samples", "TEST", 61, 78], ["this study", "TEST", 96, 106], ["RVA", "TEST", 111, 114], ["positive fecal samples", "PROBLEM", 115, 137], ["nt sequence analysis", "TEST", 205, 225], ["the VP7 and VP4 amplicons", "TREATMENT", 229, 254], ["fecal", "ANATOMY", 65, 70], ["fecal", "ANATOMY", 124, 129]]], ["The analysis enabled the identification of the genotypes, which were G10P [11] in all of the wildtype RVA strains with a high (99.3 to 100%) nt similarity between them.Results and discussionViruses with the G10 and P[11] genotypes are not included in the RVA vaccine used by the dairy farm evaluated in this study.", [["The analysis", "TEST", 0, 12], ["the genotypes", "PROBLEM", 43, 56], ["the wildtype RVA strains", "PROBLEM", 89, 113], ["the G10 and P[11] genotypes", "TREATMENT", 203, 230], ["the RVA vaccine", "TREATMENT", 251, 266], ["this study", "TEST", 303, 313], ["high", "OBSERVATION_MODIFIER", 121, 125]]], ["The sequence obtained of VP7 gene of RVA had the highest (94%) nt similarity with that of the prototype B223 strain (GenBank accession number: X52650 (Xu et al., 1991) ), which belongs to G10 lineage IV (Fig. 1A) , and the VP4 gene had the highest similarity (96.1%) to that from the Turkish E16TR strain (GenBank accession number: FJ598314 (unpublished data)) of P[11] lineage III (Fig. 1B) .Results and discussionA putative vaccine breakthrough associated with heterotypic RVA infection in newborn calves was described in Turkey, where the emergence of an RVA strain with the genotype G8P[5] was reported in a cattle herd vaccinated with the G6P[5] RVA strain, which demonstrated a failure of heterologous protection (Karayel et al., 2017) .", [["RVA infection", "DISEASE", 475, 488], ["G6P", "CHEMICAL", 644, 647], ["VP7", "GENE_OR_GENE_PRODUCT", 25, 28], ["Fig. 1A", "GENE_OR_GENE_PRODUCT", 204, 211], ["VP4", "GENE_OR_GENE_PRODUCT", 223, 226], ["calves", "ORGANISM", 500, 506], ["G6P[5] RVA", "ORGANISM", 644, 654], ["VP7 gene", "DNA", 25, 33], ["G10 lineage IV", "PROTEIN", 188, 202], ["VP4 gene", "DNA", 223, 231], ["calves", "SPECIES", 500, 506], ["cattle", "SPECIES", 612, 618], ["Turkish E16TR strain", "SPECIES", 284, 304], ["RVA", "SPECIES", 475, 478], ["cattle", "SPECIES", 612, 618], ["The sequence", "TEST", 0, 12], ["RVA", "TEST", 37, 40], ["the VP4 gene", "TEST", 219, 231], ["discussionA putative vaccine breakthrough", "TREATMENT", 405, 446], ["heterotypic RVA infection in newborn calves", "PROBLEM", 463, 506], ["an RVA strain", "PROBLEM", 555, 568], ["the G6P", "TEST", 640, 647], ["RVA strain", "PROBLEM", 651, 661], ["heterologous protection", "TREATMENT", 695, 718], ["RVA", "OBSERVATION_MODIFIER", 475, 478], ["infection", "OBSERVATION", 479, 488], ["failure", "OBSERVATION", 684, 691]]], ["The occurrence of emerging heterologous RVA genotypes is a phenomenon has been previously observed in Brazilian dairy and beef cattle herds after the administration of a RV vaccine (Medeiros et al., 2015; Rocha et al., 2017) .", [["beef", "SPECIES", 122, 126], ["cattle", "SPECIES", 127, 133], ["beef", "SPECIES", 122, 126], ["cattle", "SPECIES", 127, 133], ["emerging heterologous RVA genotypes", "PROBLEM", 18, 53], ["a phenomenon", "PROBLEM", 57, 69], ["a RV vaccine", "TREATMENT", 168, 180], ["heterologous RVA", "OBSERVATION", 27, 43]]], ["Similar occurrences have also been described in humans in Brazil and other countries around the world (Banyai et al., 2012; Cowley et al., 2013; Doro et al., 2014; Khandoker et al., 2018; Santos et al., 2018) .Results and discussionHowever, depending on other factors, such as the type of cattle (beef or dairy herds), the method of cow and calf management (intensive or extensive), and the inclusion of vaccination for neonatal diarrhea in the health program, different results can be found between studies.", [["neonatal diarrhea", "DISEASE", 420, 437], ["humans", "ORGANISM", 48, 54], ["cattle", "ORGANISM", 289, 295], ["beef", "ORGANISM_SUBDIVISION", 297, 301], ["cow", "ORGANISM_SUBDIVISION", 333, 336], ["calf", "ORGANISM_SUBDIVISION", 341, 345], ["humans", "SPECIES", 48, 54], ["cattle", "SPECIES", 289, 295], ["beef", "SPECIES", 297, 301], ["cow", "SPECIES", 333, 336], ["calf", "SPECIES", 341, 345], ["humans", "SPECIES", 48, 54], ["cattle", "SPECIES", 289, 295], ["beef", "SPECIES", 297, 301], ["cow", "SPECIES", 333, 336], ["cow and calf management", "TREATMENT", 333, 356], ["vaccination", "TREATMENT", 404, 415], ["neonatal diarrhea", "PROBLEM", 420, 437], ["calf", "ANATOMY", 341, 345]]], ["In France, Kaplon et al. (2013) evaluated beef cattle herds subject to extensive management and found no differences in the frequencies of diarrhea and RVA-positive fecal samples between vaccinated and unvaccinated herds; the majority of the genotyped RVA-positive diarrheic fecal samples were found to have the same genotype (G6P[5]) as that of the vaccine strain.Results and discussionAmong the measures used to mitigate the risk of neonatal diarrhea outbreaks, the vaccination of cow herds appears to be the most important.", [["fecal samples", "ANATOMY", 165, 178], ["fecal samples", "ANATOMY", 275, 288], ["diarrhea", "DISEASE", 139, 147], ["diarrhea", "DISEASE", 444, 452], ["fecal samples", "ORGANISM_SUBSTANCE", 275, 288], ["cow", "ORGANISM", 483, 486], ["cattle", "SPECIES", 47, 53], ["cow", "SPECIES", 483, 486], ["beef", "SPECIES", 42, 46], ["cattle", "SPECIES", 47, 53], ["cow", "SPECIES", 483, 486], ["extensive management", "TREATMENT", 71, 91], ["diarrhea", "PROBLEM", 139, 147], ["RVA", "PROBLEM", 152, 155], ["positive fecal samples between vaccinated", "PROBLEM", 156, 197], ["the genotyped RVA", "TEST", 238, 255], ["positive diarrheic fecal samples", "PROBLEM", 256, 288], ["the vaccine strain", "PROBLEM", 346, 364], ["neonatal diarrhea outbreaks", "PROBLEM", 435, 462], ["the vaccination of cow herds", "TREATMENT", 464, 492]]], ["In humans, the World Health Organization recommends the inclusion of the RVA vaccination in all national immunization programs (WHO, 2009) .", [["humans", "ORGANISM", 3, 9], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["the RVA vaccination", "TREATMENT", 69, 88]]], ["Several studies have demonstrated that vaccination does not totally eliminate the risk of infection, but it certainly reduces both the frequency and severity of the episodes of neonatal diarrhea caused by RVA infection in calves (Kaplon et al., 2013; Parreno et al., 2004) .", [["infection", "DISEASE", 90, 99], ["diarrhea", "DISEASE", 186, 194], ["RVA infection", "DISEASE", 205, 218], ["calves", "ORGANISM", 222, 228], ["calves", "SPECIES", 222, 228], ["RVA", "SPECIES", 205, 208], ["Several studies", "TEST", 0, 15], ["vaccination", "TREATMENT", 39, 50], ["infection", "PROBLEM", 90, 99], ["neonatal diarrhea", "PROBLEM", 177, 194], ["RVA infection in calves", "PROBLEM", 205, 228], ["infection", "OBSERVATION", 90, 99], ["RVA", "OBSERVATION_MODIFIER", 205, 208], ["infection", "OBSERVATION", 209, 218]]], ["Considering that the immune pressure exerted by routine vaccination may have the potential to select strains containing specific G and P genotypes, it is important to monitor the genotypes present in the RVA strains that are circulating among and within vaccinated cattle herds (Cashman et al., 2010) .Results and discussionIn summary, in this longitudinal study evaluating 1220 fecal samples (122 calves), the low occurrence of RVA in diarrheic fecal samples from calves born from regularly RVA G6P[5]-vaccinated cows was determined.", [["fecal samples", "ANATOMY", 379, 392], ["fecal samples", "ANATOMY", 446, 459], ["G6P[5]", "CHEMICAL", 496, 502], ["G", "GENE_OR_GENE_PRODUCT", 129, 130], ["fecal samples", "MULTI-TISSUE_STRUCTURE", 379, 392], ["calves", "ORGANISM", 398, 404], ["fecal samples", "ORGANISM_SUBSTANCE", 446, 459], ["calves", "ORGANISM", 465, 471], ["G6P[5", "ORGANISM", 496, 501], ["cows", "ORGANISM", 514, 518], ["cattle", "SPECIES", 265, 271], ["calves", "SPECIES", 398, 404], ["calves", "SPECIES", 465, 471], ["cows", "SPECIES", 514, 518], ["cattle", "SPECIES", 265, 271], ["the immune pressure", "TEST", 17, 36], ["routine vaccination", "TREATMENT", 48, 67], ["specific G and P genotypes", "TREATMENT", 120, 146], ["the genotypes", "PROBLEM", 175, 188], ["the RVA strains", "PROBLEM", 200, 215], ["this longitudinal study", "TEST", 339, 362], ["fecal samples", "TEST", 379, 392], ["RVA", "PROBLEM", 429, 432], ["diarrheic fecal samples", "PROBLEM", 436, 459], ["vaccinated cows", "TREATMENT", 503, 518]]], ["In addition, the genotype G6P [5] , present in the RVA vaccine strain used on the farm, was not identified in any RVA field strains identified in calves in this study.", [["G6P [5", "ORGANISM", 26, 32], ["calves", "ORGANISM", 146, 152], ["calves", "SPECIES", 146, 152], ["the genotype G6P", "TEST", 13, 29], ["the RVA vaccine strain", "TREATMENT", 47, 69], ["any RVA field strains", "PROBLEM", 110, 131], ["this study", "TEST", 156, 166]]], ["Additionally, the presence of the RVA G10P[11] genotype was verified, which was different from the vaccine strain, reinforcing the vaccine protection.", [["genotype", "TEST", 47, 55], ["the vaccine strain", "TREATMENT", 95, 113], ["the vaccine protection", "TREATMENT", 127, 149]]], ["The presence of RVA in vaccinated herds may occurs due to immune pressure, individual factors, management procedures, nutrition, and environmental variations.", [["RVA", "DISEASE", 16, 19], ["RVA", "PROBLEM", 16, 19], ["vaccinated herds", "TREATMENT", 23, 39], ["immune pressure", "PROBLEM", 58, 73], ["management procedures", "TREATMENT", 95, 116], ["nutrition", "TREATMENT", 118, 127], ["RVA", "OBSERVATION", 16, 19]]], ["The constant monitoring of circulating RVA strains in neonatal diarrhea in dairy cattle herds is important to identify the emergence of new RVA strains, highlighting those with higher virulence and/or zoonotic potential.", [["neonatal diarrhea", "DISEASE", 54, 71], ["cattle", "SPECIES", 81, 87], ["cattle", "SPECIES", 81, 87], ["circulating RVA strains", "PROBLEM", 27, 50], ["neonatal diarrhea", "PROBLEM", 54, 71], ["new RVA strains", "PROBLEM", 136, 151], ["constant", "OBSERVATION_MODIFIER", 4, 12]]]], "9046c95b831f07022b9212c09af9fd2232b02363": [["IntroductionNoroviruses are a well-studied, leading cause of non-bacterial gastroenteritis in human adults, classified in the family Caliciviridae [10] .", [["gastroenteritis", "DISEASE", 75, 90], ["Noroviruses", "GENE_OR_GENE_PRODUCT", 12, 23], ["human", "ORGANISM", 94, 99], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99], ["IntroductionNoroviruses", "PROBLEM", 0, 23], ["non-bacterial gastroenteritis", "PROBLEM", 61, 90], ["non-bacterial", "OBSERVATION_MODIFIER", 61, 74], ["gastroenteritis", "OBSERVATION", 75, 90]]], ["Recently, bovine viruses identified some years ago were identified as noroviruses [5, 25] .", [["noroviruses", "DISEASE", 70, 81], ["bovine", "ORGANISM", 10, 16], ["bovine", "SPECIES", 10, 16], ["bovine viruses", "PROBLEM", 10, 24], ["noroviruses", "PROBLEM", 70, 81], ["bovine viruses", "OBSERVATION", 10, 24]]], ["Human noroviruses belong to genogroups I and II [10] , whereas the bovine noroviruses have been placed in a separate genogroup, III [1, 5, 25, 33] .", [["Human", "ORGANISM", 0, 5], ["bovine", "ORGANISM", 67, 73], ["noroviruses", "ORGANISM", 74, 85], ["Human", "SPECIES", 0, 5], ["bovine", "SPECIES", 67, 73], ["Human noroviruses", "SPECIES", 0, 17], ["bovine", "SPECIES", 67, 73], ["Human noroviruses", "PROBLEM", 0, 17], ["the bovine noroviruses", "PROBLEM", 63, 85]]], ["Comparisons of partial genomic sequences of the two original bovine viruses identified two genetic clusters (genotypes) within genogroup III, represented by the Bo/Jena/80/DE virus (genogroup III/1), and the Bo/Newbury2/76/UK virus (genogroup III/2). as a homologous challenge control and was given a primary inoculation with Newbury2 plus primary and secondary challenge inoculations with Newbury2.", [["Newbury2", "CHEMICAL", 326, 334], ["Newbury2", "CHEMICAL", 390, 398], ["bovine", "ORGANISM", 61, 67], ["Jena/80/DE virus", "ORGANISM", 164, 180], ["genogroup III/1", "ORGANISM", 182, 197], ["Newbury2/76/UK virus", "ORGANISM", 211, 231], ["Newbury2", "SIMPLE_CHEMICAL", 326, 334], ["bovine", "SPECIES", 61, 67], ["Bo/Jena/80/DE virus", "SPECIES", 161, 180], ["genogroup III/1", "SPECIES", 182, 197], ["Bo/Newbury2/76/UK virus", "SPECIES", 208, 231], ["partial genomic sequences", "TEST", 15, 40], ["the Bo/Jena", "TEST", 157, 168], ["the Bo/Newbury2", "TEST", 204, 219], ["a homologous challenge control", "TREATMENT", 254, 284], ["a primary inoculation", "TREATMENT", 299, 320], ["Newbury2 plus primary and secondary challenge inoculations", "TREATMENT", 326, 384], ["Newbury2", "TREATMENT", 390, 398], ["bovine viruses", "OBSERVATION", 61, 75], ["genogroup III", "OBSERVATION_MODIFIER", 127, 140]]], ["Two calves (P137 and P142) were given a primary inoculation and primary challenge inoculation with Newbury2 and secondary challenge to Newbury1.", [["calves", "ANATOMY", 4, 10], ["Newbury2", "CHEMICAL", 99, 107], ["Newbury1", "CHEMICAL", 135, 143], ["calves", "ORGANISM", 4, 10], ["calves", "SPECIES", 4, 10], ["a primary inoculation", "TREATMENT", 38, 59], ["primary challenge inoculation", "TREATMENT", 64, 93], ["Newbury2", "TREATMENT", 99, 107]]], ["The fourth calf (Q21) served as a Newbury2 challenge control and was inoculated for the first time with Newbury2 at the time of challenge.", [["calf", "ORGANISM_SUBDIVISION", 11, 15], ["calf", "SPECIES", 11, 15], ["a Newbury2 challenge control", "TREATMENT", 32, 60], ["Newbury2", "TREATMENT", 104, 112], ["fourth calf", "ANATOMY", 4, 15]]], ["Preinoculation and post-primary, post-primary challenge and post-secondary challenge sera were taken (see Table 2 ) and had been stored at \u221220 \u2022 C. No evidence of antibody degradation was obtained during storage by monitoring antibody titres from calves infected with bovine rotavirus (unpublished) .", [["sera", "ANATOMY", 85, 89], ["sera", "ORGANISM_SUBSTANCE", 85, 89], ["calves", "ORGANISM", 247, 253], ["bovine", "ORGANISM", 268, 274], ["rotavirus", "ORGANISM", 275, 284], ["calves", "SPECIES", 247, 253], ["bovine", "SPECIES", 268, 274], ["calves", "SPECIES", 247, 253], ["bovine", "SPECIES", 268, 274], ["post-secondary challenge sera", "TREATMENT", 60, 89], ["antibody degradation", "PROBLEM", 163, 183], ["monitoring antibody titres", "TEST", 215, 241], ["bovine rotavirus", "PROBLEM", 268, 284], ["No evidence of", "UNCERTAINTY", 148, 162], ["antibody", "OBSERVATION", 163, 171]]], ["Two gnotobiotic calves were orally inoculated with Bo/Dumfries/1994/UK, and sera were taken 14 days later, then again 8 and 15 days after homologous challenge.", [["calves", "ANATOMY", 16, 22], ["sera", "ANATOMY", 76, 80], ["calves", "ORGANISM", 16, 22], ["UK", "GENE_OR_GENE_PRODUCT", 68, 70], ["sera", "ORGANISM_SUBSTANCE", 76, 80], ["calves", "SPECIES", 16, 22], ["Bo/Dumfries/1994/UK", "SPECIES", 51, 70], ["Two gnotobiotic calves", "PROBLEM", 0, 22], ["Bo/Dumfries", "TEST", 51, 62], ["sera", "TEST", 76, 80], ["gnotobiotic calves", "OBSERVATION", 4, 22]]], ["Bovine antisera from calves inoculated with bovine rotavirus UK, the bovine enteric coronavirus, bovine astrovirus and the Haden strain of parvovirus [3] were used in the Newbury2 ELISA to determine specificity.Genome sequencingViral RNA extraction and reverse transcription were performed as described previously [30] using MMLV reverse transcriptase and random hexamers (Promega).", [["enteric coronavirus", "DISEASE", 76, 95], ["Bovine", "ORGANISM", 0, 6], ["calves", "ORGANISM", 21, 27], ["bovine", "ORGANISM", 44, 50], ["rotavirus UK", "ORGANISM", 51, 63], ["bovine", "ORGANISM", 69, 75], ["enteric coronavirus", "ORGANISM", 76, 95], ["bovine", "ORGANISM", 97, 103], ["astrovirus", "ORGANISM", 104, 114], ["Haden strain", "ORGANISM", 123, 135], ["parvovirus", "ORGANISM", 139, 149], ["MMLV", "ORGANISM", 325, 329], ["MMLV reverse transcriptase", "PROTEIN", 325, 351], ["Bovine", "SPECIES", 0, 6], ["calves", "SPECIES", 21, 27], ["bovine", "SPECIES", 44, 50], ["bovine", "SPECIES", 69, 75], ["coronavirus", "SPECIES", 84, 95], ["bovine", "SPECIES", 97, 103], ["Bovine", "SPECIES", 0, 6], ["bovine", "SPECIES", 44, 50], ["bovine enteric coronavirus", "SPECIES", 69, 95], ["bovine astrovirus", "SPECIES", 97, 114], ["Bovine antisera", "TREATMENT", 0, 15], ["bovine rotavirus UK", "TREATMENT", 44, 63], ["the bovine enteric coronavirus", "PROBLEM", 65, 95], ["bovine astrovirus", "PROBLEM", 97, 114], ["parvovirus", "PROBLEM", 139, 149], ["the Newbury2 ELISA", "TEST", 167, 185], ["Viral RNA extraction", "TREATMENT", 228, 248], ["reverse transcription", "TREATMENT", 253, 274], ["MMLV reverse transcriptase", "TREATMENT", 325, 351], ["random hexamers (Promega)", "TREATMENT", 356, 381], ["enteric coronavirus", "ANATOMY", 76, 95], ["bovine astrovirus", "OBSERVATION", 97, 114]]], ["PCR was performed using the Hi Fidelity PCR system (ROCHE).", [["PCR", "TEST", 0, 3]]], ["An amino acid alignment of polyproteins from the genus Norovirus (Bo/Jena/1980/DE, 17 human noroviruses from genogroup I or II plus the murine norovirus) was used to identify conserved sequences in the NTPase region of the polyprotein, DRIEK/NK and APQGGFD.", [["NK", "ANATOMY", 242, 244], ["amino acid", "CHEMICAL", 3, 13], ["Norovirus", "DISEASE", 55, 64], ["amino acid", "CHEMICAL", 3, 13], ["amino acid", "AMINO_ACID", 3, 13], ["Norovirus", "ORGANISM", 55, 64], ["human", "ORGANISM", 86, 91], ["murine", "ORGANISM", 136, 142], ["DRIEK", "GENE_OR_GENE_PRODUCT", 236, 241], ["APQGGFD", "GENE_OR_GENE_PRODUCT", 249, 256], ["genogroup I or II", "PROTEIN", 109, 126], ["NTPase region", "PROTEIN", 202, 215], ["DRIEK", "PROTEIN", 236, 241], ["NK", "PROTEIN", 242, 244], ["APQGGFD", "PROTEIN", 249, 256], ["human", "SPECIES", 86, 91], ["murine", "SPECIES", 136, 142], ["Bo/Jena/1980/DE", "SPECIES", 66, 81], ["human", "SPECIES", 86, 91], ["An amino acid alignment of polyproteins", "PROBLEM", 0, 39], ["the genus Norovirus", "PROBLEM", 45, 64], ["the murine norovirus", "TREATMENT", 132, 152], ["amino", "OBSERVATION", 3, 8], ["acid alignment", "OBSERVATION", 9, 23], ["NK", "ANATOMY", 242, 244]]], ["Primers JENA01 and JENA02 were designed to the conserved region in the NTPase corresponding to the Jena virus nucleotide sequence ( Table 3 ).", [["nucleotide", "CHEMICAL", 110, 120], ["JENA01", "GENE_OR_GENE_PRODUCT", 8, 14], ["JENA02", "GENE_OR_GENE_PRODUCT", 19, 25], ["NTPase", "GENE_OR_GENE_PRODUCT", 71, 77], ["JENA01", "DNA", 8, 14], ["JENA02", "DNA", 19, 25], ["NTPase", "PROTEIN", 71, 77], ["Jena virus nucleotide sequence", "DNA", 99, 129], ["Jena virus", "SPECIES", 99, 109], ["Primers JENA01", "TEST", 0, 14], ["JENA02", "TREATMENT", 19, 25], ["the Jena virus nucleotide sequence", "TEST", 95, 129]]], ["The subsequent nucleotide sequence of a 262-bp amplicon generated from the Dumfries genome that was cloned into a pCR2.1-TOPO vector was used to design additional primers, which were used to amplify two regions (JANA01/BoCVhelR 02 -1851 nucleotides; BoCVhel 01/BoCVproR 01 -1944 nucleotides) of the Newbury2 and Dumfries genomes.", [["nucleotide", "CHEMICAL", 15, 25], ["nucleotide", "CHEMICAL", 15, 25], ["nucleotides", "CHEMICAL", 279, 290], ["pCR2", "GENE_OR_GENE_PRODUCT", 114, 118], ["TOPO", "GENE_OR_GENE_PRODUCT", 121, 125], ["262-bp amplicon", "DNA", 40, 55], ["Dumfries genome", "DNA", 75, 90], ["pCR2.1-TOPO vector", "DNA", 114, 132], ["JANA01", "DNA", 212, 218], ["BoCVhelR 02", "DNA", 219, 230], ["1851 nucleotides", "DNA", 232, 248], ["BoCVhel 01", "DNA", 250, 260], ["BoCVproR 01", "DNA", 261, 272], ["1944 nucleotides", "DNA", 274, 290], ["Newbury2 and Dumfries genomes", "DNA", 299, 328], ["The subsequent nucleotide sequence", "TEST", 0, 34], ["bp amplicon", "TEST", 44, 55], ["the Dumfries genome", "TREATMENT", 71, 90], ["a pCR2", "TREATMENT", 112, 118], ["TOPO vector", "TREATMENT", 121, 132], ["additional primers", "TREATMENT", 152, 170], ["JANA01/BoCVhelR 02", "TREATMENT", 212, 230], ["nucleotides", "TREATMENT", 237, 248], ["BoCVhel", "TREATMENT", 250, 257]]], ["Amplicons cloned into pCR2.1 (Invitrogen) were sequenced in both directions using overlapping primers ( Table 3 ).", [["pCR2.1", "GENE_OR_GENE_PRODUCT", 22, 28], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 30, 40], ["pCR2.1", "DNA", 22, 28], ["Amplicons", "TREATMENT", 0, 9], ["overlapping primers", "TREATMENT", 82, 101]]], ["The 5 end of the Newbury2 genome was deduced using 5 rapid amplification of cDNA ends (RACE). cDNA generated by reverse transcription using the primer BoCV5 RACE 05 was purified using a QIAquick gel extraction kit (Qiagen).", [["Newbury2 genome", "DNA", 17, 32], ["cDNA ends", "DNA", 76, 85], ["RACE", "DNA", 87, 91], ["cDNA", "DNA", 94, 98], ["primer BoCV5 RACE 05", "DNA", 144, 164], ["the Newbury2 genome", "TREATMENT", 13, 32], ["5 rapid amplification of cDNA ends", "TREATMENT", 51, 85], ["the primer BoCV5 RACE", "TREATMENT", 140, 161], ["a QIAquick gel extraction kit", "TREATMENT", 184, 213]]], ["Terminal deoxynucleotide transferase (Promega) was used to add a poly-C tail to the 5 end of the purified cDNA.", [["deoxynucleotide", "CHEMICAL", 9, 24], ["Terminal deoxynucleotide transferase", "GENE_OR_GENE_PRODUCT", 0, 36], ["Promega", "GENE_OR_GENE_PRODUCT", 38, 45], ["Terminal deoxynucleotide transferase", "PROTEIN", 0, 36], ["poly-C tail", "PROTEIN", 65, 76], ["purified cDNA", "DNA", 97, 110], ["Terminal deoxynucleotide transferase (Promega)", "TREATMENT", 0, 46], ["a poly-C tail", "TREATMENT", 63, 76], ["deoxynucleotide transferase", "OBSERVATION", 9, 36]]], ["The 5 end of the Newbury2 genome was amplified using the Hi Fidelity PCR system (ROCHE) with an abridged anchor primer (Invitrogen) and BoCV5 RACE 06 ( Table 3 ).", [["Newbury2 genome", "DNA", 17, 32], ["abridged anchor primer", "DNA", 96, 118], ["BoCV5 RACE 06", "DNA", 136, 149], ["the Newbury2 genome", "TREATMENT", 13, 32], ["an abridged anchor primer", "TREATMENT", 93, 118]]], ["The resulting 337-bp amplicon was cloned into pCR2.1, and 5 clones were sequenced in both directions to establish a consensus nucleotide sequence.", [["nucleotide", "CHEMICAL", 126, 136], ["pCR2.1", "GENE_OR_GENE_PRODUCT", 46, 52], ["337-bp amplicon", "DNA", 14, 29], ["pCR2.1", "DNA", 46, 52], ["consensus nucleotide sequence", "DNA", 116, 145], ["bp amplicon", "TEST", 18, 29], ["a consensus nucleotide sequence", "TEST", 114, 145]]], ["The MRC gene service performed sequencing and the sequences were assembled using Staden [39] .Genome sequencingThe Simplot computer program [27] was used to generate identity plots of the complete genomes and the complete ORF1 polyproteins of the bovine noroviruses Newbury2, Dumfries and Jena using a window size of 200 and step size of 20 with gap strip off and J-C correction on.", [["bovine", "ORGANISM", 247, 253], ["MRC gene", "DNA", 4, 12], ["ORF1 polyproteins", "DNA", 222, 239], ["bovine", "SPECIES", 247, 253], ["the sequences", "TEST", 46, 59], ["the bovine noroviruses", "PROBLEM", 243, 265], ["a window size", "TEST", 300, 313], ["gap strip", "TEST", 346, 355], ["J-C correction", "TREATMENT", 364, 378], ["size", "OBSERVATION_MODIFIER", 330, 334]]], ["A multiple alignment of the translated amino acid sequences of the complete polyprotein (ORF1) was generated using Clustal X version 1.8 [43] , which was used for phylogenetic analyses.", [["amino acid", "CHEMICAL", 39, 49], ["amino acid", "CHEMICAL", 39, 49], ["amino acid", "AMINO_ACID", 39, 49], ["ORF1", "DNA", 89, 93], ["Clustal X version", "TREATMENT", 115, 132], ["phylogenetic analyses", "TEST", 163, 184], ["multiple", "OBSERVATION_MODIFIER", 2, 10], ["alignment", "OBSERVATION_MODIFIER", 11, 20]]], ["PHYLIP (J. Felsenstein, Department of Genetics, University of Washington, Seattle; Phylogeny Inference Package, version 3.5c) was used for parsimony (DNApars and Protpars), UPGMA, Fitch-Margoliash and bootstrap analyses, plus TreePuzzle 5.2 [37] for additional maximum likelihood with quartet puzzling analyses.Genome sequencingThe nucleotide sequence accession numbers for the noroviruses referred to in the text are: Genogroup I; Norwalk -NC 001959, Southampton -L07418, Chiba -AB042808, WUG1 -AB081723, SzUG1 -AB039774: Genogroup II; Snow Mountain -AY134748, Lordsdale -X86557, Langen1061 -AY485642, Gifu -AB045603, U1 -AB039775, U3 -AB039776, U4 -AB039777, U16 -AB039778, U17 -AB039779, U25 -AB039780, U18 -AB039781, U201 -AB039782: Genogroup III; Jena -AJ011099, Newbury2 -AF097917, Dumfries -AY126474: Unassigned; Murine -AY228235.Expression of the Newbury2 capsid protein as VLPsThe primers BoCVCap5 EcoRI (5 -GAATTCATGAAGATGACTGACAGA-3 -the initiation codon is underlined) and NA2Capsid3 XhoI (5 -CTCGAGTCAGAAGCCATGAAG GCG-3 -the reverse complementary sequence of the termination codon is underlined) were designed using the genomic sequence at the 5 and the 3 end of the Newbury2 ORF2 gene that incorporated the restriction sites EcoRI and an XhoI.", [["nucleotide", "CHEMICAL", 332, 342], ["U18 -AB039781, U201 -AB039782", "CHEMICAL", 706, 735], ["Newbury2 -AF097917", "CHEMICAL", 768, 786], ["nucleotide", "CHEMICAL", 332, 342], ["Norwalk -NC 001959", "ORGANISM", 432, 450], ["Southampton -L07418", "CELL", 452, 471], ["Chiba -AB042808", "ORGANISM", 473, 488], ["WUG1 -AB081723", "CELL", 490, 504], ["Lordsdale -X86557", "CELL", 562, 579], ["Langen1061 -AY485642", "CELL", 581, 601], ["Gifu -AB045603", "CELL", 603, 617], ["U1 -AB039775", "CELL", 619, 631], ["U3 -AB039776", "ORGANISM", 633, 645], ["U4 -AB039777", "ORGANISM", 647, 659], ["U16 -AB039778", "ORGANISM", 661, 674], ["U17 -AB039779", "ORGANISM", 676, 689], ["U25 -AB039780", "ORGANISM", 691, 704], ["U201 -AB039782", "ORGANISM", 721, 735], ["Newbury2 -AF097917", "SIMPLE_CHEMICAL", 768, 786], ["Dumfries -AY126474", "SIMPLE_CHEMICAL", 788, 806], ["Murine", "ORGANISM", 820, 826], ["-AY228235", "ORGANISM", 827, 836], ["Newbury2", "GENE_OR_GENE_PRODUCT", 855, 863], ["EcoRI", "GENE_OR_GENE_PRODUCT", 907, 912], ["5 -GAATTCATGAAGATGACTGACAGA-3", "GENE_OR_GENE_PRODUCT", 914, 943], ["NA2Capsid3 XhoI", "GENE_OR_GENE_PRODUCT", 985, 1000], ["GCG-3", "GENE_OR_GENE_PRODUCT", 1027, 1032], ["Newbury2 ORF2", "GENE_OR_GENE_PRODUCT", 1180, 1193], ["EcoRI", "GENE_OR_GENE_PRODUCT", 1239, 1244], ["XhoI", "GENE_OR_GENE_PRODUCT", 1252, 1256], ["U3", "DNA", 633, 635], ["Murine -AY228235", "DNA", 820, 836], ["Newbury2 capsid protein", "PROTEIN", 855, 878], ["VLPs", "PROTEIN", 882, 886], ["primers BoCVCap5 EcoRI", "DNA", 890, 912], ["5 -GAATTCATGAAGATGACTGACAGA-3", "DNA", 914, 943], ["initiation codon", "DNA", 949, 965], ["NA2Capsid3 XhoI", "DNA", 985, 1000], ["reverse complementary sequence", "DNA", 1038, 1068], ["termination codon", "DNA", 1076, 1093], ["genomic sequence", "DNA", 1133, 1149], ["5 and the 3 end", "DNA", 1157, 1172], ["Newbury2 ORF2 gene", "DNA", 1180, 1198], ["restriction sites EcoRI", "DNA", 1221, 1244], ["XhoI", "DNA", 1252, 1256], ["Murine", "SPECIES", 820, 826], ["parsimony", "TEST", 139, 148], ["UPGMA", "TEST", 173, 178], ["Fitch", "TEST", 180, 185], ["bootstrap analyses", "TEST", 201, 219], ["TreePuzzle", "TEST", 226, 236], ["The nucleotide sequence accession", "TEST", 328, 361], ["the noroviruses", "PROBLEM", 374, 389], ["WUG1", "TEST", 490, 494], ["SzUG1", "TEST", 506, 511], ["Snow Mountain", "TEST", 537, 550], ["Lordsdale", "TEST", 562, 571], ["U1", "TEST", 619, 621], ["U3", "TEST", 633, 635], ["U4", "TEST", 647, 649], ["U16", "TEST", 661, 664], ["U17", "TEST", 676, 679], ["U25", "TEST", 691, 694], ["U18", "TEST", 706, 709], ["U201", "TEST", 721, 725], ["AB", "TEST", 727, 729], ["Jena", "TEST", 752, 756], ["Newbury2", "TEST", 768, 776], ["Dumfries", "TEST", 788, 796], ["The primers BoCVCap5 EcoRI", "TEST", 886, 912], ["GAATTCATGAAGATGACTGACAGA", "TEST", 917, 941], ["the initiation codon", "TREATMENT", 945, 965], ["NA2Capsid3 XhoI", "TREATMENT", 985, 1000], ["the termination codon", "TREATMENT", 1072, 1093], ["the genomic sequence", "TEST", 1129, 1149], ["the Newbury2 ORF2 gene", "TREATMENT", 1176, 1198], ["an XhoI", "TREATMENT", 1249, 1256]]], ["A 1581-bp RT-PCR amplicon of the expected size was cloned using pCR2.1-TOPO-TA cloning kit (Invitrogen) to create the construct pCR2.1-Newbury2-ORF2.", [["1-TOPO", "CHEMICAL", 69, 75], ["1-TOPO", "CHEMICAL", 69, 75], ["pCR2", "GENE_OR_GENE_PRODUCT", 64, 68], ["TOPO", "GENE_OR_GENE_PRODUCT", 71, 75], ["pCR2", "GENE_OR_GENE_PRODUCT", 128, 132], ["1581-bp RT-PCR amplicon", "DNA", 2, 25], ["pCR2", "PROTEIN", 64, 68], ["pCR2", "PROTEIN", 128, 132], ["Newbury2", "DNA", 135, 143], ["ORF2", "DNA", 144, 148], ["A", "TEST", 0, 1], ["bp RT-PCR amplicon", "TREATMENT", 7, 25], ["pCR2", "TREATMENT", 64, 68], ["TOPO-TA cloning kit (Invitrogen)", "TREATMENT", 71, 103], ["size", "OBSERVATION_MODIFIER", 42, 46]]], ["A clone of pCR2.1-Newbury2-ORF2, which had been sequenced in both directions to confirm the integrity of ORF2 gene, and the pFastBac TM 1 transfer vector (Invitrogen) were digested with EcoRI and XhoI (Promega).", [["clone", "CELL", 2, 7], ["pCR2", "GENE_OR_GENE_PRODUCT", 11, 15], ["Newbury2", "GENE_OR_GENE_PRODUCT", 18, 26], ["ORF2", "GENE_OR_GENE_PRODUCT", 27, 31], ["ORF2", "GENE_OR_GENE_PRODUCT", 105, 109], ["pFastBac TM 1", "GENE_OR_GENE_PRODUCT", 124, 137], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 155, 165], ["EcoRI", "GENE_OR_GENE_PRODUCT", 186, 191], ["XhoI", "GENE_OR_GENE_PRODUCT", 196, 200], ["Promega", "GENE_OR_GENE_PRODUCT", 202, 209], ["pCR2", "DNA", 11, 15], ["Newbury2", "DNA", 18, 26], ["ORF2", "DNA", 27, 31], ["ORF2 gene", "DNA", 105, 114], ["pFastBac TM 1 transfer vector", "DNA", 124, 153], ["Invitrogen", "DNA", 155, 165], ["EcoRI", "DNA", 186, 191], ["XhoI", "DNA", 196, 200], ["A clone of pCR2", "TEST", 0, 15], ["the pFastBac TM", "TREATMENT", 120, 135], ["EcoRI and XhoI (Promega)", "TREATMENT", 186, 210]]], ["The Newbury2-ORF2 gene and the pFastBac TM 1 transfer vector were ligated to create the construct pFastBac TM 1-Newbury2-ORF2 that was used to transform TOP10 E. coli from which the construct was amplified and purified.Expression of the Newbury2 capsid protein as VLPsDonor plasmid pFastBac TM 1-Newbury2-ORF2 was transformed into DH10Bac (Invitrogen) competent cells for transposition.", [["cells", "ANATOMY", 362, 367], ["Newbury2-ORF2", "GENE_OR_GENE_PRODUCT", 4, 17], ["pFastBac TM 1", "GENE_OR_GENE_PRODUCT", 31, 44], ["TOP10 E. coli", "ORGANISM", 153, 166], ["Newbury2", "GENE_OR_GENE_PRODUCT", 237, 245], ["pFastBac TM 1-Newbury2-ORF2", "GENE_OR_GENE_PRODUCT", 282, 309], ["cells", "CELL", 362, 367], ["Newbury2-ORF2 gene", "DNA", 4, 22], ["pFastBac TM 1 transfer vector", "DNA", 31, 60], ["pFastBac TM 1-Newbury2", "DNA", 98, 120], ["ORF2", "DNA", 121, 125], ["Newbury2 capsid protein", "PROTEIN", 237, 260], ["VLPsDonor plasmid pFastBac TM 1", "DNA", 264, 295], ["Newbury2", "DNA", 296, 304], ["ORF2", "DNA", 305, 309], ["DH10Bac (Invitrogen) competent cells", "CELL_LINE", 331, 367], ["E. coli", "SPECIES", 159, 166], ["E. coli", "SPECIES", 159, 166], ["The Newbury2-ORF2 gene", "TREATMENT", 0, 22], ["the pFastBac TM 1 transfer vector", "TREATMENT", 27, 60], ["Newbury2-ORF2", "TREATMENT", 112, 125], ["E. coli", "PROBLEM", 159, 166], ["the Newbury2 capsid protein", "TREATMENT", 233, 260], ["VLPsDonor plasmid pFastBac TM", "TREATMENT", 264, 293], ["transposition", "TREATMENT", 372, 385]]], ["After the recombinant bacmids were determined to be correct by two successive blue-white colonies analysis, the recombinant bacmid DNA was used to lipofect Spodoptera frugiperda (Sf9) cells.", [["Sf9) cells", "ANATOMY", 179, 189], ["bacmids", "GENE_OR_GENE_PRODUCT", 22, 29], ["bacmid", "ORGANISM", 124, 130], ["DNA", "CELLULAR_COMPONENT", 131, 134], ["Spodoptera frugiperda", "ORGANISM", 156, 177], ["Sf9) cells", "CELL", 179, 189], ["recombinant bacmid DNA", "DNA", 112, 134], ["lipofect Spodoptera frugiperda (Sf9) cells", "CELL_LINE", 147, 189], ["Spodoptera frugiperda", "SPECIES", 156, 177], ["Spodoptera frugiperda", "SPECIES", 156, 177], ["the recombinant bacmids", "TREATMENT", 6, 29], ["white colonies analysis", "TEST", 83, 106], ["the recombinant bacmid DNA", "TREATMENT", 108, 134]]], ["The resulting recombinant baculovirus was amplified twice, and expression of ORF2 was checked by Coomassie blue staining of SDS-PAGE of infected Sf9 cells lysate.", [["cells lysate", "ANATOMY", 149, 161], ["Coomassie blue", "CHEMICAL", 97, 111], ["baculovirus", "ORGANISM", 26, 37], ["ORF2", "GENE_OR_GENE_PRODUCT", 77, 81], ["Coomassie", "SIMPLE_CHEMICAL", 97, 106], ["Sf9 cells", "CELL", 145, 154], ["ORF2", "DNA", 77, 81], ["Sf9 cells", "CELL_LINE", 145, 154], ["baculovirus", "SPECIES", 26, 37], ["Sf9", "SPECIES", 145, 148], ["The resulting recombinant baculovirus", "TREATMENT", 0, 37], ["ORF2", "TEST", 77, 81], ["SDS", "PROBLEM", 124, 127], ["infected Sf9 cells lysate", "TREATMENT", 136, 161], ["recombinant baculovirus", "OBSERVATION", 14, 37], ["infected Sf9 cells lysate", "OBSERVATION", 136, 161]]], ["For VLP production, Sf9 cell monolayers were infected with recombinant baculovirus at a multiplicity of infection of 5 PFU/cell and incubated in Hink's medium supplemented with 1% fetal calf serum for 5 days at 26 \u2022 C. VLPs were extracted from supernatant of freezed-thawed infected Sf9 cells as described previously [22] except that Freon 113 was substituted by Vertrel XF as described by Mendez et al. [28] .", [["Sf9 cell monolayers", "ANATOMY", 20, 39], ["cell", "ANATOMY", 123, 127], ["fetal calf serum", "ANATOMY", 180, 196], ["supernatant", "ANATOMY", 244, 255], ["cells", "ANATOMY", 287, 292], ["infection", "DISEASE", 104, 113], ["Freon 113", "CHEMICAL", 334, 343], ["Sf9 cell monolayers", "CELL", 20, 39], ["baculovirus", "ORGANISM", 71, 82], ["cell", "CELL", 123, 127], ["fetal calf", "ORGANISM_SUBSTANCE", 180, 190], ["serum", "ORGANISM_SUBSTANCE", 191, 196], ["VLPs", "ORGANISM", 219, 223], ["Sf9 cells", "CELL", 283, 292], ["Freon 113", "SIMPLE_CHEMICAL", 334, 343], ["Vertrel XF", "SIMPLE_CHEMICAL", 363, 373], ["Sf9 cell monolayers", "CELL_LINE", 20, 39], ["freezed-thawed infected Sf9 cells", "CELL_LINE", 259, 292], ["calf", "SPECIES", 186, 190], ["Sf9", "SPECIES", 20, 23], ["baculovirus", "SPECIES", 71, 82], ["Sf9", "SPECIES", 283, 286], ["VLP production", "PROBLEM", 4, 18], ["Sf9 cell monolayers", "TREATMENT", 20, 39], ["recombinant baculovirus", "TREATMENT", 59, 82], ["infection", "PROBLEM", 104, 113], ["1% fetal calf serum", "TREATMENT", 177, 196], ["VLPs", "TEST", 219, 223], ["infected Sf9 cells", "PROBLEM", 274, 292], ["Sf9 cell monolayers", "OBSERVATION", 20, 39], ["infection", "OBSERVATION", 104, 113], ["calf", "ANATOMY", 186, 190], ["Sf9 cells", "OBSERVATION", 283, 292]]], ["VLPs were purified by isopicnic centrifugation in cesium chloride gradients and quantified by the method of Bradford using bovine serum albumin as standard.", [["serum", "ANATOMY", 130, 135], ["cesium chloride", "CHEMICAL", 50, 65], ["cesium chloride", "CHEMICAL", 50, 65], ["VLPs", "ORGANISM", 0, 4], ["isopicnic", "SIMPLE_CHEMICAL", 22, 31], ["cesium chloride", "SIMPLE_CHEMICAL", 50, 65], ["bovine", "ORGANISM", 123, 129], ["serum", "ORGANISM_SUBSTANCE", 130, 135], ["albumin", "GENE_OR_GENE_PRODUCT", 136, 143], ["bovine", "SPECIES", 123, 129], ["bovine", "SPECIES", 123, 129], ["VLPs", "TREATMENT", 0, 4], ["cesium chloride gradients", "TREATMENT", 50, 75], ["bovine serum albumin", "TEST", 123, 143]]], ["Recombinant VLPs were negatively stained with 2% uranyl acetate and examined in a Philips CM12 electron microscope operated at 80kV.", [["uranyl acetate", "CHEMICAL", 49, 63], ["uranyl acetate", "CHEMICAL", 49, 63], ["VLPs", "ORGANISM", 12, 16], ["uranyl acetate", "SIMPLE_CHEMICAL", 49, 63], ["Recombinant VLPs", "PROBLEM", 0, 16], ["2% uranyl acetate", "TREATMENT", 46, 63]]], ["Micrographs were taken at 25,000 magnification on Kodak SO163 Image plates.Western blot analysisBovine serum albumin (BSA) was used to establish the protein concentrations of double CsClpurified VLPs with a Micro-BCA assay (Pierce).", [["serum", "ANATOMY", 103, 108], ["analysisBovine", "SIMPLE_CHEMICAL", 88, 102], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["albumin", "SIMPLE_CHEMICAL", 109, 116], ["BSA", "SIMPLE_CHEMICAL", 118, 121], ["Micrographs", "TEST", 0, 11], ["Kodak", "TEST", 50, 55], ["Image plates", "TEST", 62, 74], ["serum albumin (BSA)", "TEST", 103, 122], ["the protein concentrations", "TEST", 145, 171], ["double CsClpurified VLPs", "TREATMENT", 175, 199]]], ["The Newbury2 capsid protein (250 ng/lane) was blotted onto nitrocellulose membranes (Invitrogen) following electrophoresis with PAGEr Duramide 4-20% Tris-Glycine pre-cast gels (Cambrex) and western transfer.", [["membranes", "ANATOMY", 74, 83], ["PAGEr Duramide 4-20% Tris-Glycine", "CHEMICAL", 128, 161], ["nitrocellulose", "CHEMICAL", 59, 73], ["Tris-Glycine", "CHEMICAL", 149, 161], ["Newbury2 capsid", "GENE_OR_GENE_PRODUCT", 4, 19], ["membranes", "CELLULAR_COMPONENT", 74, 83], ["Tris-Glycine pre-cast gels", "SIMPLE_CHEMICAL", 149, 175], ["Newbury2 capsid protein", "PROTEIN", 4, 27], ["The Newbury2 capsid protein", "TREATMENT", 0, 27], ["nitrocellulose membranes", "TREATMENT", 59, 83], ["PAGEr Duramide", "TREATMENT", 128, 142], ["Tris-Glycine pre-cast gels", "TREATMENT", 149, 175]]], ["Prior to immunostaining, the nitrocellulose membranes were stained with Ponceau S (Sigma) to establish that the Newbury2 capsid protein had been successfully transferred.", [["nitrocellulose membranes", "ANATOMY", 29, 53], ["nitrocellulose", "CHEMICAL", 29, 43], ["membranes", "CELLULAR_COMPONENT", 44, 53], ["Ponceau S", "GENE_OR_GENE_PRODUCT", 72, 81], ["Newbury2", "GENE_OR_GENE_PRODUCT", 112, 120], ["Ponceau S", "PROTEIN", 72, 81], ["Newbury2 capsid protein", "PROTEIN", 112, 135], ["Ponceau S", "SPECIES", 72, 81], ["immunostaining", "TEST", 9, 23], ["the nitrocellulose membranes", "TREATMENT", 25, 53], ["the Newbury2 capsid protein", "PROBLEM", 108, 135]]], ["Membranes were blocked with 2% non-fat dried skimmed milk in Tris-buffered saline (TBS; 10mM Tris-HCl [pH 7.4], 0.15 M NaCl) and washing steps performed with TBST (TBS + 0.05% Tween 20) .", [["Membranes", "ANATOMY", 0, 9], ["milk", "ANATOMY", 53, 57], ["Tris-HCl", "CHEMICAL", 93, 101], ["NaCl", "CHEMICAL", 119, 123], ["Tris", "CHEMICAL", 61, 65], ["Tris-HCl", "CHEMICAL", 93, 101], ["NaCl", "CHEMICAL", 119, 123], ["Tween 20", "CHEMICAL", 176, 184], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["fat", "TISSUE", 35, 38], ["milk", "ORGANISM_SUBSTANCE", 53, 57], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 61, 81], ["Tris-HCl", "SIMPLE_CHEMICAL", 93, 101], ["Tris", "TEST", 93, 97], ["pH", "TEST", 103, 105], ["washing steps", "TEST", 129, 142], ["TBST", "TEST", 158, 162], ["TBS", "TEST", 164, 167]]], ["Convalescent bovine antisera to Newbury2 and rotavirus UK (as a negative control serum) were diluted 1:100 in TBST + 1% non-fat dried skimmed milk powder and detected using a 1:5000 dilution of rabbit anti-bovine IgG horseradish-peroxidase conjugate (Sigma).", [["serum", "ANATOMY", 81, 86], ["milk", "ANATOMY", 142, 146], ["bovine", "ORGANISM", 13, 19], ["Newbury2", "GENE_OR_GENE_PRODUCT", 32, 40], ["rotavirus UK", "ORGANISM", 45, 57], ["serum", "ORGANISM_SUBSTANCE", 81, 86], ["fat", "TISSUE", 124, 127], ["milk", "ORGANISM_SUBSTANCE", 142, 146], ["rabbit", "ORGANISM", 194, 200], ["horseradish-peroxidase conjugate", "SIMPLE_CHEMICAL", 217, 249], ["rabbit anti-bovine IgG horseradish-peroxidase conjugate", "PROTEIN", 194, 249], ["bovine", "SPECIES", 13, 19], ["rotavirus", "SPECIES", 45, 54], ["milk", "SPECIES", 142, 146], ["rabbit", "SPECIES", 194, 200], ["horseradish", "SPECIES", 217, 228], ["bovine", "SPECIES", 13, 19], ["rotavirus", "SPECIES", 45, 54], ["rabbit", "SPECIES", 194, 200], ["Convalescent bovine antisera", "TREATMENT", 0, 28], ["TBST", "TEST", 110, 114], ["fat dried skimmed milk powder", "TREATMENT", 124, 153], ["a 1:5000 dilution", "TREATMENT", 173, 190], ["rabbit anti-bovine IgG horseradish", "TREATMENT", 194, 228]]], ["HRP activity was detected using TMB (3,3 ,5, 5 -tetramethylbenzidine) stabilised substrate (Promega).", [["TMB (3,3 ,5, 5 -tetramethylbenzidine", "CHEMICAL", 32, 68], ["TMB", "CHEMICAL", 32, 35], ["3,3 ,5, 5 -tetramethylbenzidine", "CHEMICAL", 37, 68], ["HRP", "GENE_OR_GENE_PRODUCT", 0, 3], ["TMB (3,3 ,5, 5 -tetramethylbenzidine", "SIMPLE_CHEMICAL", 32, 68], ["HRP", "PROTEIN", 0, 3], ["TMB", "TEST", 32, 35], ["tetramethylbenzidine", "TREATMENT", 48, 68]]], ["The molecular mass of the Newbury agent-2 capsid protein was calculated from a standard curve produced using the Prosieve Color (Cambrex) molecular mass marker.Antibody detection ELISAMaxisorb plates (Nunc) were coated overnight at 4 \u2022 C with 5 \u00b5g/ml of antigen in carbonate buffer pH 9.6.", [["carbonate", "CHEMICAL", 265, 274], ["carbonate", "SIMPLE_CHEMICAL", 265, 274], ["Newbury agent-2 capsid protein", "PROTEIN", 26, 56], ["The molecular mass", "PROBLEM", 0, 18], ["2 capsid protein", "PROBLEM", 40, 56], ["a standard curve", "TEST", 77, 93], ["the Prosieve Color (Cambrex) molecular mass marker", "TREATMENT", 109, 159], ["Antibody detection ELISAMaxisorb plates", "TREATMENT", 160, 199], ["antigen in carbonate buffer pH", "TREATMENT", 254, 284], ["molecular", "OBSERVATION_MODIFIER", 4, 13], ["mass", "OBSERVATION", 14, 18], ["mass", "OBSERVATION", 148, 152]]], ["Antigens used were double CsCl-purified Newbury2 VLPs or rotavirus 2/6 VLPs produced from the bovine rotavirus RF strain, or the supernatant from wild-type baculovirus-infected Sf9 cells (mock antigen).", [["supernatant", "ANATOMY", 129, 140], ["Sf9 cells", "ANATOMY", 177, 186], ["CsCl", "CHEMICAL", 26, 30], ["Newbury2 VLPs", "ORGANISM", 40, 53], ["rotavirus 2/6 VLPs", "ORGANISM", 57, 75], ["bovine", "ORGANISM", 94, 100], ["rotavirus RF strain", "ORGANISM", 101, 120], ["baculovirus", "ORGANISM", 156, 167], ["Sf9 cells", "CELL", 177, 186], ["mock antigen", "GENE_OR_GENE_PRODUCT", 188, 200], ["wild-type baculovirus-infected Sf9 cells", "CELL_LINE", 146, 186], ["mock antigen", "PROTEIN", 188, 200], ["bovine", "SPECIES", 94, 100], ["bovine rotavirus RF strain", "SPECIES", 94, 120], ["baculovirus", "SPECIES", 156, 167], ["Sf9", "SPECIES", 177, 180], ["double CsCl", "TREATMENT", 19, 30], ["Newbury2 VLPs", "TREATMENT", 40, 53], ["rotavirus 2/6 VLPs", "TREATMENT", 57, 75], ["the bovine rotavirus RF strain", "PROBLEM", 90, 120], ["type baculovirus", "PROBLEM", 151, 167], ["infected Sf9 cells", "PROBLEM", 168, 186], ["Sf9 cells", "OBSERVATION", 177, 186]]], ["Plates were blocked with 2% non-fat dried skimmed milk in PBS and washed with PBST (PBS + 0.05% Tween 20 [Sigma]) between steps.", [["milk", "ANATOMY", 50, 54], ["Tween 20", "CHEMICAL", 96, 104], ["fat", "TISSUE", 32, 35], ["milk", "ORGANISM_SUBSTANCE", 50, 54], ["Plates", "TEST", 0, 6], ["2% non-fat dried skimmed milk in PBS", "TREATMENT", 25, 61], ["PBST", "TREATMENT", 78, 82], ["PBS", "TEST", 84, 87]]], ["Antisera from experimental calves were serially diluted from 1:50 in a 2-fold dilution series in 1% non-fat dried skimmed milk in PBST, dispensed into wells previously coated with test or mock antigen, and incubated at room temperature for 1 h.", [["milk", "ANATOMY", 122, 126], ["Antisera", "ORGANISM_SUBSTANCE", 0, 8], ["calves", "ORGANISM", 27, 33], ["fat", "TISSUE", 104, 107], ["milk", "ORGANISM_SUBSTANCE", 122, 126], ["calves", "SPECIES", 27, 33], ["calves", "SPECIES", 27, 33], ["Antisera", "TREATMENT", 0, 8], ["a 2-fold dilution series", "TREATMENT", 69, 93], ["test or mock antigen", "TEST", 180, 200]]], ["Binding was detected by incubation with a 1:10,000 dilution of rabbit anti-bovine IgG horseradish peroxidase-conjugate (Sigma) in 1% non-fat dried skimmed milk in PBST at room temperature.", [["milk", "ANATOMY", 155, 159], ["rabbit", "ORGANISM", 63, 69], ["horseradish peroxidase-conjugate", "SIMPLE_CHEMICAL", 86, 118], ["Sigma", "SIMPLE_CHEMICAL", 120, 125], ["fat", "TISSUE", 137, 140], ["milk", "ORGANISM_SUBSTANCE", 155, 159], ["rabbit anti-bovine IgG horseradish peroxidase", "PROTEIN", 63, 108], ["rabbit", "SPECIES", 63, 69], ["horseradish", "SPECIES", 86, 97], ["rabbit", "SPECIES", 63, 69], ["a 1:10,000 dilution", "TREATMENT", 40, 59], ["rabbit anti-bovine IgG horseradish peroxidase", "TREATMENT", 63, 108], ["conjugate (Sigma)", "TREATMENT", 109, 126]]], ["TMB was used as substrate (Sigma).", [["TMB", "CHEMICAL", 0, 3], ["TMB", "CHEMICAL", 0, 3], ["TMB", "SIMPLE_CHEMICAL", 0, 3]]], ["Serum titres were calculated by linear regression using Prism 4 (GraphPad Software).", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum titres", "TEST", 0, 12], ["Prism", "TEST", 56, 61]]], ["Endpoints were defined as the highest dilution at which the net absorbance value (absorbance units of the serum with the test antigen minus absorbance units with the mock antigen) was twice the absorbance value for antigen-coated wells without a test bovine serum.Molecular modellingThe homology model of the Newbury2 capsid protein was generated using the translated amino acid sequence of the complete Newbury2 ORF2 gene, which was submitted to the Swiss-model server http://swissmodel.expasy.org/.", [["serum", "ANATOMY", 106, 111], ["serum", "ANATOMY", 258, 263], ["amino acid", "CHEMICAL", 368, 378], ["amino acid", "CHEMICAL", 368, 378], ["serum", "ORGANISM_SUBSTANCE", 106, 111], ["bovine", "ORGANISM", 251, 257], ["serum", "ORGANISM_SUBSTANCE", 258, 263], ["Newbury2", "GENE_OR_GENE_PRODUCT", 309, 317], ["amino acid", "AMINO_ACID", 368, 378], ["Newbury2 ORF2", "GENE_OR_GENE_PRODUCT", 404, 417], ["mock antigen", "PROTEIN", 166, 178], ["Newbury2 capsid protein", "PROTEIN", 309, 332], ["Newbury2 ORF2 gene", "DNA", 404, 422], ["Swiss-model server", "DNA", 451, 469], ["bovine", "SPECIES", 251, 257], ["bovine", "SPECIES", 251, 257], ["the net absorbance value", "TEST", 56, 80], ["the serum", "TEST", 102, 111], ["the test antigen", "TEST", 117, 133], ["the mock antigen", "TEST", 162, 178], ["the absorbance value", "TEST", 190, 210], ["antigen", "TEST", 215, 222], ["a test bovine serum", "TEST", 244, 263], ["the Newbury2 capsid protein", "TEST", 305, 332], ["the translated amino acid sequence", "TREATMENT", 353, 387]]], ["The software programme VMD 1.8.2 [15] was used to visualise the co-ordinate data and generate the image, which was rendered using Pov-ray TM for Windows TM .Analysis of the complete Bo/Newbury2/1976/UK genome and ORF1 geneCompletion of the sequence of the Newbury2 genome showed that it was 7311 nucleotides in length, excluding the poly-A tail, that is, 27 nucleotides shorter than the Jena virus genome.", [["nucleotides", "CHEMICAL", 296, 307], ["nucleotides", "CHEMICAL", 358, 369], ["Newbury2", "GENE_OR_GENE_PRODUCT", 185, 193], ["UK", "GENE_OR_GENE_PRODUCT", 199, 201], ["ORF1", "GENE_OR_GENE_PRODUCT", 213, 217], ["Newbury2", "GENE_OR_GENE_PRODUCT", 256, 264], ["Jena virus", "ORGANISM", 387, 397], ["Bo/Newbury2/1976/UK genome", "DNA", 182, 208], ["ORF1 geneCompletion", "DNA", 213, 232], ["Newbury2 genome", "DNA", 256, 271], ["poly-A tail", "DNA", 333, 344], ["Jena virus genome", "DNA", 387, 404], ["Jena virus", "SPECIES", 387, 397], ["The software programme VMD", "TEST", 0, 26], ["the image", "TEST", 94, 103], ["the Newbury2 genome", "TEST", 252, 271], ["length", "TEST", 311, 317], ["tail", "ANATOMY", 340, 344], ["virus genome", "OBSERVATION", 392, 404]]], ["The shorter length was attributed to deletions in the Newbury2 ORF3 gene and the shorter 3 untranslated region reported previously [33] .", [["Newbury2 ORF3", "GENE_OR_GENE_PRODUCT", 54, 67], ["Newbury2 ORF3 gene", "DNA", 54, 72], ["3 untranslated region", "DNA", 89, 110], ["deletions", "PROBLEM", 37, 46], ["shorter", "OBSERVATION_MODIFIER", 4, 11], ["length", "OBSERVATION_MODIFIER", 12, 18], ["attributed to", "UNCERTAINTY", 23, 36], ["deletions", "OBSERVATION", 37, 46]]], ["The 5 untranslated region of Newbury2 was identical in length (21 nucleotides) and composition to that of Jena [25] except for a single transition substitution (U-C) at the 21 st nucleotide.", [["nucleotide", "CHEMICAL", 179, 189], ["Newbury2", "GENE_OR_GENE_PRODUCT", 29, 37], ["U-C", "GENE_OR_GENE_PRODUCT", 161, 164], ["5 untranslated region", "DNA", 4, 25], ["Newbury2", "DNA", 29, 37], ["21 st nucleotide", "DNA", 173, 189], ["a single transition substitution", "TREATMENT", 127, 159], ["length", "OBSERVATION_MODIFIER", 55, 61]]], ["The G + C content of the Newbury2 genome was 57%, similar to that of Jena (56%) [25] .", [["G + C", "CHEMICAL", 4, 9], ["G + C", "SIMPLE_CHEMICAL", 4, 9], ["Newbury2 genome", "DNA", 25, 40], ["The G + C content", "TEST", 0, 17], ["the Newbury2 genome", "TEST", 21, 40], ["G + C content", "OBSERVATION_MODIFIER", 4, 17]]], ["The Newbury2 ORF1 gene was 5055 nucleotides in length and coded for a protein of 1684 amino acids with a predicted molecular mass of 186 kDa.", [["amino acids", "CHEMICAL", 86, 97], ["nucleotides", "CHEMICAL", 32, 43], ["amino acids", "CHEMICAL", 86, 97], ["Newbury2 ORF1", "GENE_OR_GENE_PRODUCT", 4, 17], ["amino acids", "AMINO_ACID", 86, 97], ["Newbury2 ORF1 gene", "DNA", 4, 22], ["a protein", "TEST", 68, 77], ["amino acids", "TEST", 86, 97], ["mass", "OBSERVATION", 125, 129]]], ["It was 12 nucleotides longer than the Jena ORF1 gene.", [["nucleotides", "CHEMICAL", 10, 21], ["Jena ORF1 gene", "DNA", 38, 52]]], ["There were 2 insertions, of 3 and 21 nucleotides, towards the 5 end of the Newbury2 ORF1 gene at nucleotide positions 130-132 and 157-177.", [["nucleotide", "CHEMICAL", 97, 107], ["nucleotides", "CHEMICAL", 37, 48], ["nucleotide", "CHEMICAL", 97, 107], ["Newbury2 ORF1", "GENE_OR_GENE_PRODUCT", 75, 88], ["5 end", "DNA", 62, 67], ["Newbury2 ORF1 gene", "DNA", 75, 93], ["nucleotide positions 130-132 and 157-177", "DNA", 97, 137], ["nucleotide positions", "TEST", 97, 117], ["insertions", "OBSERVATION_MODIFIER", 13, 23]]], ["In contrast, compared with the Newbury2 genome, there were 2 insertions, of 9 and 3 nucleotides, in the Jena ORF1 gene, at nucleotide positions 2650-2658 and 2689-2691.Analysis of the complete Bo/Newbury2/1976/UK genome and ORF1 geneThe Newbury2 and Jena ORF1 genes had, overall, 73% nucleotide identity (range 38-83%) (Fig. 1A) and 84% amino acid identity (range 71-92%) ( Table 1 ).", [["amino acid", "CHEMICAL", 337, 347], ["nucleotides", "CHEMICAL", 84, 95], ["nucleotide", "CHEMICAL", 123, 133], ["nucleotide", "CHEMICAL", 284, 294], ["amino acid", "CHEMICAL", 337, 347], ["Newbury2", "GENE_OR_GENE_PRODUCT", 196, 204], ["UK", "GENE_OR_GENE_PRODUCT", 210, 212], ["ORF1", "GENE_OR_GENE_PRODUCT", 224, 228], ["Newbury2", "GENE_OR_GENE_PRODUCT", 237, 245], ["amino acid", "AMINO_ACID", 337, 347], ["Newbury2 genome", "DNA", 31, 46], ["Jena ORF1 gene", "DNA", 104, 118], ["nucleotide positions 2650-2658 and 2689-2691", "DNA", 123, 167], ["Bo/Newbury2/1976/UK genome", "DNA", 193, 219], ["ORF1 gene", "DNA", 224, 233], ["Newbury2 and Jena ORF1 genes", "DNA", 237, 265], ["nucleotide positions", "TEST", 123, 143], ["ORF1 gene", "TEST", 224, 233], ["Jena ORF1 genes", "TEST", 250, 265], ["nucleotide identity", "TEST", 284, 303], ["amino acid identity", "TEST", 337, 356]]], ["The majority of the variation was within the first 500 nucleotides and between nucleotides 2000 and 3000, which included the 3A-B(VPg) region, with only 71% [33] amino acid identity.", [["amino acid", "CHEMICAL", 162, 172], ["nucleotides", "CHEMICAL", 55, 66], ["nucleotides", "CHEMICAL", 79, 90], ["amino acid", "CHEMICAL", 162, 172], ["3A-B", "GENE_OR_GENE_PRODUCT", 125, 129], ["amino acid", "AMINO_ACID", 162, 172], ["nucleotides 2000 and 3000", "DNA", 79, 104], ["3A-B(VPg) region", "DNA", 125, 141], ["nucleotides", "TEST", 79, 90], ["the 3A-B(VPg) region", "TREATMENT", 121, 141], ["amino acid identity", "TEST", 162, 181], ["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["The NTPase regions of the two viruses showed a remarkably high level of identity (92% amino acid), higher than that of the 3D-polymerase regions.", [["amino acid", "CHEMICAL", 86, 96], ["amino acid", "CHEMICAL", 86, 96], ["NTPase", "GENE_OR_GENE_PRODUCT", 4, 10], ["amino acid", "AMINO_ACID", 86, 96], ["NTPase regions", "PROTEIN", 4, 18], ["3D-polymerase regions", "PROTEIN", 123, 144], ["the two viruses", "PROBLEM", 22, 37], ["amino acid", "TEST", 86, 96], ["viruses", "OBSERVATION", 30, 37], ["high", "OBSERVATION_MODIFIER", 58, 62], ["higher", "OBSERVATION_MODIFIER", 99, 105]]], ["Extensive variation between the Newbury2 and Jena genomes was also seen for the ORF2 and 3 genes, but this was reported previously [30] .", [["Newbury2", "GENE_OR_GENE_PRODUCT", 32, 40], ["ORF2", "GENE_OR_GENE_PRODUCT", 80, 84], ["3", "GENE_OR_GENE_PRODUCT", 89, 90], ["Newbury2 and Jena genomes", "DNA", 32, 57], ["ORF2", "DNA", 80, 84], ["Extensive variation", "PROBLEM", 0, 19], ["the ORF2", "TEST", 76, 84], ["variation", "OBSERVATION_MODIFIER", 10, 19]]], ["All regions of the Newbury2 genome, including the ORF2 and 3 genes reported previously [30] , had low levels of amino acid identities with genogroups I and II noroviruses and the murine norovirus ( Table 1) .", [["amino acid", "CHEMICAL", 112, 122], ["norovirus", "DISEASE", 186, 195], ["amino acid", "CHEMICAL", 112, 122], ["Newbury2", "GENE_OR_GENE_PRODUCT", 19, 27], ["ORF2", "GENE_OR_GENE_PRODUCT", 50, 54], ["3", "GENE_OR_GENE_PRODUCT", 59, 60], ["amino acid", "AMINO_ACID", 112, 122], ["murine norovirus", "ORGANISM", 179, 195], ["Newbury2 genome", "DNA", 19, 34], ["ORF2", "DNA", 50, 54], ["murine", "SPECIES", 179, 185], ["the ORF2", "TEST", 46, 54], ["low levels of amino acid identities", "PROBLEM", 98, 133], ["genogroups I and II noroviruses", "PROBLEM", 139, 170], ["the murine norovirus", "PROBLEM", 175, 195], ["Newbury2 genome", "OBSERVATION", 19, 34]]], ["The Newbury2 genome showed moderate nucleotide conservation (11 of 24 nucleotides) between its 5 terminus region and the region of the ORF1 and 2 overlap ( Fig. 1 panel A) .", [["nucleotide", "CHEMICAL", 36, 46], ["nucleotide", "CHEMICAL", 36, 46], ["nucleotides", "CHEMICAL", 70, 81], ["Newbury2 genome", "DNA", 4, 19], ["5 terminus region", "DNA", 95, 112], ["ORF1", "DNA", 135, 139], ["moderate nucleotide conservation", "PROBLEM", 27, 59], ["the ORF1", "TREATMENT", 131, 139], ["moderate", "OBSERVATION_MODIFIER", 27, 35], ["nucleotide conservation", "OBSERVATION", 36, 59], ["region", "ANATOMY_MODIFIER", 121, 127], ["ORF1", "ANATOMY", 135, 139]]], ["This is typical for all members of the family Caliciviridae, especially members of the genus Norovirus [10] and including the bovine Jena genome.", [["Norovirus", "DISEASE", 93, 102], ["Caliciviridae", "GENE_OR_GENE_PRODUCT", 46, 59], ["bovine", "ORGANISM", 126, 132], ["bovine Jena genome", "DNA", 126, 144], ["bovine", "SPECIES", 126, 132], ["the family Caliciviridae", "TREATMENT", 35, 59], ["the genus Norovirus", "PROBLEM", 83, 102], ["the bovine Jena genome", "TREATMENT", 122, 144]]], ["This finding suggests that the transcription/translation mechanism of ORFs 1 and 2 of bovine noroviruses is similar to other caliciviruses.", [["noroviruses", "DISEASE", 93, 104], ["ORFs 1", "GENE_OR_GENE_PRODUCT", 70, 76], ["2", "GENE_OR_GENE_PRODUCT", 81, 82], ["bovine", "ORGANISM", 86, 92], ["noroviruses", "ORGANISM", 93, 104], ["caliciviruses", "CANCER", 125, 138], ["ORFs 1 and 2", "DNA", 70, 82], ["bovine", "SPECIES", 86, 92], ["the transcription", "PROBLEM", 27, 44], ["ORFs", "TEST", 70, 74], ["bovine noroviruses", "PROBLEM", 86, 104], ["noroviruses", "OBSERVATION", 93, 104]]], ["Consistent with Jena, the putative protease cleavage sites, LQGP and LQAP, on either side of the NTPase, plus FQAP and LEGG, on either side of the 3C protease, were conserved for Newbury2 (Fig. 1B) .", [["LQGP", "GENE_OR_GENE_PRODUCT", 60, 64], ["LQAP", "GENE_OR_GENE_PRODUCT", 69, 73], ["NTPase", "GENE_OR_GENE_PRODUCT", 97, 103], ["FQAP", "GENE_OR_GENE_PRODUCT", 110, 114], ["LEGG", "GENE_OR_GENE_PRODUCT", 119, 123], ["putative protease cleavage sites", "PROTEIN", 26, 58], ["LQGP", "DNA", 60, 64], ["LQAP", "DNA", 69, 73], ["NTPase", "PROTEIN", 97, 103], ["FQAP", "PROTEIN", 110, 114], ["LEGG", "PROTEIN", 119, 123], ["3C protease", "PROTEIN", 147, 158], ["Newbury2", "PROTEIN", 179, 187], ["the putative protease cleavage sites", "TREATMENT", 22, 58], ["the NTPase", "TEST", 93, 103], ["LEGG", "TEST", 119, 123], ["the 3C protease", "TREATMENT", 143, 158], ["LEGG", "ANATOMY", 119, 123]]], ["A cleavage site could not be identified for the 3A-B(VPg) region because the conserved human noroviruses dipeptides used to predict the cleavage sites were not present for the bovine noroviruses.", [["3A-B", "GENE_OR_GENE_PRODUCT", 48, 52], ["human", "ORGANISM", 87, 92], ["bovine", "ORGANISM", 176, 182], ["3A-B(VPg) region", "DNA", 48, 64], ["human", "SPECIES", 87, 92], ["bovine", "SPECIES", 176, 182], ["human", "SPECIES", 87, 92], ["A cleavage site", "PROBLEM", 0, 15], ["the conserved human noroviruses dipeptides", "PROBLEM", 73, 115], ["the cleavage sites", "PROBLEM", 132, 150], ["the bovine noroviruses", "PROBLEM", 172, 194]]], ["The amino acid motifs typical of caliciviruses were present in the Newbury2 ORF1 polyprotein in the NTPase (GPPGIGKT), the 3C protease (GDCG) and the 3D polymerase (GLPSG and YGDD), as previously described for Jena [25] .Analysis of the complete Bo/Newbury2/1976/UK genome and ORF1 genePhylogenetic analyses of the Newbury2 complete ORF1 protein confirmed that bovine noroviruses formed two distinct clusters in genogroup III, most closely related to, but distinct from, genogroup I (Fig. 2) .", [["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "AMINO_ACID", 4, 14], ["caliciviruses", "GENE_OR_GENE_PRODUCT", 33, 46], ["NTPase", "GENE_OR_GENE_PRODUCT", 100, 106], ["GPPGIGKT", "GENE_OR_GENE_PRODUCT", 108, 116], ["GDCG", "GENE_OR_GENE_PRODUCT", 136, 140], ["GLPSG", "GENE_OR_GENE_PRODUCT", 165, 170], ["YGDD", "GENE_OR_GENE_PRODUCT", 175, 179], ["Newbury2", "GENE_OR_GENE_PRODUCT", 249, 257], ["UK", "GENE_OR_GENE_PRODUCT", 263, 265], ["ORF1", "GENE_OR_GENE_PRODUCT", 333, 337], ["bovine", "ORGANISM", 361, 367], ["noroviruses", "ORGANISM", 368, 379], ["amino acid motifs", "PROTEIN", 4, 21], ["Newbury2 ORF1 polyprotein", "PROTEIN", 67, 92], ["NTPase", "PROTEIN", 100, 106], ["GPPGIGKT", "PROTEIN", 108, 116], ["3C protease", "PROTEIN", 123, 134], ["GDCG", "PROTEIN", 136, 140], ["3D polymerase", "PROTEIN", 150, 163], ["GLPSG", "PROTEIN", 165, 170], ["YGDD", "PROTEIN", 175, 179], ["Bo/Newbury2/1976/UK genome", "DNA", 246, 272], ["ORF1", "DNA", 277, 281], ["Newbury2 complete ORF1 protein", "PROTEIN", 315, 345], ["genogroup I", "PROTEIN", 471, 482], ["bovine", "SPECIES", 361, 367], ["The amino acid motifs", "TEST", 0, 21], ["caliciviruses", "PROBLEM", 33, 46], ["the 3C protease (GDCG)", "TREATMENT", 119, 141], ["the 3D polymerase", "TEST", 146, 163], ["ORF1 genePhylogenetic analyses", "TEST", 277, 307], ["the Newbury2 complete ORF1 protein", "TEST", 311, 345], ["bovine noroviruses", "PROBLEM", 361, 379], ["caliciviruses", "OBSERVATION", 33, 46], ["bovine noroviruses", "OBSERVATION", 361, 379], ["distinct", "OBSERVATION_MODIFIER", 391, 399], ["clusters", "OBSERVATION_MODIFIER", 400, 408], ["genogroup III", "OBSERVATION_MODIFIER", 412, 425]]], ["The internal branch node thatAnalysis of the complete Bo/Dumfries/1994/UK genome and ORF1 geneThe complete Dumfries genome was identical to that of Newbury2 in its overall length (7311 nucleotides), organization, and the length of the 3 ORFs.", [["branch node", "ANATOMY", 13, 24], ["branch node", "MULTI-TISSUE_STRUCTURE", 13, 24], ["UK", "GENE_OR_GENE_PRODUCT", 71, 73], ["ORF1", "GENE_OR_GENE_PRODUCT", 85, 89], ["Newbury2", "GENE_OR_GENE_PRODUCT", 148, 156], ["Bo/Dumfries/1994/UK genome", "DNA", 54, 80], ["ORF1 gene", "DNA", 85, 94], ["Dumfries genome", "DNA", 107, 122], ["Newbury2", "DNA", 148, 156], ["ORFs", "DNA", 237, 241], ["ORF1 gene", "TREATMENT", 85, 94], ["internal", "ANATOMY", 4, 12], ["branch", "OBSERVATION_MODIFIER", 13, 19], ["node", "OBSERVATION", 20, 24], ["overall", "OBSERVATION_MODIFIER", 164, 171], ["length", "OBSERVATION_MODIFIER", 172, 178]]], ["ORF1 was 5055 nucleotides in length, ORF2 was 1569 nucleotides and ORF3 was 849 nucleotides in length.", [["nucleotides", "CHEMICAL", 14, 25], ["nucleotides", "CHEMICAL", 80, 91], ["ORF1", "GENE_OR_GENE_PRODUCT", 0, 4], ["ORF2", "GENE_OR_GENE_PRODUCT", 37, 41], ["ORF3", "GENE_OR_GENE_PRODUCT", 67, 71], ["ORF1", "DNA", 0, 4], ["ORF2", "DNA", 37, 41], ["ORF3", "DNA", 67, 71], ["ORF1", "TEST", 0, 4], ["ORF2", "TEST", 37, 41], ["nucleotides", "TEST", 51, 62], ["ORF3", "TEST", 67, 71], ["nucleotides in length", "TEST", 80, 101]]], ["The genome had the same G + C content (57%) as Newbury2.", [["G + C", "GENE_OR_GENE_PRODUCT", 24, 29]]], ["The amino acids motifs in the 2C NTPase, the 3C protease and 3D polymerase, typical of the caliciviruses, were present in the Dumfries genome.", [["amino acids", "CHEMICAL", 4, 15], ["amino acids", "CHEMICAL", 4, 15], ["amino acids", "AMINO_ACID", 4, 15], ["3D polymerase", "GENE_OR_GENE_PRODUCT", 61, 74], ["caliciviruses", "GENE_OR_GENE_PRODUCT", 91, 104], ["amino acids motifs", "PROTEIN", 4, 22], ["2C NTPase", "PROTEIN", 30, 39], ["3C protease", "PROTEIN", 45, 56], ["3D polymerase", "PROTEIN", 61, 74], ["Dumfries genome", "DNA", 126, 141], ["The amino acids motifs", "TREATMENT", 0, 22], ["the 2C NTPase", "TREATMENT", 26, 39], ["the 3C protease and 3D polymerase", "TREATMENT", 41, 74], ["the caliciviruses", "PROBLEM", 87, 104], ["caliciviruses", "OBSERVATION", 91, 104]]], ["The putative protease cleavage sites LQGP and LQAP on either side of the NTPase, plus FQAP and LEGG on either side of the 3C protease, were also conserved.", [["LQGP", "GENE_OR_GENE_PRODUCT", 37, 41], ["LQAP", "GENE_OR_GENE_PRODUCT", 46, 50], ["NTPase", "GENE_OR_GENE_PRODUCT", 73, 79], ["putative protease cleavage sites", "PROTEIN", 4, 36], ["LQGP", "PROTEIN", 37, 41], ["LQAP", "PROTEIN", 46, 50], ["NTPase", "PROTEIN", 73, 79], ["FQAP", "PROTEIN", 86, 90], ["LEGG", "PROTEIN", 95, 99], ["3C protease", "PROTEIN", 122, 133], ["The putative protease cleavage", "TREATMENT", 0, 30], ["the NTPase", "TEST", 69, 79], ["FQAP", "TEST", 86, 90], ["the 3C protease", "TREATMENT", 118, 133], ["sites", "OBSERVATION_MODIFIER", 31, 36], ["LQGP", "OBSERVATION_MODIFIER", 37, 41], ["LEGG", "ANATOMY", 95, 99]]], ["The nucleotide and amino acid variation between the Dumfries and Newbury2 ORF1 genes was surprisingly low for two RNA viruses isolated 18 years apart and from disparate geographical locations.", [["nucleotide", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 19, 29], ["nucleotide", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 19, 29], ["amino acid", "AMINO_ACID", 19, 29], ["Newbury2 ORF1", "GENE_OR_GENE_PRODUCT", 65, 78], ["Dumfries and Newbury2 ORF1 genes", "DNA", 52, 84], ["The nucleotide and amino acid variation", "PROBLEM", 0, 39], ["the Dumfries", "TEST", 48, 60], ["Newbury2 ORF1 genes", "PROBLEM", 65, 84], ["two RNA viruses", "PROBLEM", 110, 125], ["amino acid", "OBSERVATION", 19, 29]]], ["Nucleotide identities across the ORF1 gene ranged from 82 to 95% (Fig. 1A) .", [["ORF1", "GENE_OR_GENE_PRODUCT", 33, 37], ["ORF1 gene", "DNA", 33, 42], ["Nucleotide identities", "TEST", 0, 21], ["the ORF1 gene", "TEST", 29, 42]]], ["Amino acid identities of the N-terminal, NTPase, 3A-3B (VPg), 3C-protease and 3D-polymerase proteins were high, ranging from 95 to 99% (Table 1) .", [["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "CHEMICAL", 0, 10], ["N", "CHEMICAL", 29, 30], ["Amino acid", "AMINO_ACID", 0, 10], ["3A-3B", "GENE_OR_GENE_PRODUCT", 49, 54], ["VPg", "GENE_OR_GENE_PRODUCT", 56, 59], ["3C-protease", "GENE_OR_GENE_PRODUCT", 62, 73], ["3D-polymerase", "GENE_OR_GENE_PRODUCT", 78, 91], ["N-terminal, NTPase, 3A-3B (VPg), 3C-protease and 3D-polymerase proteins", "PROTEIN", 29, 100], ["Amino acid identities", "TEST", 0, 21], ["NTPase", "TEST", 41, 47], ["3A", "TEST", 49, 51], ["VPg", "TEST", 56, 59], ["3C-protease", "TREATMENT", 62, 73], ["3D-polymerase proteins", "TEST", 78, 100], ["high", "OBSERVATION_MODIFIER", 106, 110]]], ["Similar levels of identity were found between the Dumfries and Newbury2 ORF2 and 3 proteins, including the hypervariable capsid P2 region [33] .", [["3", "GENE_OR_GENE_PRODUCT", 81, 82], ["Dumfries and Newbury2 ORF2", "DNA", 50, 76], ["hypervariable capsid P2 region", "DNA", 107, 137], ["the hypervariable capsid P2 region", "PROBLEM", 103, 137], ["hypervariable", "OBSERVATION_MODIFIER", 107, 120], ["capsid P2", "ANATOMY", 121, 130]]], ["Because of the high similarity of the Newbury2 and Dumfries genomes, the variation seen between the Dumfries and Jena genomes was almost identical to that between the Newbury2 and Jena genomes.", [["Newbury2", "GENE_OR_GENE_PRODUCT", 38, 46], ["Newbury2 and Dumfries genomes", "DNA", 38, 67], ["Dumfries and Jena genomes", "DNA", 100, 125], ["Newbury2 and Jena genomes", "DNA", 167, 192], ["the Newbury2 and Dumfries genomes", "PROBLEM", 34, 67], ["Jena genomes", "OBSERVATION", 180, 192]]], ["The N-terminal region of Dumfries and Jena had 75% amino acid identity, the NTPase 92%, 3A-3B(VPg) 72%, the 3C-protease 88% and the 3D-polymerase 90% amino acid identity.", [["amino acid", "CHEMICAL", 51, 61], ["amino acid", "CHEMICAL", 150, 160], ["amino acid", "CHEMICAL", 51, 61], ["amino acid", "CHEMICAL", 150, 160], ["amino acid", "AMINO_ACID", 51, 61], ["3A-3B", "GENE_OR_GENE_PRODUCT", 88, 93], ["amino acid", "AMINO_ACID", 150, 160], ["N-terminal region", "PROTEIN", 4, 21], ["Dumfries", "PROTEIN", 25, 33], ["NTPase", "PROTEIN", 76, 82], ["3A", "PROTEIN", 88, 90], ["VPg", "PROTEIN", 94, 97], ["3C", "PROTEIN", 108, 110], ["protease", "PROTEIN", 111, 119], ["3D", "PROTEIN", 132, 134], ["Dumfries", "TEST", 25, 33], ["amino acid identity", "TEST", 51, 70], ["the NTPase", "TEST", 72, 82], ["3A", "TEST", 88, 90], ["VPg", "TEST", 94, 97], ["the 3C", "TEST", 104, 110], ["protease", "TEST", 111, 119], ["the 3D-polymerase", "TEST", 128, 145], ["amino acid identity", "TEST", 150, 169]]], ["Extensive variation between the Dumfries and Jena genomes was also seen for the ORF2 and 3 genes (33) .", [["3", "GENE_OR_GENE_PRODUCT", 89, 90], ["Dumfries and Jena genomes", "DNA", 32, 57], ["ORF2", "DNA", 80, 84], ["Extensive variation between the Dumfries", "PROBLEM", 0, 40], ["variation", "OBSERVATION_MODIFIER", 10, 19]]], ["Phylogenetic analysis of the complete ORF1 gene (Fig. 2 ) and the ORF2 capsid and ORF3 genes [33] confirmed that the Dumfries and Newbury2 genomes were closely related but distinct from that of Jena, thus forming two genotypes in genogroup III.Expression of Bo/Newbury2/1976/UK VLPs and antigenic relationshipsNewbury2 VLPs, similar in morphology to native virions, were produced in milligram quantities when the Newbury2 ORF2 capsid gene was expressed using (Fig. 3A) .", [["virions", "ANATOMY", 357, 364], ["ORF1", "GENE_OR_GENE_PRODUCT", 38, 42], ["Fig. 2", "GENE_OR_GENE_PRODUCT", 49, 55], ["ORF2", "GENE_OR_GENE_PRODUCT", 66, 70], ["ORF3", "GENE_OR_GENE_PRODUCT", 82, 86], ["Dumfries", "GENE_OR_GENE_PRODUCT", 117, 125], ["Newbury2", "GENE_OR_GENE_PRODUCT", 130, 138], ["Bo", "GENE_OR_GENE_PRODUCT", 258, 260], ["Newbury2", "GENE_OR_GENE_PRODUCT", 261, 269], ["UK", "GENE_OR_GENE_PRODUCT", 275, 277], ["Newbury2", "GENE_OR_GENE_PRODUCT", 310, 318], ["Newbury2", "GENE_OR_GENE_PRODUCT", 413, 421], ["ORF1 gene", "DNA", 38, 47], ["ORF2 capsid and ORF3 genes", "DNA", 66, 92], ["Dumfries and Newbury2 genomes", "DNA", 117, 146], ["Newbury2", "PROTEIN", 261, 269], ["1976", "PROTEIN", 270, 274], ["Newbury2 ORF2 capsid gene", "DNA", 413, 438], ["Phylogenetic analysis", "TEST", 0, 21], ["the ORF2 capsid and ORF3 genes", "TEST", 62, 92], ["the Dumfries", "TEST", 113, 125], ["Newbury2 genomes", "PROBLEM", 130, 146], ["the Newbury2 ORF2 capsid gene", "TREATMENT", 409, 438], ["genogroup III", "OBSERVATION_MODIFIER", 230, 243], ["native virions", "ANATOMY", 350, 364]]], ["The molecular mass of the capsid protein monomer from denatured VLPs was approximately 56 kDa by SDS-PAGE (Fig. 3B ), in agreement with the molecular mass predicted from translated amino acids of the capsid gene [33] .", [["amino acids", "CHEMICAL", 181, 192], ["amino acids", "CHEMICAL", 181, 192], ["amino acids", "AMINO_ACID", 181, 192], ["capsid protein monomer", "PROTEIN", 26, 48], ["capsid gene", "DNA", 200, 211], ["The molecular mass", "PROBLEM", 0, 18], ["the capsid protein monomer", "PROBLEM", 22, 48], ["denatured VLPs", "PROBLEM", 54, 68], ["SDS", "TEST", 97, 100], ["the molecular mass", "PROBLEM", 136, 154], ["molecular", "OBSERVATION_MODIFIER", 4, 13], ["mass", "OBSERVATION", 14, 18], ["capsid protein monomer", "OBSERVATION", 26, 48], ["mass", "OBSERVATION", 150, 154]]], ["Denatured Newbury2 VLPs reacted weakly in western blots with a Newbury2 convalescent calf serum but non-denatured Newbury2 VLPs reacted strongly with a high-molecular-weight band (not shown).", [["serum", "ANATOMY", 90, 95], ["Newbury2", "GENE_OR_GENE_PRODUCT", 10, 18], ["calf", "ORGANISM", 85, 89], ["serum", "ORGANISM_SUBSTANCE", 90, 95], ["Newbury2", "GENE_OR_GENE_PRODUCT", 114, 122], ["non-denatured Newbury2 VLPs", "PROTEIN", 100, 127], ["calf", "SPECIES", 85, 89], ["a Newbury2 convalescent calf serum", "TEST", 61, 95], ["Newbury2 VLPs", "TEST", 114, 127]]], ["Good antibody responses were detected by ELISA using the VLPs and sera from four gnotobiotic calves inoculated with Newbury2 virus as a primary or challenge inoculation (mean IgG titre log 10 3.9, range 3.1-4.4) ( (Fig. 4A ).", [["sera", "ANATOMY", 66, 70], ["VLPs", "ORGANISM", 57, 61], ["sera", "ORGANISM_SUBSTANCE", 66, 70], ["calves", "ORGANISM", 93, 99], ["Newbury2 virus", "ORGANISM", 116, 130], ["calves", "SPECIES", 93, 99], ["Newbury2 virus", "SPECIES", 116, 130], ["ELISA", "TEST", 41, 46], ["the VLPs", "TEST", 53, 61], ["sera", "TEST", 66, 70], ["Newbury2 virus", "PROBLEM", 116, 130], ["challenge inoculation", "TEST", 147, 168], ["mean IgG titre log", "TEST", 170, 188], ["range", "TEST", 197, 202], ["antibody responses", "OBSERVATION", 5, 23]]], ["A homology model of the Newbury2 capsid protein showed that the amino acid substitutions in the Dumfries capsid protein formed two clusters in the P-domain, one tight cluster in the P2 domain and a less well-defined cluster in the P1 domain (Fig. 4B) .", [["amino acid", "CHEMICAL", 64, 74], ["amino acid", "CHEMICAL", 64, 74], ["Newbury2", "GENE_OR_GENE_PRODUCT", 24, 32], ["amino acid", "AMINO_ACID", 64, 74], ["Newbury2 capsid protein", "PROTEIN", 24, 47], ["Dumfries capsid protein", "PROTEIN", 96, 119], ["P-domain", "PROTEIN", 147, 155], ["P2 domain", "PROTEIN", 182, 191], ["P1 domain", "PROTEIN", 231, 240], ["Fig. 4B", "PROTEIN", 242, 249], ["the Newbury2 capsid protein", "TEST", 20, 47], ["the amino acid substitutions", "PROBLEM", 60, 88], ["the Dumfries capsid protein", "PROBLEM", 92, 119], ["one tight cluster in the P2 domain", "PROBLEM", 157, 191], ["a less well-defined cluster in the P1 domain", "PROBLEM", 196, 240], ["amino", "OBSERVATION", 64, 69], ["acid substitutions", "OBSERVATION", 70, 88], ["two", "OBSERVATION_MODIFIER", 127, 130], ["clusters", "OBSERVATION_MODIFIER", 131, 139], ["tight", "OBSERVATION_MODIFIER", 161, 166], ["cluster", "OBSERVATION_MODIFIER", 167, 174], ["less", "OBSERVATION_MODIFIER", 198, 202]]], ["Thus, these two clusters of amino acid substitutions did not prevent the development of cross-reactive antibodies.DiscussionComplete genomic characterization of the bovine noroviruses, Newbury2 and Dumfries, showed that they had the genomic organization and conserved motifs expected of noroviruses and suggested that Newbury2 was genomically and antigenically representative of genogroup III, genotype 2 bovine noroviruses.", [["amino acid", "CHEMICAL", 28, 38], ["bovine noroviruses", "DISEASE", 405, 423], ["amino acid", "CHEMICAL", 28, 38], ["amino acid", "AMINO_ACID", 28, 38], ["bovine", "ORGANISM", 165, 171], ["Newbury2", "GENE_OR_GENE_PRODUCT", 185, 193], ["Newbury2", "GENE_OR_GENE_PRODUCT", 318, 326], ["genogroup III", "ORGANISM", 379, 392], ["bovine", "ORGANISM", 405, 411], ["noroviruses", "ORGANISM", 412, 423], ["cross-reactive antibodies", "PROTEIN", 88, 113], ["Newbury2", "PROTEIN", 318, 326], ["bovine", "SPECIES", 165, 171], ["bovine", "SPECIES", 405, 411], ["amino acid substitutions", "PROBLEM", 28, 52], ["cross-reactive antibodies", "PROBLEM", 88, 113], ["the bovine noroviruses", "PROBLEM", 161, 183], ["noroviruses", "PROBLEM", 287, 298], ["genogroup III, genotype 2 bovine noroviruses", "PROBLEM", 379, 423], ["amino acid", "OBSERVATION", 28, 38], ["cross-reactive antibodies", "OBSERVATION", 88, 113], ["bovine noroviruses", "OBSERVATION", 165, 183]]], ["The levels of genomic identity between the Newbury2 and Dumfries ORF1 genes reported in the present study, and between the ORF2 and 3 genes of Newbury2, Dumfries and the Newbury2-like viruses [14, 32, 33, 38, 44, 45] , was surprisingly high for RNA viruses identified over almost 3 decades.", [["Newbury2", "GENE_OR_GENE_PRODUCT", 43, 51], ["Dumfries ORF1", "GENE_OR_GENE_PRODUCT", 56, 69], ["ORF2", "GENE_OR_GENE_PRODUCT", 123, 127], ["3", "GENE_OR_GENE_PRODUCT", 132, 133], ["Newbury2", "GENE_OR_GENE_PRODUCT", 143, 151], ["Dumfries", "GENE_OR_GENE_PRODUCT", 153, 161], ["Newbury2-like viruses", "ORGANISM", 170, 191], ["Newbury2 and Dumfries ORF1 genes", "DNA", 43, 75], ["ORF2", "DNA", 123, 127], ["the present study", "TEST", 88, 105], ["Dumfries", "TEST", 153, 161], ["RNA viruses", "PROBLEM", 245, 256], ["genomic identity", "OBSERVATION", 14, 30], ["viruses", "OBSERVATION", 249, 256]]], ["The tight clustering of the Newbury2 viruses resembled the tight clustering seen, for example, for human genogroup II/4 Lordsdale-type viruses.", [["Newbury2 viruses", "ORGANISM", 28, 44], ["human genogroup II/4 Lordsdale-type viruses", "ORGANISM", 99, 142], ["human", "SPECIES", 99, 104], ["human genogroup II/4 Lordsdale-type viruses", "SPECIES", 99, 142], ["the Newbury2 viruses", "PROBLEM", 24, 44], ["type viruses", "PROBLEM", 130, 142], ["tight", "OBSERVATION_MODIFIER", 4, 9], ["clustering", "OBSERVATION_MODIFIER", 10, 20], ["Newbury2 viruses", "OBSERVATION", 28, 44], ["tight", "OBSERVATION_MODIFIER", 59, 64]]], ["It remains to be seen whether this tight clustering will persist and whether the number of bovine genotypes will increase as more studies are conducted.", [["bovine", "ORGANISM", 91, 97], ["bovine", "SPECIES", 91, 97], ["bovine genotypes", "PROBLEM", 91, 107]]], ["The levels of identity observed between the Newbury2 and Dumfries genomes was not a consequence of selection by the RT-PCR primers used to amplify these viruses.", [["Newbury2 and Dumfries genomes", "DNA", 44, 73], ["RT-PCR primers", "DNA", 116, 130], ["the RT-PCR primers", "TREATMENT", 112, 130], ["these viruses", "PROBLEM", 147, 160], ["viruses", "OBSERVATION", 153, 160]]], ["Both Newbury2 and Dumfries were originally identified by electron microscopy, from disparate geographical locations and 18 years apart [46; D. Snodgrass, personal communication] .", [["electron microscopy", "TEST", 57, 76]]], ["The apparent stability of the genotype 2 bovine norovirus genome will simplify diagnostic tests based on RT-PCR.", [["bovine", "ORGANISM", 41, 47], ["norovirus", "ORGANISM", 48, 57], ["genotype 2 bovine norovirus genome", "DNA", 30, 64], ["bovine", "SPECIES", 41, 47], ["bovine norovirus", "SPECIES", 41, 57], ["the genotype 2 bovine norovirus genome", "TREATMENT", 26, 64], ["diagnostic tests", "TEST", 79, 95], ["RT-PCR", "TEST", 105, 111], ["stability", "OBSERVATION_MODIFIER", 13, 22]]], ["Most recent studies have used primers designed to the polymerase region that might favour detection of Newbury2-like viruses [33, 38, 44, 45] but the finding that the NTPase was also highly conserved between genotype 1 and 2 bovine noroviruses (92% amino acid identity) offers an opportunity to use RT-PCR primers based on the NTPase region which might identify a wider range of bovine noroviruses, if they exist.", [["amino acid", "CHEMICAL", 249, 259], ["amino acid", "CHEMICAL", 249, 259], ["Newbury2-like viruses", "ORGANISM", 103, 124], ["NTPase", "GENE_OR_GENE_PRODUCT", 167, 173], ["bovine", "ORGANISM", 225, 231], ["amino acid", "AMINO_ACID", 249, 259], ["bovine", "ORGANISM", 379, 385], ["polymerase region", "DNA", 54, 71], ["Newbury2", "PROTEIN", 103, 111], ["NTPase", "PROTEIN", 167, 173], ["NTPase region", "DNA", 327, 340], ["bovine", "SPECIES", 225, 231], ["bovine", "SPECIES", 379, 385], ["bovine", "SPECIES", 379, 385], ["Most recent studies", "TEST", 0, 19], ["primers", "TEST", 30, 37], ["Newbury2-like viruses", "PROBLEM", 103, 124], ["the NTPase", "TEST", 163, 173], ["genotype", "TEST", 208, 216], ["2 bovine noroviruses", "PROBLEM", 223, 243], ["RT-PCR primers", "TREATMENT", 299, 313], ["bovine noroviruses", "PROBLEM", 379, 397], ["bovine noroviruses", "OBSERVATION", 379, 397]]], ["The high amino acid identities in the capsid regions of Newbury2 and Dumfries genomes correlated with the ability of Newbury2 VLPs to detect Dumfries virus antibodies.", [["amino acid", "CHEMICAL", 9, 19], ["amino acid", "CHEMICAL", 9, 19], ["amino acid", "AMINO_ACID", 9, 19], ["Newbury2", "GENE_OR_GENE_PRODUCT", 56, 64], ["Newbury2 VLPs", "ORGANISM", 117, 130], ["Dumfries virus", "ORGANISM", 141, 155], ["capsid regions", "PROTEIN", 38, 52], ["Newbury2 and Dumfries genomes", "DNA", 56, 85], ["Newbury2 VLPs", "PROTEIN", 117, 130], ["Dumfries virus antibodies", "PROTEIN", 141, 166], ["Dumfries virus", "SPECIES", 141, 155], ["The high amino acid identities", "PROBLEM", 0, 30], ["Newbury2 VLPs", "TREATMENT", 117, 130], ["Dumfries virus antibodies", "PROBLEM", 141, 166], ["high", "OBSERVATION_MODIFIER", 4, 8], ["amino acid", "OBSERVATION", 9, 19], ["capsid", "ANATOMY_MODIFIER", 38, 44], ["regions", "ANATOMY_MODIFIER", 45, 52]]], ["The results of the present paper, combined with observations that other genotype 2 bovine noroviruses have 94% or greater amino acid identity with Newbury2 [14, 33, 45] , suggested that serological assays based on Newbury2 will be suitable to detect genogroup III/2 bovine noroviruses and their antibodies.", [["amino acid", "CHEMICAL", 122, 132], ["amino acid", "CHEMICAL", 122, 132], ["bovine", "ORGANISM", 83, 89], ["noroviruses", "ORGANISM", 90, 101], ["amino acid", "AMINO_ACID", 122, 132], ["Newbury2", "SIMPLE_CHEMICAL", 214, 222], ["bovine", "ORGANISM", 266, 272], ["noroviruses", "ORGANISM", 273, 284], ["antibodies", "PROTEIN", 295, 305], ["bovine", "SPECIES", 83, 89], ["bovine", "SPECIES", 266, 272], ["genogroup III/2 bovine noroviruses", "SPECIES", 250, 284], ["other genotype 2 bovine noroviruses", "PROBLEM", 66, 101], ["greater amino acid identity", "PROBLEM", 114, 141], ["Newbury2", "TEST", 147, 155], ["serological assays", "TEST", 186, 204], ["Newbury2", "TEST", 214, 222], ["genogroup III/2 bovine noroviruses", "PROBLEM", 250, 284]]], ["This view is endorsed by studies with human noroviruses with similar identities in their capsid proteins and which show antigenic cross-reactivity [12, 19] .", [["human", "ORGANISM", 38, 43], ["capsid proteins", "PROTEIN", 89, 104], ["human", "SPECIES", 38, 43], ["human noroviruses", "SPECIES", 38, 55], ["human noroviruses", "PROBLEM", 38, 55], ["their capsid proteins", "TEST", 83, 104]]], ["In contrast, a recent study of the antigenic relationship of Newbury2 and the genotype 1 Jena virus, which have 68% amino acid identify in their capsid proteins, showed that they were poorly related antigenically and that independent ELISAs are required to detect both [31] .", [["amino acid", "CHEMICAL", 116, 126], ["amino acid", "CHEMICAL", 116, 126], ["Newbury2", "GENE_OR_GENE_PRODUCT", 61, 69], ["genotype 1 Jena virus", "ORGANISM", 78, 99], ["amino acid", "AMINO_ACID", 116, 126], ["Newbury2", "PROTEIN", 61, 69], ["capsid proteins", "PROTEIN", 145, 160], ["Jena virus", "SPECIES", 89, 99], ["a recent study", "TEST", 13, 27], ["the genotype 1 Jena virus", "PROBLEM", 74, 99], ["amino acid", "TEST", 116, 126], ["their capsid proteins", "TEST", 139, 160], ["independent ELISAs", "TEST", 222, 240]]], ["Similarly, studies of human norovirus capsid proteins with 73% amino acid identity or less showed little or no cross reactivity in ELISA [12, 19] .", [["amino acid", "CHEMICAL", 63, 73], ["amino acid", "CHEMICAL", 63, 73], ["human", "ORGANISM", 22, 27], ["norovirus capsid", "ORGANISM", 28, 44], ["amino acid", "AMINO_ACID", 63, 73], ["human norovirus capsid proteins", "PROTEIN", 22, 53], ["human", "SPECIES", 22, 27], ["human norovirus", "SPECIES", 22, 37], ["human norovirus capsid proteins", "TEST", 22, 53], ["amino acid identity", "TEST", 63, 82], ["cross reactivity in ELISA", "PROBLEM", 111, 136], ["no", "UNCERTAINTY", 108, 110], ["cross reactivity", "OBSERVATION_MODIFIER", 111, 127]]], ["Although not tested by ELISA, the capsid amino acid identities of Newbury2 with human genogroup I and II noroviruses of 48 and 43% make it unlikely that the Newbury2 viruses cross-react with human genogroup I and II noroviruses in ELISA.", [["amino acid", "CHEMICAL", 41, 51], ["amino acid", "CHEMICAL", 41, 51], ["amino acid", "AMINO_ACID", 41, 51], ["Newbury2", "GENE_OR_GENE_PRODUCT", 66, 74], ["human genogroup I", "ORGANISM", 80, 97], ["II noroviruses", "ORGANISM", 102, 116], ["Newbury2 viruses", "ORGANISM", 157, 173], ["human", "ORGANISM", 191, 196], ["II noroviruses", "ORGANISM", 213, 227], ["Newbury2", "PROTEIN", 66, 74], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 191, 196], ["human genogroup I", "SPECIES", 80, 97], ["human genogroup I", "SPECIES", 191, 208], ["ELISA", "TEST", 23, 28], ["human genogroup I and II noroviruses", "PROBLEM", 80, 116], ["the Newbury2 viruses cross-react", "PROBLEM", 153, 185]]], ["However, it should be noted that a cross-reactive epitope between some genogroup II human noroviruses and the Newbury2 and Jena viruses has been identified using a monoclonal antibody [31] .", [["human", "ORGANISM", 84, 89], ["Newbury2", "GENE_OR_GENE_PRODUCT", 110, 118], ["Jena viruses", "ORGANISM", 123, 135], ["monoclonal antibody", "PROTEIN", 164, 183], ["human", "SPECIES", 84, 89], ["human noroviruses", "SPECIES", 84, 101], ["Jena viruses", "SPECIES", 123, 135], ["a cross-reactive epitope", "PROBLEM", 33, 57], ["some genogroup II human noroviruses", "PROBLEM", 66, 101], ["the Newbury2 and Jena viruses", "PROBLEM", 106, 135], ["a monoclonal antibody", "TEST", 162, 183], ["noroviruses", "OBSERVATION", 90, 101]]], ["The lack of reactivity of Newbury1 antiserum in the Newbury2 ELISA reported in the present study, and the lack of cross-protection between the two viruses [3] is explained by the recent finding that Newbury1 belongs to a new genus in the family Caliciviridae [30] .DiscussionThe Newbury2 VLPs were composed of a protein of similar molecular mass to VLPs expressed from the Newbury2-like virus Bo/CV186-OH/00/US [14] .", [["Newbury1", "CHEMICAL", 199, 207], ["Newbury1 antiserum", "GENE_OR_GENE_PRODUCT", 26, 44], ["Newbury1", "GENE_OR_GENE_PRODUCT", 199, 207], ["Newbury2 VLPs", "ORGANISM", 279, 292], ["VLPs", "ORGANISM", 349, 353], ["Newbury2-like virus", "ORGANISM", 373, 392], ["Newbury1 antiserum", "PROTEIN", 26, 44], ["Newbury1", "PROTEIN", 199, 207], ["Newbury2", "PROTEIN", 373, 381], ["Newbury1 antiserum", "TEST", 26, 44], ["the Newbury2 ELISA", "TEST", 48, 66], ["the present study", "TEST", 79, 96], ["The Newbury2 VLPs", "TREATMENT", 275, 292], ["similar molecular mass", "PROBLEM", 323, 345], ["the Newbury2", "TEST", 369, 381], ["mass", "OBSERVATION", 341, 345]]], ["They appeared antigenically authentic.", [["antigenically", "OBSERVATION_MODIFIER", 14, 27], ["authentic", "OBSERVATION", 28, 37]]], ["Antibody titres in experimental calf sera were similar to those obtained previously [14] and similar to those obtained with human patients [9] .", [["sera", "ANATOMY", 37, 41], ["calf", "ORGANISM", 32, 36], ["sera", "ORGANISM_SUBSTANCE", 37, 41], ["human", "ORGANISM", 124, 129], ["patients", "ORGANISM", 130, 138], ["calf", "SPECIES", 32, 36], ["human", "SPECIES", 124, 129], ["patients", "SPECIES", 130, 138], ["calf", "SPECIES", 32, 36], ["human", "SPECIES", 124, 129], ["Antibody titres", "TEST", 0, 15], ["experimental calf sera", "TEST", 19, 41], ["calf", "ANATOMY", 32, 36]]], ["Homologous protection to Newbury2 disease and virus shedding was reported in calves [3] , thus allowing calves to be used as an experimental model for immunity to disease.", [["Newbury2 disease", "DISEASE", 25, 41], ["Newbury2", "GENE_OR_GENE_PRODUCT", 25, 33], ["calves", "ORGANISM", 104, 110], ["calves", "SPECIES", 77, 83], ["calves", "SPECIES", 104, 110], ["Homologous protection", "TREATMENT", 0, 21], ["Newbury2 disease", "PROBLEM", 25, 41], ["virus shedding", "PROBLEM", 46, 60], ["disease", "PROBLEM", 163, 170]]], ["Except for the study by Subekti et al. [42] , norovirus disease models using chimpanzees and non-human primates [36, 47] have not produced clinical signs, although serological responses and virus excretion were demonstrated.", [["norovirus disease", "DISEASE", 46, 63], ["norovirus", "ORGANISM", 46, 55], ["chimpanzees", "ORGANISM", 77, 88], ["non-human primates", "ORGANISM", 93, 111], ["the study", "TEST", 11, 20], ["norovirus disease models", "PROBLEM", 46, 70], ["clinical signs", "PROBLEM", 139, 153], ["serological responses", "TEST", 164, 185], ["virus excretion", "TEST", 190, 205]]], ["The calf model allows pre-exposure to norovirus infection to be controlled, but it does have the limitations of production of few offspring and animal size.DiscussionRotaviruses and coronaviruses are recognised as the major viral pathogens in outbreaks of neonatal calf diarrhoea [2, 35, 39] .", [["norovirus infection", "DISEASE", 38, 57], ["calf diarrhoea", "DISEASE", 265, 279], ["calf", "ORGANISM_SUBDIVISION", 4, 8], ["norovirus", "ORGANISM", 38, 47], ["coronaviruses", "ORGANISM", 182, 195], ["calf", "ORGANISM_SUBDIVISION", 265, 269], ["calf", "SPECIES", 4, 8], ["calf", "SPECIES", 265, 269], ["norovirus", "SPECIES", 38, 47], ["The calf model", "TREATMENT", 0, 14], ["norovirus infection", "PROBLEM", 38, 57], ["DiscussionRotaviruses", "PROBLEM", 156, 177], ["coronaviruses", "PROBLEM", 182, 195], ["the major viral pathogens", "PROBLEM", 214, 239], ["neonatal calf diarrhoea", "PROBLEM", 256, 279], ["calf", "ANATOMY", 4, 8], ["norovirus", "OBSERVATION", 38, 47], ["few", "OBSERVATION_MODIFIER", 126, 129], ["size", "OBSERVATION_MODIFIER", 151, 155], ["neonatal calf", "ANATOMY", 256, 269]]], ["However, in the UK, up to 30% of calf diarrhoea outbreaks are without an identifiable pathogen [2, 35, 39] and the dam vaccines are said not to be totally effective.", [["diarrhoea", "DISEASE", 38, 47], ["calf", "ORGANISM", 33, 37], ["calf", "SPECIES", 33, 37], ["calf diarrhoea outbreaks", "PROBLEM", 33, 57], ["an identifiable pathogen", "PROBLEM", 70, 94], ["the dam vaccines", "TREATMENT", 111, 127], ["calf", "ANATOMY", 33, 37], ["diarrhoea", "OBSERVATION", 38, 47]]], ["The presence of noroviruses might explain some of these undiagnosed outbreaks.", [["noroviruses", "DISEASE", 16, 27], ["noroviruses", "PROBLEM", 16, 27], ["these undiagnosed outbreaks", "PROBLEM", 50, 77], ["noroviruses", "OBSERVATION", 16, 27], ["undiagnosed", "OBSERVATION_MODIFIER", 56, 67], ["outbreaks", "OBSERVATION", 68, 77]]], ["The results from the present study will allow the role of bovine noroviruses to be established and vaccines to be developed, if necessary.", [["bovine", "ORGANISM", 58, 64], ["bovine", "SPECIES", 58, 64], ["bovine", "SPECIES", 58, 64], ["the present study", "TEST", 17, 34], ["bovine noroviruses", "TREATMENT", 58, 76], ["vaccines", "TREATMENT", 99, 107]]]], "f9fe179a4b19a62d5f5f496afb6a01ab4a34a3b0": [["MainThe worldwide pandemic of SARS-CoV-2, the coronavirus which causes COVID-19, has resulted in unprecedented responses, with many affected nations confining residents to their homes.", [["SARS", "DISEASE", 30, 34], ["coronavirus", "DISEASE", 46, 57], ["SARS-CoV-2", "ORGANISM", 30, 40], ["coronavirus", "ORGANISM", 46, 57], ["CoV-2", "SPECIES", 35, 40], ["coronavirus", "SPECIES", 46, 57], ["SARS-CoV-2", "SPECIES", 30, 40], ["SARS", "PROBLEM", 30, 34], ["CoV", "TEST", 35, 38], ["the coronavirus", "PROBLEM", 42, 57], ["COVID", "TEST", 71, 76]]], ["It was hoped that this would result in a sharp decline in ongoing spread, as was observed when China locked down following the initial emergence of the virus (1).", [["a sharp decline", "PROBLEM", 39, 54], ["the virus", "TREATMENT", 148, 157], ["sharp", "OBSERVATION_MODIFIER", 41, 46], ["decline", "OBSERVATION", 47, 54]]], ["Following a reduction in cases, the government has announced it will ease restrictions on the 11th May.", [["a reduction in cases", "TREATMENT", 10, 30], ["reduction", "OBSERVATION_MODIFIER", 12, 21]]], ["In order to appropriately exit from the lockdown, we need to understand the underlying level of population immunity and infection, identify those most at risk for severe disease and the impact of current control efforts.MainDaily reported numbers of hospitalizations and deaths only provide limited insight into the state of the epidemic.", [["infection", "DISEASE", 120, 129], ["deaths", "DISEASE", 271, 277], ["infection", "PROBLEM", 120, 129], ["severe disease", "PROBLEM", 163, 177], ["current control efforts", "TREATMENT", 196, 219], ["infection", "OBSERVATION", 120, 129], ["severe", "OBSERVATION_MODIFIER", 163, 169], ["disease", "OBSERVATION", 170, 177]]], ["Many people will either develop no symptoms or symptoms so mild they will not be detected through healthcare-based surveillance.", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11], ["symptoms", "PROBLEM", 35, 43], ["symptoms", "PROBLEM", 47, 55]]], ["The concentration of hospitalized cases in older individuals has led to hypotheses that there may be widespread 'silent' transmission in younger individuals.", [["concentration", "OBSERVATION_MODIFIER", 4, 17]]], ["For example, it has been suggested that up to half the UK population may have been infected by the middle of March, despite under 100 deaths reported at that time (2) .", [["deaths", "DISEASE", 134, 140], ["infected", "OBSERVATION", 83, 91], ["middle", "OBSERVATION_MODIFIER", 99, 105]]], ["If the majority of the population is infected, viral transmission would slow, potentially reducing the need for the stringent intervention measures currently employed.MainHere, we present a suite of modelling analyses to characterize the dynamics of SARS-CoV-2 transmission in France and the impact of the lockdown on these dynamics.", [["SARS", "DISEASE", 250, 254], ["CoV-2", "ORGANISM", 255, 260], ["SARS-CoV", "SPECIES", 250, 258], ["infected", "PROBLEM", 37, 45], ["the stringent intervention measures", "TREATMENT", 112, 147], ["modelling analyses", "TEST", 199, 217], ["SARS", "TEST", 250, 254], ["CoV", "TEST", 255, 258], ["infected", "OBSERVATION", 37, 45]]], ["We elucidate the risk of SARS-CoV-2 infection and severe outcomes by age and sex and estimate the current proportion of the national and regional populations that have been infected and might be at least temporarily immune (3) .", [["SARS-CoV-2 infection", "DISEASE", 25, 45], ["SARS-CoV-2", "ORGANISM", 25, 35], ["SARS-CoV", "SPECIES", 25, 33], ["SARS", "PROBLEM", 25, 29], ["CoV", "PROBLEM", 30, 33], ["2 infection", "PROBLEM", 34, 45], ["SARS", "OBSERVATION", 25, 29], ["infection", "OBSERVATION", 36, 45], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["regional populations", "OBSERVATION", 137, 157], ["infected", "OBSERVATION", 173, 181]]], ["These models support healthcare planning of the French government by forecasting Intensive Care Unit (ICU) bed capacity requirements.MainAs of 14 April 2020, there had been 71,903 incident hospitalizations due to SARS-CoV-2 reported in France and 10,129 deaths in hospitals, with the east of the country and the capital, Paris, particularly affected ( Figure 1A -B).", [["SARS", "DISEASE", 213, 217], ["deaths", "DISEASE", 254, 260], ["SARS-CoV", "SPECIES", 213, 221], ["ICU) bed capacity requirements", "TREATMENT", 102, 132], ["SARS", "PROBLEM", 213, 217], ["CoV", "TEST", 218, 221], ["capital", "ANATOMY", 312, 319]]], ["The mean age of hospitalized patients was 68y and the mean age of the deceased was 79y with 50.0% of hospitalizations occurring in individuals >70y and 81.6% of deaths within that age bracket; 56.2% of hospitalizations and 60.3% of deaths were male ( Figures 1C-E) .", [["deaths", "DISEASE", 161, 167], ["deaths", "DISEASE", 232, 238], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37]]], ["Hospitalization and death data only capture the most severe infections.", [["death", "DISEASE", 20, 25], ["infections", "DISEASE", 60, 70], ["Hospitalization", "TREATMENT", 0, 15], ["death data", "TEST", 20, 30], ["the most severe infections", "PROBLEM", 44, 70], ["most severe", "OBSERVATION_MODIFIER", 48, 59], ["infections", "OBSERVATION", 60, 70]]], ["To reconstruct the dynamics of all infections, including mild ones, we jointly analyze them with data documenting the risk of death among persons infected by SARS-CoV-2 coming from a detailed investigation of an outbreak aboard the Princess Diamond cruise ship where all passengers were subsequently tested (719 infections and 13 deaths).", [["infections", "DISEASE", 35, 45], ["death", "DISEASE", 126, 131], ["SARS", "DISEASE", 158, 162], ["infections", "DISEASE", 312, 322], ["deaths", "DISEASE", 330, 336], ["persons", "ORGANISM", 138, 145], ["SARS-CoV-2", "ORGANISM", 158, 168], ["persons", "SPECIES", 138, 145], ["SARS-CoV", "SPECIES", 158, 166], ["all infections", "PROBLEM", 31, 45], ["mild ones", "PROBLEM", 57, 66], ["death", "PROBLEM", 126, 131], ["infections", "OBSERVATION", 35, 45], ["mild", "OBSERVATION_MODIFIER", 57, 61]]], ["By coupling the French passive surveillance hospital data with the active surveillance performed aboard the Princess Diamond, we can disentangle the risk of being hospitalized in those infected from the underlying probability of infection (4) (5) (6) .MainWe find that 2.6% of infected individuals are hospitalized (95% CrI: 1.4-4.4), ranging from 0.09% (95% CrI: 0.05-0.2) in females under <20y to 31.4% (95% CrI: 16.7-52.", [["infection", "DISEASE", 229, 238], ["individuals", "ORGANISM", 286, 297], ["infection", "PROBLEM", 229, 238], ["infected individuals", "PROBLEM", 277, 297], ["CrI", "TEST", 320, 323], ["CrI", "TEST", 359, 362], ["CrI", "TEST", 410, 413], ["infection", "OBSERVATION", 229, 238]]], ["Once hospitalized, 18 .2% (95% CrI: 18.0%-18.6%) patients enter ICU after a mean delay of 1.5 days ( Figure S1 ).", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["CrI", "TEST", 31, 34]]], ["There is an increasing probability of entering ICU with age -however, this drops for those >70y ( Figure 2B , Table S2 ).", [["increasing", "OBSERVATION_MODIFIER", 12, 22], ["probability", "OBSERVATION_MODIFIER", 23, 34]]], ["Overall, 20.0% (95% CrI: 19.", [["Overall", "TEST", 0, 7], ["CrI", "TEST", 20, 23]]], ["The overall probability of death among those infected (the Infection Fatality Ratio, IFR) is 0.53% (95% CrI: 0.28-0.88), ranging from 0.001% in those under 20y to 8.3% (95% CrI: 4.4-13.9) in those >80y ( Figure 2D , Table S2 ).", [["death", "DISEASE", 27, 32], ["death", "PROBLEM", 27, 32], ["the Infection Fatality Ratio", "TEST", 55, 83], ["IFR", "TEST", 85, 88], ["CrI", "TEST", 104, 107], ["CrI", "TEST", 173, 176], ["infected", "OBSERVATION_MODIFIER", 45, 53]]], ["Our estimate of overall IFR is similar to other recent studies that found values of between 0.5%-0.7% for the Chinese epidemic (5, 8, 9) .", [["other recent studies", "TEST", 42, 62], ["values", "TEST", 74, 80]]], ["We find men have a consistently higher risk than women of hospitalization (RR 1.26, 95% CrI: 1.21-1.31), ICU admission once hospitalized (RR: 1.69, 95% CrI: 1.61-1.78) and death (RR: 1.45, 95% CrI: 1.26-1.74) across all age groups ( Figure S2 ).MainWe identify two clear subpopulations in delays between hospitalization and death: individuals that die quickly upon hospital admission (15% of fatal cases, mean time to death of 0.67 days) and individuals who die after longer time periods (85% of fatal cases, mean time to death of 13.2 days) ( Figure S3 ).", [["death", "DISEASE", 172, 177], ["death", "DISEASE", 324, 329], ["death", "DISEASE", 418, 423], ["death", "DISEASE", 522, 527], ["men", "ORGANISM", 8, 11], ["women", "ORGANISM", 49, 54], ["men", "SPECIES", 8, 11], ["women", "SPECIES", 49, 54], ["RR", "TEST", 75, 77], ["CrI", "TEST", 88, 91], ["RR", "TEST", 138, 140], ["CrI", "TEST", 152, 155], ["death", "PROBLEM", 172, 177], ["RR", "TEST", 179, 181], ["CrI", "TEST", 193, 196], ["two", "OBSERVATION_MODIFIER", 261, 264], ["clear", "OBSERVATION_MODIFIER", 265, 270], ["subpopulations", "OBSERVATION_MODIFIER", 271, 285]]], ["The proportion of fatal cases who die rapidly remains approximately constant across age-groups ( Figure S4 , Table S3 ).", [["fatal", "OBSERVATION_MODIFIER", 18, 23]]], ["These observations, combined with the substantial differences in risk of death by age and sex, suggest complex patterns of disease manifestation.", [["death", "DISEASE", 73, 78], ["disease manifestation", "PROBLEM", 123, 144], ["substantial", "OBSERVATION_MODIFIER", 38, 49], ["complex", "OBSERVATION_MODIFIER", 103, 110], ["disease", "OBSERVATION", 123, 130]]], ["The underlying mechanisms that can explain why subsets of the population are substantially more at risk than others remain unclear although a role for immunopathogenesis has been proposed, including through antibody-dependent enhancement, where non-neutralizing antibodies trigger an immune response through cytokine storms, and cell-based enhancement, such as with allergic inflammation (10) (11) (12) .", [["cell", "ANATOMY", 329, 333], ["allergic inflammation", "DISEASE", 366, 387], ["cell", "CELL", 329, 333], ["non-neutralizing antibodies", "PROTEIN", 245, 272], ["cytokine", "PROTEIN", 308, 316], ["immunopathogenesis", "PROBLEM", 151, 169], ["through antibody-dependent enhancement", "PROBLEM", 199, 237], ["non-neutralizing antibodies", "TEST", 245, 272], ["cytokine storms", "TEST", 308, 323], ["cell-based enhancement", "PROBLEM", 329, 351], ["allergic inflammation", "PROBLEM", 366, 387], ["dependent", "OBSERVATION_MODIFIER", 216, 225], ["enhancement", "OBSERVATION", 226, 237], ["enhancement", "OBSERVATION_MODIFIER", 340, 351]]], ["Understanding these processes with regards to SARS-CoV-2 will be key to the development of a safe vaccine.MainWe next fit national and regional transmission models for the epidemic to ICU admission and bed occupancy ( Figure 3A -B, Figure S5 , Tables S4-S6).", [["SARS", "DISEASE", 46, 50], ["SARS-CoV-2", "ORGANISM", 46, 56], ["S6", "PROTEIN", 254, 256], ["SARS-CoV", "SPECIES", 46, 54], ["a safe vaccine", "TREATMENT", 91, 105], ["bed occupancy", "TEST", 202, 215]]], ["We find that the basic reproductive number R0 prior to the implementation of the lockdown was 3.31 (95% CrI: 3.18-3.43).", [["CrI", "TEST", 104, 107]]], ["At a national level, the lockdown resulted in a 84% reduction in transmission, with the reproduction number R dropping to 0.52 (95% CrI: 0.50-0.55).", [["CrI", "TEST", 132, 135], ["reduction", "OBSERVATION_MODIFIER", 52, 61]]], ["We forecast that by the 11th May, 3.7 million (range 2.3 -6.7, when accounting for uncertainty in the probability of entering ICU) people will have been infected, representing 5.7% (range 3.5 -10.3) of the French population ( Figure 3E ).", [["people", "ORGANISM", 131, 137], ["people", "SPECIES", 131, 137], ["infected", "OBSERVATION", 153, 161]]], ["Assuming a basic reproductive number of R0=3.3, it would require around 70% of the population to be immune for the epidemic to be controlled by immunity alone.", [["R0", "TEST", 40, 42], ["the epidemic", "PROBLEM", 111, 123], ["reproductive", "OBSERVATION_MODIFIER", 17, 29], ["number", "OBSERVATION_MODIFIER", 30, 36]]], ["Our results therefore strongly suggest that, without a vaccine, herd immunity on its own will be insufficient to avoid a second wave at the end of the lockdown.", [["a vaccine", "TREATMENT", 53, 62]]], ["Efficient control measures need to be maintained beyond the 11th May.MainOur model projections can help inform the ongoing and future response to COVID-19.", [["COVID-19", "CHEMICAL", 146, 154], ["COVID-19", "DNA", 146, 154], ["Efficient control measures", "TREATMENT", 0, 26], ["COVID", "TEST", 146, 151]]], ["If current trends continue, by the 11th May we project between 10 and 45 ICU daily admissions, between 1370 and 1900 ICU beds occupied by COVID-19 cases as well as 1300 (range 840 -2300) daily infections, down from between 270,000-770,000 immediately prior to the lockdown.", [["infections", "DISEASE", 193, 203], ["infections", "PROBLEM", 193, 203]]], ["In addition, other external factors, such as temperature fluctuations may affect the dynamics over time (13) .MainUsing our framework, we are able to recover the observed number of hospitalizations by age and sex in France and the number of deaths in the Princess Diamond ( Figure S6 ).", [["deaths", "DISEASE", 241, 247], ["other external factors", "PROBLEM", 13, 35], ["temperature fluctuations", "PROBLEM", 45, 69]]], ["As a validation, our approach is also able to recover parameters in simulated datasets where the true values are known ( Figure S7 ).", [["the true values", "TEST", 93, 108]]], ["We run a suite of sensitivity analyses that considers additional future COVID-19 deaths on the Princess Diamond, longer delays between symptom onset and ICU admission, equal attack rates across all ages, reduced infectivity in younger individuals, a contact matrix with unchanged structure before/during the lockdown and one with extremely high isolation of elderly individuals during the lockdown.", [["deaths", "DISEASE", 81, 87], ["matrix", "CELLULAR_COMPONENT", 258, 264], ["sensitivity analyses", "TEST", 18, 38], ["reduced infectivity", "PROBLEM", 204, 223], ["reduced", "OBSERVATION_MODIFIER", 204, 211], ["infectivity", "OBSERVATION_MODIFIER", 212, 223]]], ["These different scenarios result in mean IFRs ranging from 0.4% to 0.7%, the level of immunity in the population by the 11 May ranging from 1.9-12.5, the number of daily infections at this date ranging from 200-4600 and a range of reproductive numbers post lockdown of 0.38-0.64 ( Figure 4 , Figures S8-S10) .MainHere, we focused on deaths occurring in hospitals.", [["infections", "DISEASE", 170, 180], ["deaths", "DISEASE", 333, 339], ["mean IFRs", "TEST", 36, 45], ["daily infections", "PROBLEM", 164, 180], ["lockdown", "TEST", 257, 265], ["Figure", "TEST", 281, 287], ["Figures", "TEST", 292, 299], ["infections", "OBSERVATION", 170, 180]]], ["There are also non-hospitalized COVID-19 deaths.", [["deaths", "DISEASE", 41, 47]]], ["For example there have been >6,000 non-hospitalized deaths in retirement homes in France (14).", [["deaths", "DISEASE", 52, 58]]], ["A number of additional non-hospitalized deaths may also be occurring, in which case we would underestimate the proportion infected.MainThis study shows the massive impact the French lockdown had on SARS-CoV-2 transmission.", [["deaths", "DISEASE", 40, 46], ["SARS", "DISEASE", 198, 202], ["CoV-2", "ORGANISM", 203, 208], ["MainThis study", "TEST", 131, 145], ["SARS", "TEST", 198, 202], ["may also be", "UNCERTAINTY", 47, 58], ["proportion", "OBSERVATION_MODIFIER", 111, 121], ["infected", "OBSERVATION", 122, 130], ["massive", "OBSERVATION_MODIFIER", 156, 163], ["impact", "OBSERVATION_MODIFIER", 164, 170]]], ["It estimates underlying probabilities of infection, hospitalization and death, which is essential for the interpretation of COVID-19 surveillance data.", [["infection", "DISEASE", 41, 50], ["death", "DISEASE", 72, 77], ["infection", "PROBLEM", 41, 50], ["COVID", "TEST", 124, 129], ["surveillance data", "TEST", 133, 150], ["infection", "OBSERVATION", 41, 50]]], ["The forecasts we provide can inform planning of ICU bed occupancy and lockdown exit strategies.", [["ICU bed occupancy", "TREATMENT", 48, 65], ["exit strategies", "TREATMENT", 79, 94]]], ["The estimated low level of immunity against SARS-CoV-2 indicates that efficient control measures that limit transmission risk will have to be maintained beyond the 11th May to avoid a rebound of the epidemic.Main.", [["SARS", "DISEASE", 44, 48], ["SARS-CoV-2", "ORGANISM", 44, 54], ["SARS-CoV", "SPECIES", 44, 52], ["SARS", "PROBLEM", 44, 48], ["CoV", "TEST", 49, 52], ["efficient control measures", "TREATMENT", 70, 96], ["the epidemic", "PROBLEM", 195, 207], ["low level", "OBSERVATION_MODIFIER", 14, 23]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)MainThe copyright holder for this preprint this version posted April 24, 2020.Case dataWe work with daily hospitalization and death data from the SI-VIC database, maintained by the ANS (Agence du Num\u00e9rique en Sant\u00e9, formerly named ASIP) and sent daily to Sant\u00e9 Publique France, the French national public health agency.", [["CC", "CHEMICAL", 0, 2], ["death", "DISEASE", 325, 330], ["death data", "TEST", 325, 335], ["med", "ANATOMY", 102, 105]]], ["This database provides real time data on the COVID-19 patients hospitalized in French public and private hospitals, including their age, date of hospitalization and region.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62]]], ["All cases are either biologically confirmed or present with a computed tomographic image highly suggestive of SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 110, 130], ["SARS-CoV-2", "ORGANISM", 110, 120], ["SARS-CoV", "SPECIES", 110, 118], ["a computed tomographic image", "TEST", 60, 88], ["SARS", "PROBLEM", 110, 114], ["CoV", "PROBLEM", 115, 118], ["2 infection", "PROBLEM", 119, 130], ["suggestive of", "UNCERTAINTY", 96, 109], ["SARS", "OBSERVATION", 110, 114], ["infection", "OBSERVATION", 121, 130]]], ["The SI-VIC web portal was activated for the COVID-19 epidemic on 13 March 2020, with a progressive increase in the number of hospitals transmitting data.", [["the COVID", "TEST", 40, 49], ["a progressive increase", "PROBLEM", 85, 107], ["portal", "ANATOMY", 15, 21], ["progressive", "OBSERVATION_MODIFIER", 87, 98], ["increase", "OBSERVATION_MODIFIER", 99, 107]]], ["Every day, we receive a case line-list with the latest hospitalization status of each patient.", [["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 86, 93], ["a case line", "TREATMENT", 22, 33]]], ["We collate the daily files for metropolitan France to reconstruct individual trajectories from hospital admission to discharge or death.", [["death", "DISEASE", 130, 135], ["death", "PROBLEM", 130, 135]]], ["We report as hospitalized in ICU patients hospitalized in \"Hospitalisation r\u00e9animatoire (R\u00e9animation, soins intensifs or unit\u00e9 de surveillance continue)\".Case dataSince the status of each patient is updated with a few days of delay, we correct the observed time series for these reporting delays.", [["patients", "ORGANISM", 33, 41], ["patient", "ORGANISM", 188, 195], ["patients", "SPECIES", 33, 41], ["patient", "SPECIES", 188, 195]]], ["Let \",$ denote the number of hospital admissions that were reported for time at time of the epidemic ( \u2264 ).", [["Let", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["Let \",$ denote the probability that a hospital admission that occured at time has been reported before time .", [["Let", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["We apply the same method to correct the daily time series of ICU admissions, deaths and discharges, as well as ICU releases in order to compute the corrected times series of occupied ICU beds.Case dataSince the SI-VIC web portal started recording COVID-19 cases on March 13 th , a certain number of hospital admissions prior to or around this date may have been missed.", [["deaths", "DISEASE", 77, 83], ["portal", "ANATOMY", 222, 228]]], ["This surveillance system was created in 2004.", [["This surveillance system", "TEST", 0, 24]]], ["It collects data on patients presenting to emergency departments in all regions of France.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["To correct the SI-VIC data we computed the median ratio between hospital admissions in the SI-VIC and in the OSCOUR\u00ae datasets past March 15 th and multiplied by the same ratio to the OSCOUR\u00ae data before March 15 th (see Figure S11 ).Active surveillance dataThe Princess Diamond is a cruise ship that suffered a SARS-CoV-2 outbreak in early February 2020.", [["SARS", "DISEASE", 311, 315], ["OSCOUR", "DNA", 109, 115], ["OSCOUR", "DNA", 183, 189], ["a SARS", "PROBLEM", 309, 315]]], ["The age distribution of the positive individuals is available for a subset of 619 individuals (15) .", [["the positive individuals", "PROBLEM", 24, 48], ["positive individuals", "OBSERVATION", 28, 48]]], ["There have been 13 deaths, seven were individuals in their 70s, four were in their 80s, one in their 60s.", [["deaths", "DISEASE", 19, 25]]], ["No age was reported for one death.Estimating delays from hospitalization to death and from hospitalization to ICUIn a growing epidemic, the time to death among individuals who have already experienced the outcome will be an underestimate of overall time to death, as many of those who take longer will not yet have died.", [["death", "DISEASE", 28, 33], ["death", "DISEASE", 76, 81], ["ICUIn", "DISEASE", 110, 115], ["death", "DISEASE", 148, 153], ["death", "DISEASE", 257, 262], ["individuals", "ORGANISM", 160, 171], ["one death", "PROBLEM", 24, 33], ["Estimating delays", "PROBLEM", 34, 51]]], ["We need to account for these delays when estimating the infection fatality ratio as otherwise we would underestimate the probability of death (8).Estimating delays from hospitalization to death and from hospitalization to ICUTo capture the delay to death for the different age groups we use data from cases throughout France that had dates of hospitalization and dates of death.", [["infection", "DISEASE", 56, 65], ["death", "DISEASE", 136, 141], ["death", "DISEASE", 188, 193], ["death", "DISEASE", 249, 254], ["death", "DISEASE", 372, 377], ["these delays", "PROBLEM", 23, 35], ["the infection fatality ratio", "PROBLEM", 52, 80], ["death", "PROBLEM", 136, 141], ["Estimating delays", "PROBLEM", 146, 163], ["death", "PROBLEM", 188, 193], ["death", "PROBLEM", 372, 377]]], ["We assume that the delays follow a lognormal distribution as this has previously been shown to work well for SARS-CoV-2 infections (17) .Estimating delays from hospitalization to death and from hospitalization to ICUWe use the number of hospitalizations on a given day to account for the state of the epidemic at that time, similar to what has previously been used (5) .", [["SARS", "DISEASE", 109, 113], ["infections", "DISEASE", 120, 130], ["death", "DISEASE", 179, 184], ["SARS-CoV-2", "ORGANISM", 109, 119], ["SARS-CoV", "SPECIES", 109, 117], ["SARS", "PROBLEM", 109, 113], ["CoV-2 infections", "PROBLEM", 114, 130], ["Estimating delays", "PROBLEM", 137, 154]]], ["We therefore use a mixture distribution composed of an exponential distribution for those that die within a short delay and a lognormal distribution for those that die after longer delays ( Figure S3 ).Estimating delays from hospitalization to death and from hospitalization to ICUWe denote by 4 \"567 the true probability density function (pdf) of the delay, and 4 89: the observed density, which will be biased to be right skewed as most individuals will not have had their outcome.", [["death", "DISEASE", 244, 249], ["a short delay", "PROBLEM", 106, 119], ["Estimating delays", "PROBLEM", 202, 219], ["exponential", "OBSERVATION_MODIFIER", 55, 66], ["density", "OBSERVATION", 382, 389], ["right", "ANATOMY_MODIFIER", 418, 423]]], ["We can approximate the expected delay distribution 4 7<= , for a given age group i, at a given time T during the epidemic, thereby adjusting for the stage of the epidemic, given the true pdf for the delay 4 \"567 using the following adjustment:Estimating delays from hospitalization to death and from hospitalization to ICU.", [["death", "DISEASE", 285, 290]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.20.20072413 doi: medRxiv preprint where 4,> is the total number of hospitalized cases of age i at time j.(which was not certified by peer review)For the correct pdf 4 \"567 , we should have:(which was not certified by peer review)We estimate parameters of the true delay from hospitalization to death distribution 4 \"567 for each group in turn by minimizing the sum of squared error (SSE) of the distribution 4 7<= to the observed data 4 89: .", [["CC", "CHEMICAL", 0, 2], ["death", "DISEASE", 601, 606], ["The copyright holder", "TREATMENT", 198, 218], ["the true delay", "PROBLEM", 562, 576], ["med", "ANATOMY", 102, 105]]], ["Given the small number of deaths in younger age groups, we consider three age groups: <70y, 70-80, 80+.", [["deaths", "DISEASE", 26, 32], ["small", "OBSERVATION_MODIFIER", 10, 15], ["number", "OBSERVATION_MODIFIER", 16, 22]]], ["To get an overall estimate, we also repeat the calculation using all individuals across all age groups.(which was not certified by peer review)To fit the delays from hospitalization to ICU admission we use the same approach, however, we consider the delays are constant across age groups and that they follow an exponential distribution ( Figure S1 ).Modeling the risk of hospitalization, ICU admission and deathWe consider the population of mainland France for the transmission model in eight age bands (<20y, 20-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80+) and consider males and females separately.", [["the calculation", "TEST", 43, 58], ["the delays", "PROBLEM", 246, 256]]], ["We exclude the population in retirement communities (N=730,000 individuals, mainly over the age of 70 and 74% female), as there have been a number of outbreaks in these enclosed communities and the underlying risk of infection in these locations is unlikely to be the same as the wider population.", [["infection", "DISEASE", 217, 226], ["infection", "PROBLEM", 217, 226], ["population", "OBSERVATION_MODIFIER", 15, 25], ["infection", "OBSERVATION", 217, 226], ["unlikely to be", "UNCERTAINTY", 249, 263]]], ["Deaths in these communities are not captured in hospital records.Modeling the risk of hospitalization, ICU admission and deathOutside retirement communities, we assume that all recorded deaths occurred in hospital and that the probability of death is linked to age and sex.Modeling the risk of hospitalization, ICU admission and deathAs SARS-CoV-2 is principally transmitted from close contact between individuals, we assume that the probability of infection is proportional to the number of contacts an individual makes, which has previously been measured for individuals in France (7).Modeling the risk of hospitalization, ICU admission and deathWhere represents the mean cumulative probability of having been infected across the entire population and 4 represents the relative risk of infection for an individual of age i compared to a randomly selected person from the population.", [["deaths", "DISEASE", 186, 192], ["death", "DISEASE", 242, 247], ["death", "DISEASE", 329, 334], ["SARS", "DISEASE", 337, 341], ["infection", "DISEASE", 449, 458], ["infection", "DISEASE", 788, 797], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 337, 347], ["person", "SPECIES", 857, 863], ["SARS-CoV", "SPECIES", 337, 345], ["death", "PROBLEM", 242, 247], ["infection", "PROBLEM", 449, 458], ["infection", "PROBLEM", 788, 797], ["infection", "OBSERVATION", 449, 458], ["infected", "OBSERVATION", 712, 720], ["infection", "OBSERVATION", 788, 797]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.20.20072413 doi: medRxiv preprint individual of age group i has on a daily basis as measured in France, weighted by the proportion of the population that is within age group i (7) .(which was not certified by peer review)In order to disentangle the underlying probability of infection from the probability of hospitalization and death, we use the results of an active surveillance campaign in a different population (cruise ship) where all individuals were tested, and therefore the probability of detection is not linked to the presence of severe disease that requires hospitalization.", [["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 582, 591], ["death", "DISEASE", 636, 641], ["individuals", "ORGANISM", 747, 758], ["The copyright holder", "TREATMENT", 198, 218], ["infection", "PROBLEM", 582, 591], ["severe disease", "PROBLEM", 848, 862], ["med", "ANATOMY", 102, 105], ["infection", "OBSERVATION", 582, 591], ["active", "OBSERVATION_MODIFIER", 668, 674], ["severe", "OBSERVATION_MODIFIER", 848, 854], ["disease", "OBSERVATION", 855, 862]]], ["Where the age of the individuals is reported, we can estimate the probability of death given infection for each age group.(which was not certified by peer review)For the passive French hospital surveillance system, we use a Poisson Likelihood for the number of hospitalizations, ICU admissions and deaths within each age group and sex.(which was not certified by peer review)Where B8:=,4,> is the probability of hospitalization for an individual within age group i of sex j, CDE,4,> is the probability of entering ICU and F7G\"H,4,> is the probability of death for hospitalized individuals within age group i of sex j.", [["death", "DISEASE", 81, 86], ["infection", "DISEASE", 93, 102], ["deaths", "DISEASE", 298, 304], ["death", "DISEASE", 554, 559], ["death", "PROBLEM", 81, 86], ["infection", "PROBLEM", 93, 102], ["infection", "OBSERVATION", 93, 102]]], ["J is the proportion of hospitalized individuals in the dataset that have experienced their ICU outcome and K ,i is the proportion of individuals of age group i that have experienced their death outcome.(which was not certified by peer review)For the active surveillance portion of the model, we use a Poisson likelihood to capture the number of deaths on the Princess Diamond cruise ship.", [["death", "DISEASE", 188, 193], ["deaths", "DISEASE", 345, 351], ["K ,i", "GENE_OR_GENE_PRODUCT", 107, 111], ["active", "OBSERVATION_MODIFIER", 250, 256]]], ["We assume that sufficient time has passed that all deaths that were going to occur by the passengers as a result of SARS-CoV-2 infection have now occurred.", [["deaths", "DISEASE", 51, 57], ["SARS", "DISEASE", 116, 120], ["infection", "DISEASE", 127, 136], ["SARS-CoV-2", "ORGANISM", 116, 126], ["SARS", "PROBLEM", 116, 120], ["CoV-2 infection", "PROBLEM", 121, 136], ["infection", "OBSERVATION", 127, 136]]], ["However, we conduct a sensitivity analysis where half of the remaining six patients that are still within ICU go on to die.(which was not certified by peer review)As this is a growing epidemic, many of the hospitalizations may yet end up being fatal.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["a sensitivity analysis", "TEST", 20, 42], ["a growing epidemic", "PROBLEM", 174, 192], ["growing", "OBSERVATION_MODIFIER", 176, 183], ["epidemic", "OBSERVATION_MODIFIER", 184, 192]]], ["To adjust for this, we estimate the proportion of current hospitalizations where the outcome is known.(which was not certified by peer review)K,4 represents the proportion of hospitalizations, where the death outcome is known for an individual of age i.(which was not certified by peer review)To estimate K,4 , we calculate the proportion of hospitalized individuals who have already experienced their outcome (18) .(which was not certified by peer review).", [["death", "DISEASE", 203, 208], ["K", "TEST", 142, 143], ["estimate K", "TEST", 296, 306]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.20.20072413 doi: medRxiv preprint Where 4,> is the number of cases at time j of age i and 4,> is the proportion of all hospitalized cases in our dataset of age i that have a delay between hospitalization and death of j days.(which was not certified by peer review)We take a similar approach to estimate the proportion of hospitalized individuals who have experienced their ICU outcome ( J ).(which was not certified by peer review)We use RStan (19) to fit the B8:=,4,> , CDE,4,> , F7G\"H,4,> and parameters using logit transformed parameters.", [["CC", "CHEMICAL", 0, 2], ["death", "DISEASE", 515, 520], ["The copyright holder", "TREATMENT", 198, 218], ["CDE", "TEST", 778, 781], ["med", "ANATOMY", 102, 105]]], ["We run four chains of 10,000 iterations each and remove 50% for burn-in.", [["burn", "DISEASE", 64, 68], ["burn", "PROBLEM", 64, 68], ["chains", "OBSERVATION_MODIFIER", 12, 18]]], ["We use 2.5% and 97.5% percentiles from the resulting posterior distributions for 95% credible intervals for the parameters.", [["the parameters", "TEST", 108, 122], ["posterior", "ANATOMY_MODIFIER", 53, 62]]], ["To calculate the overall probability of hospitalization following infection for the whole population we compute an average across the individual B8:=,4,> estimates, weighted by the estimated number of people infected in each age-sex group.", [["infection", "DISEASE", 66, 75], ["people", "ORGANISM", 201, 207], ["people", "SPECIES", 201, 207], ["infection", "PROBLEM", 66, 75], ["the whole population", "PROBLEM", 80, 100], ["infection", "OBSERVATION", 66, 75]]], ["Similarly, to calculate the overall probability of death following hospitalisation, we compute an average across the individual F7G\"H,4,> estimates, weighted by the estimated number of people hospitalised in each age-sex group.Transmission model fit to ICU dataWe use a deterministic compartmental model stratified by age to describe the transmission of SARS-CoV-2 in the French population ( Figure S12 ).", [["death", "DISEASE", 51, 56], ["SARS", "DISEASE", 354, 358], ["people", "ORGANISM", 185, 191], ["SARS-CoV-2", "ORGANISM", 354, 364], ["people", "SPECIES", 185, 191], ["SARS-CoV", "SPECIES", 354, 362], ["SARS", "PROBLEM", 354, 358], ["CoV", "TEST", 359, 362]]], ["Upon infection, susceptible individuals will enter a latent compartment (first exposed compartment K ), in which they will on average stay 4.0 days.", [["infection", "DISEASE", 5, 14], ["individuals", "ORGANISM", 28, 39], ["infection", "PROBLEM", 5, 14], ["susceptible individuals", "PROBLEM", 16, 39], ["infection", "OBSERVATION", 5, 14], ["susceptible", "OBSERVATION_MODIFIER", 16, 27]]], ["During this period, they are not infectious.", [["infectious", "PROBLEM", 33, 43], ["not", "UNCERTAINTY", 29, 32], ["infectious", "OBSERVATION", 33, 43]]], ["Upon entry in the J compartment, infected individuals become infectious.", [["J compartment", "ANATOMY", 18, 31], ["infectious", "PROBLEM", 61, 71], ["entry", "OBSERVATION_MODIFIER", 5, 10], ["J compartment", "OBSERVATION_MODIFIER", 18, 31], ["infected", "OBSERVATION", 33, 41], ["infectious", "OBSERVATION", 61, 71]]], ["They then move to the compartment I where they stay for an average duration of 3 days, where all individuals are infectious and a subset develop symptoms.", [["infectious", "PROBLEM", 113, 123], ["a subset develop symptoms", "PROBLEM", 128, 153], ["infectious", "OBSERVATION", 113, 123]]], ["This parametrization gives a mean incubation period of 5 days and allows for one day of presymptomatic transmissions, in the line with several estimates from Chinese data (20, 21) .", [["presymptomatic transmissions", "PROBLEM", 88, 116], ["Chinese data", "TEST", 158, 170]]], ["It is also in line with generation interval estimates obtained from analyses of infector-infectee pairs from mainland China (20) .Transmission model fit to ICU dataA subset of infected individuals develop severe disease that results in ICU admission.", [["individuals", "ORGANISM", 185, 196], ["infector", "PROBLEM", 80, 88], ["infectee pairs", "PROBLEM", 89, 103], ["infected individuals", "PROBLEM", 176, 196], ["severe disease", "PROBLEM", 205, 219], ["severe", "OBSERVATION_MODIFIER", 205, 211], ["disease", "OBSERVATION", 212, 219]]], ["Finally, we assume that patients will enter ICU on average 7 days after symptom onset, consistent with previous estimates (22) .Transmission model fit to ICU dataThe model is initiated with Q cases in the K compartment on the 22nd January 2020 ( Q ).Contacts patterns in the French population prior to the lockdown.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["symptom onset", "PROBLEM", 72, 85], ["ICU data", "TEST", 154, 162]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["Age-specific daily contacts for the French population are obtained from the study COMES-F performed in 2012 (7) .", [["the study", "TEST", 72, 81]]], ["To compute the matrix, we divide the population equally from 0 to 80 years old into 8 classes of ten years each.", [["matrix", "CELLULAR_COMPONENT", 15, 21]]], ["For the elderly, we consider one unique class that contains over-80 years old people.", [["people", "ORGANISM", 78, 84], ["people", "SPECIES", 78, 84]]], ["Data on contacts are retrieved and computed using the SocialmixR package (23) .Computing the transmission rate prior to the lockdownFrom the definition of the contact matrix, the parametrization of our transmission model and a given reproduction number Q , we can obtain the following expression for the transmission rate (24, 25):Computing the transmission rate prior to the lockdown[ ]is the maximum eigenvalue of the contact matrix and is the mean infectious period.Trajectories of patients in ICUWe assume that the time spent in ICU is constant across age-groups and that it follows a Gamma distribution of shape 2 and of rate 86\" .", [["matrix", "CELLULAR_COMPONENT", 167, 173], ["matrix", "CELLULAR_COMPONENT", 428, 434], ["patients", "ORGANISM", 485, 493], ["patients", "SPECIES", 485, 493], ["the SocialmixR package", "TREATMENT", 50, 72], ["the lockdown", "TREATMENT", 120, 132], ["the transmission rate", "TEST", 300, 321], ["contact matrix", "OBSERVATION", 159, 173]]], ["The mean time spent in ICU is thus equal to 2/ 86\" .Impact of the lockdown on transmissionIn response to the growing epidemic, from March 17th, the French population was asked to remain confined to their homes and to avoid non-essential movement outside the household (26).Impact of the lockdown on transmissionWe adjusted our contact matrix to reflect the impact on the lockdown on the distribution of daily contacts between individuals after this date.", [["the lockdown", "TREATMENT", 283, 295], ["transmissionWe", "TREATMENT", 299, 313], ["growing", "OBSERVATION_MODIFIER", 109, 116], ["epidemic", "OBSERVATION_MODIFIER", 117, 125]]], ["We denote , the contact matrix prior to the lockdown (7) and transmission rates prior to the lockdown are modelled as .Impact of the lockdown on transmissionIn order to model the impact of the lockdown on transmission, one potential approach is to predict how the standard contact matrix is modified during the lockdown due to reductions in contacts in different settings.", [["matrix", "CELLULAR_COMPONENT", 24, 30], ["matrix", "CELLULAR_COMPONENT", 281, 287], ["transmission rates", "TEST", 61, 79]]], ["If we denote the predicted contact matrix during the lockdown period, the transmission rates for the lockdown period would then simply be .", [["contact matrix", "CELLULAR_COMPONENT", 27, 41]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.20.20072413 doi: medRxiv preprint approach is that given the unprecedented nature of the lockdown, it is hard to predict precisely what the new contact matrix may look like.", [["CC", "CHEMICAL", 0, 2], ["matrix", "CELLULAR_COMPONENT", 459, 465], ["The copyright holder", "TREATMENT", 198, 218], ["medRxiv preprint approach", "TREATMENT", 324, 349], ["med", "ANATOMY", 102, 105]]], ["Any slight error in the assumed reduction of the average number of contacts would have a strong impact on estimates of the reproduction number for the lockdown period.(which was not certified by peer review)To avoid such risk, we instead estimate a transmission parameter separately for the time period before ( ) and during the lockdown ( d8efg8hi ).", [["Any slight error", "PROBLEM", 0, 16], ["the lockdown ( d8efg8hi )", "TREATMENT", 325, 350], ["slight", "OBSERVATION_MODIFIER", 4, 10], ["error", "OBSERVATION", 11, 16], ["reduction", "OBSERVATION_MODIFIER", 32, 41]]], ["Comparison of these two parameters will determine the reduction in the reproduction number due to the lockdown.", [["reduction", "OBSERVATION_MODIFIER", 54, 63]]], ["Since the reduction in average number of contacts will be captured by transmission parameters ( , d8efg8hi ), we work with normalized contact matrices, i.e. contact matrices whose maximum eigenvalues are equal to 1.", [["the reduction", "TREATMENT", 6, 19], ["reduction", "OBSERVATION_MODIFIER", 10, 19], ["average", "OBSERVATION_MODIFIER", 23, 30], ["number", "OBSERVATION_MODIFIER", 31, 37]]], ["This allows us to define as Q / and d8efg8hi as j8efg8hi / and to compute transmission rates before and after lockdown as and j8efg8hi .", [["d8efg8hi", "GENE_OR_GENE_PRODUCT", 36, 44], ["Q", "DNA", 28, 29], ["d8efg8hi", "DNA", 36, 44], ["j8efg8hi", "DNA", 48, 56], ["j8efg8hi", "PROTEIN", 126, 134]]], ["We modify the contact matrix for the lockdown to capture the impact of the lockdown on the structure of the matrix.", [["matrix", "CELLULAR_COMPONENT", 22, 28], ["matrix", "CELLULAR_COMPONENT", 108, 114], ["the contact matrix", "TREATMENT", 10, 28], ["the lockdown", "TREATMENT", 33, 45], ["matrix", "ANATOMY_MODIFIER", 108, 114]]], ["This normalization ensures that estimates of R after the lockdown are little impacted by the matrix we choose (see Figure 4 ).(which was not certified by peer review)The normalized contact matrices we consider for the lockdown matrices are: -K (baseline): the original contact matrix by removing all contacts in school settings and further assume a reduction of 80% in the contacts associated with the workplace and 90% in the ones outside work and home.", [["matrix", "CELLULAR_COMPONENT", 93, 99], ["the lockdown matrices", "TEST", 214, 235], ["a reduction", "TREATMENT", 347, 358], ["little", "OBSERVATION_MODIFIER", 70, 76], ["impacted", "OBSERVATION", 77, 85], ["contact matrices", "OBSERVATION", 181, 197]]], ["We note that k and l are less likely to represent the true situation than K and J . l would lead to only very few contacts for the elderly, and the model then predicts a substantial drop in the proportion of elderly individuals in ICU.", [["k", "TEST", 13, 14], ["a substantial drop", "PROBLEM", 168, 186], ["less likely to represent", "UNCERTAINTY", 25, 49], ["substantial", "OBSERVATION_MODIFIER", 170, 181], ["drop", "OBSERVATION_MODIFIER", 182, 186]]], ["Such reduction in ICU was not observed in France.", [["reduction", "OBSERVATION_MODIFIER", 5, 14]]], ["Additionally, in the context of lockdowns that apply to the whole population, a recent study reports a fairly constant reduction in mean contacts across age classes from 18 years old and upwards before and after the lockdown (27)Statistical framework for the transmission modelWe fit the transmission model using a Bayesian framework and jointly infer parameters.", [["a recent study", "TEST", 78, 92], ["a fairly constant reduction", "PROBLEM", 101, 128], ["a Bayesian framework", "TREATMENT", 313, 333]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.20.20072413 doi: medRxiv preprint(which was not certified by peer review)where ( \u22c5 | ) is a negative binomial distribution of mean and overdispersion parameter v , being a parameter to be estimated.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105], ["negative", "OBSERVATION", 399, 407]]], ["We calibrate the model on corrected SI-VIC data from the 15th of March (denoted K ).(which was not certified by peer review)The parameter space is explored by Markov Chain Monte Carlo sampling.", [["The parameter space", "TREATMENT", 124, 143]]], ["We implement a Metropolis-Hastings (MH) algorithm with lognormal proposals for all the parameters and uniform priors.", [["a Metropolis-Hastings (MH) algorithm", "TREATMENT", 13, 49], ["lognormal proposals", "TREATMENT", 55, 74]]], ["Chains are run for 10,000 iterations with 2,000 iterations of burn-in.(which was not certified by peer review)In early attempts to estimate model parameters, the initial number of cases at the start of the simulation Q was highly correlated to the reproduction number.", [["burn", "DISEASE", 62, 66], ["burn", "PROBLEM", 62, 66]]], ["This is because slight variations in Q or the reproduction number can lead to major changes in the trajectory of cumulative number of cases.", [["slight variations in Q", "PROBLEM", 16, 38], ["slight", "OBSERVATION_MODIFIER", 16, 22], ["variations", "OBSERVATION_MODIFIER", 23, 33]]], ["We use the approach by Wallinga et al. (28) to relate the basic reproduction number to the epidemic growth rate .Incorporation of uncertainty from the probability of entering ICu following uncertaintyWe incorporate uncertainty from the probability of entering ICU following infection in our estimates of the number of new infections and the immunity in the population over time.", [["infection", "DISEASE", 274, 283], ["infections", "DISEASE", 322, 332], ["ICu", "PROTEIN", 175, 178], ["the approach", "TREATMENT", 7, 19], ["infection", "PROBLEM", 274, 283], ["new infections", "PROBLEM", 318, 332], ["infection", "OBSERVATION", 274, 283], ["new", "OBSERVATION_MODIFIER", 318, 321], ["infections", "OBSERVATION", 322, 332]]], ["To do this, we separately rerun the transmission model using the 2.5% and 97.5% quantiles from the posterior of B8:=,4 \u00d7 CDE,4 .", [["posterior", "ANATOMY_MODIFIER", 99, 108]]], ["The results of these estimates are included in Figures 3C, 3E , 4D,4E and S4(A-M)3.", [["A-M)3", "GENE_OR_GENE_PRODUCT", 77, 82], ["these estimates", "TEST", 15, 30]]], ["Uncertainty in these parameters had little effect on our estimates of the number of required ICU beds and ICU admissions.Simulation study to assess model performance in estimating IFR and hospitalization riskTo assess the performance of the approach to estimate probabilities of infection, hospitalization, ICU entry, and death, we developed a simulation framework where the true parameters ( B8:=,4 , CDE,4 , , F7G\"H,4 ) were known.Simulation study to assess model performance in estimating IFR and hospitalization riskFor a period of 45 days we simulate a growing epidemic, seeded by a single infection, where the number of cases grows exponentially each day with an exponential growth rate of 0.3.", [["infection", "DISEASE", 279, 288], ["death", "DISEASE", 322, 327], ["infection", "DISEASE", 595, 604], ["ICU beds", "TREATMENT", 93, 101], ["Simulation study", "TEST", 121, 137], ["infection", "PROBLEM", 279, 288], ["the true parameters", "TEST", 371, 390], ["CDE", "TEST", 402, 405], ["Simulation study", "TEST", 433, 449], ["a growing epidemic", "PROBLEM", 556, 574], ["a single infection", "PROBLEM", 586, 604], ["an exponential growth rate", "TEST", 666, 692], ["little", "OBSERVATION_MODIFIER", 36, 42], ["effect", "OBSERVATION_MODIFIER", 43, 49], ["infection", "OBSERVATION", 279, 288], ["growing", "OBSERVATION_MODIFIER", 558, 565], ["epidemic", "OBSERVATION_MODIFIER", 566, 574], ["infection", "OBSERVATION", 595, 604]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.20.20072413 doi: medRxiv preprint a population with the same age structure as France and assume no difference in risk of infection by age or sex.", [["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 428, 437], ["The copyright holder", "TREATMENT", 198, 218], ["medRxiv", "TREATMENT", 324, 331], ["infection", "PROBLEM", 428, 437], ["med", "ANATOMY", 102, 105], ["no", "UNCERTAINTY", 403, 405], ["infection", "OBSERVATION", 428, 437]]], ["For each of the infections in the simulation we assign: -The age group, i, drawn according to the age distribution of France -Whether or not the individual was hospitalized, using a random draw from a Bernoulli distribution with parameter B8:=,4 -If the individual was hospitalized, whether or not the individual entered ICU, using a random draw from a Bernoulli distribution with parameter CDE,4 -If the individual was hospitalized, whether or not the individual died, using a random draw from a Bernoulli distribution with parameter F7G\"H,4 -If the individual was hospitalized, the day of hospitalization using an exponential distribution with a mean of 11 days. -If the individual entered ICU, the delay from hospitalization to ICU using a random draw from an exponential distribution with a mean of 2 days. -If the individual died, the delay from hospitalization to death using a random draw from an exponential distribution with a mean of 15 days.(which was not certified by peer review)We then compute the total counts of hospitalizations, ICU and deaths by age over the first 45 days of the simulation (Figures S7).(which was not certified by peer review)To simulate active surveillance, we select a random subset of 1000 individuals that were infected and record the outcome (death or not) and age for all of them (irrespective of delays to death).(which was not certified by peer review)We use the simulated data to estimate the proportion of cases with outcome observed ( ) and the model parameters using our probabilistic framework.(which was not certified by peer review).", [["infections", "DISEASE", 16, 26], ["death", "DISEASE", 870, 875], ["deaths", "DISEASE", 1054, 1060], ["death", "DISEASE", 1284, 1289], ["death", "DISEASE", 1349, 1354], ["the infections", "PROBLEM", 12, 26], ["a random draw", "TEST", 180, 193], ["a Bernoulli distribution", "TEST", 199, 223], ["a random draw", "TEST", 332, 345], ["a random draw", "TEST", 741, 754], ["a random draw", "TEST", 882, 895], ["active surveillance", "TEST", 1174, 1193], ["infections", "OBSERVATION", 16, 26], ["active", "OBSERVATION_MODIFIER", 1174, 1180]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["The different scenarios correspond to: Children less inf. -Individuals <20y are half as infectious as adults ; No Change CM -the structure of the contact matrix is modified by the lockdown ; CM SDE -Contact matrix after lockdown with social distancing of the elderly ; Constant AR -Attack rates are constant across age groups ; Higher delays -9 days on average between illness onset and ICU admission instead of 7 days ; More deaths DP -Three additional deaths will occur amongst the six passengers of the Diamond Princess cruise ship that are still in ICU.", [["CM", "DISEASE", 121, 123], ["CM", "DISEASE", 191, 193], ["illness", "DISEASE", 369, 376], ["deaths", "DISEASE", 426, 432], ["deaths", "DISEASE", 454, 460], ["Children", "ORGANISM", 39, 47], ["matrix", "CELLULAR_COMPONENT", 154, 160], ["AR", "PROTEIN", 278, 280], ["Children", "SPECIES", 39, 47], ["Change CM", "PROBLEM", 114, 123], ["Attack rates", "PROBLEM", 282, 294], ["infectious", "OBSERVATION", 88, 98], ["contact matrix", "OBSERVATION", 146, 160]]], ["For estimates of daily new infections and proportion of the population infected by May 11th, we report the 95% uncertainty range stemming from the uncertainty in the probability of entering ICU given infection.(which was not certified by peer review).", [["infections", "DISEASE", 27, 37], ["infection", "DISEASE", 200, 209], ["daily new infections", "PROBLEM", 17, 37], ["infection", "PROBLEM", 200, 209], ["new", "OBSERVATION_MODIFIER", 23, 26], ["infections", "OBSERVATION", 27, 37], ["infection", "OBSERVATION", 200, 209]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.20.20072413 doi: medRxiv preprintSupplementary tablesTable S1: Probability of hospitalization and ICU by age and sex Table S2 : Probability of death by age and sex Table S3 : Estimated delays from hospitalization to death Table S4 : Parameter estimates from the national model Table S5 : Parameter estimates from the regional model Table S6 : Proportion infected by region by the 11th May.", [["CC", "CHEMICAL", 0, 2], ["death", "DISEASE", 450, 455], ["death", "DISEASE", 523, 528], ["The copyright holder", "TREATMENT", 198, 218], ["medRxiv preprintSupplementary tables", "TREATMENT", 324, 360], ["death", "PROBLEM", 450, 455], ["Estimated delays", "PROBLEM", 482, 498], ["med", "ANATOMY", 102, 105], ["infected", "OBSERVATION", 661, 669]]], ["Figure S1 : Fit of delay from hospitalization to ICU admission is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. .", [["The copyright holder", "TREATMENT", 197, 217], ["med", "ANATOMY", 101, 104]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.20.20072413 doi: medRxiv preprint Figure S1 : Fit of delay from hospitalization to ICU admission.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["Figure S1 : Model and observed fit of exponential model use times from hospitalization to ICU entry across all ages, taking account for the exponentially growing nature of the epidemic.(which was not certified by peer review).", [["the epidemic", "PROBLEM", 172, 184], ["epidemic", "OBSERVATION", 176, 184]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["(B) Model estimates of distribution of rapid decline and slow decline.", [["rapid decline", "PROBLEM", 39, 52], ["slow decline", "PROBLEM", 57, 69], ["rapid", "OBSERVATION_MODIFIER", 39, 44], ["decline", "OBSERVATION", 45, 52], ["slow", "OBSERVATION_MODIFIER", 57, 61], ["decline", "OBSERVATION_MODIFIER", 62, 69]]], ["Models fitted to take into account that in a growing epidemic, observed deaths will be biased towards ones that die quickly.(which was not certified by peer review).", [["deaths", "DISEASE", 72, 78]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.20.20072413 doi: medRxiv preprint Figure S4 : Fit of delays from hospitalization to death by age Figure S4 .", [["CC", "CHEMICAL", 0, 2], ["death", "DISEASE", 391, 396], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["Fit of mixture models to time from hospitalization to death for different age groups.", [["death", "DISEASE", 54, 59]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.20.20072413 doi: medRxiv preprint Figure S5 : Trajectories predicted by the regional model .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105], ["regional model", "OBSERVATION", 383, 397]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.20.20072413 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["medRxiv preprint", "TREATMENT", 324, 340], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.20.20072413 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["medRxiv preprint", "TREATMENT", 324, 340], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.20.20072413 doi: medRxiv preprint Figure S7 : Simulation results Figure S7 : Simulation results where epidemics are simulated with known probabilities of infection, hospitalization, ICU and death.", [["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 461, 470], ["death", "DISEASE", 497, 502], ["The copyright holder", "TREATMENT", 198, 218], ["epidemics", "PROBLEM", 409, 418], ["infection", "PROBLEM", 461, 470], ["med", "ANATOMY", 102, 105], ["infection", "OBSERVATION", 461, 470]]], ["We then use our model framework to re-estimate the parameters.", [["our model framework", "TREATMENT", 12, 31]]], ["(A) Estimated (blue) and true (red) probability of hospitalization by age.", [["Estimated (blue) and true (red", "PROBLEM", 4, 34]]], ["(B) Estimated (blue) and true (red) probability of ICU admission by age.", [["Estimated (blue) and true (red", "PROBLEM", 4, 34]]], ["(C) Estimated (blue) and true (red) probability of death by age among those hospitalized.(which was not certified by peer review).", [["death", "DISEASE", 51, 56], ["Estimated (blue) and true (red) probability of death", "PROBLEM", 4, 56]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.20.20072413 doi: medRxiv preprint Figure S8 : Sensitivity analysis with increased deaths on Princess Diamond.", [["CC", "CHEMICAL", 0, 2], ["deaths", "DISEASE", 430, 436], ["The copyright holder", "TREATMENT", 239, 259], ["Sensitivity analysis", "TEST", 394, 414], ["increased deaths", "PROBLEM", 420, 436], ["med", "ANATOMY", 102, 105], ["increased", "OBSERVATION_MODIFIER", 420, 429]]], ["Figure S8 : Six infected individuals remain in ICU.", [["individuals", "ORGANISM", 25, 36], ["Six", "OBSERVATION_MODIFIER", 12, 15], ["infected", "OBSERVATION", 16, 24]]], ["This sensitivity analysis assumes that half of these will go on to die.", [["This sensitivity analysis", "TEST", 0, 25]]], ["(C) probability of death among those hospitalized as a function of age and sex.", [["death", "DISEASE", 19, 24], ["death", "PROBLEM", 19, 24]]], ["(D) Probability of death among those infected as a function of age and sex.", [["death", "DISEASE", 19, 24], ["death", "PROBLEM", 19, 24]]], ["For each panel, the black line and grey shaded region represents the overall mean across all ages.(which was not certified by peer review).", [["each panel", "TEST", 4, 14], ["the black line and grey shaded region", "PROBLEM", 16, 53], ["black line", "OBSERVATION", 20, 30], ["grey shaded", "OBSERVATION", 35, 46], ["overall", "OBSERVATION_MODIFIER", 69, 76], ["mean", "OBSERVATION_MODIFIER", 77, 81]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 239, 259], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 239, 259], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.20.20072413 doi: medRxiv preprint Figure S11 : Time-series of hospitalizations, ICU admissions and deaths corrected for reporting delays Figure S11 : Times-series of hospitalizations (A), ICU admissions (B) and deaths (C) from SI-VIC data, corrected for reporting delays and under-reporting.", [["CC", "CHEMICAL", 0, 2], ["deaths", "DISEASE", 447, 453], ["deaths", "DISEASE", 559, 565], ["The copyright holder", "TREATMENT", 239, 259], ["med", "ANATOMY", 102, 105]]], ["The SI-VIC system became operational on the 13th of March.", [["VIC system", "ANATOMY", 7, 17]]], ["We also account for delays in reporting to estimate the number of hospitalizations, ICU admissions and deaths at the right end of the curves (red line in each panel).", [["deaths", "DISEASE", 103, 109], ["red line", "TREATMENT", 142, 150], ["right", "ANATOMY_MODIFIER", 117, 122], ["red line", "OBSERVATION", 142, 150]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.20.20072413 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 239, 259], ["medRxiv", "TREATMENT", 365, 372], ["med", "ANATOMY", 102, 105]]]], "PMC7161525": [["IntroductionParmi la soixantaine de cannabino\u00efdes pr\u00e9sents dans le cannabis sativa indica on trouve essentiellement des terp\u00e9noph\u00e9nols, parmi lesquels figure le delta-9-trans t\u00e9trahydrocannabinol (\u03949-THC) qui constitue le principal produit psychoactif chez l\u2019homme.IntroductionLe THC subit, au niveau des microsomes h\u00e9patiques, un m\u00e9tabolisme oxydatif conduisant la formation de 11-hydroxy-t\u00e9trahydrocannabinol (11-OH-THC) m\u00e9tabolite psychoactif et de 11-nor-9-carboxy-\u03949-t\u00e9trahydrocannabinol (THC-COOH), sans activit\u00e9 pharmacologique av\u00e9r\u00e9e.", [["t\u00e9trahydrocannabinol", "CHEMICAL", 175, 195], ["THC", "CHEMICAL", 200, 203], ["THC", "CHEMICAL", 280, 283], ["de 11-hydroxy-t\u00e9trahydrocannabinol", "CHEMICAL", 376, 410], ["11-OH-THC", "CHEMICAL", 412, 421], ["11-nor-9-carboxy-\u03949-t\u00e9trahydrocannabinol", "CHEMICAL", 452, 492], ["THC", "CHEMICAL", 494, 497], ["delta-9-trans t\u00e9trahydrocannabinol", "CHEMICAL", 161, 195], ["\u03949-THC", "CHEMICAL", 197, 203], ["THC", "CHEMICAL", 280, 283], ["11-hydroxy-t\u00e9trahydrocannabinol", "CHEMICAL", 379, 410], ["11-OH-THC", "CHEMICAL", 412, 421], ["11-nor-9-carboxy-\u03949-t\u00e9trahydrocannabinol", "CHEMICAL", 452, 492], ["THC", "CHEMICAL", 494, 497], ["COOH", "CHEMICAL", 498, 502], ["delta-9-trans t\u00e9trahydrocannabinol", "SIMPLE_CHEMICAL", 161, 195], ["\u03949-THC", "SIMPLE_CHEMICAL", 197, 203], ["11-hydroxy-t\u00e9trahydrocannabinol", "SIMPLE_CHEMICAL", 379, 410], ["11-OH-THC", "SIMPLE_CHEMICAL", 412, 421], ["11-nor-9-carboxy-\u03949-t\u00e9trahydrocannabinol", "SIMPLE_CHEMICAL", 452, 492], ["THC-COOH", "SIMPLE_CHEMICAL", 494, 502], ["sativa indica", "SPECIES", 76, 89], ["IntroductionParmi la soixantaine", "TREATMENT", 0, 32], ["trans t\u00e9trahydrocannabinol", "TREATMENT", 169, 195], ["hydroxy", "TEST", 382, 389], ["t\u00e9trahydrocannabinol", "TREATMENT", 390, 410], ["carboxy", "TEST", 461, 468], ["t\u00e9trahydrocannabinol", "TREATMENT", 472, 492]]], ["Au cours des \u00e9tapes successives de distribution et de m\u00e9tabolisme du \u03949-THC, les concentrations en THC-COOH dans le sang augmentent tandis que celles de \u03949-THC d\u00e9croissent.IntroductionSeulement 15 \u00e0 30 % du THC sanguin sont \u00e9limin\u00e9s dans les urines sous forme de THC-COOH.", [["THC", "CHEMICAL", 72, 75], ["THC", "CHEMICAL", 99, 102], ["THC", "CHEMICAL", 156, 159], ["THC", "CHEMICAL", 207, 210], ["THC", "CHEMICAL", 263, 266], ["Au", "CHEMICAL", 0, 2], ["THC", "CHEMICAL", 99, 102], ["THC", "CHEMICAL", 156, 159], ["THC", "CHEMICAL", 263, 266], ["COOH", "CHEMICAL", 267, 271], ["THC-COOH", "SIMPLE_CHEMICAL", 263, 271], ["et de m\u00e9tabolisme du", "TEST", 48, 68], ["les concentrations", "TEST", 77, 95], ["IntroductionSeulement", "TEST", 172, 193]]], ["En raison de sa forte fixation tissulaire, l\u2019\u00e9limination urinaire est lente.", [["En raison de sa forte fixation tissulaire", "TREATMENT", 0, 41], ["fixation tissulaire", "OBSERVATION", 22, 41]]], ["Les demi-vies d\u2019\u00e9limination sont tr\u00e8s variables selon la dose et selon qu\u2019il s\u2019agit de consommateurs occasionnels ou r\u00e9guliers.", [["Les demi-vies d\u2019\u00e9limination", "PROBLEM", 0, 27]]], ["Cible principale de l\u2019analyse urinaire, le dosage de THC-COOH ne donne pas d\u2019information sur la voie d\u2019administration, la quantit\u00e9 de cannabis qui a \u00e9t\u00e9 utilis\u00e9e, le moment de l\u2019exposition, ni le niveau d\u2019alt\u00e9ration du comportement.", [["THC", "CHEMICAL", 53, 56], ["cannabis", "CHEMICAL", 134, 142]]], ["Le dosage simultan\u00e9 du \u03949-THC et du 11-OH-THC pourrait permettre d\u2019appr\u00e9hender le moment de la derni\u00e8re consommation mais ce type d\u2019investigations n\u2019est en pratique jamais r\u00e9alis\u00e9.", [["THC", "CHEMICAL", 26, 29], ["THC", "CHEMICAL", 42, 45], ["THC", "CHEMICAL", 26, 29], ["11-OH-THC", "CHEMICAL", 36, 45]]], ["En effet, ces 2 marqueurs signent l\u2019usage tr\u00e8s r\u00e9cent lorsque identifi\u00e9s dans les urines [1].", [["ces", "TEST", 10, 13], ["dans les urines", "TEST", 73, 88]]], ["Il serait m\u00eame possible d\u2019aller plus loin, avec la caract\u00e9risation du \u03949-THC glucuronide [2].IntroductionSi la d\u00e9termination analytique est ais\u00e9e pour le cannabis, tant ce produit a \u00e9t\u00e9 \u00e9tudi\u00e9, il n\u2019en est pas de m\u00eame avec les cannabino\u00efdes de synth\u00e8se.", [["\u03949-THC glucuronide", "CHEMICAL", 70, 88], ["cannabis", "CHEMICAL", 154, 162], ["\u03949-THC glucuronide", "CHEMICAL", 70, 88], ["\u03949-THC glucuronide", "SIMPLE_CHEMICAL", 70, 88], ["Il serait m\u00eame", "TREATMENT", 0, 14], ["THC glucuronide", "TREATMENT", 73, 88]]], ["La premi\u00e8re difficult\u00e9 est d\u2019arriver \u00e0 se procurer la ou les substances pures pour \u00e9talonner les appareils de mesure, d\u2019identifier ses m\u00e9tabolites (par des \u00e9tudes in vitro, en particulier avec des microsomes h\u00e9patiques humains), de v\u00e9rifier qu\u2019ils sont pr\u00e9sents dans les diff\u00e9rents pr\u00e9l\u00e8vements biologiques et enfin d\u2019\u00e9tablir leur stabilit\u00e9 [3], [4].IntroductionIl appara\u00eet donc que les informations g\u00e9n\u00e9r\u00e9es par les analyses biologiques sont tr\u00e8s diff\u00e9rentes en fonction de la matrice utilis\u00e9e pour le dosage et que l\u2019interpr\u00e9tation finale en termes de dur\u00e9e d\u2019action, d\u2019alt\u00e9ration de la vigilance ou de niveau d\u2019addiction est tr\u00e8s d\u00e9pendante des informations obtenues.Sang ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueLe sang constitue un milieu id\u00e9al pour la confirmation car il permet de doser le \u03949-THC, le 11-OH-THC et le THC-COOH et de diff\u00e9rencier g\u00e9n\u00e9ralement, selon les termes du l\u00e9gislateur les sujets \u00ab ayant fait usage de \u00bb de ceux \u00ab sous influence \u00bb de cannabis.", [["THC", "CHEMICAL", 827, 830], ["THC", "CHEMICAL", 841, 844], ["THC", "CHEMICAL", 851, 854], ["cannabis", "CHEMICAL", 990, 998], ["THC", "CHEMICAL", 827, 830], ["11-OH-THC", "CHEMICAL", 835, 844], ["vitro, en particulier avec des", "TREATMENT", 166, 196], ["D\u00e9tection des", "TREATMENT", 679, 692], ["COOH et de diff\u00e9rencier g\u00e9n\u00e9ralement", "PROBLEM", 855, 891]]], ["C\u2019est le milieu de choix d\u00e8s lors qu\u2019une composante l\u00e9gale entre en jeu, mais ne peut pas \u00eatre utilis\u00e9 pour un d\u00e9pistage rapide \u00e0 cause du caract\u00e8re invasif du pr\u00e9l\u00e8vement et du temps d\u2019analyse.Urines ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueDans les urines, on retrouve essentiellement le THC-COOH, m\u00e9tabolite inactif, \u00e0 fortes concentrations et sous forme conjugu\u00e9e.", [["THC", "CHEMICAL", 317, 320], ["D\u00e9tection des", "TREATMENT", 205, 218], ["les urines", "TEST", 274, 284]]], ["En raison de la forte lipophilie du \u03949-THC, celui-ci sera lib\u00e9r\u00e9 tr\u00e8s lentement des tissus adipeux.", [["THC", "CHEMICAL", 39, 42], ["celui-ci sera lib\u00e9r\u00e9 tr\u00e8s", "TREATMENT", 44, 69]]], ["Ainsi, apr\u00e8s consommation de cannabis, le THC-COOH sera encore pr\u00e9sent jusqu\u2019\u00e0 8 \u00e0 12 jours apr\u00e8s la prise chez un fumeur r\u00e9gulier et jusqu\u2019\u00e0 3 semaines chez un gros consommateur.", [["cannabis", "CHEMICAL", 29, 37], ["THC", "CHEMICAL", 42, 45], ["Ainsi", "TEST", 0, 5], ["sera", "TEST", 51, 55], ["jusqu", "TEST", 71, 76], ["la", "TEST", 98, 100]]], ["Les possibilit\u00e9s d\u2019adult\u00e9ration sont nombreuses et largement explicit\u00e9es sur Internet o\u00f9 l\u2019on peut trouver des sites d\u00e9di\u00e9s \u00e0 ces pratiques [10].Salive ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueEn pratique, un \u00e9chantillon de salive peut \u00eatre collect\u00e9 directement dans un r\u00e9cipient, en balayant la cavit\u00e9 orale avec un coton-tige (ou un outil similaire) ou en stimulant la production salivaire avec des mati\u00e8res acidul\u00e9es, des cristaux d\u2019acide citrique, ou en mastiquant un mat\u00e9riau inerte tel que le t\u00e9flon.", [["salive peut \u00eatre collect\u00e9 directement dans un r\u00e9cipient, en balayant la cavit\u00e9 orale avec un coton-tige (ou un outil similaire) ou en stimulant la production salivaire avec des mati\u00e8res acidul\u00e9es, des cristaux d\u2019acide citrique, ou en mastiquant un mat\u00e9riau inerte tel que le t\u00e9flon", "SPECIES", 251, 532], ["d\u2019adult\u00e9ration", "PROBLEM", 17, 31], ["D\u00e9tection des", "TREATMENT", 156, 169], ["ou en stimulant la production", "TREATMENT", 379, 408]]], ["De plus, une r\u00e9duction de flux salivaire peut \u00eatre observ\u00e9e suite \u00e0 la consommation d\u2019amph\u00e9tamines et de certains antid\u00e9presseurs.Salive ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueIl existe une demande croissante pour des tests de d\u00e9pistage (aussi dans le cadre des d\u00e9pistage en entreprise) pouvant \u00eatre effectu\u00e9s sur le site m\u00eame du pr\u00e9l\u00e8vement de l\u2019\u00e9chantillon.", [["D\u00e9tection des", "TREATMENT", 141, 154], ["pour des tests", "TEST", 238, 252], ["aussi dans le cadre des d\u00e9pistage en entreprise", "TREATMENT", 267, 314]]], ["Ces derni\u00e8res ann\u00e9es [11], quelques prototypes ont \u00e9t\u00e9 introduits pour un d\u00e9pistage rapide des substances psychotropes dans la salive : le Drugwipe (Securetec, Allemagne) ou l\u2019Oraline (Sun, USA), le syst\u00e8me Rapiscan (Cozart Bioscience Ltd., UK) ou encore le dispositif Drager (Allemagne).", [["quelques prototypes", "TREATMENT", 27, 46], ["pour un d\u00e9pistage rapide des substances", "TREATMENT", 66, 105], ["le Drugwipe (Securetec, Allemagne)", "TREATMENT", 136, 170], ["le", "ANATOMY", 136, 138]]], ["Il existe des m\u00e9thodes de r\u00e9f\u00e9rence [12] pour le dosage du cannabis dans la salive, mais celles-ci sont longues et n\u00e9cessitent un \u00e9quipement lourd et on\u00e9reux de chromatographie en phase gazeuse ou liquide, toujours coupl\u00e9e \u00e0 la spectrom\u00e9trie de masse.", [["nt", "PROBLEM", 101, 103], ["masse", "OBSERVATION", 245, 250]]], ["La salive est alors recueillie par un coton (Salivette, Sarstedt, Floqswab) ou un tampon (Intercept, Orasure, NeoSal, Quantisal).Salive ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueLes cannabino\u00efdes ne sont pas ou peu excr\u00e9t\u00e9s dans la salive, mais leur voie d\u2019administration \u00e9tant quasiment toujours buccale, le \u03949-t\u00e9trahydrocannabinol est d\u00e9tectable dans ce milieu pendant plusieurs heures, suite \u00e0 la contamination buccale par la fum\u00e9e inhal\u00e9e.", [["La salive est alors recueillie par un coton (Salivette, Sarstedt, Floqswab) ou un tampon", "SPECIES", 0, 88], ["La salive est", "TREATMENT", 0, 13], ["Sarstedt, Floqswab)", "TREATMENT", 56, 75], ["buccale", "TEST", 323, 330], ["le", "ANATOMY", 332, 334]]], ["Dans la demi-heure suivant l\u2019inhalation, des concentrations salivaires de \u03949-THC sup\u00e9rieures \u00e0 100 ng/mL peuvent \u00eatre mesur\u00e9es.", [["THC", "CHEMICAL", 77, 80], ["Dans la demi-heure suivant l\u2019inhalation", "TREATMENT", 0, 39], ["des concentrations salivaires", "TREATMENT", 41, 70]]], ["Les concentrations salivaires sont plus \u00e9lev\u00e9es que les concentrations plasmatiques dans les premi\u00e8res heures.", [["Les concentrations salivaires", "PROBLEM", 0, 29]]], ["Le \u03949-THC reste d\u00e9tectable dans la salive durant 3 \u00e0 6 heures en moyenne.", [["Le \u03949-THC", "CHEMICAL", 0, 9], ["THC", "CHEMICAL", 6, 9], ["Le", "TEST", 0, 2]]], ["Le 11-OH-THC et le THC-COOH ne sont qu\u2019exceptionnellement retrouv\u00e9s dans la salive, \u00e0 des concentrations tr\u00e8s faibles (< 100 pg/mL).Salive ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueDans des conditions extr\u00eames (habitacle de voiture), une contamination passive de la salive (venant d\u2019un fumeur vers un non-fumeur) pendant environ 30 min peut \u00eatre observ\u00e9e [13].Sueur ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueCe milieu biologique est peu utilis\u00e9 car le \u03949-THC \u00e9ventuellement pr\u00e9sent (r\u00e9sultat d\u2019une concentration par \u00e9vaporations successives) peut \u00eatre \u00e9limin\u00e9 par simple lavage et sa pr\u00e9sence peut aussi r\u00e9sulter d\u2019une exposition passive.", [["Le 11-OH-THC", "CHEMICAL", 0, 12], ["THC", "CHEMICAL", 19, 22], ["THC", "CHEMICAL", 507, 510], ["11-OH-THC", "CHEMICAL", 3, 12], ["THC", "CHEMICAL", 19, 22], ["COOH", "CHEMICAL", 23, 27], ["Le 11-OH", "SIMPLE_CHEMICAL", 0, 8], ["THC-COOH", "SIMPLE_CHEMICAL", 19, 27], ["Le", "TEST", 0, 2], ["\u00e0 des concentrations tr\u00e8s faibles", "TREATMENT", 84, 117], ["D\u00e9tection des cannabino\u00efdes", "TREATMENT", 143, 170], ["D\u00e9tection des", "TREATMENT", 396, 409], ["THC \u00e9ventuellement", "TREATMENT", 507, 525], ["r\u00e9sultat d\u2019une concentration par \u00e9vaporations successives", "TREATMENT", 535, 592], ["peut \u00eatre \u00e9limin\u00e9 par simple lavage et sa pr\u00e9sence", "TREATMENT", 594, 644]]], ["N\u00e9anmoins, il existe des applications aux USA \u00e0 partir de patchs destin\u00e9s \u00e0 recueillir la sueur sur une p\u00e9riode d\u2019une semaine [14].", [["N\u00e9anmoins", "TREATMENT", 0, 9], ["il existe des", "TREATMENT", 11, 24], ["partir de patchs", "TREATMENT", 48, 64]]], ["Dans la sueur, les concentrations de \u03949-THC sont particuli\u00e8rement faibles, probablement du fait d\u2019un pKa et d\u2019une liposolubilit\u00e9 peu favorables \u00e0 la diffusion passive depuis le plasma de ce compos\u00e9.", [["THC", "CHEMICAL", 40, 43], ["plasma", "ORGANISM_SUBSTANCE", 177, 183], ["liposolubilit\u00e9", "TEST", 114, 128], ["peu", "TEST", 129, 132], ["la diffusion", "TEST", 146, 158]]], ["On ne retrouve pas de m\u00e9tabolite dans la sueur.Sueur ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueLa r\u00e9volution technologique est apparue sur le march\u00e9 avec l\u2019approbation par la \u00ab Food and Drug Administration \u00bb am\u00e9ricaine d\u2019un patch collectant la sueur, d\u00e9velopp\u00e9 par les laboratoires PharmChem (Menlo Park, CA).", [["D\u00e9tection des", "TREATMENT", 57, 70], ["r\u00e9volution", "TEST", 124, 134], ["est", "TEST", 149, 152], ["Drug Administration", "TREATMENT", 212, 231], ["am\u00e9ricaine d\u2019un patch", "TREATMENT", 234, 255]]], ["Les composants liquides et non volatils de la sueur sont captur\u00e9s par une membrane absorbante de 14 cm2, situ\u00e9e au centre du patch et recouverte d\u2019un film transparent assurant le maintien sur la peau et une protection contre les contaminations de l\u2019environnement.", [["situ\u00e9e au centre du patch et recouverte d\u2019un film", "TREATMENT", 105, 154], ["le maintien sur la peau et une protection", "TREATMENT", 176, 217]]], ["Seuls peuvent diffuser \u00e0 travers ce film, l\u2019eau et le dioxyde de carbone afin de laisser la peau saine.", [["ce film", "TEST", 33, 40], ["l\u2019eau et le dioxyde", "TREATMENT", 42, 61]]], ["Afin d\u2019\u00eatre conforme avec les proc\u00e9dures de qualit\u00e9, un num\u00e9ro d\u2019identification est imprim\u00e9 sur chaque patch.Sueur ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueSelon la p\u00e9riode souhait\u00e9e, le patch peut \u00eatre port\u00e9 de 1 \u00e0 10 jours, soit au niveau du flanc, soit sur les r\u00e9gions bicipitales ou scapulaires apr\u00e8s d\u00e9sinfection par un coton imbib\u00e9 d\u2019isopropanol \u00e0 70 %.", [["D\u00e9tection des", "TREATMENT", 119, 132], ["d\u2019isopropanol \u00e0", "TREATMENT", 365, 380]]], ["Apr\u00e8s retrait du patch, la membrane absorbante est conserv\u00e9e \u00e0 \u221220 \u00b0C. Les x\u00e9nobiotiques peuvent \u00eatre extraits apr\u00e8s incubation dans un m\u00e9lange tampon-surfactant, tampon-m\u00e9thanol ou tout simplement dans du m\u00e9thanol.", [["tampon-m\u00e9thanol", "CHEMICAL", 163, 178], ["m\u00e9thanol", "CHEMICAL", 206, 214], ["m\u00e9thanol", "CHEMICAL", 206, 214], ["tampon-m\u00e9thanol", "SIMPLE_CHEMICAL", 163, 178], ["du m\u00e9thanol", "SIMPLE_CHEMICAL", 203, 214], ["tampon", "TEST", 144, 150], ["surfactant", "TREATMENT", 151, 161], ["tampon", "TREATMENT", 163, 169]]], ["Par m\u00e9thode immunochimique (Elisa) il est possible d\u2019effectuer un criblage directement sur le m\u00e9lange d\u2019extraction ; le couplage chromatographie/spectrom\u00e9trie de masse, plus sensible et surtout plus sp\u00e9cifique n\u00e9cessitera une \u00e9tape compl\u00e9mentaire de pr\u00e9paration.Air expir\u00e9 ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueL\u2019air expir\u00e9 est une matrice usuelle pour mesurer l\u2019impr\u00e9gnation \u00e9thylique, mais il a \u00e9t\u00e9 r\u00e9cent montr\u00e9 un int\u00e9r\u00eat pour la caract\u00e9risation des conduites addictives.Air expir\u00e9 ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueL\u2019ExaBreath\u00ae est un outil qui fixe sur un filtre les particules d\u2019a\u00e9rosol de l\u2019air expir\u00e9.", [["D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueL\u2019ExaBreath\u00ae est un outil qui fixe sur un filtre les particules d\u2019a\u00e9rosol de l\u2019air expir\u00e9", "SPECIES", 520, 673], ["sur le m\u00e9lange d\u2019extraction", "TREATMENT", 87, 114], ["sensible et surtout", "TREATMENT", 174, 193], ["pour la caract\u00e9risation des", "TREATMENT", 456, 483], ["masse", "ANATOMY", 162, 167]]], ["Le syst\u00e8me est ensuite envoy\u00e9 au laboratoire, o\u00f9 pourront \u00eatre lib\u00e9r\u00e9es les mol\u00e9cules d\u2019int\u00e9r\u00eat avec du m\u00e9thanol.Air expir\u00e9 ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueLors d\u2019une \u00e9tude contr\u00f4l\u00e9e [15], impliquant 4 fumeurs de cannabis, l\u2019excr\u00e9tion du \u03949-THC et de ses m\u00e9tabolites a \u00e9t\u00e9 suivie de fa\u00e7on simultan\u00e9e dans la salive et l\u2019air expir\u00e9.", [["cannabis", "CHEMICAL", 249, 257], ["THC", "CHEMICAL", 277, 280], ["D\u00e9tection des", "TREATMENT", 128, 141]]], ["Toutes les analyses ont \u00e9t\u00e9 r\u00e9alis\u00e9es par GC/MS-MS et ont montr\u00e9 des fen\u00eatres de d\u00e9tection tr\u00e8s superposables, de l\u2019ordre de 6 heures.", [["Toutes les analyses", "TEST", 0, 19], ["MS", "PROBLEM", 45, 47], ["MS", "PROBLEM", 48, 50]]], ["Nul doute que l\u2019avenir est \u00e0 des dispositifs semblables \u00e0 ceux destin\u00e9s \u00e0 la v\u00e9rification de l\u2019impr\u00e9gnation alcoolique.Cheveux ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueSeule la d\u00e9termination dans le sang des cannabino\u00efdes peut confirmer une alt\u00e9ration du comportement ou une intoxication aigu\u00eb.", [["intoxication aigu\u00eb", "DISEASE", 302, 320], ["D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueSeule la d\u00e9termination dans le sang des cannabino\u00efdes peut confirmer une alt\u00e9ration du comportement ou une intoxication aigu\u00eb", "SPECIES", 131, 320], ["D\u00e9tection des", "TREATMENT", 131, 144]]], ["L\u2019approche urinaire permet d\u2019obtenir des informations uniquement qualitatives sur les jours pr\u00e9c\u00e9dant le pr\u00e9l\u00e8vement.Cheveux ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueCette fen\u00eatre de d\u00e9tection a pu \u00eatre compl\u00e8tement modifi\u00e9e par l\u2019introduction du cheveu dans l\u2019arsenal analytique.", [["D\u00e9tection des", "TREATMENT", 129, 142], ["a pu \u00eatre compl\u00e8tement", "TREATMENT", 220, 242]]], ["Ce tissu poss\u00e8de la propri\u00e9t\u00e9 unique d\u2019\u00eatre le marqueur des expositions r\u00e9p\u00e9t\u00e9es ou chroniques, permettant en outre d\u2019\u00e9tablir le profil de consommation \u00e0 long terme et son \u00e9volution.", [["Ce tissu", "TEST", 0, 8]]], ["Les travaux publi\u00e9s montrent tous que les analyses de cheveux identifient mieux que les analyses urinaires les consommateurs r\u00e9cidivistes (effet discriminant) et que le nombre de positifs diminue chaque ann\u00e9e (effet \u00e9ducatif).Cheveux ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueLe m\u00e9canisme g\u00e9n\u00e9ralement propos\u00e9 pour l\u2019incorporation des x\u00e9nobiotiques dans les cheveux consiste en une diffusion interne des substances du sang vers les cellules en croissance des bulbes pileux et une diffusion externe \u00e0 partir des secr\u00e9tions sudorales ou s\u00e9bac\u00e9es.", [["Les travaux publi\u00e9s", "TEST", 0, 19], ["que les analyses", "TEST", 34, 50], ["D\u00e9tection des", "TREATMENT", 238, 251], ["m\u00e9canisme g\u00e9n\u00e9ralement", "TREATMENT", 305, 327], ["pour l\u2019incorporation des", "TREATMENT", 336, 360], ["dans les cheveux", "TEST", 375, 391], ["en croissance des", "TREATMENT", 467, 484], ["et une diffusion", "TEST", 499, 515]]], ["En fusionnant pour former le cheveu, les cellules en croissance pi\u00e8geraient les substances dans la structure k\u00e9ratinis\u00e9e.", [["En fusionnant pour former le cheveu, les cellules en croissance pi\u00e8geraient les substances", "TREATMENT", 0, 90]]], ["Les cin\u00e9tiques d\u2019incorporation sont d\u00e9pendantes des liaisons du x\u00e9nobiotique incorpor\u00e9 \u00e0 la m\u00e9lanine, un pigment des cheveux.", [["la m\u00e9lanine", "TREATMENT", 89, 100], ["un pigment des cheveux", "TREATMENT", 102, 124]]], ["Il semble qu\u2019il existe une diff\u00e9rence quantitative d\u2019incorporation suivant la couleur des cheveux, c\u2019est-\u00e0-dire, en fonction du degr\u00e9 d\u2019oxydation de la m\u00e9lanine.", [["c\u2019est", "TEST", 99, 104]]], ["Cette observation n\u2019est pas sans poser des probl\u00e8mes d\u2019\u00e9quit\u00e9, puisqu\u2019il est admis par la communaut\u00e9 scientifique qu\u2019\u00e0 dose \u00e9quivalente administr\u00e9e, les concentrations mesur\u00e9es dans les cheveux noirs sont plus importantes que dans les cheveux blonds.Cheveux ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueLes traitements cosm\u00e9tiques peuvent affecter les analyses.", [["\u00e9quivalente administr\u00e9e", "TREATMENT", 124, 147], ["D\u00e9tection des", "TREATMENT", 262, 275]]], ["Cette diminution est de l\u2019ordre de 60 \u00e0 70 % pour la coca\u00efne et ses m\u00e9tabolites et de 70 \u00e0 90 % pour les opiac\u00e9s.Cheveux ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueLa fixation des x\u00e9nobiotiques dans les cheveux pourrait \u00e9galement s\u2019effectuer par le biais de l\u2019environnement atmosph\u00e9rique et concerne plus particuli\u00e8rement les substances \u00e0 l\u2019\u00e9tat de particules en suspension.", [["Cette", "SIMPLE_CHEMICAL", 0, 5], ["D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueLa fixation des", "TREATMENT", 125, 204], ["dans les cheveux", "TREATMENT", 219, 235], ["par le biais de l\u2019environnement atmosph\u00e9rique", "TREATMENT", 267, 312], ["particuli\u00e8rement les substances", "TREATMENT", 330, 361]]], ["Les substances d\u00e9pos\u00e9es sur les cheveux par voie passive seraient moins bien li\u00e9es \u00e0 la matrice, ce qui a conduit les toxicologues \u00e0 d\u00e9velopper des m\u00e9thodes de d\u00e9contamination des \u00e9chantillons.Cheveux ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueL\u2019incorporation se faisant dans tous les poils, si les cheveux ne peuvent \u00eatre pr\u00e9lev\u00e9s ou sont manquants, d\u2019autres poils conviennent \u00e9galement comme les poils pubiens ou axillaires.", [["a conduit les toxicologues", "TREATMENT", 104, 130], ["D\u00e9tection des", "TREATMENT", 205, 218]]], ["Ces poils sont particuli\u00e8rement recommand\u00e9s lorsque les cheveux sont teints ou d\u00e9color\u00e9s.Cheveux ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueLes cheveux sont g\u00e9n\u00e9ralement pr\u00e9lev\u00e9s en vertex post\u00e9rieur.", [["D\u00e9tection des", "TREATMENT", 101, 114]]], ["Une m\u00e8che de 80 cheveux (diam\u00e8tre d\u2019un crayon \u00e0 papier) est suffisante.Cheveux ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueUne revue r\u00e9cente de la litt\u00e9rature a largement d\u00e9crit les avantages et les limitations de l\u2019analyse des cheveux [16].Cheveux ::: D\u00e9tection des cannabino\u00efdes en fonction de la matrice biologiqueDu fait d\u2019une augmentation tr\u00e8s importante du nombre de jeunes enfants intoxiqu\u00e9s au cannabis [17] en France, l\u2019analyse des cheveux a \u00e9t\u00e9 propos\u00e9e pour documenter les circonstances d\u2019exposition [18].", [["cannabis", "CHEMICAL", 426, 434], ["D\u00e9tection des", "TREATMENT", 83, 96], ["D\u00e9tection des", "TREATMENT", 277, 290], ["Du fait d\u2019une augmentation", "TREATMENT", 341, 367], ["l\u2019analyse des", "TREATMENT", 451, 464]]], ["Il faut n\u00e9anmoins tenir compte, lors de l\u2019interpr\u00e9tation, des sp\u00e9cificit\u00e9s des cheveux des jeunes enfants (cheveux plus fins et plus poreux que ceux des adultes, et qui sont donc plus facilement expos\u00e9s \u00e0 des risques de contamination environnementale).PerspectivesLa confusion sur le statut l\u00e9gal des d\u00e9riv\u00e9s du cannabis, comme le cannabidiol (CBD), a conduit \u00e0 la commercialisation de nombreux produits, plus ou moins interdits, y compris pour le vapotage.", [["confusion", "DISEASE", 267, 276], ["cannabis", "CHEMICAL", 312, 320], ["cannabidiol", "CHEMICAL", 331, 342], ["cannabidiol", "CHEMICAL", 331, 342], ["CBD", "CHEMICAL", 344, 347], ["lors de l\u2019interpr\u00e9tation", "TREATMENT", 32, 56], ["des sp\u00e9cificit\u00e9s des", "TREATMENT", 58, 78], ["cheveux plus fins et plus poreux que ceux des", "TREATMENT", 107, 152], ["La confusion", "PROBLEM", 264, 276], ["a conduit \u00e0 la commercialisation", "TREATMENT", 350, 382], ["y compris pour le vapotage", "TREATMENT", 430, 456], ["CBD", "ANATOMY", 344, 347], ["conduit", "OBSERVATION", 352, 359]]], ["Sur le plan analytique, l\u2019identification du CBD ne pose aucun probl\u00e8me, les m\u00e9thodes classiques peuvent \u00eatre compl\u00e9t\u00e9es pour inclure ce type de d\u00e9riv\u00e9s naturels [19].PerspectivesSi l\u2019usage classique du cannabis sous forme d\u2019herbe ou de r\u00e9sine reste tr\u00e8s majoritaire en France, de plus en plus de consommateurs se tournent vers les cannabino\u00efdes de synth\u00e8se [20].", [["CBD", "ANATOMY", 44, 47]]], ["Outre une activit\u00e9 pharmacologique plus marqu\u00e9e [21], les cannabino\u00efdes de synth\u00e8se ne sont pas reconnus par les m\u00e9thodes de d\u00e9pistage focalis\u00e9es sur le THC-COOH, et sont difficiles \u00e0 mettre en \u00e9vidence car trop peu d\u2019\u00e9tudes contr\u00f4l\u00e9es ont identifi\u00e9 la ou les mol\u00e9cules cibles selon la matrice biologique analys\u00e9e.", [["THC", "CHEMICAL", 153, 156], ["et sont difficiles", "TEST", 163, 181], ["car trop peu d\u2019\u00e9tudes", "TEST", 203, 224]]], ["En outre, le passage entre le cannabis et les cannabino\u00efdes de synth\u00e8se est favoris\u00e9 par la l\u00e9gislation dans le cadre de la s\u00e9curit\u00e9 routi\u00e8re, puisque seul le \u03949-THC et ses m\u00e9tabolites sont recherch\u00e9s.", [["THC", "CHEMICAL", 162, 165], ["le", "ANATOMY_MODIFIER", 10, 12]]], ["Des m\u00e9thodes existent dans le sang [23], les urines [24], la salive [25] et les cheveux [26].", [["dans le sang", "TEST", 22, 34], ["les urines", "TEST", 41, 51], ["la salive", "TEST", 58, 67], ["et les cheveux", "TEST", 73, 87], ["dans", "OBSERVATION_MODIFIER", 22, 26], ["le", "ANATOMY_MODIFIER", 27, 29], ["sang", "ANATOMY", 30, 34]]], ["Toutes ces m\u00e9thodes mettent en avant plusieurs difficult\u00e9s : conna\u00eetre les nouveaux compos\u00e9s disponibles dans la rue et sur Internet, obtenir les substances de r\u00e9f\u00e9rence pour \u00e9talonner les instruments analytiques et surtout identifier correctement la mol\u00e9cule cible, du fait d\u2019une m\u00e9tabolisation extensive.PerspectivesLa caract\u00e9risation des cannabino\u00efdes de synth\u00e8se est donc difficile dans les milieux biologiques.", [["PerspectivesLa caract\u00e9risation des cannabino\u00efdes", "TREATMENT", 306, 354]]], ["La premi\u00e8re approche est d\u2019\u00e9tudier la fluorescence induite par le noyau indole ou imidazole, commun \u00e0 tous les cannabino\u00efdes de synth\u00e8se, dans un environnement sp\u00e9cifique [27].", [["induite par le noyau indole ou imidazole", "CHEMICAL", 51, 91], ["La", "TEST", 0, 2], ["la fluorescence", "TEST", 35, 50], ["imidazole", "TREATMENT", 82, 91]]], ["La r\u00e9ponse sur la pr\u00e9sence d\u2019un ou plusieurs canabino\u00efdes de synth\u00e8se pourra \u00eatre obtenue tr\u00e8s rapidement, par exemple sur de la salive, mais sera uniquement qualitative.", [["sera", "ORGANISM_SUBSTANCE", 142, 146]]], ["Encore plus originale est l\u2019approche bas\u00e9e sur l\u2019activation mesurable des r\u00e9cepteurs CB1 et CB2 sous l\u2019action d\u2019un agoniste [28].", [["Encore", "TEST", 0, 6], ["originale est l\u2019approche", "TREATMENT", 12, 36]]], ["Il appara\u00eet que l\u2019activation des r\u00e9cepteurs est variable en fonction de la structure chimique du ligand, ce qui permet une corr\u00e9lation avec l\u2019importance de l\u2019effet toxique apr\u00e8s consommation.PerspectivesDans un laboratoire id\u00e9al, comme celui que d\u00e9tiennent les experts des s\u00e9ries t\u00e9l\u00e9vis\u00e9es \u00e0 la mode, le technicien chimiste re\u00e7oit un \u00e9chantillon (une poudre, une trace biologique, un morceau de verre ou encore un aliment), le met en suspension dans un liquide translucide, agite le flacon, d\u00e9pose 1 \u03bcL sur un passeur d\u2019\u00e9chantillon et enfin lit sur un chromatogramme \u00e0 un seul pic le nom de la mol\u00e9cule identifi\u00e9e \u2026 L\u2019analyse totale aura pris 45 secondes !PerspectivesNous en sommes encore loin\u2026D\u00e9claration de liens d\u2019int\u00e9r\u00eatsL\u2019auteur d\u00e9clare ne pas avoir de liens d\u2019int\u00e9r\u00eats.", [["aura", "DISEASE", 634, 638], ["technicien chimiste re\u00e7oit un \u00e9chantillon (une poudre, une trace biologique, un morceau de verre ou encore un aliment), le met en suspension dans un liquide translucide", "SPECIES", 305, 473], ["Il appara\u00eet que l\u2019activation des", "TREATMENT", 0, 32], ["la mode", "TEST", 293, 300], ["le technicien", "TEST", 302, 315]]]]}